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Abstract	  
Heart	   failure	  affects	  1-­‐2%	  of	   the	  adult	  population	   in	   the	  United	  Kingdom	  and	  accounts	   for	   the	  
majority	  of	  hospitalisations	  in	  patients	  with	  cardiovascular	  disease.	  The	  financial	  implications	  are	  
enormous	   as	   it	   consumes	   1-­‐2%	   of	   the	   national	   health	   care	   budget	   with	   70%	   of	   these	   costs	  
relating	  to	  hospitalisation	  expenses.	  
Prevention	  of	   these	  admissions	  may	  be	  possible	  by	  detecting	  early	  signs	  of	  decompensation	   in	  
patients	  with	  chronic	  heart	  failure	  (CHF)	  and	  instituting	  interventions	  that	  may	  steer	  the	  course	  
of	  disease	  back	  to	  stability	  without	  the	  need	  for	  a	  hospital	  inpatient	  stay.	  
Further,	  Sleep	  Disordered	  Breathing	  (SDB)	  and	  in	  particular	  Central	  Sleep	  Apnoea	  (CSA)	  is	  found	  
in	  patients	  with	  CHF	  and	  at	  any	  symptomatic	  stage	  of	  the	  condition.	  This	  may	  be	  associated	  with	  
Cheyne-­‐Stokes	   Respiration	   (CSR),	   which	   has	   been	   shown	   to	   be	   an	   independent	   predictor	   of	  
mortality.	  
In	   the	   first	   study	   of	   this	   thesis,	   I	   investigated	   the	   accuracy	   of	   the	   SleepMinderTM	   (SM)	   device;	  
which	  is	  a	  non-­‐contact	  monitor	  of	  nocturnal	  respiratory	  patterns;	  in	  diagnosing	  SDB	  by	  deriving	  
measures	   of	   the	   Apnoea	   Hypopnea	   Index	   (AHI)	   and	   percentage	   overnight	   CSR	   from	   the	   SM	  
signals.	   I	   found	   that	  SM	  was	  good	   in	   terms	  of	  diagnostic	  accuracy	  with	  an	  area	  under	   receiver	  
operator	   characteristic	   curve	   (ROC)	   of	   0.82	   (p=0.02)	   for	   an	   AHI	   threshold	   >15,	   but	   only	  
moderately	  so	  for	  %	  overnight	  CSR>0,	  with	  an	  area	  under	  ROC	  curve	  of	  0.72	  (p=0.06).	  
In	   the	   second	   study,	   I	   examined	   the	   changes	   that	  occur	   in	   SM	  derived	   respiratory	  parameters	  
over	  a	  long	  period	  of	  monitoring	  and	  found	  that	  the	  AHI,	  quantity	  of	  CSR,	  Total	  Sleep	  Time	  (TST)	  
and	   Respiratory	   Rate	   (RR)	   were	   highly	   variable	   with	   Intra-­‐Class	   Correlation	   (ICC)	   measures	   of	  
0.32,	  0.39,	  0.25,	  0.36	  respectively	  over	  a	  period	  of	  12	  months.	  Relying	  on	  data	  from	  a	  year	  rather	  
than	  a	  single	  night	  resulted	  in	  misclassification	  of	  patients	  into	  a	  different	  severity	  group	  of	  SDB	  
during	  35%	  of	  the	  follow	  up	  period	  and	  placed	  patients	  into	  a	  different	  treatment	  group	  during	  
21%	  of	  this	  period.	  I	  also	  observed	  that	  a	  high	  proportion	  (59%)	  of	  patients	  studied	  had	  a	  mean	  
AHI	   that	   was	   consistently	   above	   the	   accepted	   threshold	   for	   treatment	   (AHI>15).	   This	   was	  
consistent	   even	   over	   a	   shorter	   follow	   up	   period	   of	   2	   weeks	   suggesting	   that	   a	   single	   night	  
measure	  of	  the	  AHI	  may	  not	  be	  a	  sufficient	  risk	  assessment	  of	  SDB	  in	  heart	  failure	  patients.	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In	   the	   final	   study,	   I	   have	   investigated	   the	   predictive	   value	   of	   the	   SleepMinderTM	   for	   acute	  
decompensation	  of	  heart	   failure	   (ADHF)	  using	  algorithms	  derived	   from	   its	   signals.	   I	   found	   that	  
the	  SM	  was	  not	  accurate	   for	   this	  purpose,	  performing	  with	  a	   sensitivity	  and	  specificity	  of	  0.38	  
and	  0.71,	  respectively.	  
In	   summary	   this	   study	   has	   demonstrated	   that	   the	   SleepMinderTM	   device	   provides	   a	   novel	  
screening	   method,	   which	   is	   convenient	   for	   the	   detection	   of	   sleep	   disordered	   breathing	   in	  
patients	   with	   CHF.	   It	   performs	   with	   a	   good	   diagnostic	   accuracy	   and	   is	   acceptable	   to	   these	  
patients	  due	  to	  its	  non-­‐contact	  operation.	  Algorithms	  derived	  from	  its	  signals	  however	  cannot	  be	  
used	  to	  predict	  acute	  decompensation	  of	  chronic	  heart	  failure.	  Further,	  longitudinal	  analyses	  of	  
nocturnal	  respiratory	  patterns	  in	  these	  patients	  have	  demonstrated	  that	  the	  Apnoea	  Hypopnea	  
Index	  (AHI)	  is	  highly	  variable	  over	  a	  prolonged	  period	  of	  monitoring	  and	  a	  mean	  value	  rather	  that	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  –	  Intra-­‐class	  Correlation	  Co-­‐efficient	  
ICD	  –	  Implantable	  Cardiac	  Defibrillator	  	  
IMP	  –	  Impedance	  
IQR	  –	  Interquartile	  Range	  
LoV	  –	  Limits	  of	  Variation	  
LVEF	  –	  Left	  Ventricular	  Ejection	  Fraction	  
MDT	  –	  Multidisciplinary	  Team	  Meeting	  	  
MRA	  –	  Mineralocorticoid	  Receptor	  Antagonist	  
NYHA	  –	  New	  York	  Heart	  Association	  	  
ODI	  –	  Oxygen	  Desaturation	  Index	  
OSA	  –	  Obstructive	  Sleep	  Apnoea	  
PCWP	  –	  Pulmonary	  Capillary	  Wedge	  Pressure	  
PLM	  –	  Periodic	  Leg	  Movement	  
PLM	  –	  Periodic	  Leg	  Movement	  
PSG	  –	  Polysomnography	  	  
RDI	  –	  Respiratory	  Disturbance	  Index	  
REM	  –	  Rapid	  Eye	  Movement	  	  
RIP	  –	  Respiratory	  Inductance	  Plethysmography	  
ROC	  –	  Receiver	  Operator	  Characteristic	  Curve	  
SDB	  –	  Sleep	  Disordered	  Breathing	  	  
SM	  –	  SleepMinderTM	  
SMApA	  –	  SleepMinderTM	  ADHF	  Predictor	  Algorithm	  
TST	  –	  Total	  Sleep	  Time	  	  
TTE	  –	  Transthoracic	  Echocardiography	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Background	  
About	  900,000	  people	  suffer	  from	  Chronic	  Heart	  Failure	  (CHF)	  in	  the	  United	  Kingdom	  and	  5%	  of	  
all	   emergency	  medical	   admissions	   to	  hospital	   are	   related	   to	   this,	   accounting	   for	  2%	  of	  all	  NHS	  
inpatient	  bed	  days	  (1).	  1-­‐2%	  of	  the	  national	  health	  care	  budget	  is	  consumed	  by	  this	  burden,	  with	  
70%	  of	  these	  costs	  relating	  to	  hospitalisation	  expenses	  (2)	  
Preventing	  these	  admissions	  may	  be	  possible	  by	  detecting	  early	  signs	  of	  Acute	  Decompensation	  
of	  Chronic	  Heart	  Failure	  (ADHF)	  and	  instituting	  interventions	  that	  may	  steer	  the	  course	  of	  disease	  
back	  to	  stability	  without	  the	  need	  for	  a	  hospital	  inpatient	  stay.	  
Meta-­‐analysis	  of	  multidisciplinary	   team	   (MDT)	  approaches	   to	   	   the	  management	  of	  patients	   (3)	  	  
with	  heart	   failure	  suggests	   that	   there	   is	  potential	  mortality	  benefit	   from	  this	   strategy	  and	  as	  a	  
result	  this	  has	  now	  been	  included	  in	  international	  guidelines	  (4).	  Unfortunately	  this	  is	  sometimes	  
not	  accessible	  to	  all	  patients,	  and	  even	  when	  available,	  some	  patients	  frequently	  have	  periods	  of	  
instability	  of	  their	  heart	  failure.	  	  
It	   therefore	   seems	  prudent	   to	   identify	  other	  management	   strategies	   that	  may	  be	  of	  benefit	   in	  
the	  early	  identification	  of	  patients	  who	  may	  be	  deteriorating.	  	  
Furthermore,	   varying	   and	   inconsistent	   results	   have	   been	   obtained	   from	   studies	   that	   have	  
investigated	   various	   physiological	   parameters;	   monitored	   directly	   or	   from	   implanted	   devices;	  
that	  may	  be	  predictive	  of	  patients	  who	  are	  likely	  to	  decompensate	  (5).	  
It	   therefore	   becomes	   necessary	   to	   identify	   other	   variables	   that	   could	   give	   potential	   signals	   of	  
heart	  failure	  instability,	  which	  could	  be	  targeted	  to	  prevent	  hospital	  admissions,	  to	  the	  benefit	  of	  
the	  patients	  and	  cost	  saving	  to	  health	  funders.	  
Sleep	  Disordered	  Breathing	  (SDB)	  is	  found	  in	  patients	  with	  CHF	  and	  at	  any	  symptomatic	  stage	  of	  
the	  condition	  (6-­‐8).	  This	  may	  present	  as	  Obstructive	  Sleep	  Apnoea	  (OSA)	  or	  Central	  Sleep	  Apnoea	  
(CSA)	   associated	   with	   Cheyne-­‐Stokes’	   Respiration	   (CSR).	   The	   latter	   has	   been	   shown	   to	   be	   an	  
independent	  predictor	  of	  mortality	  and	  the	  need	  for	  urgent	  cardiac	  transplantation,	  (9)	  while	  the	  
former	   is	  associated	  with	  the	  development	  and	  progression	  of	  cardiovascular	  disease	   including	  
systemic	  hypertension	  and	  heart	  failure	  (10).	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The	  majority	  of	  patients	  with	  CHF	  have	  mild	  symptoms	  of	  disease	  (11);	  however	  the	  presence	  of	  
SDB	  may	  accelerate	  progression	  of	  disease.	  For	  this	  reason,	  early	  identification	  of	  this	  problem	  is	  
desirable.	  
In	  the	  first	  section	  of	  this	  chapter,	  I	  will	  discuss	  the	  epidemiology,	  pathophysiology,	  diagnosis	  and	  
current	   treatment	   of	   CHF.	   In	   the	   following	   section,	   I	   will	   discuss	   the	   burden	   of	   Acute	  
Decompensated	   Heart	   Failure	   (ADHF)	   and	   review	   the	   literature	   regarding	   variables	   currently	  
used	  in	  clinical	  practice.	  Furthermore,	  I	  will	  highlight	  the	  role	  monitoring	  of	  respiratory	  patterns	  
may	  have	  in	  predicting	  ADHF.	  	  
In	   the	   third	   section	   I	  will	   review	  Sleep	  Disordered	  Breathing	   in	  Heart	  Failure,	   the	   impact	   these	  
group	   of	   breathing	   disorders	   have	   on	   heart	   failure,	   and	   the	   potential	   utility	   of	   some	   of	   the	  
measures	  of	   SDB	   in	  predicting	  deterioration.	   In	   the	  penultimate	   section,	   I	  discuss	  digital	   signal	  
processing	  in	  medicine,	  as	  this	  was	  a	  key	  process	  used	  for	  developing	  the	  algorithms	  used	  in	  this	  
thesis.	  	  
In	   the	   final	   section,	   I	   will	   introduce	   the	   clinical	   evaluations	   I	   have	   performed	   with	   the	  
SleepMinderTM	   device	   (ResMed	   Ltd.	   Australia),	   which	   is	   a	   novel,	   non-­‐contact	   monitor	   of	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1.1. Definitions	  
There	  is	  no	  universal	  definition	  for	  heart	  failure	  and	  attempts	  at	  describing	  this	  condition	  dates	  
as	  far	  back	  as	  1500BC	  when	  the	  ancient	  Egyptians	  described	  it	  as	  [‘….an	  inundation	  of	  the	  heart,	  
where	  saliva	  is	  in	  excess	  and	  therefore	  the	  body	  is	  weak’’].	  A	  widely	  referenced	  description	  is	  one	  
from	   Hippocrates	   who	   described	   this	   condition	   in	   460-­‐370BC	   as	   ‘...one	   where	   the	   flesh	   is	  
consumed	   and	   becomes	   water…the	   abdomen	   fills	   with	   water;	   the	   feet	   and	   legs	   swell;	   the	  
shoulders,	  clavicles,	  chest,	  and	  thigh	  melt	  away.’	  (12).	  
A	   modern	   definition	   describes	   heart	   failure	   as	   a	   clinical	   syndrome	   with	   a	   constellation	   of	  
symptoms	  and	  signs	  caused	  by	  an	  abnormality	  of	  the	  heart	  resulting	  in	  a	  characteristic	  pattern	  of	  
hemodynamic,	   renal,	   neural	   and	   hormonal	   responses	   (13).	   This	   definition	   encompasses	   both	  
clinical	   criteria	   sometimes	  used	   solely	   to	  define	  heart	   failure	  and	  other	  definitions	   that	   isolate	  
specific	  physiological	  features	  to	  explain	  this	  condition.	  
	  
1.2. Epidemiology	  of	  Chronic	  Heart	  Failure	  
The	  prevalence	  of	  heart	  failure	  is	  predicted	  to	  continue	  to	  rise	  as	  we	  develop	  new	  strategies	  that	  
improve	   survival	   from	   coronary	   artery	   disease,	   congenital	   heart	   disease	   and	   sudden	   cardiac	  
death.	   It	   is	   estimated	   that	   an	   average	   hospital	   trust	   in	   the	   United	   Kingdom	   would	   see	  
approximately	  1500	  cases	  who	  present	  with	  symptoms	  of	  heart	  failure	  in	  a	  year,	  with	  at	  least	  400	  
of	  them	  been	  incident	  cases	  (14).	  
Community	   and	   population-­‐based	   studies	   have	   demonstrated	   that	   the	   prevalence	   of	   heart	  
failure	   is	   higher	   in	   older	   patients	   (>75	   years)	   and	   in	  men	   (15;16).	   The	   Rotterdam	   heart	   study	  
examined	   5540	   participants	   over	   the	   age	   of	   55	   years	   and	   found	   an	   overall	   prevalence	   rate	   of	  
heart	   failure	   of	   3.7%.	   In	   the	   sub-­‐group	   of	   these	   patients	   who	   had	   trans-­‐thoracic	  
echocardiographic	   examination,	   2.2%	   had	   asymptomatic	   left	   ventricular	   systolic	   dysfunction	  
(LVSD)	   suggesting	   that	   a	   significant	   number	   of	   patients	   with	   organic	   disease	   may	   not	   exhibit	  
clinical	   symptoms	   or	   signs.	   It	   is	   possible	   therefore	   that	   prevalence	   rates	   might	   be	   higher	   in	  
populations	  where	  cardiac	  ultrasound	  was	  not	  employed	  to	  aid	  diagnosis	  (17).	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Those	   findings	   mirrored	   that	   of	   the	   North	   Glasgow	   Multinational	   Monitoring	   of	   trends	   and	  
determinants	   in	  cardiovascular	  disease	   (MONICA)	  study	  that	  reported	  an	  estimated	  prevalence	  
of	   heart	   failure	   of	   2.9%	   based	   on	   the	   presence	   of	   LVSD	   with	   half	   of	   these	   patients	   being	  
asymptomatic	  (15).	  	  
More	  recent	  data	  show	  that	  on	  average,	   the	  diagnosis	  of	  heart	   failure	   is	  made	   in	  men	  5	  years	  
earlier	   than	  women	  and	  significantly	  more	  men	  than	  women	  have	  evidence	  of	  Left	  Ventricular	  
Systolic	   Dysfunction	   (LVSD)	   (Figure	   1).	   	   It	   has	   also	   been	   observed	   that	   people	   of	   a	   lower	  
socioeconomic	  background	  are	  more	   likely	   to	  develop	   this	   syndrome	  at	   an	  earlier	   age.	   	   These	  
patients	  are	  less	  likely	  to	  seek	  or	  have	  access	  to	  clinical	  care	  and	  may	  therefore	  have	  a	  delay	  in	  
diagnosis.	  As	  a	  consequence	   the	  potential	   for	   such	  patients	   to	  decompensate	  would	  be	  higher	  
until	  they	  are	  appropriately	  managed	  on	  prognostically	  relevant	  treatment	  (18).	  	  
	  
Figure	  1:	  Age	  and	  Sex	  Distribution	  in	  Chronic	  Heart	  Failure	  Based	  on	  The	  National	  Heart	  Failure	  Audit	  2012	  
There	  are	  fewer	  studies	  on	  incidence	  of	  heart	  failure.	  In	  the	  Hillingdon	  study,	  it	  was	  ascertained	  
in	  a	  west	  London	  district;	  (population	  151,000);	  that	  the	  incidence	  of	  heart	  failure	  was	  0.02/1000	  
per	  year	   in	   the	  25-­‐34	  year	  age	  group	  rising	   to	  11.6/1000	  per	  year	   in	   those	  aged	  over	  85	  years	  
showing	  that	  this	  was	  a	  disease	  predominantly	  of	  the	  elderly	  with	  a	  median	  age	  at	  presentation	  
of	  76	  years	  (16).	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Data	   from	   the	  United	   States,	   suggest	   incidence	   rates	   of	   19.3/1000	   person	   years	   in	   a	   5.5	   year	  
follow	  up	  period	  (19),	  and	  this	   is	  similar	  to	  a	  much	   larger	  study	  using	  a	  General	  Practice	  based	  
cohort	  of	  patients	  in	  the	  United	  Kingdom	  where	  the	  overall	  incidence	  rose	  to	  20.2/1000	  person	  
years	  if	  patients	  with	  a	  classification	  for	  ‘probable	  diagnosis’	  of	  heart	  failure	  were	  included	  	  (20).	  
Mortality	   rates	  up	   to	  62%	   in	  Men	  and	  42%	   in	  women	  at	  5	   years	   from	   incident	  diagnosis	  have	  
previously	   been	   reported	   (21).	   Over	   the	   past	   decades	   however,	   it	   is	   clear	   that	   advances	   in	  
pharmacological	   and	   device	   therapy	   for	   heart	   failure	   have	   had	   a	   positive	   impact	   on	   survival	  
outcomes.	  This	  is	  demonstrated	  by	  a	  fall	  in	  all-­‐cause	  mortality	  over	  a	  6	  month	  follow-­‐up	  period	  
from	  25%	  to	  14%	  from	  a	  recent	  comparison	  of	  secular	  trends	  in	  survival	  for	  the	  same	  geographic	  
population	  (22).	  
Overall	  the	  incidence	  of	  heart	  failure	  has	  not	  increased	  over	  the	  last	  40	  years	  of	  the	  Framingham	  
study,	   and	   in	   fact	   may	   have	   declined.	   The	   trend	   however	   is	   towards	   an	   upward	   increase	   in	  
prevalence	   rates	   as	   we	   improve	   our	   diagnostic	   abilities	   for	   this	   syndrome	   and	   halt	   the	  
progression	   of	   previously	   fatal	   cardiovascular	   diseases	   as	   a	   result	   of	   improved	   treatment	   and	  
with	  a	  rapidly	  ageing	  population.	  	  
It	  is	  important	  to	  note	  that	  majority	  of	  these	  epidemiological	  studies	  have	  utilised	  patients	  with	  
LVSD	   to	   define	   heart	   failure	   however	   the	   clinical	   syndrome	   of	   CHF	   also	   occurs	   in	   a	   cohort	   of	  
patients	  who	  have	  a	  preserved	  ejection	  fraction.	  Up	  to	  half	  of	  patients	  with	  HF	  may	  have	  Heart	  
failure	   with	   preserved	   ejection	   fraction	   (HFPEF),	   and	   this	   may	   skew	   prevalence	   rates	   of	   CHF	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1.3. Clinical	  Course	  
Heart	   Failure	   runs	   a	   highly	   variable	   and	   sometimes	   unpredictable	   course.	   Two	   patterns	   are	  
described.	  
1.3.1. Acute	  Heart	  Failure	  
1.3.1.1. 	  De	  novo	  Acute	  Heart	  Failure	  (De	  novo	  AHF)	  
This	   is	  usually	   the	  presenting	   state	  of	  heart	   failure	  at	  diagnosis	   following	   insult	  or	   injury	   to	  an	  
undamaged	  heart.	  The	  most	  likely	  precipitant	  particularly	  when	  symptoms	  develop	  abruptly	  is	  an	  
acute	   coronary	   syndrome.	   The	   patient	   may	   present	   to	   the	   emergency	   room	   in	   pulmonary	  
oedema	   or	   in	   cardiogenic	   shock.	   Once	   this	   acute	   phase	   resolves	   the	   patient	   may	   over	   time	  
develop	  a	  stable	  CHF	  syndrome	  if	  there	  was	  significant	  persisting	  myocardial	  injury.	  	  
1.3.1.2. Acute	  Decompensated	  Heart	  Failure	  (ADHF)	  
While	  there	  is	  no	  consensus	  definition	  for	  ADHF,	  it	  is	  generally	  agreed	  that	  a	  patient	  has	  arrived	  
at	   a	   state	   of	   decompensated	   heart	   failure	  when	   they	   have	   developed	   signs	   and	   symptoms	   of	  
fluid	  overload	  to	  the	  extent	  that	  they	  require	  a	  hospital	  admission	  for	  intravenous	  administration	  
of	  diuretics	  to	  ‘offload’.	  
A	  patient	  with	  stable	  CHF	  may	  periodically	  deteriorate	  and	  this	  may	  happen	  acutely,	  with	  acute	  
coronary	  ischaemia	  and	  arrhythmias	  been	  the	  main	  precipitants	  leading	  to	  a	  hospital	  admission,	  
or	  it	  may	  occur	  sub-­‐acutely,	  over	  days	  or	  weeks,	  with	  the	  usual	  precipitants	  in	  this	  case	  including	  
non-­‐compliance	   with	   medication	   or	   dietary	   restrictions,	   uncontrolled	   hypertension,	   and	  
infections.	   Other	   known	   causes	   include,	   anaemia,	   renal	   dysfunction	   and	   side	   effects	   of	  
medication	  such	  as	  non-­‐steroidal	  anti-­‐inflammatory	  drugs	  (NSAIDS)	  and	  calcium	  channel	  blockers	  
(24;24).	  	  
If	  the	  patient	  succumbs	  to	  any	  one	  of	  these	  triggers,	  compensatory	  mechanisms	  and	  medication	  
become	  insufficient	  to	  maintain	  a	  euvolaemic	  status,	  and	  fluid	  overload	  ensues.	  At	  this	  point,	  the	  
patient	  is	  said	  to	  have	  entered	  a	  state	  of	  acute	  decompensated	  heart	  failure	  (ADHF).	  This	  process	  
may	  occur	  over	  days	  or	  weeks	  (25)	  (See	  Figure	  2).	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Figure	  2:	  Number	  of	  days	  from	  onset	  of	  worsening	  of	  selected	  symptoms	  of	  heart	  failure	  to	  hospital	  
admission	  in	  83	  patients	  admitted	  with	  heart	  failure.	  Most	  symptoms	  were	  present	  1	  week	  before	  
admission,	  which	  suggests	  that	  earlier	  outpatient	  intervention	  might	  reduce	  hospitalisations	  (26)	  
Generally,	  the	  clinical	  course	  of	  heart	  failure	  may	  see	  a	  patient	  have	  repeated	  periods	  of	  ADHF	  
leading	  to	  potential	  hospitalisation	  for	  treatment	  followed	  by	  a	  recovery	  period	  leading	  back	  to	  
stability.	  Importantly,	  each	  episode	  of	  ADHF	  and	  subsequent	  hospitalisation	  reduces	  the	  chances	  
for	   complete	   recovery	   of	   the	  myocardium	   back	   to	   baseline	   and	   there	   is	   often	   progression	   of	  
ventricular	  dysfunction	   (27).	   The	   trajectory	   that	   follows	   therefore	   is	  often	  one	  of	   longer	  ADHF	  
episodes	  and	  shorter	  stable	  periods,	  which	  ultimately	  leads	  to	  worse	  outcomes	  (Figure	  3).	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Figure	  3:	  Median	  survival	  (50%	  mortality)	  and	  95%	  confidence	  limits	  in	  patients	  with	  HF	  after	  each	  HF	  
hospitalization	  (27)	  	  
1.3.2. Chronic	  Heart	  Failure	  
This	  is	  the	  clinical	  state	  in	  which	  majority	  of	  heart	  failure	  patients	  are	  found,	  and	  at	  various	  levels	  
of	   symptomatology,	  according	   to	   their	  New	  York	  Heart	  Association	   (NYHA)	  classification	   (Table	  
1).	   Patients	   in	   NYHA	   class	   I	   have	   no	   symptoms	   attributable	   to	   heart	   disease;	   those	   in	   NYHA	  
classes	  II,	  III	  or	  IV	  are	  sometimes	  said	  to	  have	  mild,	  moderate	  or	  severe	  symptoms,	  respectively	  
Most	  patients	  with	  CHF	  usually	  have	  some	  symptoms	  but	  cope	  with	  this	  by	  minimising	  activity.	  	  
In	  clinical	  practice,	  a	  patient	  is	  considered	  to	  be	  in	  a	  ‘stable	  state’	  of	  CHF	  if	  following	  drug	  and/or	  
device	   therapy,	   there	   are	   minimal	   restrictions	   to	   activities	   of	   daily	   living	   from	   heart	   failure	  
symptoms	   and	   they	   have	   a	   reasonable	   quality	   of	   life	   regardless	   of	   NHYA	   class.	   These	   treated	  
patients	   may	   have	   symptoms	   and	   signs	   that	   have	   been	   unchanged	   for	   at	   least	   a	   month	   (4).	  	  
Important	  markers	  of	   stability	   include	   freedom	  from	  clinical	   congestion,	  usually	  defined	  as	   the	  
absence	  of	  orthopnoea	  or	  Paroxysmal	  Nocturnal	  Dyspnoea	  (PND),	  peripheral	  oedema,	  a	  recent	  
increase	   in	  weight	  or	  diuretic	  doses	  and	  a	   raised	   JVP	   (28).	  These	  patients	  may	  continue	   in	   this	  
state	  for	  months	  or	  years	  following	  initial	  diagnosis	  and	  especially	  if	  the	  patient	  was	  on	  optimum	  
medical	  management.	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The	   usual	   outcomes	   from	   this	   position	   is	   that	   the	   patient	   may	   remain	   in	   this	   situation	   for	  
prolonged	  spells	  and	   in	  some	  cases	  completely	   recover	  myocardial	   function,	  depending	  on	   the	  
cause;	   for	   example	   a	   viral	   cardiomyopathy;	   or	   alternatively	   develop	   periodic	   states	   of	   acute	  
decompensation	  of	  heart	  failure	  (ADHF)	  leading	  to	  hospitalisation	  for	  treatment.	  There	  is	  also	  a	  
group	  of	  CHF	  patients	  who	  would	  progressively	  decline;	  in	  a	  less	  punctuated	  and	  more	  relentless	  
way	  towards	  death	  or	  transplantation	  even	  when	  on	  the	  appropriate	  drug	  or	  device	  treatment	  
(29).	  
Regardless	  of	   the	  course	  taken,	   the	  patient	  with	  CHF	   is	  always	  at	  risk	  of	  sudden	  death;	  usually	  
from	   arrhythmias	   and	   these	   patients	   may	   have	   related	   symptoms	   such	   as	   palpitations	   and	  
presyncope.	  
	  
Table	  1:	  New	  York	  Heart	  Association	  Functional	  Classification	  of	  Heart	  Failure	  
1.4. Pathophysiology	  of	  Chronic	  Heart	  Failure	  
CHF	  results	  from	  a	  complex	  inter-­‐play	  of	  structural,	  neurohormonal,	  vascular	  and	  hemodynamic	  
mechanisms.	  A	  variety	  of	  causes	  are	  well	  documented	  but	  in	  some	  cases	  the	  exact	  trigger	  cannot	  
be	  identified	  (30).	  Irrespective	  of	  the	  cause	  however,	  what	  is	  critical	   in	  this	  vicious	  circle	  is	  that	  
the	  patient	  arrives	  at	  a	  critical	  point	  where	  there	  is	  an	  inability	  of	  the	  myocardium	  to	  maintain	  a	  
sufficient	  cardiac	  output	  to	  meet	  what	  is	  required	  for	  normal	  organ	  function.	  It	  is	  this	  shortage	  in	  
supply	   against	   the	   body’s	   usual	   demands;	   which	   goes	   up	   during	   exercise,	   which	   results	   in	  
majority	  of	  the	  symptoms	  that	  accompanies	  this	  syndrome.	  
The	  failing	  heart	  responds	  to	  this	  by	  activating	  mechanism	  that	  try	  to	  restore	  cardiac	  output	  and	  
ensure	   that	   organ	   tissue	   perfusion	   is	   maintained	   at	   a	   near	   normal	   level.	   These	   mechanisms	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include	  structural	  changes	   to	   the	  heart	  muscle,	  as	  well	  as	  hormonal	  and	  neural	  processes.	  The	  
long-­‐term	  effects	  of	   these	  changes	  are	  deleterious	  but	   in	  the	  short	  term	  they	  augment	  cardiac	  
function	  to	  a	  reasonable	  degree.	  
1.4.1. Frank-­‐Starling	  Mechanism	  
The	   Frank-­‐Starling	   mechanism	   is	   one	   of	   the	   most	   important	   physiological	   principles	   for	  
regulation	   of	   myocardial	   contractile	   performance.	   It	   is	   intrinsic	   to	   cardiac	   muscle	   and	   this	  
principle	  describes	  the	  ability	  of	  the	  heart	  to	  change	  its	  force	  of	  contraction	  and	  therefore	  stroke	  
volume	   in	   response	   to	   changes	   in	   venous	   return	   –	   the	   end	   diastolic	   volume	   (EDV)	   –	  when	   all	  
other	  factors	  remain	  constant.	  	  
This	  mechanism	   is	   particularly	   important	   in	   Acute	  Heart	   Failure	   following	   abrupt	   insult	   to	   the	  
myocardium	  and	   is	  evident	  within	  minutes	  of	  cardiac	   injury.	  As	   left	  ventricular	   filling	  pressures	  
rises	   following	   the	   sudden	   fall	   in	   stroke	   volume,	   this	   mechanism	   ensures	   that	   an	   adequate	  
cardiac	   output	   is	   delivered	   by	  matching	   this	  with	   the	   increased	   venous	   return.	   It	   does	   this	   by	  
increasing	   myocardial	   sarcomere	   length,	   which	   up	   to	   a	   point	   increases	   myocyte	   tension,	   in	  
response	  to	  the	  increased	  EDV	  and	  thereby	  increasing	  stroke	  volume.	  	  	  
The	  exact	  mechanism	  relates	  to	  the	  stretch	  or	  length	  of	  myocardial	  fibres,	  which	  is	  determined	  
by	  the	  resting	  force,	  myocardial	  compliance,	  and	  the	  degree	  of	  filling	  from	  the	  left	  atrium.	  This	  
distending	   force	   is	   the	   preload	   of	   the	   muscle	   and	   ventricular	   performance	   is	   enhanced	   with	  
increasing	  sarcomere	  length,	  which	  results	  in	  an	  improved	  cardiac	  output.	  	  
In	   Chronic	   heart	   failure,	   this	   mechanism	   is	   attenuated	   (31)	   but	   is	   still	   present,	   even	   though	  
significant	  alterations	  of	  diastolic	  myocardial	  distensibility	  may	  be	  evident.	   In	  this	  situation,	  the	  
body	  utilises	  the	  Frank-­‐Starling	  mechanism	  by	  increasing	  sodium	  and	  water	  retention	  as	  well	  as	  
venoconstriction	   in	   an	   attempt	   to	   increase	   left	   ventricular	   filling	   pressures	   and	   preload.	   The	  
consequence	  of	  this	  haemodynamic	  change	  is	  an	  increasing	  venous	  return	  to	  the	  heart;	  preload;	  
which	  stretches	  the	  ventricular	  wall	  increasing	  EDV	  and	  causing	  cardiac	  muscle	  to	  contract	  more	  
forcefully.	  This	  initial	  increased	  stroke	  volume	  is	  beneficial	  to	  maintain	  a	  normal	  cardiac	  output.	  	  
However	   in	   patients	   with	   CHF	   there	   are	   little	   changes	   in	   cardiac	   output	   even	  with	   increasing	  
stretch	  or	  left	  ventricular	  end	  diastolic	  volume	  (See	  Figure	  4).	  This	  is	  because sarcomere-­‐length	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reserve	   becomes	   rapidly	   exhausted,	   and	   there	   is	   inadequate	   sarcomere	   extension	   due	   to	  
impaired	  relaxation	  or	  reduced	  distensibility	  of	  the	  damaged	  ventricular	  wall	  (32).	  	  
This	  mechanism	  therefore	  becomes	  inadequate	  to	  continue	  to	  maintain	  normal	  haemodynamics.	  
Further,	   abnormally	   increased	   left	   atrial	   pressures	   leads	   to	   increase	   pulmonary	   capillary	  
pressures,	   which	   contribute	   to	   increased	   symptoms	   of	   shortness	   of	   breath	   experienced	   by	  
patients	  with	  chronic	  heart	  failure.	   In	  addition	  sodium	  and	  water	  retention	   in	  the	  vascular	  wall	  
causes	  arterial	  stiffening	  and	  constriction	  leading	  to	  an	  increased	  afterload	  that	  causes	  the	  heart	  




Figure	  4:	  Graphical	  Representation	  of	  Frank-­‐Starling	  Curve.	  In	  the	  normal	  heart,	  as	  Preload	  (End-­‐
Diastolic	  Volume/Pressure)	  increases,	  there	  is	  an	  increase	  in	  the	  stroke	  volume.	  In	  Heart	  failure	  this	  
response	  is	  attenuated	  and	  a	  plateau	  of	  response	  is	  reached	  early.	  
1.4.2. Ventricular	  Remodelling	  
The	   healthy	   human	   heart	   is	   estimated	   to	   contain	   3	   billion	   cardiomyocytes	   in	   the	   ventricular	  
myocardium,	   which	   are	   arranged	   in	   a	   complex	   three-­‐dimensional	   pattern	   within	   myocardial	  
tissue.	  In	  a	  diseased	  state,	  these	  cells	  may	  elongate,	  increase	  in	  size	  or	  may	  undergo	  cell	  death	  by	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necrosis	  or	  apoptosis.	  	  Three	  distinct	  macroscopic	  patterns	  may	  occur	  in	  myocytes	  of	  the	  failing	  
myocardium	   in	   the	   context	   of	   chronic	   heart	   failure.	   These	   include	  dilatation,	   hypertrophy	   and	  
the	  formation	  of	  scar	  tissue.	  These	  changes	  are	  grouped	  under	  the	  heading	  ‘remodelling’	  which	  
is	   the	   term	   commonly	   used	   to	   describe	   the	   changes	   in	   size,	   shape	   and	   function	   of	   the	   left	  
ventricle	  that	  may	  occur	  following	  myocardial	  injury.	  These	  changes	  may	  be	  the	  consequence	  of	  
the	  primary	   insult	   to	  the	  myocardium	  and	  can	  occur	  within	  hours	  to	  days,	  or	  may	  be	  part	  of	  a	  
much	  longer	  pathophysiological	  process	  over	  months.	  	  
1.4.2.1. Dilatation	  
Dilatation	   results	   in	   an	   enlargement	   of	   the	   cardiac	   chambers	   with	   the	   initial	   effect	   being	   an	  
augmentation	  of	  cardiac	  output	  as	  a	   result	  of	  greater	  stroke	  volume.	  The	   latter	  effects	   include	  
functional	  valvular	  regurgitation,	  arrhythmias	  from	  micro	  re-­‐entry	  and	  mechanical	  dysynchrony	  
as	   the	  heart	   loses	   its	  geometry	  and	  consequently	   its	  efficiency	   leading	  to	  a	  worsening	  of	  heart	  
function.	  Dilatation	  occurs	  when	  there	  is	  volume	  overload	  of	  the	  ventricle	  but	  may	  also	  be	  from	  
de-­‐novo	  cardiomyopathies,	  primary	  valvular	  disease	  or	  myocardial	  infarction.	  
1.4.2.2. Hypertrophy	  
The	   cardiac	   myocytes	   may	   hypertrophy	   in	   response	   to	   an	   excessive	   afterload	   such	   as	   in	  
hypertension,	   so	  as	   to	  maintain	  a	  normal	   stroke	  volume.	  Other	  stimuli	   for	   this	  process	   include	  
oxidative	   stress,	   inflammation	   and	   neurohormonal	   driven	   signalling	   pathways.	   Hypertrophy	  
results	  in	  a	  non-­‐compliant	  ventricle	  that	  does	  not	  relax	  appropriately,	  the	  resultant	  effect	  been	  
an	   increase	   in	   left	   atrial	   pressures	   from	   impaired	   filling	   of	   the	   ventricles,	  which	   is	   transmitted	  
back	   into	   the	   pulmonary	   vasculature	   leading	   to	   congestion.	   	   Initially	   systolic	   function	   of	   the	  
ventricles	  may	  be	  preserved	  but	  as	  the	  process	  carries	  on,	  there	  may	  be	  dilatation	  and	  thinning	  
of	  the	  ventricular	  walls	  leading	  to	  a	  decline	  in	  function	  (33).	  
1.4.2.3. Myocardial	  Cell	  Death	  
Focal	   myocardial	   injury	   may	   lead	   to	   scar	   tissue	   formation	   and	   a	   reduction	   in	   the	   amount	   of	  
myocytes	  that	  can	  contribute	  effectively	  to	  the	  cardiac	  output.	  The	  aetiology	  is	  usually	  coronary	  
ischaemia	   leading	   to	  myocardial	   infarction	   and	   if	   a	   large	   area	   of	   the	  myocardium	   is	   affected,	  
there	  may	  also	  be	  associated	  changes	  of	  hypertrophy	  or	  dilation	  in	  adjacent	  myocytes.	  Cell	  death	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in	   this	   case	   is	   a	   result	   of	   acute	   cell	   necrosis	   but	   programmed	   cell	   death	   or	   apoptosis	   is	   also	  
known	  to	  occur.	  Apoptosis	  is	  rare	  in	  the	  healthy	  heart	  but	  the	  rates	  are	  significantly	  increased	  in	  
the	  chronically	  failing	  heart	  irrespective	  of	  aetiology	  (34).	  It	   is	  an	  energy	  consuming	  process	  via	  
protein	   and	   chromatin	   fragmentation	   that	   does	   not	   trigger	   an	   immune	   response.	   In	   contrast,	  
necrosis	   is	   characterised	   by	   cell	   swelling,	  membrane	   lysis	   and	   release	   of	   intracellular	   contents	  
into	   the	   interstitial	   space	   resulting	   in	   inflammation	   and	   secondary	   injury.	   Both	   processes	  may	  
lead	  to	  scar	  tissue	  formation	  as	  the	  body	  works	  to	  replace	  infarcted	  myocardium.	  Scar	  tissue	  is	  
dynamic	   tissue,	   which	   is	   cellular,	   vascularised	   and	   metabolically	   active,	   it	   however	   remains	  
functionally	  dormant	  in	  its	  contributions	  to	  cardiac	  output	  (35).	  
In	   summary	   the	  architectural	   changes	   in	   the	  hearts	   structure	   following	  damage	  are	   in	   the	   first	  
instance	   compensatory,	   aimed	   at	   preservation	  of	   cardiac	   function,	   but	   eventually	   the	   changes	  
results	  in	  inefficiencies	  ultimately	  leading	  to	  a	  worsened	  situation.	  
1.4.3. Neurohormonal	  Activation	  
These	   processes	   primarily	   refer	   to	   activation	   of	   the	   sympathetic	   system	   and	   the	   renin	  
angiotensin	  aldosterone	  system	  which	  are	  well	  developed	  response	  systems	  in	  place	  designed	  to	  
respond	  to	  altered	  cardiac	  function	  by	  maintaining	  blood	  pressure	  and	  critical	  organ	  perfusion	  in	  
the	  short	  term	  but	  becoming	  maladaptive	  when	  chronically	  stimulated.	  	  
1.4.3.1. Sympathetic	  Nervous	  System	  (SNS)	  
When	   cardiac	  output	   and	  blood	  pressure	   falls,	   afferent	   signals	   are	   carried	   from	  baroreceptors	  
mainly	  in	  the	  carotids	  and	  aortic	  arch,	  to	  the	  sympathetic	  chain	  and	  adrenal	  medulla	  leading	  to	  
an	   increase	   in	   central	   sympathetic	   flow.	   There	   is	   an	   attendant	   increase	   in	   the	   amount	   of	  
circulating	   catecholamines,	   noradrenaline	   and	   adrenaline,	   which	   act	   rapidly	   but	   for	   a	   short	  
period	   to	   increase	   the	   myocardial	   contractility	   by	   catecholamine-­‐mediated	   intracellular	   signal	  
transduction	  pathways	  which	  improve	  the	  efficiency	  of	  myocardial	  excitation-­‐coupling	  function.	  
There	   is	  also	  a	  decreased	  re-­‐uptake	  of	  these	  neurohormones,	  which	  prolongs	  their	  presence	   in	  
peripheral	  circulation.	  
The	   immediate	   effect	   is	   an	   increase	   in	   cardiac	   output	   from	   a	   direct	   increase	   in	   myocardial	  
contractility,	   vasoconstriction	   and	   an	   increase	   in	   heart	   rate	   which	   immediately	   supports	   the	  
failing	  circulation	  by	  improving	  perfusion	  pressures	  to	  the	  vital	  organs.	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In	  the	  long	  term	  however	  this	  process	  is	  damaging	  to	  the	  heart	  from	  direct	  toxic	  damage	  to	  the	  
myocytes	   from	   these	   catecholamines,	   which	   promote	   apoptosis,	   calcium	   overload	   and	  
ventricular	   remodelling	   from	   hypertrophy	   (36).	   Furthermore	   there	   is	   an	   eventual	   down	  
regulation	   of	   β1-­‐adrenoceptors	   as	   well	   as	   a	   maximising	   of	   intracellular	   signalling	   pathway	  
effecter	   mechanisms,	   which	   further	   limits	   the	   ability	   of	   the	   heart	   to	   respond	   to	   this	  
catecholamine	  surge	  (37).	  	  
1.4.3.2. Renin	  Aldosterone	  Angiotensin	  System	  (RAAS)	  
The	  RAAS	  plays	  an	  instrumental	  role	  as	  a	  systemic	  response	  to	  the	  failing	  heart.	  Renin	  is	  released	  
from	  the	   juxtaglomerular	  apparatus	   in	  the	  Bowman’s	  capsule	  of	  the	  nephron	   in	  response	  to	  β-­‐
adrenoceptor	  stimulation	  and	  a	  fall	  in	  renal	  blood	  flow.	  Its	  actions	  on	  circulating	  angiotensinogen	  
leads	   to	   the	   production	   on	   angiotensin	   I,	   which	   is	   converted	   by	   the	   angiotensin	   converting	  
enzyme	  (ACE)	  to	  angiotensin	  II	  which	  is	  the	  main	  effector	  hormone	  of	  RAAS.	  	  	  
Its	  main	   actions	   are	   to	   increase	  blood	  pressure	  by	  potent	   vasoconstriction	   and	   salt	   and	  water	  
retention,	   a	   direct	   effect	   of	   aldosterone	   release	   from	   the	   renal	   cortex.	   It	   also	   stimulates	   the	  
release	   of	   other	   hormones	   including	   vasopressin,	   endothelin	   and	   catecholamines	   from	  
stimulation	  of	   the	  SNS.	  Angiotensin	   II	  mediates	   this	  effects	  via	   two	  main	  receptors	   type	   I	   (AT1)	  
and	  II	  (AT2),	  the	  former	  mainly	  accounting	  for	  most	  of	  the	  deleterious	  effects	  of	  this	  hormone.	  
1.4.3.3. Inflammatory	  Responses	  
Several	   inflammatory	  markers	   are	   known	   to	   have	   elevated	   plasma	   concentrations	   in	   patients	  
with	  heart	  failure	  and	  potentially	  play	  an	   important	  role	   in	   its	  pathophysiology	  by	  activation	  of	  
the	   immune	   system	   (38).	   C-­‐reactive	   protein	   (CRP)	   may	   be	   raised	   as	   part	   of	   a	   non-­‐specific	  
generalised	   inflammation	   in	   heart	   failure	   and	   is	   also	   known	   to	   be	   associated	   with	   a	   worse	  
outcome	  particularly	  in	  severe	  heart	  failure	  (39).	  Tumour	  necrosis	  factor	  (TNFα)	  is	  predominantly	  
released	  from	  macrophages	  and	  studies	  have	  shown	  that	  an	  increased	  level	  along	  with	  its	  soluble	  
receptors	  suggest	  an	  increase	  in	  severity	  of	  heart	  failure	  (40).	  Interleukins	  1	  (IL1)	  and	  6	  (IL-­‐6)	  are	  
other	  cytokines	  that	  have	  been	  widely	  studied	  and	  are	  an	  independent	  predictor	  of	  prognosis	  in	  
HF	  (41),	  exerting	  their	  effects	  via	  negative	  haemodynamic	  and	  pro-­‐inflammatory	  toxic	  effects	  on	  
the	   myocardium	   contributing	   to	   apoptosis,	   myocyte	   hypertrophy	   and	   progressive	   adverse	  
ventricular	  re-­‐modelling	  (42).	  
	   42	  
1.4.3.4. The	  Role	  of	  Natriuretic	  Peptides	  
These	  hormones	  are	  released	  in	  response	  to	  increase	  myocardial	  wall	  stress	  as	  well	  as	  stimulus	  
from	  other	  circulating	  neurohormones,	  aldosterone,	  angiotensin	  II,	  endothelin,	  vasopressin	  and	  
noradrenaline.	  There	  are	  two	  main	  types,	  the	  Atrial	  Natriuretic	  Peptide	  (ANP)	  released	  from	  both	  
atria	  and	  ventricles	  and	  the	  B-­‐type	  natriuretic	  peptide	  (BNP)	  released	  from	  cardiac	  ventricles.	  	  
In	   HF,	   natriuretic	   peptides	   represent	   a	   weak	   counter-­‐regulatory	   system,	   which	   attempts	   to	  
maintain	   cardiovascular	   homeostasis	   by	   increasing	   natriuresis,	   diuresis	   and	   vasodilation	   of	  
peripheral	   vasculature.	   In	   essence	   they	   directly	   antagonise	   the	   actions	   of	   angiotensin	   II,	  
catecholamines	   and	   aldosterone	   but	   the	   effects	   are	   ultimately	   insufficient	   to	   prevent	   the	  
progression	  of	  HF	  (43).	  
1.5. Diagnosis	  of	  Chronic	  Heart	  Failure	  
There	   are	   no	   pathognomonic	   symptoms	   or	   signs	   of	   heart	   failure	   and	   so	   a	   diagnosis	   based	   on	  
clinical	  features	  alone	  is	  difficult	  to	  achieve	  (44;45).	  	  
Patients	   may	   complain	   of	   symptoms	   that	   include	   dyspnoea,	   fatigue	   and	   a	   reduced	   exercise	  
tolerance.	   Signs	   that	   may	   be	   identified	   include	   a	   raised	   jugular	   venous	   pressure,	   peripheral	  
oedema	  and	  basal	  lung	  crepitation.	  These	  features	  are	  not	  specific	  to	  the	  heart	  failure	  syndrome	  
and	  may	  be	  difficult	  to	  detect	   in	  early	  disease	  and	  also	  in	  certain	  individuals	  (obese	  patients	  or	  
those	  with	  chronic	  obstructive	  airway	  disease).	  They	  are	  also	  not	  always	  reproducible	  (46).	  	  
In	   addition	   to	   clinical	   features	   therefore,	   current	   guidelines	   recommend	   early	   diagnosis	   of	  
suspected	  heart	  failure	  using	  imaging,	  in	  particular	  transthoracic	  echocardiography,	  to	  assess	  left	  
ventricular	   systolic	   function	   and	   valvular	   disease	   (47).	   Radionuclide	   angiography	   and	   cardiac	  
magnetic	   resonance	   imaging	   are	   other	   modalities	   that	   can	   be	   employed	   for	   this	   assessment	  
where	  necessary.	  Where	  there	  is	  a	  history	  of	  previous	  myocardial	  infarction,	  an	  echocardiogram	  
should	   be	   performed	   within	   2	   weeks.	   Alternatively,	   if	   measured	   plasma	   levels	   of	   natriuretic	  
peptides	  are	  high,	  imaging	  should	  be	  performed	  within	  6	  weeks.	  	  
NICE	  has	  recommended	  that	  a	  specialist,	  usually	  a	  cardiologist	  with	  an	  interest	  in	  heart	  failure	  is	  
recommended	  to	  lead	  a	  multidisciplinary	  team	  tasked	  to	  manage	  these	  patients.	  Figure	  5	  shows	  
the	  current	  NICE	  recommended	  pathway	  to	  diagnosis	  of	  heart	  failure.	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Figure	  5:	  NICE	  recommended	  pathway	  for	  diagnosing	  Heart	  Failure.	  (47)	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1.6. Treatment	  of	  Chronic	  Heart	  Failure	  (due	  to	  LVSD)	  
1.6.1. Goals	  of	  Treatment	  
The	   main	   objectives	   of	   treating	   patients	   with	   heart	   failure	   are	   to	   reduce	   symptoms,	   prevent	  
hospitalisations	  and	  to	  reduce	  mortality.	  These	  targets	  are	  achieved	  using	  a	  variety	  of	  strategies	  
that	  are	  complimentary.	  	  
1.6.2. Contemporary	  Pharmacological	  Treatment	  
A	  good	  body	  of	  evidence	  that	  demonstrate	  mortality	  benefit	  supports	  drug	  treatment	  of	  heart	  
failure	   (48-­‐50).	   Provided	   that	   there	   are	   no	   contra-­‐indications,	   all	   patients	   should	   be	   offered	  
disease	  modifying	  drug	  therapy	  that	  includes	  an	  ACE-­‐inhibitor	  or	  Angiotensin	  II	  receptor	  blocker	  
(AIIRB),	   a	   beta-­‐blocker	   and	   a	   mineralocorticoid	   receptor	   antagonist	   (MRA).	   Other	   drug	  
treatments	   include	   the	   use	   Hydralazine	   where	   intolerant	   of	   ACEi	   or	   AIIRBs	   and	   the	   use	   of	  
Ivabradine	   for	   heart	   rate	   reduction	   where	   a	   patient	   has	   failed	   to	   achieve	   optimal	   control	   on	  
maximally	  tolerated	  beta	  blockade	  (51).	  In	  addition,	  diuretics	  are	  usually	  prescribed	  for	  symptom	  
control	  and	  to	  maintain	  euvolaemia.	  (See	  Figure	  6)	  
1.6.3. Non-­‐Surgical	  Device	  Therapy	  
Heart	   failure	  patients	  who	  are	  currently	  experiencing	  or	  have	   recently	  experienced	  NYHA	  class	  
III–IV	  symptoms,	  with	  a	  broad	  QRS	  complex	  on	  ECG	  (>120ms)	  and	  on	  optimal	  drug	  therapy	  are	  
usually	  recommended	  to	  have	  treatment	  with	  Cardiac	  Resynchronisation	  therapy.	  This	  has	  been	  
shown	   to	   improve	   symptoms	   and	   reduce	   mortality	   (52;53).	   Where	   these	   patients	   fulfil	   risk	  
criteria	   for	   sudden	   cardiac	   death,	   an	   Implanted	   Cardioverter	   Defibrillator	   (ICD)	   is	   also	  
recommended	  as	  part	  of	  their	  therapy	  (4;47)	  (54).	  
1.6.4. Treatment	  of	  Co-­‐Morbidities	  
Aggressive	  treatment	  of	  co-­‐morbidities	  including	  Hypertension,	  Diabetes,	  Obesity,	  Anaemia	  and	  
Sleep	   disordered	   breathing	   improves	   outcomes	   in	   these	   patients	   and	   as	   such	   they	   should	   be	  
aggressively	  managed	  (55-­‐58)	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1.6.5. Non	  Pharmacological	  Therapy	  
1.6.5.1. Lifestyle	  Modification	  
Smoking	   cessation	   and	   the	   reduction	   of	   alcohol	   intake	   (10-­‐20g	   per	   day)	   is	   a	   general	  
recommendation	  as	  part	  of	   lifestyle	  changes	  in	  these	  patients.	  Regular	  exercise	  and	  a	  balanced	  
nutrition	  with	  low	  salt	  intake	  (not	  exceeding	  2-­‐3g	  per	  day)	  are	  also	  recommended	  to	  reduce	  risk	  
(4)	  (47).	  
Oxygen	  therapy	   is	  advisable	  for	  patients	  with	  New	  York	  Heart	  Association	  (NYHA)	  class	   III	  or	   IV	  
symptoms	   that	   embark	   on	   air	   travel	   (59).	   Patients	   who	   are	   this	   symptomatic	   are	   usually	  
disqualified	  from	  driving	  low	  or	  heavy	  goods	  vehicles	  (60).	  
1.6.5.2. Multidisciplinary	  Management	  and	  Palliative	  Care	  
An	  integrated	  approach	  for	  managing	  heart	  failure	  patients	  involving	  primary	  and	  secondary	  care	  
is	  usually	  recommended	  and	  end-­‐of-­‐life	  care	  should	  be	  in	  place	  for	  those	  with	  advanced	  forms	  of	  
the	  syndrome.	  	  
A	  summary	  of	  recommended	  treatment	  pathway	  for	  heart	  failure	  due	  to	  left	  ventricular	  systolic	  
dysfunction	  is	  shown	  in	  Figure	  6.	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Figure	  6:	  Treatment	  options	  for	  patients	  with	  chronic	  symptomatic	  systolic	  heart	  failure	  (NYHA	  
functional	  class	  II–IV).	  (4)	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1.7. The	  Burden	  of	  Acute	  Decompensated	  Heart	  Failure	  
Acute	   Decompensation	   of	   Heart	   Failure	   (ADHF)	   is	   associated	   with	   increased	   morbidity	   and	  
mortality	  and	  around	  4-­‐7%	  of	  patients	  who	  suffer	  a	  decompensation	  do	  not	  survive	  to	  hospital	  
discharge	  (27;61).	  This	  rises	  to	  up	  to	  45%	  in	  patients	  who	  were	  admitted	  initially	  in	  cardiogenic	  
shock	   (61).	   Even	   in	   those	   patients	   who	   survive,	   there	   is	   still	   a	   high	   risk	   of	   subsequent	   re-­‐
admission.	  In	  one	  study	  up	  to	  30%	  of	  patients	  who	  were	  discharged	  following	  an	  admission	  with	  
ADHF	  were	  re-­‐admitted	  within	  3	  months	  and	  this	   included	  up	   to	  9%	  who	  also	  died	  during	   this	  
period	  (62).	  In	  the	  United	  Kingdom	  about	  12%	  of	  patients	  who	  are	  admitted	  in	  a	  decompensated	  
state	  of	  heart	  failure	  will	  die	  (63).	  It	  is	  therefore	  desirable	  to	  keep	  patients	  with	  CHF	  as	  stable	  as	  
possible,	   which	   may	   prevent	   progression	   of	   disease	   and	   a	   hospital	   admission	   for	  
decompensation.	  
Deterioration	  of	  heart	  failure	  is	  also	  expensive	  and	  this	  mainly	  relates	  to	  the	  costs	  of	  admitting	  
patients	  into	  hospital	  and	  consequent	  number	  of	  inpatient	  days	  required	  to	  achieve	  stability.	  It	  is	  
estimated	  that	  up	  to	  2%	  of	  the	  NHS	  budget	   is	  spent	  on	  patients	  with	  chronic	  heart	   failure	  and	  
70%	  of	  these	  costs	  relate	  to	  inpatient	  stay	  for	  treatment	  of	  ADHF	  (2).	  
	  
1.8. Definition	  
There	   is	   no	   consensus	   definition	   for	   acute	   decompensated	   heart	   failure	   (ADHF);	   however	   it	   is	  
generally	  agreed	  that	  a	  patient	  has	  arrived	  at	  a	  decompensated	  state	  when	  they	  have	  developed	  
symptoms	  and	  signs	  of	  fluid	  overload	  usually	  to	  the	  extent	  that	  they	  require	  a	  hospital	  admission	  
for	  intravenous	  administration	  of	  diuretics	  to	  ‘offload’.	  	  	  
Acute	  decompensation	  of	  heart	  failure	  (ADHF)	  is	  associated	  with	  a	  rapid	  onset	  of,	  or	  change	  in,	  
symptoms	   and	   signs	   of	   HF.	   It	   is	   usually	   life-­‐threatening	   and	   requires	   immediate	   medical	  
attention,	   which	   usually	   leads	   to	   urgent	   admission	   to	   hospital.	   Diagnosis	   and	   treatment	   are	  
usually	   carried	   out	   in	   parallel,	   especially	   in	   patients	   who	   are	   particularly	   unwell,	   and	  
management	  must	  be	  initiated	  promptly.	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In	   some	   cases,	   expert	   patients	   who	   are	   experienced	   in	   managing	   their	   disease	   may	   avert	   a	  
hospital	   admission	   by	   increasing	   the	   dose	   of	   their	   oral	   diuretics	   at	   the	   first	   sign	   of	   change	   of	  
symptoms	  and	  this	  may	  be	  sufficient	  to	  restore	  stability.	  
1.9. Classification	  
Acute	  heart	   failure	  has	  previously	  been	  classified	  according	   to	  various	  clinical	  presentations	  by	  
the	  European	  Society	  of	  Cardiology	  (ESC)	  (64)	  see	  Table	  2.	  	  
• Acute	  decompensated	  heart	  failure	  (de	  novo	  or	  as	  decompensation	  of	  chronic	  heart	  failure)	  	  
• Hypertensive	  AHF-­‐	  relatively	  preserved	  LVEF	  
• Pulmonary	  oedema	  (verified	  by	  chest	  X-­‐ray)	  
• Cardiogenic	  shock	  –	  characterised	  by	  tissue	  hypoperfusion	  
• High	  output	  Failure-­‐	  for	  example	  in	  Thyrotoxicosis,	  Anaemia,	  and	  Pregnancy	  
• Right	  heart	  Failure	  
Table	  2:	  Clinical	  classification	  of	  acute	  heart	  failure	  syndrome.	  (64)	  
Other	  classifications	   that	  have	  been	  used	   include	   the	  Killip	  and	  Forrester	  classifications	  system	  
but	  these	  have	  only	  been	  validated	  in	  a	  population	  presenting	  with	  acute	  myocardial	  infarction.	  
The	  Killip	  classification	  was	  designed	  to	  provide	  a	  clinical	  estimate	  of	  the	  severity	  of	  myocardial	  
derangement	  in	  the	  treatment	  of	  AMI(65)	  while	  the	  Forrester	  classification	  describes	  four	  groups	  
of	  heart	  failure	  patients,	  according	  to	  clinical	  and	  haemodynamic	  status	  (66)	  .	  
In	   the	   clinical	   setting,	   because	   there	   is	   a	   lot	   of	   overlap	   of	   these	   presentations	   which	   do	   not	  
necessarily	   affect	   the	   management	   goals	   of	   the	   patient,	   this	   method	   of	   classification	   is	   not	  
included	  in	  current	  guidelines	  (4).	  	  
1.10. Risk	  Factors	  For	  Decompensation	  of	  Heart	  Failure	  
Patients	  with	   a	  more	   severe	   form	   of	   the	   heart	   failure	   syndrome	   (higher	   NYHA	   status)	   have	   a	  
higher	   risk	  of	  decompensation.	   In	  addition	  a	  previous	  history	  of	  hospitalisation	   in	   the	   last	  year	  
and	  a	  higher	  resting	  heart	  rate	  attributes	  a	  higher	  risk	  of	  clinical	  destabilisation	  in	  these	  patients	  
(27;67).	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Opasich	  and	  colleagues,	  using	  The	   Italian	  Network	  on	  Congestive	  Heart	  Failure	   (IN-­‐CHF),	  which	  
was	  a	  registry	  of	  2,701	  outpatients	  followed	  by	  133	  cardiology	  centres	  examined	  variables	  that	  
were	  independent	  predictors	  of	  short	  term	  (an	  average	  of	  2	  months	  from	  index	  outpatient	  visit)	  
worsening	  of	  heart	   failure.	   They	   found	   that	   a	  previous	  hospitalization	   for	  HF,	   long	  duration	  of	  
symptoms,	  faster	  heart	  rate,	  atrial	  fibrillation,	  high	  functional	  class,	  ischemic	  aetiology,	  and	  low	  
systolic	  blood	  pressure	  resulted	  as	  independently	  associated	  with	  clinical	  destabilization	  (30).	  See	  
Figure	  7.	  	  
	  
Figure	  7:	  Independent	  predictors	  of	  short-­‐term	  destabilization.	  CHD-­‐coronary	  heart	  disease;	  EF-­‐ejection	  
fraction;	  Na	  -­‐	  natraemia;	  SBP-­‐	  systolic	  blood	  pressure.	  From	  the	  IN-­‐CHF	  Registry	  (30)	  	  
1.11. Precipitants	  
It	   is	   important	   to	   establish	   aetiology	   for	   any	   decompensation	   episode	   as	   this	   provides	   vital	  
information	   for	   the	   index	   treatment	  but	  may	  also	   identify	  preventable	  causes.	  However,	  up	   to	  
50%	  of	  ADHF	  episodes	  have	  no	  readily	  identifiable	  cause	  (30).	  
The	  Randomised	  Evaluation	  of	  Strategies	  for	  Left	  Ventricular	  Dysfunction	  Pilot	  Study	  (RESOLVD),	  
was	  a	  crossover	  study	  where	  768	  patients	  with	  an	  EF	  of	  less	  than	  40%	  were	  randomly	  assigned	  to	  
receive	  an	  ACEi	  or	  AIIRB	  or	  both	   for	  17	  weeks	  and	  then	  randomly	  assigned	  to	  placebo	  or	  beta	  
blockers	   for	   26	  weeks.	  During	   a	   7-­‐month	  period,	   there	  were	  323	  episodes	  of	  worsening	  heart	  
failure	   and	   143	   patients	   required	   hospitalisation.	   The	   factors	   implicated	   in	   these	   episodes	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included,	  non-­‐compliance	  with	  salt	  and	  water	  restriction,	  pulmonary	   infective	  processes	   (20%),	  
study	  medication	   (15%),	   use	   of	   anti-­‐arrhythmic	   drugs	   in	   the	   last	   48	   hours	   (15%),	   arrhythmias	  
(13%),	  calcium	  channel	  blockers	  (13%)	  and	  inappropriate	  reductions	  in	  CHF	  therapy	  (10%)	  (68).	  
In	   the	   European	   Heart	   Failure	   Surveys	   EHFS	   II,	   decompensation	   of	   CHF	   was	   the	   commonest	  
clinical	   presentation	   of	   acute	   heart	   failure	   and	   almost	   25%	   of	   these	   patients	   presented	   as	   a	  
consequence	  of	  acute	  coronary	  ischaemia.	  37%	  of	  patients	  did	  not	  have	  a	  prior	  diagnosis	  of	  heart	  
failure	   and	   in	   these	   patients	   the	   commonest	   cause	   for	   acute	   heart	   failure	  was	   also	   related	   to	  
acute	  coronary	  ischaemia,	  which	  occurred	  in	  42%	  of	  these	  patients	  (69).	  
The	   issue	  of	  compliance	  with	  drug	   therapy	  was	   identified	  as	  causative	  of	  decompensation	   in	  a	  
third	  of	  this	  cohort.	  
Other	   causative	   factors,	   some	   of	  which	   are	   preventable	   that	   have	   been	   identified	   as	   possible	  
triggers	  fore	  ADHF	  are	  listed	  in	  Table	  3	  (24).	  These	  have	  also	  been	  identified	  in	  other	  studies	  and	  
include	  arrhythmia	  (particularly	  atrial	  fibrillation)	  and	  concurrent	  sepsis	  (70;71).	  	  
	  
Table	  3:	  Factors	  Identified	  as	  Precipitating	  Hospital	  Admissions	  for	  Heart	  Failure	  and	  Clinical	  Outcomes:	  
findings	  From	  OPTIMIZE-­‐HF.	  (24)	  
1.12. Pathophysiology	  
Most	  patients	  who	  decompensate	  have	  usually	  been	   in	  a	   stable	   state	  of	  CHF	  with	  appropriate	  
fluid	   balance	   management	   and	   taking	   disease	   modifying	   drug	   therapy.	   There	   is	   however	   a	  
precipitant	  that	  causes	  a	  failure	  of	  the	  compensatory	  mechanisms	  that	  for	  the	  most	  of	  the	  time	  
have	   played	   an	   important	   role	   in	   maintaining	   cardiac	   stability.	   In	   a	   number	   of	   patients,	   no	  
precipitants	  are	  found	  and	  their	  decompensation	  is	  part	  of	  a	  progressive	  heart	  failure	  syndrome,	  
which	  is	  ultimately	  terminal.	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The	   clinical	   presentation	   of	   ADHF	   is	   characterised	   by	   an	   accumulation	   of	   fluid	   within	   the	  
periphery	   (predominantly	   leg	   oedema)	   and	   within	   the	   lung’s	   interstitial	   spaces	   and	   alveolar	  
spaces	   as	   a	   result	   of	   elevated	   left	   ventricular	   filling	   pressures.	   Depending	   on	   the	   aetiology	   of	  
decompensation,	  this	  process	  may	  happen	  over	  hours	  and	  in	  some	  cases	  days	  or	  weeks	  before	  
the	  patient	  is	  symptomatic.	  
1.12.1. Haemodynamic	  Response	  
At	  the	  start	  of	  a	  decompensation,	  there	  is	  a	  failure	  of	  the	  Frank-­‐Starlings	  mechanism	  to	  maintain	  
an	  adequate	  stroke	  volume.	  As	  end	  diastolic	  pressure	  representing	  preload	  of	  the	  left	  ventricle	  
increases,	  left	  atrial	  pressures	  and	  eventually	  pulmonary	  venous	  and	  capillary	  pressures	  increase	  
which	  results	  in	  dysfunction	  at	  the	  level	  of	  the	  alveolar	  basement	  membrane	  and	  overload	  of	  the	  
pulmonary	  lymphatics.	  This	  leads	  to	  protein-­‐poor	  fluid	  transudation	  from	  the	  vessel	  wall	  into	  the	  
alveolar	   spaces	   and	   this	   occurs	   in	   the	   absence	   of	   a	   primary	   change	   in	   the	   permeability	   or	  
integrity	  of	  the	  endothelial	  and	  epithelial	  layers	  of	  the	  pulmonary	  capillaries.	  The	  consequence	  is	  
accumulation	  of	  fluid	  in	  the	  pulmonary	  interstitium,	  then	  alveoli	  and	  ultimately	  airways	  (72).	  	  In	  
addition	  continued	  sodium	  and	  water	  retention	  as	  the	  body	  attempts	  to	  increase	  venous	  return	  
to	  the	  heart	  leads	  to	  further	  fluid	  overload.	  
1.12.2. Neurohormonal	  Response	  
Pulmonary	   congestion	   increases	   the	   work	   of	   breathing	   and	   reduces	   gas	   exchange	   leading	   to	  
tissue	  hypoxia.	  The	  body	  responds	  to	  this	  by	  increasing	  its	  compensatory	  sympathetic	  drive	  and	  
activating	  of	  the	  renin-­‐angiotensin	  aldosterone	  system.	  These	  promote	  further	  sodium	  and	  water	  
retention,	   which	   in	   conjunction	   with	   increased	   pulmonary	   venous	   capillary	   pressures	   and	  
reduced	  plasma	  oncotic	  pressure,	  results	  in	  fluid	  extravasation	  and	  peripheral	  oedema.	  
Further,	  an	  enhanced	  sympathetic	  tone	  results	  in	  tachycardia	  which	  shortens	  diastolic	  filling	  time	  
and	  further	   impairs	   left	  ventricular	  filling,	  while	  peripheral	  vasoconstriction	  raises	  the	  afterload	  
against	  which	  the	  failing	  heart	  now	  has	  to	  work,	  further	  worsening	  the	  situation.	  These	  processes	  
all	   lead	   to	   a	   further	   increase	   in	   left	   ventricular	   end-­‐diastolic	   pressure	   and	   more	   oedema	  
formation	  as	  a	  vicious	  cycle	  ensues.	  
At	  the	  peak	  of	  a	  decompensation	  episode,	  the	  patient	  experiences	  worsening	  of	  their	  symptoms	  
and	  may	  be	  unable	  to	  perform	  usual	  activities	  of	  daily	  living.	  In	  addition,	  the	  patient’s	  usual	  oral	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drug	   therapy	   becomes	   insufficient	   to	   curb	   further	   deterioration.	   As	   a	   result,	   restoration	   to	  
stability	   usually	   involves	   a	   hospital	   admission	  with	   the	   administration	   of	   intravenous	   diuretics	  
and	  in	  some	  cases	  inotropes.	  
	  
1.13. Clinical	  Features	  
Unfortunately	  signs	  and	  symptoms	  of	  CHF	  are	  neither	  sensitive	  nor	  specific	  (73;74).	  Similarly	  in	  a	  
decompensated	  state,	  it	  has	  been	  reported	  that	  between	  10-­‐20%	  of	  patients	  who	  are	  admitted	  
via	   the	   emergency	   department	   may	   have	   initial	   treatment	   for	   an	   alternative	   diagnosis	   for	  
example	  chronic	  obstructive	  airway	  disease	  (75).	  
The	  predominant	  feature	  in	  ADHF	  is	  fluid	  overload.	  This	  may	  present	  as	  symptoms	  of	  worsening	  
dyspnoea	  as	  a	  result	  of	  pulmonary	  congestion	  or	  as	  leg	  oedema	  and	  ascites.	  
It	   is	   important	   to	   note	   that	   while	   increasing	   dyspnoea	   at	   rest	   is	   expected	   to	   be	   a	   common	  
symptom	  at	  presentation,	  as	  little	  as	  32%	  of	  patients	  may	  complain	  of	  this	  at	  an	  admission	  with	  
decompensation.	  (62)	  
The	  pathophysiological	  processes	  leading	  up	  to	  ADHF	  may	  occur	  over	  a	  period	  of	  days	  to	  weeks	  
and	   most	   patients	   may	   have	   accumulated	   litres	   of	   extracellular	   fluid	   before	   they	   become	  
symptomatic.	  	  
Consequently	  the	  clinical	  features	  that	  one	  would	  find	  depend	  largely	  on	  the	  aetiology	  and	  time	  
course	  of	  the	  decompensation.	  Pulmonary	  signs	  for	  instance	  may	  not	  be	  so	  apparent	  if	  there	  has	  
been	   sufficient	   time	   for	   compensatory	   mechanisms	   to	   be	   established,	   such	   as	   lymphatic	  
hypertrophy,	  which	  may	   increase	   the	  capacity	  of	   the	  heart	   to	  deal	  with	  high	  pulmonary	  artery	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! Dyspnoea	  
! Paroxysmal	  Nocturnal	  Dyspnoea	  
! Increasing	  Fatigue	  
! Increased	  leg	  and	  abdominal	  swellings	  
! Raised	  JVP	  
! Lung	  crepitation	  (Bibasal)	  
! Leg	  and	  Sacral	  oedema	  
Table	  4:	  Some	  Symptoms	  and	  Signs	  of	  ADHF	  	  
	  
1.14. Management	  
1.14.1. At	  Home	  Treatment	  
In	  a	  number	  of	  patients	  simple	  advice	  to	  increase	  their	  doses	  of	  oral	  diuretics	  may	  be	  sufficient	  
to	   restore	   stability	   and	   symptomatic	   benefit	   may	   be	   evident	   within	   the	   first	   few	   days	   of	  
institution	   of	   dose	   changes	  with	   a	   return	   to	   baseline	   clinical	   state	   shortly	   thereafter.	   Another	  
measure	  in	  the	  community	  that	  may	  alter	  course	  of	  an	  on-­‐going	  decompensation	  include	  strict	  
adherence	  to	  fluid	  and	  dietary	  salt	  restriction,	  however	  this	  strategy	  may	  be	  more	  effective	  if	  it	  is	  
tailored	  to	  individual	  patient	  requirement	  (76).	  Patients	  may	  receive	  this	  advice	  from	  their	  usual	  
general	  practitioner	  or	  from	  specialist	  heart	  failure	  nurses	  in	  hospital	  or	  within	  the	  community.	  A	  
number	  of	  patients	  are	  also	  experienced	  enough	  to	  alter	  doses	  of	  their	  diuretics	  in	  response	  to	  
their	  symptoms,	  without	  the	  need	  for	  formal	  advice.	  
	  
1.14.2. In-­‐Hospital	  Treatment	  
Some	  patients	  however	  may	  not	   respond	   to	   the	  above	   therapies	   and	  may	   require	   a	  period	  of	  
hospitalisation.	   In	   patients	   who	   present	   with	   severe	   weight	   gain,	   signs	   and	   symptoms	   of	  
pulmonary	   or	   systemic	   congestion;	   major	   electrolyte	   disturbances;	   repeated	   implantable	  
cardioverter-­‐defibrillator	   firings;	   or	   pneumonia,	   it	   may	   be	   prudent	   to	   consider	   hospital	  
admissions	  in	  the	  first	  instance.	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1.14.2.1. Intravenous	  Loop	  Diuretics	  
This	  is	  the	  mainstay	  of	  treatment	  of	  patients	  who	  are	  hospitalised	  for	  treatment	  of	  ADHF	  and	  the	  
commonest	  drug	  used	  in	  clinical	  practice	  is	  intravenous	  Furosemide.	  It	  acts	  mainly	  on	  the	  loop	  of	  
Henle	   and	   reduces	   sodium	   and	   water	   reabsorption	   in	   this	   section	   of	   the	   nephron.	   Its	   other	  
actions	  are	  a	  venodilating	  effect	  similar	  to	  that	  of	  morphine,	  which	  leads	  to	  decrease	  pulmonary	  
congestion	   before	   the	   onset	   of	   diuresis,	   which	   normally	   peaks	   about	   30-­‐60	   minutes	   after	  
administration	  (77).	  
Because	   volume	   overload	   is	   usually	   present	   and	   the	   major	   cause	   of	   the	   most	   distressing	  
symptoms	  in	  these	  patients,	  early	  initiation	  of	  treatment	  is	  advisable.	  Better	  outcomes	  have	  also	  
been	  reported	  with	  this	  prompt	  approach	  (78)	  (79).	  	  
Diuretics	   reduce	   intravascular	   volume,	   lowers	   central	   venous	   and	   capillary	   wedge	   pressures	  
which	  decreases	  pulmonary	  oedema	  and	  results	  in	  better	  cardiac	  output.	  Other	  benefits	  include	  
reductions	  in	  tricuspid	  and	  mitral	  regurgitation,	  consequent	  to	  decreases	  in	  filling	  volumes	  in	  the	  
right	   and	   left	   ventricles	   (80).	   In	   the	  majority	  of	  patients,	   this	   is	   successful	  however,	   treatment	  
may	   be	   complicated	   by	   hypotension,	   worsening	   renal	   function,	   electrolyte	   abnormalities	   and	  
sometimes	   arrhythmia.	   These	   problems	   are	   more	   likely	   where	   aggressive	   and	   higher	   dose	  
diuresis,	   are	   administered	   (81).	   Continuous	   infusion	   diuretic	   therapy	   has	   previously	   been	  
demonstrated	  in	  some	  studies	  (82;83)	  to	  be	  of	  benefit,	  in	  avoiding	  these	  side	  effects.	  However	  a	  
recent	  prospective	  randomised	  control	  trial	  has	  however	  shown	  no	  evidence	  of	  superiority	  of	  a	  
bolus	  over	  a	  continuous	  infusion	  strategy	  at	  either	  low	  and	  high	  doses,	  across	  a	  broad	  range	  of	  
efficacy	  and	  safety	  end	  points	  	  (primary	  efficacy	  end-­‐point	  of	  patient-­‐reported	  global	  assessment	  
of	   symptoms	   [mean	   AUC,	   4236±1440	   with	   boluses	   and	   4373±1404	   with	   continuous	   infusion;	  
P=0.47])	  and	  primary	  safety	  end	  point	  of	  the	  change	  in	  serum	  creatinine	  level	  from	  baseline	  to	  72	  
hours	  (mean	  change	  in	  creatinine	  level,	  0.05±0.3	  mg	  per	  decilitre	  [4.4±26.5	  μmol	  per	  litre]	  with	  
boluses	  and	  0.07±0.3	  mg	  per	  decilitre	  [6.2±26.5	  μmol	  per	  litre]	  with	  continuous	  infusion;	  P=0.45).	  
The	   high-­‐dose	   strategy	   was,	   however	   associated	   with	   greater	   improvement	   in	   a	   number	   of	  
secondary	   outcomes	   (including	   dyspnoea)	   but	   at	   the	   expense	   of	  more	   transient	  worsening	   of	  
renal	  function	  (84).	  	  
In	   the	   acute	   stage	   thiazide	   diuretics	   and	   aldosterone	   antagonists	   are	   less	   potent	   when	   used	  
alone	   and	   the	   former	   is	   known	   the	   cause	   more	   potassium	   losses	   for	   the	   same	   quantity	   of	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diuresis.	  Furthermore,	  where	  there	  is	  severe	  renal	   insufficiency,	  with	  glomerular	  filtration	  rates	  
less	   than	  30ml/min,	   thiazide	  diuretics	  are	   ineffective	   (85).	   In	  patients	  with	   resistant	  peripheral	  
oedema	  (and	  ascites),	  a	  combination	  of	  a	  loop	  and	  a	  thiazide	  produces	  a	  greater	  diuretic	  effect	  
but	  at	  the	  expense	  of	  worsening	  renal	  function	  (86).	  	  
1.14.2.2. Intravenous	  Vasodilators	  
These	  work	  by	  stimulating	  granulocyte	  cyclase	  within	  vascular	  smooth	  muscle	  cells	  to	  cause	  both	  
arterial	  and	  venous	  dilation	  with	  an	  attendant	  fall	  in	  LV	  filling	  pressures,	  increased	  stroke	  volume	  
and	  improved	  cardiac	  output	  without	  been	  arrhythmogenic.	  They	  do	  this	  by	  denitration	  of	  GTN	  
to	   produce	   Nitric	   Oxide	   (NO)	   which	   is	   a	   potent	   activator	   of	   guanylate	   cyclase	   through	   heme-­‐
dependent	  mechanisms.	  The	  most	  commonly	  used	  in	  practice	  is	  Nitroglycerin.	  	  
On	   large	   randomised	   control	   trial,	   The	  Vasodilation	   in	   the	  Management	   of	  Acute	  CHF	   (VMAC)	  
evaluated	  the	  efficacy	  of	  IV	  nitroglycerin	  in	  AHF	  (87).	  285	  patients	  with	  dyspnoea	  at	  rest	  due	  to	  
heart	  failure	  were	  randomized	  to	  IV	  nitroglycerin	  or	  standard	  care	  and	  while	  there	  was	  a	  trend	  
toward	  reduced	  pulmonary	  capillary	  wedge	  pressure	  (PCWP)	  in	  patients	  receiving	  nitroglycerin,	  
there	  was	  no	  difference	   in	   the	   co-­‐primary	   endpoint	   of	   dyspnoea.	  A	  post-­‐hoc	   analysis	   of	   these	  
patients	  however	  showed	  that	  those	  patients	  who	  received	  a	  higher	  dose	  of	  nitroglycerin	  had	  a	  
larger	  reduction	  in	  PCWP.	  
Where	   indicated	   it	   is	   has	   been	   demonstrated	   that	   early	   initiation	   of	   vasodilator	   therapy	   is	  
beneficial	  as	  highlighted	  in	  the	  ADHERE	  trial	  where	  those	  who	  received	  vasoactive	  agents	  within	  
6	  hours	  of	  hospital	  admission,	  had	  a	  significantly	   lower	   in-­‐hospital	  mortality	  rate	  and	   length	  of	  
hospital	  stay	  (62).	  	  
Other	  vasodilators	  such	  as	  Nitroprusside	  have	  been	  used,	  albeit	  infrequently	  in	  the	  Intensive	  care	  
setting,	  but	  usually	  in	  experienced	  hands.	  It	  is	  a	  vasodilator	  agent	  that	  shares	  many	  features	  with	  
nitroglycerin,	  one	  of	  these	  been	  the	  participation	  of	  nitric	  oxide	  in	  the	  vasodilator	  actions	  of	  the	  
drug.	  It	  had	  been	  favoured	  because	  of	  its	  prompt	  and	  short-­‐lived	  action	  allowing	  for	  rapid	  dose	  
titration;	   however	   a	   potentially	   dangerous	   effect	   of	   the	   drug	   is	   cyanide	   accumulation	   during	  
infusions.	   For	   this	   reason	   it	   is	   not	   commonly	   used.	   However	   simultaneous	   administration	   of	  
sodium	   thiosulfate	   provides	   the	   sulphur	   donor	   to	   prevent	   cyanide	   accumulation	   without	  
reducing	  the	  efficacy	  of	  Nitroprusside.	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Nesiritide	   a	   recombinant	   form	   of	   BNP	   and	   vasoactive	   agent	   was	   recently	   found	   have	   neutral	  
benefit	   in	   addition	   to	   standard	   treatment	   for	   ADHF.	   Two	   meta-­‐analyses	   had	   questioned	   its	  
impact	   on	  mortality	   and	   association	  with	  worsening	   renal	   function	   (88;89).	   To	   clarify	   this,	   the	  
ASCEND-­‐HF	   trial	   (Effect	   of	   Nesiritide	   in	   Patients	   with	   Acute	   Decompensated	   Heart	   Failure)	  
randomized	  7141	  patients	  hospitalized	  with	  ADHF	  to	  receive	  either	  nesiritide	  or	  placebo	  for	  24	  
hours	   to	   seven	  days	  on	   top	  of	   standard	   care,	  which	   could	   include	  other	   vasoactive	  drugs.	   The	  
hazard	  ratio	  for	  death	  from	  any	  cause	  or	  hospitalization	  for	  heart	  failure,	  the	  primary	  clinical	  end	  
point,	   for	   nesiritide	   vs	   placebo	   was	   0.93	   (95%	   CI	   0.80-­‐1.08)	   (90).	   This	   drug	   is	   therefore	   not	  
recommended	  for	  routine	  use	  in	  the	  broad	  population	  of	  patients	  with	  acute	  heart	  failure.	  	  
The	  2012	  ESC	  Heart	  Failure	  Guidelines	  recommend	  a	  nitrate	   infusion	  be	  considered	   in	  patients	  
with	  pulmonary	  oedema	  and	  SBP > 110	  mmHg	  to	  reduce	  PCWP	  and	  systemic	  vascular	  resistance	  
(4)	  
1.14.2.3. Inotropes	  
The	   use	   of	   inotropes	   such	   as	   dopamine	   or	   dobutamine	   or	   milrinone	   should	   be	   reserved	   for	  
patients	   who	   have	   advanced	   heart	   failure	   with	   severe	   LV	   systolic	   dysfunction	   and	   severe	  
symptoms	   due	   to	   low	   cardiac	   output;	   such	   as	   hypotension	   and	   end-­‐organ	   dysfunction;	   or	   in	  
those	   who	   are	   refractory	   to	   vasodilator	   or	   diuretic	   therapy.	   The	   reasons	   are	   the	   significantly	  
higher	  incidence	  of	  arrhythmia,	  hypotension	  and	  potential	  to	  worsen	  in	  hospital	  mortality	  that	  is	  
associated	  with	  this	  form	  of	  therapy	  (91).	  In	  some	  UK	  heart	  failure	  centres,	  a	  ‘low-­‐dose’	  (‘renal-­‐
dose’)	   dopamine	   is	   employed	   where	   anecdotal	   evidence	   shows	   this	   dose	   of	   about	   2.5	   -­‐	   5	  
mcg/kg/min	   is	   sufficient	   to	   encourage	   diuresis	   without	   the	   attendant	   arrythmogenicity	  
associated	  with	  higher	  doses.	  	  
1.14.2.4. Ultrafiltration	  (UF)	  
This	  is	  emerging	  as	  a	  useful	  way	  of	  treating	  ADHF	  patients,	  particularly	  those	  who	  are	  refractory	  
to	  or	  develop	  side	  effects/toxicity	  from	  the	  use	  of	   intravenous	  diuretics	  or	   inotropes.	  The	  main	  
benefit	   of	   this	   strategy	   is	   the	   adjustable	   fluid	   removal	   volume	   and	   rates,	   decreased	  
neurohormonal	   activation	   and	   reduction	   in	   the	   development	   of	   electrolyte	   imbalances.	   It	   is	  
however	   an	   invasive	   strategy	   and	   requires	   a	   skilled	   practitioner	   able	   to	   insert	   central	   venous	  
catheters	  as	  well	  as	  a	  hospital	  high	  dependency	  level	  of	  care	  in	  order	  to	  manage	  these	  patients.	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The	   UNLOAD	   trial	   demonstrated	   in	   200	   patients	   that	   UF	   had	   a	   sustained	   clinical	   benefit,	   as	  
indicated	  by	  fewer	  re-­‐hospitalizations	  and	  unscheduled	  HF	  clinic	  or	  emergency	  room	  visits	  in	  this	  
group	  of	  patients	  compared	  with	  standard	  care	  with	  the	  use	  of	  IV	  diuretics	  as	  a	  bolus	  or	  infusion.	  
This	   was	   despite	   both	   strategies	   having	   similar	   overall	   fluid	   losses.	   It	   was	   also	   noted	   by	  
comparing	  isotonic	  fluid	  removed	  by	  UF	  to	  hypotonic	  urine	  removed	  by	  diuretics,	  that	  total	  body	  
sodium	  removal	  was	  more	  effective	  in	  the	  former	  group	  (92).	  
More	   recent	   trials	   have	   been	   less	   impressive.	   The	   Cardiorenal	   Rescue	   Study	   in	   Acute	  
Decompensated	  Heart	   Failure	   (CARRESS-­‐HF)	   trial	   randomized	  188	  patients	  who	  were	  admitted	  
into	   hospital	   with	   acute	   decompensation	   of	   heart	   failure,	   on-­‐going	   congestion	   and	   worsened	  
renal	   function	   to	   ultrafiltration	   or	   stepped	   pharmacologic	   therapy	   within	   10	   days	   of	  
hospitalization	  (93).	  
The	  primary	  endpoint	  was	  the	  bivariate	  change	  from	  baseline	  in	  the	  serum	  creatinine	  and	  body	  
weight,	  assessed	  96	  hours	  after	  randomization.	  UF	  was	  inferior	  to	  pharmacologic	  therapy,	  due	  to	  
an	  increase	  in	  the	  serum	  creatinine	  in	  the	  UF	  group	  (mean	  change	  of	  +0.23 ± 0.7	  mg/dL	  in	  the	  UF	  
group	   vs.	   -­‐0.04 ± 0.53	   mg/dL	   in	   the	   pharmacologic	   therapy	   group,	   p = 0.003).	   There	   was	   no	  
significant	  difference	  in	  weight	  loss	  (5.5 ± 5.1	  kg	  in	  the	  pharmacologic	  therapy	  group	  vs.	  5.7 ± 3.9	  
kg	   in	   the	   UF	   group,	   p = 0.58).	   There	   was	   also	   no	   significant	   difference	   in	   mortality	   or	   re-­‐
hospitalization	   at	   60	   days.	   Further,	   patients	   in	   the	   ultrafiltration	   arm	   had	   significantly	   more	  
serious	  adverse	  events	  over	  60	  days	  of	  follow-­‐up	  (72	  %	  vs.	  57	  %,	  p = 0.03),	  including	  higher	  rates	  
of	  renal	  failure,	  bleeding	  complications,	  and	  intravenous	  catheter-­‐related	  complications.	  
There	  were	  some	  important	  differences	  between	  the	  two	  trials,	  which	  could	  explain	  the	  differing	  
results.	  In	  the	  CARESS-­‐HF	  study,	  patients	  in	  the	  pharmacologic	  arm	  had	  a	  urine	  output	  goal	  of	  3-­‐5	  
Litres	   a	   day	   and	   as	   such	   addition	   of	   thiazides,	   vasodilators	   and	   ionotropes	  were	   permitted	   to	  
achieve	  this.	  This	  is	  in	  comparison	  to	  UNLOAD	  where	  a	  fixed	  dose	  of	  IV	  diuretic	  (at	  least	  twice	  the	  
patients	  admitting	  oral	  dose)	  was	  required	  with	  further	  titration	  only	  at	  the	  clinician’s	  discretion.	  
In	  addition	   in	  CARESS-­‐HF,	  the	  UF	  rate	  was	  fixed	  at	  200	  mL/hour,	  whereas	  UNLOAD	  allowed	  for	  
titration	  of	  rates	  up	  to	  500	  mL/hour.	  
The	  2012	  ESC	  Heart	  Failure	  Guidelines	  currently	  recommend	  that	  loop	  diuretics	  be	  given	  as	  first-­‐
line	  therapy	  to	  treat	  pulmonary	  congestion,	  and	  reserve	  ultrafiltration	  for	  those	  unresponsive	  or	  
resistant	  to	  diuretics	  but	  this	  was	  before	  CARESS-­‐HF	  was	  published	  (4).	  	  
	   59	  
1.14.2.5. Non-­‐Invasive	  Ventilation	  
Non-­‐Invasive	  ventilation	  (NIV)	  with	  Continued	  Pressure	  Airway	  Pressure	  (CPAP)	  or	  Non-­‐Invasive	  
Positive	  Pressure	  Ventilation	  (NIPPV)	  may	  be	  used	  to	  relieve	  symptoms	  of	  dyspnoea	  associated	  
with	  pulmonary	  oedema.	  These	  techniques	  are	  not	  however	  associated	  with	  a	  mortality	  benefit	  
(94).	  	  
The	  current	  recommendation	  therefore	  is	  that	  NIV	  may	  be	  used	  as	  adjunctive	  therapy	  to	  relieve	  
symptoms	   in	  patients	  with	  pulmonary	  oedema	  and	   respiratory	  distress	  or	  who	   fail	   to	   improve	  
with	   pharmacological	   therapy.	   Contraindications	   include	   hypotension,	   vomiting,	   possible	  
pneumothorax,	  and	  depressed	  consciousness	  (4).	  	  
1.14.2.6. Monitoring	  
Treatments	  with	  the	  above	  strategies	  are	  most	  effective	  if	  guided	  by	  daily	  assessments	  of	  patient	  
fluid	  balance	  and	  weight	  to	  assess	   for	  correction	  of	  volume	  overload.	  Frequent	  haemodynamic	  
and	   biochemical	   monitoring	   should	   therefore	   take	   place	   during	   hospitalisation.	   These	   include	  
telemetry	  monitoring	   for	   arrhythmia,	   electrolyte	   and	   serum	  creatinine	   levels.	  Other	   important	  
blood	   tests	   that	   guide	   management	   include	   measurement	   of	   BNP,	   and	   the	   full	   blood	   count.	  
These	  results	  from	  blood	  tests	  in	  particular	  should	  be	  examined	  as	  often	  as	  possible	  as	  a	  number	  
of	  abnormalities	  may	  not	  manifest	  as	  symptoms	  in	  the	  patient.	  	  
The	  management	  of	  ADHF	  remains	  challenging	  even	  when	  the	  patient	  is	  managed	  in	  experienced	  
hands.	   The	  main	   short-­‐term	  goals	  of	   therapy	  are	   to	   relieve	   symptoms,	   treat	   volume	  overload,	  
and	   correct	   hemodynamic	   abnormalities.	   This	   is	   achieved	   by	   reversing	   central	   volume	  
redistribution,	   a	   reduction	   in	   cardiac	   filling	   pressures,	   decreasing	   afterload,	   and	   increasing	  
cardiac	   output.	   Long-­‐term	   goals	   are	   mainly	   to	   prevent	   hospitalisation	   for	   heart	   failure	   and	  
reduce	  mortality.	  
No	   treatment	   strategy	   for	   ADHF	   succeeds	   in	   all	   cases,	   and	   treatment	   has	   to	   be	   tailored	   to	  
individual	  patient	  needs.	  Current	  knowledge	  of	  the	  available	  approaches	  and	  their	  shortcomings	  
is	   useful	   while	   results	   of	   novel	   therapies	   with	   potentially	   more	   favourable	   efficacy	   and	  
tolerability	  profiles	  are	  currently	  been	  evaluated	  (95;96).	  	  
	  
	   60	  
1.15. Predicting	  decompensation	  of	  chronic	  heart	  failure	  using	  
physiological	  variables	  
Multiple	  admissions	  for	  the	  management	  of	  decompensation	  of	  heart	  failure	  are	  associated	  with	  
worsened	   morbidity	   and	   increased	   mortality.	   However	   this	   continues	   to	   happen	   despite	   the	  
advancements	   in	   the	   care	   of	   these	   patients.	   Subjective	   assessments	   of	   degree	   of	   exercise	  
tolerance,	   breathlessness	   and	   changes	   in	   body	   weight	   are	   not	   perfect	   and	   in	   many	   cases	  
unreliable	   as	   predictors	   of	   possible	   deterioration.	   	   As	   a	   consequence,	   health	   care	   systems	  
worldwide	   are	   striving	   to	   develop	   other	   strategies	   that	   may	   help	   reduce	   the	   number	   of	  
hospitalisations	  and	  this	  has	  been	   incorporated	   into	  various	   targets	  set	  by	  health	   funders	   (97).	  
These	   newer	   strategies	   that	   are	   currently	   employed	   include	   telemonitoring	   and	   the	   use	   of	  
variables	   from	   implanted	   devices.	   Some	   of	   these	   parameters	   that	   are	   can	   be	   measured	   are	  
discussed	  below.	  
1.15.1. Weight	  
Daily	  weight	  measurements	   are	   recommended	   in	   international	   guidelines	   as	   a	   useful	   guide	   to	  
monitoring	  volume	  overload	   (4;47).	  This	   is	  most	   reliable	   if	   the	  patients	  are	  consistent	  with	  the	  
method	  and	  time	  they	  weigh	  themselves,	  so	  that	  an	  accurate	  trend	  is	  obtained.	  Furthermore,	  it	  
is	  recommended	  that	  patients	  ‘dry	  weight’	  are	  recorded	  at	  regular	  intervals	  –	  this	  is	  the	  steady	  
weight	   achieved	   after	   any	   adjustments	   to	   diuretics	   and	  when	   they	   are	   least	   symptomatic	   and	  
with	  no	  clinical	  evidence	  of	  fluid	  overload.	  	  
There	  is	  evidence	  that	  in	  patients	  who	  decompensate,	  subtle	  weight	  changes	  may	  be	  evident	  up	  
to	  one	  week	  beforehand,	  (98),	  and	  this	  supports	  current	  guidelines	  that	  recommend	  that,	  rather	  
than	  an	  absolute	  weight	  change,	  more	  sensitive	  and	  specific	  as	  a	  pointer	   towards	  potential	  HF	  
decompensation,	  is	  a	  trend	  increase	  of	  more	  than	  2	  kg	  over	  a	  period	  of	  72	  hours	  (64).	  
Simple	  ‘rule	  of	  thumb’	  guidelines	  have	  also	  been	  used	  to	  predict	  decompensation	  of	  heart	  failure	  
by	  alerting	  clinicians	  to	  respond	  to	  a	  1.36kg	  increase	  in	  weight	  over	  a	  24-­‐hour	  period	  for	  instance	  
(99)	  but	  these	  are	  largely	  unreliable	  owing	  to	  considerable	  daily	  weight	  fluctuations	  that	  may	  not	  
be	  related	  to	  worsening	  of	  heart	  failure.	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Moreover,	  a	  more	  recent	  study	  which	  trialled	  an	  alert	  system	  based	  on	  weight	  thresholds	  that	  
were	  in	  proportion	  to	  and	  individualised	  to	  each	  patients	  natural	  weight	  variability	  rather	  than	  a	  
single	  absolute	  weight	  threshold,	  showed	  that	  this	  system	  was	  significantly	  more	  sensitive	  (82%)	  
compared	   to	  guideline	  weight	   thresholds	   (21%)	  or	   rule	  of	   thumb	   thresholds	  of	  1.36kg	  over	  24	  
hours	   (46%).	   	   Specificity	   was	   however	   not	   significantly	   different	   between	   the	   two	   methods	  
(<40%)	  (100).	  	  
Even	   so,	   weight	   measurements	   are	   not	   very	   accurate	   at	   predicting	   decompensation.	   An	  
outpatient	   analysis	   of	   77	   patients	   found	   that	   a	   weight	   gain	   of	   more	   than	   2	   kg	   over	   48–72	   h	  
demonstrated	   good	   specificity	   (97%)	   but	   poor	   sensitivity	   (9%)	   for	   predicting	   clinical	  
deterioration.	  A	  weight	  increase	  of	  more	  than	  2%	  above	  dry	  weight	  had	  a	  similar	  specificity	  (94%)	  
with	  only	  marginal	   improvement	   in	  sensitivity	   (17%).	   In	  spite	  of	   the	  high	  specificities	  obtained,	  
these	   results	   suggest	   that	   the	   lack	   of	   such	   a	   change	   in	   weight	   cannot	   be	   taken	   to	   exclude	  
decompensation	  (101).	  	  
Even	  in	  patients	  studied	  with	  more	  severe	  heart	  failure	  (EF<30%),	  the	  more	  recent	  WISH	  (Weight	  
Monitoring	   in	  Severe	  Heart	   Failure)	   trial	  which	   took	  place	   in	  6	  Swedish	   centres,	  demonstrated	  
that	  more	  frequent	  monitoring	  of	  weight	  via	  electronic	  scales	  in	  the	  intervention	  group,	  did	  not	  
result	   in	  a	   reduction	  of	   the	  primary	  end-­‐point	  which	  was	  cardiac	   re-­‐hospitalisation.	   [Control	  vs	  
Intervention	  70/153	  vs	  70/166;	  Hazard	  Ratio	  0.90,	  CI	  0.61-­‐1.13;	  p=0.24)	  (102).	  
Weight	   gain	   on	   its	   own	   is	   therefore	   not	   sensitive	   enough	   to	   detect	   HF	   deterioration	   (101).	  
Furthermore,	   it	  has	  also	  been	  shown	  that	  not	  all	  decompensation	  episodes	  are	  associated	  with	  
observed	  weight	   gain	   (103).	  A	   theory	  explaining	   this	   is	   that	  during	  a	  decompensation	  of	  heart	  
failure,	   fluid	   redistribution	   into	   ‘third’	   spaces	   as	   opposed	   to	   an	   actual	   increase	   in	   the	   fluid	  
overload,	  predominates	  (104)	  .	  	  
Regardless	  of	  these	   limitations,	  the	  ease	  of	  monitoring	  makes	   it	  recommended	   in	   international	  
guidelines	  especially	  in	  the	  outpatient	  setting	  to	  guide	  diuretic	  management	  and	  when	  combined	  
with	  other	  variables	  may	  be	  useful	  in	  predicting	  episodes	  of	  deterioration	  (4)	  (105).	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1.15.2. Symptoms	  
Common	   symptoms	   that	   are	   associated	  heart	   failure	  decompensation	   include	  orthopnoea,	   leg	  
swellings	  and	  exercise	  intolerance	  (See	  Figure	  8).	  Less	  specific	  symptoms	  such	  as	  fatigue	  may	  also	  
occur.	  A	  high	  percentage	  of	  patients	  may	  be	  aware	  of	  their	  symptoms	  for	  a	  number	  of	  weeks	  and	  
only	  seek	  help	  when	  their	  symptoms	  become	  unbearable	  (26).	  
	  
Figure	  8:	  Common	  symptoms	  associated	  with	  ADHF	  and	  Duration	  of	  Worsening	  Symptoms	  before	  
Admission	  for	  Heart	  Failure	  (n-­‐83	  Patients)	  (26).	  
Unfortunately	  symptoms	  are	  very	  subjective	  and	  attempts	  at	  standardizing	  responses	  which	  has	  
been	  used	  in	  telemonitoring	  systems	  for	  instance,	  can	  be	  frustrating	  to	  the	  patient,	  who	  cannot	  
always	   ‘box’	   their	   symptoms	   into	   set	   categories.	   They	   are	   therefore	   not	   very	   reliable	  
assessments.	  The	  New	  York	  Heart	  Association	  (NYHA)	  classification	  of	  HF	  is	  a	  standard	  scale	  that	  
is	   utilised	   by	   health	   care	   professionals	   to	   grade	   the	   severity	   of	   HF	   according	   to	   patients’	  
functional	   limitation	   (106).	   It	   is	   a	   tool	   that	   is	   delivered	  by	   asking	   patients	   set	   questions	   about	  
their	   exercise	   capacity.	   Again	   because	   of	   its	   subjective	   nature,	   in	  many	   cases	   patients	   over	   or	  
under	   estimate	   their	   abilities.	   It	   is	   therefore	   limited	   by	   its	   poor	   sensitivity	   and	   poor	  
reproducibility	  among	  clinicians	  and	  amongst	  patients	  (107).	  
Peripheral	  oedema	  is	  usually	  evaluated	  from	  ankle	  pitting	  and	  this	  is	  often	  done	  in	  routine	  clinic	  
examinations.	  Most	   patients	  may	   notice	  when	   there	   is	   a	  marked	   increase	   in	   the	   size	   of	   their	  
ankles	  –helped	  by	  the	  fact	  that	  their	  shoes	  do	  not	  fit	  –	  but	  by	  this	  time	  there	  may	  be	  in	  excess	  of	  
5	  L	  of	  fluid	  overload.	  Similarly	  fluid	  accumulation	  in	  the	  abdomen	  as	  evident	  by	   increased	  girth	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may	  not	  be	  immediately	  noticeable	  in	  the	  initial	  stages	  to	  the	  patient	  and	  as	  such	  they	  may	  not	  
report	  it.	  	  
1.15.3. Blood	  Pressure	  	  
Non-­‐invasive	   blood	   pressure	   monitoring	   is	   relatively	   easy	   to	   evaluate	   and	   patients	   who	   have	  
home	  monitoring	  systems,	  utilise	  wrist	  or	  brachial	  cuff	  measurements	  for	  this	  purpose	  (5).	  Poorly	  
controlled	   hypertension	   can	   precipitate	   decompensation	   of	   CHF	   so	   this	   can	   be	   a	   useful	  
monitoring	  tool.	  In	  addition,	  a	  low	  systemic	  blood	  pressure	  with	  resulting	  symptoms	  of	  postural	  
hypotension	  may	  be	  an	  early	   indicator	  of	  over	  diuresis	  or	  high	  doses	  of	  neurohormonal	  agents	  
used	  to	  manage	  heart	  failure.	  	  
1.15.4. Heart	  Rate	  Variability	  Monitoring	  and	  Arrhythmia	  
CHF	  is	  associated	  with	  autonomic	  dysfunction,	  which	  can	  be	  quantified	  by	  measuring	  Heart	  Rate	  
Variability	   (HRV).	   This	   can	   provide	   independent	   information	   on	   the	   risk	   of	   death	   in	   ambulant	  
outpatients	  with	  CHF.	  Patients	  with	   implanted	  devices	  such	  as	  pacemakers	  or	  defibrillators	  can	  
have	  this	  parameter	  analysed,	  which	  can	  be	  used	  to	  guide	  management.	  	  
In	  the	  UK-­‐Heart	  study,	  which	  was	  a	  prospective	  study	  of	  433	  patients	  with	  CHF,	  HRV	  was	  shown	  
to	  be	  a	  powerful	  predictor	  of	  mortality,	  with	  a	  risk	  ratio	  for	  a	  41.2-­‐ms	  decrease	  in	  HRV-­‐	  measured	  
by	   the	   standard	   deviation	   of	   normal-­‐to-­‐normal	   RR	   intervals	   on	   24	   hour	   ambulatory	   ECG	  
monitoring	  (SDNN),	  of	  1.62	  (95%	  CI,	  1.16	  to	  2.44)(108).	  The	  annual	  mortality	  rate	  for	  the	  study	  
population	  in	  SDNN	  subgroups	  was	  5.5%	  for	  >100	  ms,	  12.7%	  for	  50	  to	  100	  ms,	  and	  51.4%	  for	  <50	  
ms.	  
Adamson	  and	  colleagues	  demonstrated	  the	  usefulness	  of	  this	  measure,	  in	  a	  study	  of	  288	  patients	  
with	   implanted	   devices	   and	  moderate	   to	   severe	   heart	   failure.	   They	   found	   that	   HRV	  was	   70%	  
sensitive	  at	  detecting	  hospitalisations	  but	  also	  found	  that	  it	  had	  a	  high	  false	  positive	  rate	  with 2.4	  
false-­‐positives	  per	  patient-­‐year	  of	   follow-­‐up	   (109).	  A	  disadvantage	   is	   the	   requirement	   for	   sinus	  
rhythm	   and	   non-­‐atrially	   dependent	   pacing	   which	   may	   make	   this	   impractical	   to	   measure	   in	  
certain	  patients.	  
Arrhythmia	   is	   a	   common	   cause	   of	   decompensation	   (30)	   so	   it	   is	   useful	   to	   assess	   for	   this.	  
Ventricular	  arrhythmia	  can	  be	  fatal	  while	  atrial	  arrhythmia	  may	  be	  a	  precursor	  to	  deterioration	  in	  
symptoms.	  Some	  home	  telemonitoring	  systems	  have	  single	  lead	  ECG	  as	  part	  of	  the	  recording	  but	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perhaps	   much	   easier	   to	   assess	   is	   the	   continuous	   automatic	   data	   collected	   from	   readings	   of	  
implanted	  devices	  such	  as	  pacemakers	  and	  implanted	  cardioverter	  defibrillators.	  	  
1.15.5. Pulmonary	  Artery	  Pressure	  Monitoring	  
This	   is	   a	   relatively	   new	   but	   invasive	   means	   of	   monitoring	   patients	   with	   heart	   failure.	   The	  
rationale	   for	   exploring	   this	   area	   is	   based	   on	   evidence	   that	   suggest	   an	   increase	   in	   pulmonary	  
diastolic	  pressures	  as	  patients	  move	  from	  a	  chronic	  stable	  to	  acute	  decompensated	  state	  of	  heart	  
failure	  (110).	  	  
The	  COMPASS-­‐HF	  (Chronicle	  Offers	  Management	  to	  Patients	  with	  Advanced	  Signs	  and	  Symptoms	  
of	   Heart	   Failure)	   study	   was	   a	   prospective,	   multicentre,	   randomized,	   single-­‐blind,	   parallel-­‐
controlled	  trial	  of	  134	  advanced	  HF	  patients	  (NYHA	  III	  or	  IV)	  who	  were	  randomised	  to	  receive	  an	  
implantable	   continuous	   hemodynamic	   monitor	   (Chronicle,	   Medtronic	   Inc.,	   Minneapolis,	  
Minnesota)	  where	  continuous	  intra-­‐cardiac	  pressure	  monitoring,	  including	  estimated	  pulmonary	  
arterial	   diastolic	   pressures,	  was	   used	   to	  manage	   volume	   status	   in	   addition	   to	   optimal	  medical	  
therapy.	  The	  control	  group	  consisted	  of	  140	  similar	  patients	  where	  management	  of	  HF	  was	  only	  
by	   usual	   guideline	   recommended	   care.	   There	   was	   a	   21%	   lower	   rate	   of	   all	   HF-­‐related	   events	  
compared	  with	  the	  control	  group	  but	  this	  was	  not	  statistically	  significant	  (p	  =	  0.33)(111).	  
Further	  studies	  using	  this	  method	  have	  been	  more	  promising.	  The	  CHAMPION	  trial	  (CardioMEMS	  
Heart	   Sensor	   Allows	  Monitoring	   of	   Pressure	   to	   Improve	   Outcomes	   in	   NYHA	   Class	   III	   Patients)	  
randomised	  patients	  to	  a	  treatment	  group	  where	  their	  heart	  failure	  was	  managed	  based	  on	  daily	  
measurement	   of	   pulmonary	   artery	   pressures	   in	   addition	   to	   standard	   care,	   or	   a	   control	   group	  
where	  they	  were	  managed	  based	  on	  standard	  care	  alone.	  They	  were	  able	  to	  demonstrate	  a	  37%	  
reduction	   in	   heart-­‐failure-­‐related	   hospitalisation	   with	   this	   strategy	   of	   management	   compared	  
with	  the	  control	  group	  (158	  vs	  254,	  HR	  0·∙63,	  95%	  CI	  0·∙52—0·∙77;	  p<0·∙0001)	  (112).	  	  
1.15.6. Intrathoracic	  Impedance	  (IMP)	  
IMP	  is	  a	  measure	  of	  the	  resistance	  against	  electrical	  current	  passing	  across	  the	   lung	  field.	  Fluid	  
conducts	   better	   than	   air	   and	   as	   such	  when	   there	   is	   accumulation	   of	   intrathoracic	   fluid	   during	  
pulmonary	   congestion,	   this	   form	   a	   better	   conductance	   medium	   and	   impedance	   falls.	   The	  
correlation	  between	  LV	  filling	  pressures	  and	  IMP	  is	  therefore	  inversed,	  that	  is,	  it	  decreases	  when	  
there	  is	  evolving	  fluid	  accumulation	  within	  the	  thoracic	  cage.	  In	  HF	  patients,	  serial	  measurements	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of	   thoracic	   impedance	   have	   been	   demonstrated	   to	   reflect	   pulmonary	   fluid	   status	   and,	  
importantly,	   as	   shown	   in	   a	   small	   study,	   have	   the	   ability	   to	   predict	   HF	   decompensation	   even	  
before	   the	   onset	   of	   symptoms	   (113).	   Many	   implanted	   devices	   can	   collect	   this	   data	   and	   its	  
usefulness	  will	  be	  discussed	  in	  the	  next	  sections.	  
1.16. Home	  and	  Telemonitoring	  Related	  Variables	  
Telemonitoring	  (TM)	  in	  general	  refers	  to	  monitoring	  patients	  who	  are	  not	  at	  the	  same	  location	  as	  
the	  health	  care	  provider.	  These	  patients	  are	  usually	  at	  home	  and	  send	  clinical	   information	  that	  
can	  be	  used	  to	  manage	  their	  conditions	  by	  telephone	  to	  their	  managing	  health	  care	  providers.	  
Most	   of	   these	   systems	   also	   involve	   subjective	   questioning	   regarding	   the	   patient's	   health	   and	  
comfort	  which	  takes	  place	  over	  the	  phone,	  or	  telemonitoring	  software.	  	  
A	   more	   specific	   definition	   of	   Telemonitoring	   (TM)	   in	   heart	   failure	   is	   the	   use	   of	   non-­‐invasive	  
measurements	   such	   as	   blood	   pressure	   and	  weight	   in	   addition	   to	   questions	   that	   cover	   general	  
health	  and	  symptoms	  to	  monitor	  the	  clinical	  status	  of	  patients	  with	  chronic	  heart	  failure.	  
A	  Cochrane	  meta-­‐analysis	  published	  by	  Inglis	  and	  colleagues,	  where	  8323	  patients	  who	  received	  
Telemonitoring	   (Telemonitoring	   and/or	   Structured	   Telephone	   Support	   <STS>)	   as	   the	   primary	  
component	  of	  their	  CHF	  management	  demonstrated	  a	  reduction	  in	  all-­‐cause	  mortality	  [	  (RR)	  0.66	  
[95%	  confidence	  interval	  (CI)	  0.54–0.81],	  P<	  0.0001]	  in	  the	  TM	  	  arm.	  	  STS	  showed	  a	  similar,	  but	  
non-­‐significant	  trend	  towards	  improved	  survival	  [RR	  0.88	  (95%	  CI	  0.76–1.01),	  P=	  0.08].	  However	  
both	  TM	  [RR	  0.79	  (95%	  CI	  0.67–0.94),P=	  0.008],	  and	  STS	  [RR	  0.77	  (95%	  CI	  0.68–0.87),	  P<	  0.0001]	  
reduced	   CHF-­‐related	   hospitalizations,	   improved	   quality	   of	   life,	   reduced	   costs,	   and	   were	  
acceptable	  to	  patients	  (5)	  
The	   weight	   monitoring	   in	   heart	   failure	   trial	   (WHARF-­‐HF)	   was	   one	   of	   the	   first	   clinical	   trials	   to	  
evaluate	  the	  impact	  of	  technologically	  driven	  interventions,	  which	  monitor	  weight	  and	  symptoms	  
to	  manage	  heart	   failure.	   The	  end-­‐points	   included	  hospitalisations,	  mortality	   and	  patients’	   self-­‐
assessed	  quality	  of	  life.	  	  
Two	  hundred	  and	  eighty	  patients	  were	  randomised	  to	  a	  usual	  care	  group	  consisting	  of	   routine	  
outpatient	  appointments	  and	   follow	  up	  with	  community	  nurses	  or	  a	  device	  care	  group,	  where	  
they	  received	  an	  electronic	  scale	  that	  transmitted	  daily	  weights	  twice	  a	  day	  and	  an	  online	  daily	  
symptoms	  questionnaire.	  There	  was	  no	  difference	   in	  the	  primary	  end	  point	  of	  hospital	   first	  re-­‐
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hospitalisation	   after	   180	   days	   however	   there	   was	   a	   52%	   reduction	   in	   mortality	   for	   patients	  
randomised	  to	  the	  device	  group	  (114).	  
TELE-­‐HF	  represented	  the	  single	   largest	  trial,	  which	  evaluated	  TM	  of	  patients	  with	  chronic	  heart	  
failure,	  and	  evaluated	  1653	  patients	  who	  were	  randomised	  equally	  to	  either	  receive	  a	  telephone	  
based	  system	  of	  monitoring	  and	  management	  of	  their	  heart	  failure	  or	  usual	  care.	  There	  were	  no	  
benefits	   seen	   in	   the	   primary	   end-­‐point	   of	   reducing	   re-­‐hospitalisation	   rates	   or	  mortality	   in	   the	  
treatment	  group	  compared	  to	  usual	  care	  arm.	  Furthermore	  there	  was	  no	  benefit	  seen	  in	  any	  of	  
the	   pre-­‐specified	   secondary	   endpoints	   and	   sub	   group	   analysis	   did	   not	   demonstrate	   any	  
significant	  differences	  between	  either	  groups	  (115).	  	  
There	   is	   the	  argument	  that	   the	  patients	   in	   the	  Tele-­‐HF	  study	  were	  younger	  than	   in	  most	  heart	  
failure	   studies	   (median	   age	   was	   61years)	   however	   these	   patients	   had	   a	   wide	   range	   of	   co-­‐
morbidities	   and	   the	   majority	   were	   at	   class	   NYHA	   III	   at	   enrolment.	   There	   was	   also	   a	   huge	  
commitment	   to	   adhering	   to	   the	   protocol	   and	   responding	   to	   system	   alerts	   by	   the	   trialists,	  
including	  making	  a	   significant	  effort	   towards	  ensuring	  active	  patient	  participation.	   It	   has	   to	  be	  
noted	  that	  adherence	  to	  intervention	  was	  still	  low	  at	  45%	  and	  14%	  did	  not	  even	  use	  it.	  
Following	   this,	   another	   large	   prospective	   randomised,	   multicentre	   trial,	   TIM-­‐HF,	   examined	   if	  
physician-­‐led	  remote	  telemedical	  management	  (RTM)	  compared	  with	  usual	  care	  would	  result	  in	  
reduced	  mortality	  in	  ambulatory	  patients	  with	  chronic	  heart	  failure.	  This	  study	  failed	  to	  confirm	  
the	  benefits	  seen	  in	  the	  aforementioned	  meta-­‐analysis	  (116).	  
These	   studies,	   have	  measured	   variables	   that	   include	  a	   combination	  of	  weight,	   blood	  pressure,	  
heart	  rate,	  pulse	  oximetry,	  12	  lead	  electrocardiographs,	  in	  addition	  to	  symptoms.	  (See	  Table	  5	  for	  
summary).	  Only	  a	  few	  of	  these	  studies	  have	  measured	  the	  outcome	  when	  investigators	  respond	  
to	   changes	   in	   one	   variable	   and	   most	   of	   the	   results	   from	   these	   published	   studies	   are	   a	  
consequence	  of	  outcomes	  relating	  to	  responses	  from	  a	  combination	  of	  variables.	  	  
The	  Whole	  Systems	  Demonstrator	  Telehealth	  trial,	  n=3230	  was	  a	  large	  UK	  department	  of	  health	  
funded	   trial	   designed	   to	   test	   the	   benefits	   of	   integrated	   health	   and	   social	   care	   supported	   by	  
assistive	  technologies	  on	  outcomes	  in	  patients	  with	  the	  long-­‐term	  conditions	  of	  Diabetes,	  COPD	  
and	  Heart	  Failure.	  
The	   primary	   endpoint	   was	   an	   improvement	   in	   health	   related	   quality	   of	   life	   or	   psychological	  
outcomes	   obtained	   from	   questionnaires	   that	   assessed	   generic,	   health	   related	   quality	   of	   life,	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anxiety	  and	  depressive	  episodes	  at	  4	  and	  12	  months	  after	  recruitment.	  The	  initial	  report	  of	  these	  
patients	   who	   were	   recruited	   from	   3	   regions	   in	   England	   (Cornwall,	   Kent	   and	   Newham)	   and	  
randomised	  to	  an	  interventional	  arm	  (n=	  845)	  where	  they	  received	  telehealth	  and	  a	  control	  arm	  
where	   they	   continued	   with	   usual	   care	   alone	   (n=728)	   demonstrated	   only	   a	   small	   and	   non-­‐
significant	  difference	  for	  all	  outcomes	  (telecare	  vs	  usual	  care)	  either	  using	  an	  intention-­‐to-­‐treat	  
(0.480≤P≤0.904)	   or	   per-­‐protocol	   analysis	   (0.273≤P≤0.761).	  Of	   note,	   42%	   of	   these	   patients	   had	  
heart	  failure	  (117).	  
Clearly	   these	   systems	   can	   sometimes	   be	   complex	   and	   determining	   which	   components	   are	  
beneficial	  is	  equally	  challenging	  especially	  as	  there	  is	  a	  huge	  variation	  in	  technological	  and	  inter-­‐
patient	  dynamics.	  There	  remains	  no	  real	  consensus	  on	  which	  variable	  or	  combination	  of,	  are	  the	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  Positive	  34%	  
reduction	  vs	  UC 
p<0.0001 





TM	  8.4%	  v	  UC	  
8.7%	  p	  0.87 
Table	  5:	  Summary	  of	  Key	  Variables	  from	  Telemonitoring	  Studies.	  (UC	  –	  Usual	  Care,	  ER-­‐Emergency	  
Room,	  TM	  –	  Telemonitoring,	  OPD	  –	  Outpatients	  Department,	  BP	  –	  Blood	  Pressure,	  HR	  –	  Heart	  Rate,	  ECG	  
–	  Electrocardiogram,	  6MWT	  –	  6-­‐minute	  walk	  test)	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1.17. Device	  Related	  Variables	  
Implanted	  devices,	  which	  include	  pacemakers	  and	  defibrillators,	  are	  also	  able	  to	  measure	  other	  
parameters	  that	  can	  be	  collected	  on	  a	  daily	  basis.	  These	  include	  Intrathoracic	  impedance	  (IMP),	  
which	   is	   a	   surrogate	   for	   volume	   status,	   arrhythmia	   burden	   (Ventricular	   Tachycardia,	   Atrial	  
Fibrillation),	  heart	  rate	  variability	  (HRV)	  as	  well	  as	  patients’	  symptoms.	  	  
The	   device	   related	   variables	   have	   the	   advantage	   of	   not	   always	   requiring	   patient	   initiation	   for	  
collection	   and	   as	   a	   result,	   in	   theory	   could	   be	   collected	   more	   robustly.	   No	   single	   system	   is	  
however,	  completely	  fail-­‐safe.	  
The	  Medtronic	   Impedance	   in	  Diagnostics	   in	  HF	   Trial	   (MID-­‐Heft)	   study	   retrospectively	   analysed	  
IMP	  data	  from	  33	  patients	  with	  NYHA	  III	  or	  IV	  heart	  failure	  and	  demonstrated	  a	  good	  correlation	  
between	   decompensation	   episodes	   and	   a	   fall	   in	   IMP	   that	   occurred	   at	   the	   time.	   They	   also	  
observed	  a	  good	  correlation	  between	  the	  fall	  in	  PCWP	  and	  rise	  in	  IMP	  that	  followed	  treatment.	  
Interestingly,	   when	   recommended	   thresholds	   were	   employed;	   one	   could	   potentially	   predict	  
these	  decompensation	  episodes	  up	  to	  30	  days	  prior	  to	  their	  occurrence	  (118).	  
The	  Fluid	  Accumulation	  Status	  Trial	   (FAST)	   trial	   looked	  at	   concurrent	   serial	   IMP	  measurements	  
and	  weight	  changes,	   in	  156	  NYHA	  II-­‐II	  patients	  who	  had	  an	   ICD	  or	  CRT-­‐D.	   It	  demonstrated	  that	  
weight	  gain	  data	  on	   its	  own	  was	   less	   sensitive	   than	   IMP	  data	   in	  predicting	  decompensation	  of	  
heart	  failure	  but	  combining	  both	  information	  improved	  the	  specificity	  (119).	  	  
The	  Program	  to	  Access	  and	  Review	  Trending	  Information	  and	  Evaluate	  Correlation	  to	  Symptoms	  
in	  Patients	  with	  HF	  (PARTNERS	  HF)	  was	  a	  prospective	  unblinded	  observational	  study	  that	  showed	  
that	  a	  combined	  algorithm	  which	   included	  IMP	  and	  multiple	  non-­‐IMP	  parameters	  such	  as	  HRV,	  
duration	  of	   atrial	   fibrillation	   and	  patient	   activity,	   identified	   a	   cohort	   of	   patients	   at	   high	   risk	  of	  
experiencing	   a	  HF	   event	  within	   the	   subsequent	  month.	   It	   also	   showed	   a	   link	   between	  patient	  
reported	  HF	  self-­‐management	  and	  the	  likelihood	  of	  IMP	  data	  crossing	  pre-­‐determined	  thresholds	  
suggestive	  of	  a	  decompensation	  (120).	  
The	  Sensitivity	  of	  the	  InSync	  Sentry	  OptiVol	  Feature	  for	  the	  Prediction	  of	  HF	  (SENSE-­‐HF)	  and	  the	  
Diagnostic	  Outcome	  Trial	  in	  HF	  (DOT-­‐HF)	  are	  the	  more	  recent	  trials	  that	  have	  employed	  various	  
device-­‐based	  parameters	  to	  assess	  the	  potential	  for	  decompensation.	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SENSE-­‐HF	  was	  a	  large	  prospective,	  multicentre,	  double	  blind	  study	  that	  evaluated	  an	  impedance-­‐
based	  algorithm,	  OptiVol	  (Medtronic,	  Inc.,	  Minneapolis,	  MN,	  USA),	  in	  501	  NYHA	  class	  II	  and	  class	  
III	  HF	  patients	  implanted	  with	  CRT-­‐D	  devices.	  Using	  OptiVol,	  the	  trial	  results	  demonstrated	  a	  low	  
sensitivity	  of	  42%	  and	  low	  positive	  predictive	  value	  of	  only	  38%	  for	  future	  HF	  events	  that	  is	  from	  
6	   months	   to	   24	   months	   post	   implantation.	   In	   the	   early	   period	   (34	   days	   to	   6	   months),	   post	  
implantation,	  the	  algorithm	  fared	  even	  worse	  with	  a	  sensitivity	  of	  20.7%	  and	  positive	  predictive	  
value	  of	  4.7%	  (121).	  
(DOT-­‐HF)	  was	   a	   large	   prospective	   phase	   IV	   RCT	   designed	   to	   test	  whether	  monitoring	   of	   intra-­‐
thoracic	   impedance	   (OptiVol)	   could	   reduce	   morbidity	   and	   mortality	   in	   patients	   with	   chronic	  
NYHA	   classes	   II-­‐IV	   HF.	   	   All	   study	   subjects	   were	   implanted	   with	   an	   ICD	   or	   CRT-­‐D	   capable	   of	  
monitoring	   impedance	   (Medtronic	   Inc.),	   and	   randomised	   to	   have	   all	   device-­‐based	   information	  
(including	   audible	   alerts	   for	   preset	   fluid	   threshold	   crossings)	   available	   to	   patients	   and	   doctors	  
(access	   group)	   or	   to	   a	   control	   group	   without	   that	   information.	   The	   primary	   endpoint	   was	   a	  
composite	   of	   all-­‐cause	  mortality	   and	   HF	   hospitalisation,	   and	   this	   occurred	   in	   48	   of	   168	   (29%)	  
patients	   in	   the	  access	  arm	  versus	  33	  of	  167	   (20%)	   in	   the	  control	  arm	   (p=0.063).	  Unfortunately	  
there	  was	  also	  a	  79%	  increase	  in	  HF	  hospitalisations	  in	  the	  access	  arm	  (122).	  	  
In	  some	  of	  these	  studies,	   the	  excessive	  number	  of	   false	  positive	  alerts,	  which	  resulted	   in	  more	  
frequent	   hospitalisations,	   remains	   a	   problem.	   This	   has	   resulted	   in	   difficulty	   in	   broader	  
implementation	  of	  this	  technology	  in	  current	  clinical	  practice.	  
These	  algorithms	  for	  detection	  as	  well	  as	  the	  notifications	  or	  alerts	  that	  detected	  abnormalities	  
produce,	  are	  been	  improved	  upon.	  The	  on-­‐going	  OptiLink-­‐HF	  Study	  is	  one	  such	  substantial	  study	  
with	   an	   improved	   design,	   which	   would	   look	   at	   IMP	   monitoring	   (OptiVol)	   with	   wireless	  
transmission	  of	  alerts	  versus	  usual	  care.	  The	  target	  is	  to	  recruit	  1000	  patients	  to	  demonstrate	  a	  
30%	   reduction	   in	   the	   primary	   outcome	   (composite	   of	   all-­‐cause	   death	   or	   cardiovascular	  
hospitalisation)	  (123)	  
Other	   invasive	   technologies	   looking	   at	   continuous	   hemodynamic	   monitoring	   of	   Left	   atrial	  
pressures,	   right	  ventricular	  pressures	  and	  pulmonary	  capillary	  wedge	  pressures	  have	  produced	  
varying	  results	  (111;112;124).	  There	  of	  course	  remains	  the	  practicability	  and	  cost	  effectiveness	  of	  
using	  such	  measures	  in	  a	  day-­‐to-­‐day	  management	  of	  ambulatory	  heart	  failure	  patients.	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Despite	  all	  these	  advances	  in	  technology	  and	  patient	  care,	  it	  would	  appear	  that	  there	  remains	  a	  
major	   unresolved	   challenge	   in	   reducing	   the	   number	   of	   HF	   hospitalizations	   by	   our	   inability	   to	  
adequately	  predict	  episodes	  of	  worsening	  HF,	  using	  the	  aforementioned	  physiological	  variables,	  
from	  telemonitoring	  or	  device	  monitoring	  of	  symptoms	  including	  daily	  weights.	  	  
Furthermore,	   it	  appears	   that	  while	  each	  of	   the	  diagnostic	  variables	  used	  have	  the	  capability	  of	  
stratifying	   patients	   at	   risk	   for	   HF	   hospitalizations,	   combination	   of	   these	   variables	   certainly	  
improves	   detection	   rates	   and	   in	   particular	   for	   those	   at	   extreme	   ends	   of	   risk	   for	   HF	  
hospitalizations.	  
The	  European	  Society	  of	  Cardiology	  recommends	  that	  patients	  with	  heart	  failure	  be	  enrolled	  in	  a	  
multidisciplinary-­‐care	  management	  programme	  to	  reduce	  the	  risk	  of	  heart	  failure	  hospitalization.	  
One	   of	   the	   important	   components	   of	   such	   programmes	   is	   increased	   access	   to	   healthcare	  
(through	  in-­‐person	  follow-­‐up	  and	  by	  telephone	  contact;	  possibly	  through	  remote	  monitoring)(4).	  	  
The	  mixed	  quality	  of	  evidence	  for	  remote	  monitoring,	  in	  particular	  lack	  of	  mortality	  benefit	  from	  
telemonitoring,	  makes	  the	  American	  Heart	  Failure	  Association	  guidelines	   less	  definitive	   in	  their	  
recommendations.	   They	   however	   also	   promote	   generic	   multidisciplinary	   team	   management	  
approaches,	  which	  are	  designed	  to	  support	  patients	  with	  HF	  and	  have	  been	  shown	  to	  result	  in	  a	  
significant	   improvement	   in	   outcomes	   including	   mortality	   (125).	   To	   this	   end	   they	   recommend	  
further	  evaluation	  of	  the	  usefulness	  of	  remote	  monitoring	  (105).	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Table	  6:	  	  Summary	  of	  Key	  Variables	  from	  Device	  Studies.	  (IMP	  -­‐	  Impedance,	  TM	  –	  Telemonitoring,	  PCWP	  
–	  Pulmonary	  Capillary	  Wedge	  Pressure,	  CRT	  –	  Cardiac	  Resynchronisation	  Therapy,	  HRV	  –	  Heart	  Rate	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1.18. Sleep	  Disordered	  Breathing	  in	  Heart	  Failure	  
There	  is	  a	  good	  body	  of	  evidence	  that	  nocturnal	  breathing	  disorders	  are	  very	  common	  in	  patients	  
with	  chronic	  heart	  failure	  and	  at	  any	  symptomatic	  level	  of	  the	  disease	  (8).	  The	  majority	  of	  these	  
abnormalities	  are	  characterised	  by	  various	  forms	  of	  oscillatory	  ventilatory	  patterns,	  the	  hallmark	  
of	  which	  are	  rises	  and	  falls	  in	  tidal	  volume	  (VT)	  (126).	  
Significantly	   these	   breathing	   abnormalities	   are	   associated	  with	   increased	  mortality,	   which	   are	  
independent	   of	   known	   clinical	   predictors	   of	   outcome	   (127).	   The	   cyclical	   fluctuations	   in	  
ventilation	  that	  are	  seen	  with	  these	  patterns	  have	  given	  rise	  to	  the	  loose	  term	  Periodic	  Breathing	  
(PB)	  and	  this	  is	  described	  during	  sleep	  or	  wakefulness	  (128).	  
During	   sleep	   it	   is	   more	   appropriately	   termed	   Sleep	   Disordered	   Breathing	   (SDB),	   which	   are	   a	  
group	   of	   disorders	   characterized	   by	   abnormalities	   of	   respiratory	   pattern	   or	   the	   quantity	   of	  
ventilation	   during	   sleep.	   In	   these	   patients,	   obstructive	   sleep	   apnoea	   (OSA)	   and	   central	   sleep	  
apnoea	  (CSA)	  form	  parts	  of	  a	  spectrum	  that	  depending	  on	  the	  circumstances,	  may	  take	  either	  of	  
the	   two	   forms	   as	   the	   dominant	   mechanism.	   SDB	   occurs	   in	   up	   to	   50%	   of	   patients	   with	   heart	  
failure	  and	  is	  associated	  with	  poor	  prognosis	  (6;9)	  
Ventilatory	  instability	  during	  SDB	  leads	  to	  recurrent	  changes	  in	  intrathoracic	  pressures,	  tensions	  
of	   carbon	  dioxide	  and	  oxygen	   in	  plasma,	  which	   result	   in	   intermittent	  hypercapnia	  and	  hypoxia	  
and	   sharp	   fluctuations	   in	   sympathetic	   drive.	   These	   trigger	   repetitive	   arousals	   and	   sleep	  
fragmentation,	   which	   consequently	   impact	   negatively	   on	   the	   heart	   by	   worsening	   its	   function.	  
Overall	  these	  patterns	  are	  associated	  with	  poor	  prognosis	  (10;129)	  
Normal	  breathing	  cycle	   lengths	  range	   from	  3	  to	  5	  s	   (i.e.,	  0.20–0.33	  Hz)	  while	  PB	  patterns	  have	  
cycle	  lengths	  from	  25	  to	  100	  s	  (i.e.,	  0.01–0.04	  Hz)	  (130).	  In	  the	  same	  patient	  however,	  there	  may	  
often	  co-­‐exist	  a	  mixture	  of	  breathing	  patterns,	  ranging	  from	  extremes	  of	  non-­‐periodic	  breathing	  
(nPB),	  i.e.,	  without	  cyclic	  modulation	  of	  ventilation,	  through	  to	  florid	  Cheyne-­‐Stokes	  Respiration	  
(CSR)	  patterns	  with	  varying	  degrees	  of	  PB	  in	  between.	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1.18.1. Classification	  of	  SDB	  
Patients	   with	   SDB	   have	   periods	   of	   apnoeas	   (a	   cessation	   or	   >90%	   reduction	   in	   airflow)	   and	  
hypopneas	  (a	  >	  50%	  reduction	  in	  airflow	  with	  an	  associated	  oxygen	  desaturation	  of	  at	  least	  3%).	  
SDB	  may	   be	   classified	   as	   obstructive	   sleep	   apnoea	   (OSA),	   where	   there	   is	   partial	   or	   complete	  
collapse	   of	   the	   airway,	   or	   central	   sleep	   apnoea	   (CSA)	   where	   the	   airway	   is	   largely	   open	   and	  
cessation	  of	  ventilation	   is	  due	  to	  reduced	  respiratory	  drive.	   In	  addition,	  patients	  with	  CSA	  may	  
exhibit	  a	  Cheyne	  Stokes	  pattern	  of	  respiration	  (CSR)	  characterised	  by	  the	  presence	  of	  periods	  of	  
central	  apnoeas	  or	  hypopneas	  alternating	  with	  periods	  of	   crescendo-­‐decrescendo	   tidal	   volume	  
(10;129).	  
Both	  types	  of	  SDB	  may	  co-­‐exist	  in	  the	  same	  patient	  and	  usual	  practice	  is	  to	  label	  the	  syndrome	  
depending	  on	  which	  type	  predominates.	  
The	   severity	   of	   SDB	   is	   generally	   classified	   by	   the	   Apnoea-­‐Hypopnoea	   Index	   (AHI),	   the	   average	  
number	  of	  apnoeas	  and	  hypopnoeas	  that	  occur	  per	  hour	  during	  sleep.	  An	  AHI	  ≥	  15	   is	   taken	  to	  
indicate	  clinically	  important	  disease.	  
1.18.2. Epidemiology	  
CSA	  is	  rare	  in	  patients	  without	  heart	  failure,	  but	  obstructive	  sleep	  apnoea	  is	  relatively	  common	  in	  
the	  general	  population,	  and	  particularly	   in	   those	  who	  are	  obese,	  or	  who	  have	  hypertension	  or	  
diabetes,	  or	  who	  have	  upper	  airways	  anatomically	  more	  likely	  to	  collapse	  (e.g.	  retrognathism).	  	  
The	   prevalence	   of	   SDB	   in	   systolic	   heart	   failure	   is	   high	  with	   estimates	   from	   population	   studies	  
varying	   between	   47%	   and	   71%	   (6;131).	   In	   a	   prospective	   study	   of	   male	   patients	   with	   stable	  
systolic	  heart	  failure,	  51%	  were	  reported	  to	  have	  an	  AHI	  of	  15	  per	  hour	  or	  more	  (CSA	  40%	  OSA	  
11%)	   (6).	   Ward	   and	   colleagues,	   in	   patients	   with	   low	   or	   preserved	   ejection	   fraction,	   recently	  
reported	  a	  prevalence	  of	  14%	  for	  CSA	  and	  31%	  for	  OSA	  (132).	  Prevalence	  rates	  have	  been	  shown	  
to	   be	   higher	   in	   patients	   who	   are	   awaiting	   transplantation	   (133),	   and	   those	   with	   implanted	  
cardiac	   defibrillators	   (134).	   Several	   other	   studies	   in	   patients	   with	   systolic	   heart	   failure	   have	  
shown	  varying	  prevalence	  rates	  ranging	  from	  40%	  to	  80%	  (135-­‐137)	  See	  Table	  6.	  
	   76	  
Men	  appear	  to	  be	  more	  likely	  to	  develop	  SDB	  than	  women,	  particularly	  in	  middle	  life	  (138).	  The	  
reasons	  for	  this	  are	  not	  entirely	  clear,	  but	  presumably	  relate	  to	  gender	  differences	  in	  respiratory	  
drive.	  See	  table	  7	  for	  summary	  of	  some	  landmark	  prevalence	  studies	  on	  SDB	  in	  HF	  patients.	  
Table	  7:	  Landmark	  prevalence	  studies	  for	  SDB	  in	  CHF	  
1.18.3. Risk	  Factors	  
There	   are	   several	   patient	   characteristics	   that	   affect	   the	   likelihood	   of	   SDB.	   For	   OSA,	   as	   in	   the	  
general	   population,	   male	   gender,	   increasing	   age,	   obesity,	   snoring	   and	   increased	   neck	  
circumference	   increase	   the	  probability	  of	   SDB	  being	  present.	   For	  CSA,	   risk	   factors	   also	   include	  
male	  gender	  and	  increasing	  age,	  but	  in	  addition	  the	  presences	  of	  arrhythmia	  (in	  particular	  atrial	  
fibrillation)	   as	   well	   as	   daytime	   hypocapnia	   are	   features	   that	   are	   known	   to	   be	   independently	  
associated	  with	  this	  condition	  (137).	  	  
In	  general,	   the	  more	  severe	  the	  heart	   failure	  the	  more	   likely	   that	   the	  patient	  will	  demonstrate	  
CSA,	  particularly	  if	  they	  are	  male,	  older	  or	  in	  atrial	  fibrillation,	  but	  even	  patients	  with	  mild	  heart	  
failure	  symptoms	  are	  likely	  to	  have	  SDB	  (8;135).	  	  
Author,	  Year	   Number	  of	  
Patients	  
NYHA	  Class	   Male	  (%)	   LVEF	  (%)	   AHI	  severity	   SDB	  
(%)	  
OSA	  (%)	   CSA	  (%)	  
≤II	   ≥III	  
Lanfranchi,	  
2003	  
47	   100	   0	   89	   27(6)	   ≥15/H	   66	   11	   55	  
Sin,	  1999	   450	   62	   38	   85	   27	  (16)	   15/h	   61	   29	   32	  
Ferrier,	  2005	   53	   ND	   ND	   77	   34(9)	   ≥10/h	   68	   15	   53	  
Javaheri	  1998	   81	   70	   30	   100	   25	  (9)	   ≥15/h	   51	   11	   40	  
Javaheri,	  2006	   100	   II	   	   100	   25(7)	   15/h	   41	   27	   12	  
Oldenburg,	  
2007	  
700	   ND	   ND	   80	   28(7)	   ≥15/h	   52	   19	   33	  
Schulz,	  2007	   203	   55	   45	   75	   28	   ≥10/h	   72	   43	   28	  
Vazir,	  2007	   55	   100	   0	   100	   31(10)	   ≥15/h	   53	   15	   38	  
MacDonald,	  
2008	  
108	   71	   29	   85	   20	   ≥15/h	   61	   30	   31	  
Bitter,	  2009	   244	   ND	   ND	   64	   >55	   ≥15/h	   47	   24	   23	  
Yumino,	  2009	   218	   54	   46	   77	   25(10)	   ≥15/h	   47	   26	   21	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The	  differences	  in	  pathophysiology	  for	  these	  two	  forms	  of	  SDB	  may	  in	  part	  explain	  the	  differing	  
risk	   factors.	   See	   Table	   8	   for	   a	   study	   of	   193	   patients	   newly	   referred	   with	   low	   left	   ventricular	  
ejection	  fraction	  (≤45%)	  to	  a	  Canadian	  heart	  failure	  centre,	  who	  were	  screened	  for	  SDB.	  
	  
Table	  8:	  Risk	  factors	  for	  the	  prevalence	  of	  SDB	  in	  heart	  failure	  (137).	  	  
1.18.4. Pathophysiology	  of	  SDB	  
The	  predominant	  pathological	   feature	   in	  all	   types	  of	  SDB	   is	   the	  presence	  of	  periodic	  breathing	  
associated	  with	  pauses	  (apnoeas)	  or	  transient	  reductions	  (hypopneas)	  in	  ventilation	  during	  sleep.	  
This	   is	   usually	   followed	   by	   a	   hyperpnoeic	   episode	   often	   leading	   to	   arousal	   from	   sleep	   as	   the	  
patient	  attempts	  to	  resume	  normal	  ventilation	  (10;129).	  	  
These	   arousals	   produce	   a	   sharp	   surge	   in	   sympathetic	   activity,	   with	   an	   associated	   increase	   in	  
heart	   rate	   and	   blood	   pressure,	   along	   with	   vasoconstriction	   of	   peripheral	   vessels.	   Increased	  
circulating	  catecholamines	  may	  be	  implicated	  in	  adverse	  remodelling	  of	  the	  left	  ventricle	  and	  an	  
increased	  propensity	  to	  arrhythmia,	  including	  paroxysmal	  atrial	  fibrillation	  (139).	  	  
The	  cycle	  of	  interrupted	  sleep	  (with	  frequent	  arousals	  to	  a	  lighter	  less	  refreshing	  stage	  of	  sleep)	  
can	  leave	  a	  patient	  feeling	  tired	  during	  the	  day,	  with	  a	  tendency	  to	  nap	  readily.	  However	  heart	  
failure	  patients	  do	  not	  appear	  to	  complain	  of	  this	  as	  much	  as	  non-­‐heart	  failure	  patients	  with	  OSA.	  
This	   is	   perhaps	   related	   to	   the	   higher	   background	   level	   of	   sympathetic	   activity	   in	   the	   former	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OSA	  	  	  
In	  obstructive	  sleep	  apnoea,	  ventilation	  is	  periodically	  interrupted	  by	  partial	  or	  complete	  collapse	  
of	   the	  upper	  airway	  pharyngeal	  muscles	  at	  either	   the	   level	  of	   the	  soft	  palate	   (nasopharynx)	  or	  
the	   level	   of	   the	   tongue	   (oropharynx).	   Anatomical	   variations	   in	   this	   area	   are	   associated	   with	  
varying	  risks	  of	  development	  of	  OSA	  in	  different	  individuals.	  
It	   is	  also	  known	  that	  the	  cross-­‐sectional	  area	  of	  the	  airway	  in	  patients	  with	  OSA	  is	  smaller	  than	  
that	  of	  patients	  without	  OSA;	  this	  difference	  is	  due	  to	  the	  volume	  of	  the	  soft	  tissue,	  including	  the	  
tongue,	  lateral	  pharyngeal	  walls,	  soft	  palate,	  and	  parapharyngeal	  fat	  pads	  (141).	  	  
Exaggerated	   negative	   intrathoracic	   pressures	   from	   continued	   inspiratory	   effort	   against	   an	  
occluded	  airway	  is	  generated,	  increasing	  cardiac	  transmural	  pressures,	  left	  ventricular	  afterload	  
and	  myocardial	   oxygen	   demand	   at	   a	   time	  when	  oxygen	   saturation	  may	   be	   dropping.	   This	   can	  
lead	  to	  a	  worsening	  of	  cardiac	  function	  and	  an	  increased	  risk	  of	  arrhythmia.	  	  
Posture	  plays	  an	  important	  role	  in	  increasing	  the	  risk	  of	  respiratory	  events:	  these	  are	  more	  likely	  
to	   occur	   in	   the	   supine	   rather	   than	   prone	   or	   lateral	   position.	   It	   has	   been	   suggested	   that	   the	  
amount	   of	   rostral	   fluid	   displacement	   from	   the	   legs	   of	   heart	   failure	   patients	   during	   the	   night	  
corresponds	  strongly	  with	  an	  overnight	  increase	  in	  neck	  circumference	  and	  increased	  likelihood	  
of	  OSA	  events	  (142).	  	  
CSA	  	  	  
In	   patients	  with	  CSA,	   the	  predominant	   problem	   lies	  with	   instability	   of	   the	   feedback	   control	   of	  
ventilation,	  resulting	  in	  a	  temporary	  withdrawal	  of	  central	  respiratory	  drive	  leading	  to	  a	  cessation	  
of	  airflow	  and	  respiratory	  muscle	  activity	  (10;129).	  	  
Normal	  ventilation	  is	  controlled	  by	  mechanisms	  that	  keep	  the	  partial	  pressures	  of	  arterial	  carbon	  
dioxide	   (PaCO2)	   in	   plasma	  within	   a	   tight	   range.	   Alterations	   to	   this	   homeostasis	   results	   in	   the	  
development	  of	  periodic	  breathing	  both	  during	  sleep	  and	  wakefulness.	  Intermittent	  cessation	  of	  
inspiratory	  drive	  occurs	  due	  to	  a	  fall	  in	  PaCO2	  below	  the	  apnoea	  threshold	  (the	  minimum	  partial	  
pressure	  of	   carbon	  dioxide	   in	   plasma	   that	   is	   sufficient	   to	   stimulate	   ventilation)	   (Figure	  9).	   The	  
main	   contributor	   to	   this	   process	   in	   heart	   failure	   patients	   appears	   to	   be	   an	   increased	  
chemoreceptor	   sensitivity	   to	  CO2	   (resulting	   in	  hyperventilation	  driving	  down	  PaCO2	  below	   the	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apnoeic	  threshold)	  and	  perhaps	  an	  increased	  arterial	  circulation	  time	  due	  to	  low	  cardiac	  output	  
in	  some	  patients	  increasing	  the	  feedback	  time	  in	  the	  homeostatic	  control	  mechanism	  (143).	  	  
	  
	  
Figure	  9:	  Mechanism	  of	  CSA	  –	  As	  PCO2	  levels	  fall	  below	  apnoeic	  thresholds,	  airflow	  ceases	  
	  
1.18.5. The	  Diagnosis	  of	  Sleep	  Disordered	  Breathing	  in	  Heart	  Failure	  
SDB	  is	  under	  diagnosed	  in	  patients	  with	  chronic	  heart	  failure	  even	  though	  it	  remains	  a	  prevalent	  
condition	  and	  associated	  with	   increased	  morbidity	  and	  mortality.	  One	  of	   the	  main	   reasons	   for	  
this	  is	  that	  cardiologists	  are	  reluctant	  to	  send	  their	  patients	  in	  for	  a	  diagnostic	  test	  that	  is	  seen	  as	  
cumbersome	  and	  sometimes	  tedious	  for	  a	  group	  of	  patients	  who	  are	  usually	  very	  frail.	  The	  other	  
factor	  is	  that	  the	  symptoms	  patients	  present	  with,	  which	  are	  suggestive	  of	  the	  presence	  of	  SDB	  
can	  be	  confused	  with	  the	  usual	  symptoms	  of	  heart	  failure	  and	  as	  such	  it	  is	  not	  easily	  recognised.	  	  
It	  should	  also	  be	  noted	  that	  there	  is	  no	  correlation	  between	  the	  NYHA	  class	  and	  the	  presence	  of	  
SDB	  (8).	  	  
Attended	   in-­‐hospital	   polysomnography	   (PSG)	   provides	   the	   best	   available	   tool	   for	   making	   a	  
diagnosis	   of	   SDB	   and	   it	   is	   currently	   the	   ‘gold’	   standard.	   A	   variety	   of	   other	   devices	   have	   been	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developed	   to	  offset	   the	   resource	   and	   labour	   intensiveness	   of	   PSG	   and	   these	   generally	   rely	   on	  
their	   portability,	   but	   at	   the	   cost	   of	   the	   number	   of	   signals	   they	   can	   output	   and	   therefore	  
information	   that	   can	   be	   provided	   towards	   a	   diagnosis.	   These	   tools	   include	   overnight	  
oximetry(132)	   and	   the	   use	   of	   apnoea	   link	   device(144),	   which	   combines	   pulse	   oximetry	   with	  
thoracoabdominal	   plethysmography,	   but	   a	   formal	   diagnosis	   would	   still	   require	   a	   PSG/PG	  
recording.	  As	  such	  in	  practice	  these	  devices	  are	  generally	  used	  only	  as	  screening	  tools.	  
	  
1.18.5.1	  	   Types	  of	  Portable	  Monitors	  
The	   1994	   American	   Sleep	   Disorders	   Association	   classifies	   portable	   monitors	   based	   on	   the	  
number	  and	  type	  of	  signals	  they	  record	  (145).	  This	  has	  recently	  been	  reviewed	  by	  the	  American	  
Academy	   of	   Sleep	   Medicine,	   the	   American	   College	   of	   Chest	   Physicians,	   and	   the	   American	  
Thoracic	  Society	  (146).	  
Type	  1:	  Standard	  attended	  in-­‐hospital	  polysomnography	  (PSG)	  
These	  monitors	   are	   usually	   the	   reference	   standard	   to	  which	   other	  monitors	   are	   compared.	   A	  
minimum	  of	  7	  channels	  are	  recorded	   including	  EEG,	  Electrooculogram,	  chin	  EMG,	  ECG	  or	  heart	  
rate,	   airflow,	   respiratory	   effort,	   and	   oxygen	   saturation.	   I	   will	   discuss	   PSG	   in	   detail	   in	   the	   next	  
section.	  
Type	  2:	  Comprehensive	  Portable	  Polysomnography	  
These	  monitors	  incorporate	  sleep	  staging	  as	  well	  as	  respiratory	  analysis.	  They	  rely	  on	  recordings	  
from	  a	  minimum	  of	  seven	  channels	  as	  Type	  1	  sleep	  studies,	  the	  main	  difference	  being	  that	  they	  
are	  unattended.	  
Type	  3:	  Modified	  Portable	  Sleep	  Apnea	  Testing	  
This	  type	  of	  monitor	   incorporates	  at	   least	   four	  channels	   (with	  at	   least	  three	  being	  respiratory),	  
including	   ventilation	  or	   airflow	   (at	   least	   two	   channels	   of	   respiratory	  movement,	   or	   respiratory	  
movement	  and	  airflow),	  heart	  rate	  or	  ECG,	  and	  oxygen	  saturation.	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Type	  4:	  Continuous	  Single	  or	  Dual	  Bio	  parameters	  
These	  monitors	  measure	  a	  single	  parameter	  or	  two	  parameters,	  for	  example,	  oxygen	  saturation	  
or	  airflow.	  A	  monitor	  that	  did	  not	  meet	  the	  criteria	  for	  type	  3	  (i.e.,	  a	  monitor	  that	  measured	  one	  
to	  three	  channels	  or	  did	  not	  include	  airflow	  despite	  having	  four	  channels)	  was	  classified	  as	  type	  
4.	  The	  SleepMinderTM	  device	  used	  in	  this	  thesis	  would	  be	  classified	  as	  a	  Type	  4	  Portable	  Monitor.	  
Tables	  9	  and	  10	  below	  show	  some	  examples	  of	  Type	  4	  portable	  monitors	  and	  relevant	  studies.	  As	  
a	   result	   of	   on-­‐going	   development,	   some	   of	   the	   models	   of	   monitors	   used	   in	   these	   validation	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Table	  9:	  Examples	  of	  Type	  4	  Portable	  Monitors	  using	  predominantly	  O2	  saturation	  and	  Airflow	  as	  
parameter	  for	  detecting	  SDB.	  (Abbreviations:	  AHI	  –	  Apnoea	  Hypopnea	  Index,	  ODI	  –	  Oxygen	  
Desaturation	  Index,	  HRV	  –	  Heart	  Rate	  Variability,	  ISI	  –	  I	  Snoring	  Index,	  PR	  –	  Pulse	  Rate,	  HR-­‐	  Heart	  Rate,	  
PAT	  –	  Peripheral	  Arterial	  Tone,	  CT-­‐	  Cumulative	  Total,	  NA	  –	  Not	  Available,	  RDI	  –	  Respiratory	  Disturbance	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Table	  10:	  Examples	  of	  Type	  4	  Monitoring	  using	  HRV	  as	  measure	  for	  detecting	  SDB.	  (Abbreviations:	  VLFI	  
–	  Very	  Low	  Frequency	  Increment,	  RR	  –	  R	  –	  R	  Interval	  on	  Electrocardiogram,	  LF	  –	  Low	  Frequency,	  HF	  –	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1.18.5.2	   Polysomnography/Polygraphy	  (PSG/PG)	  
Laboratory	   based	   Polysomnography	   or	   polygraphy	   usually	   involves	   an	   overnight	   inpatient	  
hospital	   stay.	   	   A	   standard	   PSG	   should	   have	   at	   least	   seven	   recording	   channels,	   which	   should	  
include	   Electroencephalogram	   (EEG),	   Electrooculogram	   (EOG),	   submental	   electromyogram	  
(EMG),	   Electrocardiogram	   (ECG),	   Oro-­‐nasal	   airflow,	   Respiratory	   Inductance	   Plethysmography	  
(RIP),	   and	  Pulse	  Oximetry.	   Body	  position	   is	   obtained	   from	   the	   recording	  device	   and	   additional	  
data	  may	  be	  obtained	  from	  anterior	  tibialis	  electromyogram	  and	  a	  snore	  electrode.	  	  
The	  main	  output	  from	  an	  overnight	  PSG	  typically	  recorded	  for	  about	  4-­‐6	  hours	  is	  information	  on	  
sleep	   architecture,	   including	   the	   total	   sleep	   time	   (TST);	   which	   is	   an	   important	   metric	   in	  
calculating	   the	  main	   index	   for	  estimating	   the	  severity	  of	  SDB,	   the	  apnoea	  and	  hypopnea	   index	  
(AHI),	  which	  is	  simply	  a	  fraction	  of	  the	  total	  number	  of	  apnoeas	  and	  hypopneas	  divided	  by	  TST;	  
sleep	   efficiency,	   sleep	   stages	   and	   frequency	   of	   arousals.	   Respiratory	   effort	   signals	   help	   to	  
distinguish	   central	   from	  obstructive	  events.	  Other	   important	   information	   that	   can	  be	  obtained	  
includes,	  number	  of	  periodic	   leg	  movements,	  number	  of	  oxygen	  desaturations	  and	  snoring	  and	  
these	  extra	  data	  may	  be	  invaluable	  especially	  where	  there	  is	  diagnostic	  doubt.	  
Many	  studies	  classify	  SDB	  severity	  by	  the	  AHI	  into	  Mild	  (>5	  <10),	  Moderate	  (>10	  <30)	  and	  Severe	  
(>30).	  However	  when	  treatment	  is	  been	  considered,	  an	  AHI	  of	  >15	  is	  usually	  considered	  clinically	  
significant.	  
PSG	   studies	   are	   time	   and	   resource	   expensive	   due	   to	   the	   need	   for	   a	   well-­‐equipped	   sleep	  
laboratory	  and	  the	  trained	  personnel	  who	  perform	  the	  studies	  but	  also	  to	  interpret	  the	  results.	  It	  
is	   also	   particularly	   obtrusive	   and	   sometimes	   is	   not	   representative	   of	   patients	   normal	   sleep	  
pattern/habit	  due	  to	  the	  laboratory	  setting	  and	  the	  extensive	  electrodes	  attached.	  	  
There	   is	  also	   the	   limitation	  of	  making	  a	  diagnosis	  on	  a	   single	  nights	   recording,	  as	   studies	  have	  
shown	   that	   a	   high	   proportion	   of	   patients	   shift	   their	   type	   of	   sleep	   disordered	   breathing	   over	  
consecutive	   nights	   (147).	   Even	   where	   the	   facilities	   exist	   to	   do	   so,	   it	   is	   often	   expensive	   and	  
impractical	  to	  perform	  PSG	  studies	  on	  consecutive	  nights.	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1.18.6. The	  Variability	  of	  the	  Apnoea	  Hypopnea	  Index	  (AHI)	  
The	  Apnoea	  Hypopnea	  Index	  (AHI)	   is	  the	  most	  frequently	  used	  measurement	  for	  diagnosis	  and	  
classification	   of	   severity	   of	   sleep-­‐disordered	   breathing.	   The	   gold	   standard	   and	   recommended	  
technique	   for	   obtaining	   this	   value	   is	   from	   a	   single	   night	   in-­‐hospital	   Polygraphy	   or	  
Polysomnography	  (148).	  
The	   AHI	   may	   however	   be	   variable	   over	   a	   period	   of	   time	   in	   the	   same	   patient	   who	   has	   heart	  
failure.	   This	   therefore	   raises	   the	   question	   about	   whether	   the	   use	   of	   a	   single	   night	  
Polysomnogram	   to	  make	  a	  diagnosis	   of	   SDB	  and	   to	   classify	   the	   severity	   and	   type	  of	   SDB.	  One	  
possible	  reason	  for	  this	  variability	  is	  due	  to	  breathing	  pattern	  changes	  that	  may	  occur	  during	  the	  
course	  of	  the	  heart	  failure	  syndrome;	  no	  doubt	  contributed	  in	  part	  by	  the	  effects	  of	  changes	  in	  
medical	  and	  device	  treatment	  strategies;	  that	  could	  potentially	  influence	  a	  change	  in	  this	  value.	  
Only	  a	  few	  studies	  have	  investigated	  the	  variability	  of	  the	  AHI,	  in	  the	  short	  term,	  in	  patients	  with	  
heart	   failure,	  mainly	  due	  to	  the	  complexities	  of	  multiple	  night	  polygraphy	  or	  polysomnography	  
examinations.	  Furthermore,	  these	  studies	  are	  largely	  heterogeneous	  in	  the	  techniques	  used,	  the	  
variables	  examined	  for	  variability	  assessment,	  and	  intervals	  between	  measurements.	  Therefore,	  
results	  from	  these	  published	  studies	  are	  largely	  contradictory.	  
Le	   Bon	   and	   colleagues	   studied	   243	   patients	  who	  were	   referred	   to	   a	   Brussels	   Sleep	   Centre	   for	  
screening	  of	  suspected	  sleep	  apnoea.	  They	  underwent	  sleep	  studies	  on	  two	  consecutive	  nights	  
and	  it	  was	  noted	  that	  the	  detection	  rate	  for	  SDB	  in	  this	  cohort	  was	  improved	  by	  a	  second	  night	  
PSG,	  by	  about	  15	  –	  25	  %	  when	  the	  result	  of	   the	  first	  night	  was	  negative	  (149).	  As	  a	  result,	   the	  
main	  conclusion	  from	  this	  study	  was	  that	  one	  night’s	  sleep	  study	  might	  be	  insufficient	  to	  make	  a	  
definitive	  diagnosis	  of	  SDB.	  
In	  a	  much	  larger	  but	  retrospective	  North	  American	  study	  of	  1091	  adult	  patients,	  who	  underwent	  
sequential	   sleep	   studies	   over	   3	   nights,	   there	   was	   a	   high	   consistency	   in	   the	   AHI,	   across	   the	   3	  
nights	   of	  measurement	  with	   an	   Intra	   Class	   Correlation	  Co-­‐efficient	   (ICC)	   value	  of	   0.90	   (95%	  CI	  
0.89-­‐0.91).	   However,	   at	   least	   1	   in	   10	   of	   these	   patients	   were	   reclassified	   into	   a	   different	   SDB	  
severity	  group	  based	  on	  the	  highest	  AHI	  obtained	  on	  any	  of	  the	  3	  nights.	  The	  AHI	  thresholds	  used	  
in	  this	  study	  were	  5,	  10	  and	  15	  (150).	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At	  the	  Royal	  Brompton	  Hospital	  in	  London,	  Vazir	  and	  colleagues,	  studied	  19	  men	  with	  stable	  CHF	  
and	   found	   that	   over	   a	   period	   of	   four	   nights,	   the	   AHI	   and	   Oxygen	   Desaturation	   Index	   (ODI)	  
demonstrated	  minimal	  variability	  (Intra-­‐class	  Correlation	  Co-­‐efficient	  0.94	  [0.76-­‐0.97];	  0.94	  [0.88-­‐
0.97]	  respectively.	  They	  however	  found	  that	  37%	  (95%	  CI	  20-­‐64%)	  of	  their	  patients	  moved	  from	  
one	   severity	   group	   to	   the	   next	   of	   Sleep	   Disordered	   Breathing	   (SDB)	   over	   the	   four	   nights	   of	  
monitoring.	   The	   severity	   thresholds	   used	   in	   this	   study	   were	   based	   on	   the	   AHI;	   mild-­‐(5-­‐14.9),	  
Moderate	  (15-­‐29.9)	  and	  severe	  (≥30).	  In	  addition	  there	  was	  a	  change	  in	  the	  predominant	  type	  of	  
SDB,	  shifting	  from	  CSA	  to	  OSA	  and	  vice	  versa	  in	  42%	  (8/19)	  of	  these	  patients	  (147).	  Using	  night	  
one	  as	  a	  reference,	  3	  patients	  moved	  from	  a	  reference	  classification	  of	  CSA	  to	  OSA	  on	  any	  other	  
night	  of	  study	  while	  5	  patients	  moved	  from	  an	  index	  classification	  of	  OSA	  on	  night	  one	  to	  CSA	  on	  
subsequent	  nights.	  
Contrastingly,	   another	   study	   which	   investigated	   patients	   across	   2	   consecutive	   nights,	   found	  
excellent	   correlation	   in	   the	  AHI	   (r=0.948	   p<0.001)	   and	  Apnoea	   Index	   (AI)	   r=0.842	   p<0.001).	   In	  
addition	  they	  found	  that	  the	  more	  severe	  the	  SDB,	  the	  more	  reproducible	  these	  indices	  were	  and	  
the	  more	  likely	  the	  patients	  were	  to	  be	  classified	  correctly	  by	  type	  of	  SDB.	  (151)	  The	  results	  on	  
these	  patients	  with	   stable	  CHF	   led	   the	  authors	   to	   conclude	   that	   in	   this	  patient	   group,	   a	   single	  
night	  of	  cardiorespiratory	  monitoring	  was	  a	  true	  representation	  of	  severity	  and	  type	  of	  SDB.	  	  
Maestri	  and	  colleagues	  investigated	  variability	   in	  the	  AHI,	  AI	  and	  Periodic	  Breathing	  (PB)	  across	  
two	  nights	  using	   the	  Embletta	  device,	  which	   is	  a	  portable	  sleep	  monitor	   that	  measures	  airflow	  
and	  ventilatory	  effort	  via	  elasticated	  chest	  and	  abdominal	  bands.	  They	  measured	  variability	  using	  
95%	  limits	  of	  random	  variation	  (LoV)	  and	  found	  significant	  night-­‐to-­‐night	  intra-­‐subject	  variation	  
(95%	  LoV,	  ±10.6,	  ±7.7,	  ±11.3	  for	  AHI,	  AI	  and	  ODI).	  However,	  the	  majority	  of	  these	  patients	  were	  
classified	  correctly	  according	  to	  severity	  using	  conventional	  cut-­‐offs	  for	  the	  AHI.(152)	  
Similarly,	   Bittencourt	   and	   colleagues	   found	   high	   variability	   when	   comparing	   the	   AHI	   values	  
obtained	  over	  4	  consecutive	  nights	   in	  20	  adult	  patients	  with	  OSA	  referred	  from	  the	  respiratory	  
sleep	  disorders	  clinic	  in	  Sao	  Paulo	  Brazil.	  They	  observed	  a	  large	  scattering	  of	  values	  using	  a	  Bland	  
Altman	  analysis.	   (Night	  1	  vs	  Night	  2;	  Night	  1	  vs	  Night	  3;	  Night	  1	  vs	  Night	  4	  –	  95%	  CI	   -­‐19.37	   to	  
+21.27,	   -­‐22.3	   to	   +25.27,	   and	   -­‐22.04	   to	   +25.24	   respectively).	   In	   addition	   50%	  of	   these	   patients	  
changed	  the	  severity	  classification	  of	  SDB	  on	  at	  least	  one	  follow	  up	  night.	  (153)	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In	  the	  Sleep	  Heart	  Health	  Study,	  91	  participants	  underwent	  2	  sleep	  studies	  4	  months	  apart.	  The	  
Respiratory	  Disturbance	  Index	  (RDI	  3%),	  which	  was	  the	  number	  of	  apnoeas	  and	  hypopneas	  per	  
hour	  of	  sleep	  associated	  with	  a	  >3%	  desaturation,	  was	  the	  variable	  measured.	  Using	  thresholds	  
of	  5,	  10	  and	  15	  events	  per	  hour,	  the	  investigators	  found	  little	  variability	  even	  when	  the	  threshold	  
for	  desaturation	  was	  increased	  to	  >4%	  (Intra-­‐class	  correlation	  co-­‐efficient	  0.77-­‐0.81).	  (154).	  
To	  summarize,	  the	  aforementioned	  studies	  show	  largely	  discrepant	  results	  in	  terms	  of	  variability	  
and	  misclassification	  of	  SDB	  according	   to	   severity	  or	   type.	  Further,	  most	  of	   these	   studies	  have	  
only	  followed	  up	  patients	  between	  2	  and	  4	  nights	  and	  at	  varying	  intervals	  between	  sleep	  studies	  
and	  most	  have	  not	  included	  heart	  failure	  patients.	  	  
One	  of	  the	  aims	  of	  this	  thesis	  is	  to	  observe	  nocturnal	  respiratory	  patterns	  in	  heart	  failure	  patients	  
over	  a	  prolonged	  period	  of	  monitoring	  using	  the	  SleepMinderTM	  device,	  which	   is	  a	  non-­‐contact	  
continuous	  monitor	  of	  nocturnal	  respiration,	  and	  to	  examine	  the	  variability	  of	  the	  AHI	  and	  other	  
measures	  of	  SDB	  and	  the	  clinical	  implications	  such	  variations	  may	  have.	  	  
	  
1.18.7. Treatment	  of	  SDB	  
It	  is	  important	  to	  treat	  heart	  failure	  optimally,	  before	  labelling	  a	  patient	  as	  having	  SDB.	  Effective	  
treatment	   of	   heart	   failure	   with	   contemporary	   drug	   and	   device	   therapy	   has	   been	   shown	   to	  
attenuate	   SDB	   (155-­‐158);	   improving	   the	   heart	   failure	   will	   often	   improve	   the	   SDB.	   The	   use	   of	  
diuretics	  to	  control	  fluid	  retention,	  in	  addition	  to	  disease	  modifying	  therapy	  (such	  as	  angiotensin	  
converting	   enzyme	   inhibitors,	   beta-­‐blockers,	   and	   aldosterone	   antagonists	   for	   systolic	   heart	  
failure),	  and	  the	  control	  of	  co-­‐morbidities	  such	  as	  hypertension,	  diabetes	  or	  obesity	  are	  central	  
to	   a	   treatment	   strategy.	   If	   the	   patient	   has	   a	   broad	   QRS	   complex	   and	   left	   ventricular	   systolic	  
dysfunction,	  cardiac	  resynchronisation	  therapy	  should	  also	  be	  considered.	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1.18.7.1. Oxygen	  
Administration	   of	   supplemental	   overnight	   oxygen	   via	   nasal	   cannula	   improves	   overnight	  mean	  
saturation	  but	  does	  not	  always	  significantly	  reduce	  the	  amount	  of	  SDB	  (159;160).	  For	  this	  reason,	  
this	  is	  therefore	  not	  a	  recommended	  treatment	  option.	  	  	  
1.18.7.2. Benzodiazepines	  	  
These	   have	   been	   used	   to	   treat	   SDB,	   but	   although	   they	   blunt	   arousals,	   they	   also	   reduce	   the	  
amount	  of	  slow	  wave	  and	  REM	  sleep	  and	  paradoxically	  worsen	  SDB	  (161).	  
1.18.7.3. Non-­‐Invasive	  Ventilation	  
Continuous	  positive	  airway	  pressure	  (CPAP)	  is	  recommended	  to	  treat	  symptomatic	  patients	  with	  
OSA	   (162).	   It	   helps	   improve	   SDB	   (and	   any	   attendant	   symptoms),	   and	   may	   also	   improve	   the	  
control	  of	  co-­‐existing	  hypertension,	  angina	  or	  arrhythmia.	  There	  is	  also	  increasing	  evidence	  that	  
it	  may	  help	  improve	  left	  ventricular	  function	  in	  patients	  with	  heart	  failure	  and	  OSA	  (58).	  There	  is	  
no	   evidence	   that	   using	   a	   strategy	   of	   CPAP	   for	   CSA	   in	   heart	   failure	   improves	   outcome.	   In	   one	  
medium	  sized	  randomised	  trial	  –	  the	  Canadian	  Positive	  Airways	  Pressure	  Trial	  (CAN-­‐PAP)	  –	  there	  
was	  no	  improvement	  in	  mortality	  or	  hospitalisation	  for	  heart	  failure,	  and	  the	  study	  was	  stopped	  
early	   because	   of,	   amongst	   other	   issues,	   low	   event	   rates	   and	   difficulty	   in	   recruitment	   (163).	   A	  
post-­‐hoc	   analysis	   of	   those	   patients	   in	  whom	   the	   CPAP	   therapy	   had	   effectively	   suppressed	   the	  
CSA,	  there	  was	  statistical	  evidence	  of	  benefit,	  (164)	  and	  this	  encouraging	  signal	  led	  to	  the	  design	  
of	   a	  much	   larger	   randomised	   trial	   of	   adaptive	   servo	   ventilation	   (ASV)	   in	  predominantly	  CSA	   in	  
systolic	  heart	  failure	  (SERVE-­‐HF)	  (165).	  This	  study	  has	  finished	  recruitment	  (1325	  patients)	  with	  
results	   expected	   in	   2015	   regarding	   the	   effect	   of	   this	   form	   of	   ventilation	   on	   mortality	   and	  
hospitalisation,	  ventricular	  function,	  control	  of	  the	  heart	  failure	  syndrome,	  and	  quality	  of	  life.	  	  	  
Unlike	   CPAP,	   ASV	   provides	   varying	   amounts	   of	   ventilatory	   support	   during	   different	   phases	   of	  
CSR:	  minimal	  during	  the	  hyperpnoeic	  phase	  and	  maximal	  during	  periods	  of	  apnoea	  or	  hypopnea.	  
This	  provides	  steady	  ventilation	  and	  abolishes	  CSA	  very	  effectively	  (Figure	  10).	  Small	  studies	  have	  
shown	   that	   this	   treatment	   is	   safe,	  more	   efficient	   at	   normalising	   CSR	   than	   CPAP,	   and	   is	   better	  
tolerated	  than	  CPAP	  or	  oxygen	  therapy.	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Another	  randomised	  trial	  (ADVENT	  –	  Effect	  of	  Adaptive	  Servo	  Ventilation	  (ASV)	  on	  Survival	  and	  
Hospital	  Admissions	  in	  Heart	  Failure)	  is	  currently	  recruiting	  patients,	  and	  will	  test	  whether	  CPAP	  
Improves	  outcome	  for	  patients	  with	  heart	  failure	  and	  SDB	  –	  whether	  OSA	  or	  CSA	  (166)	  
	  
Figure	  10:	  3-­‐minute	  epoch	  recordings	  showing	  how	  treatment	  of	  Central	  Sleep	  Apnoea	  using	  ASV	  
treatment	  abolishes	  respiratory	  events.	  Top	  Image	  –	  Untreated	  CSA.	  Bottom	  Image	  –	  Treated	  CSA	  with	  
ASV.	  
	  
1.18.8. Ventilatory	  Changes	  as	  a	  Marker	  of	  Deterioration	  
The	  main	   function	  of	   the	  respiratory	  system	   is	  gas	  exchange	  however	  a	  broad	  range	  of	   factors	  
can	   affect	   ventilation	   including	   influences	   the	   nervous	   system,	   the	   cardiovascular	   system,	   the	  
respiratory	  system,	  and	  the	  excretory	  system.	  	  
The	  respiratory	  rate	  on	  its	  own	  is	  a	  broad	  indicator	  of	  major	  physiological	  instability	  and	  can	  help	  
identify	   patients	   at	   risk	   of	   serious	   adverse	   events	   such	   as	   cardiac	   arrest	   and	   unplanned	   ICU	  
admission.	   In	   a	   small	   study,	   Fieselmann	   et	   al	   retrospectively	   examined	   59	   inpatients	   from	   12	  
wards	  at	  a	   single	   centre	   in	  an	  American	  hospital	   that	  had	  experienced	  cardiopulmonary	  arrest	  
and	  had	  at	  least	  72	  hours	  of	  inpatient	  vital	  signs	  recorded.	  They	  demonstrated	  that	  a	  respiratory	  
!
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rate	  higher	  than	  27	  breaths	  a	  minute	  had	  a	  sensitivity	  of	  0.54	  and	  a	  specificity	  of	  0.83	  (odds	  ratio	  
=	  5.56,	  95%	  CL	  =	  2.67-­‐11.49)	  in	  predicting	  cardiopulmonary	  arrest	  (167).	  	  
Subbe	  and	  colleagues	  prospectively	   studied	  1695	  acute	  medical	   admissions	   in	  UK	  medical	  unit	  
who	   had	   their	   risk	   of	   clinical	   deterioration	   stratified	   according	   to	   the	  modified	   early	   warning	  
score	  (MEWS).	  This	  tool	  records	  parameters	  that	  also	  included	  the	  systolic	  blood	  pressure,	  heart	  
rate	   and	   oxygen	   saturations	   (168).	   While	   there	   was	   no	   statistically	   significant	   difference	   in	  
mortality	  between	  the	  different	   risk	  groups,	   they	   found	  that	   the	  RR	  was	  best	  at	  discriminating	  
between	  these	  patients.	  (169).	  
Alveolar	   ventilation,	   which	   is	   a	   product	   of	   the	   respiratory	   rate	   and	   tidal	   volume,	   is	   normally	  
under	   strict	   control	  of	   chemoreceptors	  centrally	   in	   the	  medulla	  and	  peripherally	   in	   the	  carotid	  
bodies	  as	  well	  as	   lung	  baroreceptors.	  These	  mechanisms	  monitor	  changes	   in	   these	  parameters	  
and	  when	   there	   is	   an	  alteration	  or	   imbalance	   in	   the	  partial	  pressures	  of	  oxygen	   (PaO2)	  and	   in	  
particular	  carbon	  dioxide	  (paCO2),	  one	  way	  the	  body	  corrects	  for	  this	  hypoxaemia	  or	  hypercarbia	  
is	  to	  increase	  ventilation.	  	  
Therefore	  any	  condition	  that	  results	   in	  a	  metabolic	  acidosis,	  which	  results	   in	  an	   increase	   in	  the	  
concentration	  of	  hydrogen	   ions	  and	  consequently	   increased	  CO2	  production,	  would	  precipitate	  
an	  increase	  in	  tidal	  volume	  and	  respiratory	  rate.	  This	  makes	  the	  respiratory	  rate	  a	  broad	  indicator	  
of	  severe	  derangement	  in	  these	  organ	  systems,	  as	  well	  as	  an	  indicator	  of	  respiratory	  disorders.	  
Not	   only	   is	   the	   absolute	   respiratory	   rate	   important,	   RR	   trends	   are	   also	   very	  useful	  markers	   of	  
potential	  ill	  health.	  The	  RR	  trend	  can	  indicate	  progression	  of	  cardiopulmonary	  illnesses,	  including	  
acute	   respiratory	   distress	   syndrome,	   pulmonary	   oedema,	   pulmonary	   embolism,	   pneumonia,	  
COPD,	   and	   severe	   heart	   failure.	   Changes	   in	   respiratory	   rate	   can	   also	   indicate	   sepsis,	   systemic	  
inflammation,	   low	  blood	  volume,	  and	  malfunctions	  of	   the	  excretory	   system	  or	  central	  nervous	  
system	   disorders,	   including	   intracranial	   pressure,	   neurogenic,	   pain,	   and	   opioid-­‐induced	  
respiratory	  depression.	  
Ventilatory	  changes,	  which	  are	  the	  hallmark	  of	  Sleep	  Disordered	  Breathing	  (SDB),	  are	  therefore	  
potentially	  useful	  in	  the	  context	  of	  predicting	  heart	  failure	  deterioration.	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1.18.9. Sleep	  Disordered	  Breathing	  as	  a	  predictor	  of	  Acute	  
Decompensation	  of	  Heart	  Failure	  
Hospitalisations	   related	   to	   decompensation	   of	   chronic	   heart	   failure	   have	   significant	   cost	  
implications	   to	   healthcare	   systems	   and	   lead	   to	   increased	   morbidity	   and	   mortality.	   For	   this	  
reason,	  a	   lot	  of	  emphasis	   is	  now	  being	  placed	  on	  the	  early	   identification	  of	  these	  patients	  who	  
are	  deteriorating	  so	  that	  potential	  hospital	  admission	  can	  be	  averted.	  	  
In	   the	   United	   Kingdom,	   community	   heart	   failure	   services,	   which	   involve	   the	   specialist	   heart	  
failure	  nurses	  and	  patients	  have	  been	  shown	  to	  reduce	  hospitalisation	  (3).	  This	  system	  operate	  
by	  empowering	  patients	  with	  information	  regarding	  their	  disease,	  and	  is	  thought	  to	  be	  a	  useful	  
way	   of	   managing	   recurrent	   hospitalisation,	   by	   creating	   the	   ‘expert	   patient’	   who	   could	   adjust	  
their	   diuretics	   in	   particular;	   in	   response	   to	   their	   symptoms.	   However	   the	   continued	  
socioeconomic	  burden	  of	  recurrent	  hospital	  admissions	  for	  managing	  decompensation	  of	  heart	  
failure	  suggests	  that	  these	  measures	  on	  their	  own	  may	  not	  be	  adequate.	  Identifying	  other	  means	  
to	  prevent	  such	  admissions	  therefore	  becomes	  desirable.	  
Sleep	  disordered	  breathing	   (SDB)	   and	   in	   particular	   central	   sleep	   apnoea	   (CSA)	   associated	  with	  
Cheyne’s	  Stokes	  Respiration	  (CSR)	  is	  prevalent	  in	  patients	  with	  heart	  failure	  and	  may	  be	  found	  at	  
any	  symptomatic	  stage	  of	  the	  condition	  (8)..	  The	  presence	  of	  CSR	  therefore	  reflects	  severity	  of	  
CHF	  and	  prognosis.	  It	  is	  also	  an	  independent	  predictor	  of	  mortality	  and	  cardiac	  transplantation	  in	  
several	  studies	  (9;127).	  
Nocturnal	   rostral	   fluid	   shifts	   have	   been	   shown	   to	   increase	   the	   predisposition	   to	   upper	   airway	  
collapse	  in	  stable	  CHF	  patients	  with	  OSA	  or	  CSA	  (170).	  	  Upper	  airway	  instability	  is	  also	  known	  to	  
follow	  central	  apnoeas	  leading	  to	  obstructive	  events	  towards	  the	  end	  of	  the	  central	  event	  (171).	  	  
There	  is	  an	  increase	  in	  cervical	  venous	  congestion	  during	  a	  decompensated	  state	  of	  heart	  failure	  
as	   part	   of	   overall	   fluid	   overload.	   As	   patients	   with	   ADHF	   are	   a	   distinct	   group	   compared	   to	  
ambulatory	  patients,	  it	  is	  possible	  to	  speculate	  that	  worsening	  of	  upper	  airway	  collapsibility	  may	  
result	   in	  more	   respiratory	   events	   of	   apnoeas	   and	   hypopnoeas	   leading	   to	   an	   increased	   overall	  
prevalence	  of	  SDB.	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Majority	   of	   the	   studies	   that	   have	   reported	   on	   the	   prevalence	   of	   SDB	   in	   patients	  with	   chronic	  
heart	   failure,	   have	   however	   examined	  mainly	   ambulant	   and	   euvolaemic	   patients	   (6;7).	   Only	   a	  
few	  studies	  have	  assessed	  the	  significance	  of	  the	  presence	  of	  SDB	  in	  patients	  who	  are	   in	  acute	  
decompensated	  heart	  failure	  (ADHF).	  
Padeletti	  and	  colleagues	  performed	  overnight	   in-­‐hospital	  Polysomnography	   (PSG)	   studies	   in	  29	  
patients	  who	  had	  been	  admitted	  within	  48	  hours	  of	  an	  acute	  decompensation	  of	  heart	   failure	  
and	  found	  a	  high	  prevalence	  of	  SDB,	  with	  76%	  of	  their	  cohort	  having	  an	  Apnoea	  Hypopnea	  Index	  
(AHI)	  >15	  events	  per	  hour.	  These	  patients	  had	  predominantly	  CSR	   (Central	  events	  39±29/hour;	  
Obstructive	  events	  2±2/hour	  p<0.001).	  The	  mean	  ejection	  fraction	  in	  this	  group	  of	  patients	  was	  
20±6%	  (172),	  so	  they	  were	  notably	  a	  sicker	  group.	  
Similarly	  Khayat	  and	  colleagues	  found	  75%	  of	  their	  cohort	  of	  395	  patients,	  had	  evidence	  of	  SDB	  
defined	  by	  an	  AHI	  of	  ≥15	  events/hour	  (173).	  These	  patients	  had	  been	  admitted	  following	  new-­‐
onset	  acute	  heart	   failure	  or	  an	  exacerbation	  of	  already	  recognised	  chronic	  heart	   failure.	   In	  this	  
study,	  the	  prevalence	  of	  obstructive	  SDB	  (57%	  95%	  CI	  [52-­‐62])	  exceeded	  that	  of	  predominantly	  
central	  SDB	  (18%	  95%	  CI	  [14-­‐22])	  by	  up	  to	  a	  third.	  In	  these	  patients	  only	  apnoeas	  were	  employed	  
in	  the	  scoring	  criteria,	  which	  grouped	  patients	  as	  central	  SDB	  and	  this	  could	  have	  contributed	  to	  
this	  finding.	  	  
It	  has	  also	  been	  shown	  by	  Solin	  and	  colleagues,	  that	  central	  sleep	  apnoea	  episodes	  were	  more	  
frequent	  and	  more	  severe	  in	  patients	  with	  increased	  preload	  as	  is	  the	  case	  with	  decompensation	  
of	  heart	   failure	   (155).	  The	  mechanism	   for	   this	   finding	   is	   thought	   to	   relate	   to	   increased	  minute	  
ventilation	   from	   pulmonary	   congestion	   and	   the	   resultant	   hypocapnia,	   leading	   to	   respiratory	  
control	  instability,	  which	  is	  the	  key	  mechanism	  that	  drives	  CSA	  (174;175).	  	  
They	   demonstrated	   that	   in	   patients	   who	   had	   higher	   pulmonary	   capillary	   wedge	   pressures	  
(PCWP),	  determined	  by	  right	  heart	  catheterisation	  studies,	  central	  events	  predominated.	  (Mean	  
±SEM;	   central	   22.8±1.2;	   obstructive	   12.3±1.2;	   non-­‐apnoea	   11.5±1.5	   events	   per	   hour).	  
Additionally,	   in	   the	  central	  apnoea	  group,	  PCWP	  correlated	  with	   the	   frequency	  and	  severity	  of	  
central	  apnoea	  indexed	  by	  the	  AHI	  (r=0.47,	  p=0.006).	  They	  also	  noted	  a	  significant	  reduction	  in	  
the	  PCWP	  (29±2.6	  to	  22±1.8	  mmHg	  p<0.001)	  and	  central	  apnoea	  frequency	  (38.5±7.7	  to	  18.5±5.3	  
events	   per	   hour	   p=0.005)	   following	   intensive	   medical	   treatment	   that	   reduced	   pulmonary	  
congestion.	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Similarly	   in	   105	   patients	  with	   symptomatic	   but	   stable	   heart	   failure	   studied	   by	   Oldenburg	   and	  
colleagues,	   they	   found	   that	   SDB	  of	   the	  Central	   variety	  predominated.	   	   In	   these	  patients	  mean	  
PCWP	  was	  higher	  in	  CSA	  and	  OSA	  patients	  compared	  to	  those	  with	  heart	  failure	  but	  without	  SDB.	  
Furthermore	  mean	  PCWP	  correlated	  with	  AHI	  (r=0.409,	  p=0.005)	  in	  CSA	  patients	  but	  not	  in	  OSA	  
patients.	  
Overall,	  these	  studies	  suggest	  that	  during	  a	  decompensation	  of	  heart	  failure,	  there	  is	  an	  increase	  
in	   the	  amount	  of	   sleep	  disordered	  breathing	  measured	  by	   the	  Apnoea	  Hypopnea	   Index	  and	   in	  
some	   cases	   the	   amount	   of	   Cheyne-­‐Stokes	   respiration	   present.	   This	   results	   in	   a	   predominantly	  
CSA-­‐CSR	   pattern	   of	   SDB	   from	   increased	   pulmonary	   venous	   load	   or	   OSA	   pattern	   from	   cervical	  
venous	  congestion.	  
It	   is	   important	  to	  note	  that	  all	  of	  the	  studies	  described	  above	  have	  utilised	  single	  night	  PG/PSG	  
for	   determination	   of	   the	   presence	   of	   SDB	   during	   the	   index	   hospital	   admission	   or	   the	   period	  
marked	  as	  decompensation.	  In	  addition,	  none	  of	  these	  studies	  have	  made	  direct	  comparisons	  of	  
the	  amount	  of	  SDB	  or	  CSR	  in	  stable	  state	  of	  CHF	  and	  with	  patients	  when	  decompensated.	  
One	  of	   the	  aims	  of	   this	   thesis	   is	   to	   investigate	  how	  the	  amount	  of	  SDB	  varies	   from	  a	  stable	   to	  
decompensated	  state	  by	  continuous	  measurements	  of	  the	  AHI	  and	  CSR	  over	  a	  prolonged	  period	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Glossary	  
Active	  window:	  The	  window	  that	  is	  currently	  selected	  for	  moving,	  sizing,	  editing,	  closing,	  or	  some	  
other	  function.	  
Algorithm:	   This	   is	   a	   well-­‐defined,	   step-­‐by-­‐step	   set	   of	   instructions	   for	   calculating	   a	   specific	  
function	  	  
ALU:	  Arithmetic	  logic	  unit.	  
Amplitude:	  the	  maximum	  extent	  of	  variation	  from	  the	  zero	  or	  mean	  value	  of	  a	  signal	  
Binding:	  Associating	  or	  linking	  together	  two	  complementary	  software	  objects.	  
Boot:	  The	  process	  of	  loading	  a	  program	  into	  program	  memory.	  
Cache:	  A	  fast	  memory	  into	  which	  frequently	  used	  data	  or	  instructions	  from	  slower	  memory	  are	  
copied	   for	   fast	   access.	   Fast	   access	   is	   facilitated	   by	   the	   cache’s	   high	   speed	   and	   its	   on-­‐chip	  
proximity	  to	  the	  CPU.	  
Central	   processing	   unit	   (CPU):	   The	   CPU	   is	   the	   portion	   of	   the	   processor	   involved	   in	   arithmetic,	  
shifting,	  logic	  operations,	  as	  well	  as	  the	  generation	  of	  data-­‐	  and	  program-­‐memory	  addresses.	  	  
Classifier:	  A	  Classifier	  is	  essentially	  a	  mathematical	  function	  that	  can	  map	  those	  sets	  of	  features	  
extracted	  from	  the	  raw	  signals	  into	  a	  category	  
Code:	  A	  set	  of	  instructions	  written	  to	  perform	  a	  task;	  a	  computer	  program	  or	  part	  of	  a	  program.	  
Convolution:	  A	  time	  or	  frequency	  domain	  reference	  for	  digital	  filtering	  that	  makes	  extensive	  use	  
of	  sum-­‐of-­‐products.	  
Digital	   mixing:	   The	   mixing	   together	   of	   two	   digital	   signals	   into	   one;	   the	   algebraic	   sum	   of	   two	  
digital	  signals.	  
Domain:	  This	  is	  an	  administrative	  area	  where	  signal	  analysis	  and	  processing	  takes	  place	  
DSL:	  Stands	  for	  Digital	  Subscriber	  Loop.	  It	  shares	  the	  same	  phone	  line	  as	  the	  telephone	  service,	  
but	  it	  uses	  a	  different	  part	  of	  the	  phone	  line's	  bandwidth.	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Feature:	  A	  feature	  is	  a	  characteristic	  of	  the	  raw	  signal	  that	  helps	  us	  identify	  its	  morphology	  and	  
place	  it	  into	  a	  physiological	  group,	  for	  instance,	  the	  heart	  rate	  or	  respiratory	  rate.	  	  
Filters:	   These	   are	   devices	   or	   digital	   processes	   that	   aim	   to	   eliminate	   noise	   or	   unwanted	  
interference	  from	  signals	  
Frequency:	   The	   number	   of	   cycles	   per	   unit	   of	   time,	   denoted	   by	  Hertz	   (Hz).	  One	  Hz	   equals	   one	  
cycle	  per	  second.	  
Frequency	  Domain:	  the	  analysis	  of	  mathematical	  functions	  with	  respect	  to	  frequency	  
JPEG	  (Joint	  Photographic	  Experts	  Group):	  An	  industry	  standard	  for	  compressing	  images	  
Load:	  To	  enter	  data	  into	  storage	  or	  working	  registers.	  
Noise:	  This	  refers	  to	  artefact	  or	  interference	  that	  corrupts	  signals	  	  
Time	  Domain:	  the	  analysis	  of	  mathematical	  functions	  with	  respect	  to	  time	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1.19. The	  Challenge	  of	  Digital	  Signal	  Analysis	  and	  Processing	  in	  
Medicine	  
A	  signal	  is	  any	  variable	  that	  carries	  or	  contains	  some	  kind	  of	  information	  that	  can,	  for	  example,	  
be	   conveyed,	   displayed	   or	   manipulated.	   Examples	   include	   Speech,	   Biomedical	   signals	   such	   as	  
EEG,	  echocardiography,	  Sound	  and	  Music,	  Video	  and	  Image	  and	  Radar	  signals,	  which	  determine	  
range	  and	  bearing	  of	  distant	  targets.	  
The	   specific	   reasons	   for	   processing	   a	   signal	   may	   be	   to	   remove	   noise/interference,	   obtain	   a	  
spectrum	  of	  the	  data	  or	  to	  transform	  the	  data	  into	  a	  more	  suitable	  form.	  Digital	  signal	  processing	  
(DSP)	  refers	  to	  the	  digital	  representation	  of	  signals	  and	  the	  use	  of	  digital	  processors	  to	  analyse,	  
modify	  or	  extract	  information	  from	  signals.	  	  	  
Most	  signals	  found	  in	  nature	  vary	  continuously	  with	  time	  and	  represent	  the	  variations	  of	  physical	  
quantities	  such	  as	  sound	  for	  example.	  They	  may	  be	  represented	  in	  an	  analog	  or	  digital	  fashion.	  	  
Analog	  Signals	  
An	   analog	   signal	   is	   any	   continuous	   signal	   for	   which	   the	   time	   varying	   feature	   (variable)	   of	   the	  
signal	   is	  a	   representation	  of	   some	  other	   time	  varying	  quantity,	   i.e.,	   analogous	   to	  another	   time	  
varying	   signal.	   For	   example,	   in	   an	   analog	   audio	   signal,	   the	   instantaneous	   voltage	   of	   the	   signal	  
varies	  continuously	  with	  the	  pressure	  of	  the	  sound	  waves.	  The	  main	  advantage	  of	  analog	  signals	  
is	   that	   it	   is	   continuous	   and	   an	   exact	   representation	   of	   the	   information	   collected.	   The	   main	  
disadvantage	   is	   that	  because	  every	  system	  has	  noise	  –	   i.e.,	   random	  unwanted	  variation,	  as	  the	  
signal	   is	   copied	   and	   re-­‐copied,	   or	   transmitted	  over	   long	  distances,	   or	   electronically	   processed,	  
the	   unavoidable	   noise	   introduced	   by	   each	   step	   in	   the	   signal	   path	   is	   additive,	   progressively	  
degrading	  the	  signal-­‐to-­‐noise	  ratio,	  until	  in	  extreme	  cases	  the	  signal	  can	  be	  overwhelmed.	  
Digital	  Signals	  
A	  digital	   signal	   is	   a	   representation	  of	   a	   sequence	  of	   discrete	   values	  of	   an	   analog	   signal.	   These	  
values	   are	   obtained	   from	   samples	   or	   segments	   of	   the	   original	   analog	   signal.	   They	   are	   not	  
continuous	   because	   they	   only	   use	   specific	   values	   to	   represent	   samples	   of	   the	   original	  
information	  and	  so	  may	  not	  be	  an	  exact	  copy.	  The	  fidelity	  of	  a	  digital	  signal	  is	  however	  retained	  
with	  current	  technology	  that	  allow	  for	  more	  frequent	  samples	  of	  the	  original	  analog	  signal	  to	  be	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collected	  which	  means	  that	  there	  is	  an	  insignificant	  loss	  of	  information.	  The	  cost	  implications	  and	  
need	  for	  expertise	  in	  designing	  these	  systems	  is	  one	  notable	  disadvantage.	  
The	  signals	  used	  in	  most	  forms	  of	  DSP	  are	  derived	  from	  analog	  signals,	  which	  have	  been	  sampled	  
at	  regular	  intervals	  and	  converted	  into	  a	  digital	  form.	  See	  Figure	  11.	  
	  
Figure	  11:	  Digital	  signals	  are	  transformed	  analog	  signals	  sampled	  at	  regular	  intervals:	  Steps	  
The	  advantages	  of	  DSP	  over	  analog	   techniques	  are	   that	   they	  are	  more	  accurate	  and	   therefore	  
reproducible.	   This	   is	   because	   noise	   or	   interference	   can	   be	   eliminated	   at	   various	   steps	   of	  
collection,	  to	  produce	  a	  much	  cleaner	  signal.	  The	  performance	  is	  unaffected	  by	  temperature	  or	  
age,	  and	  it	  is	  flexible	  meaning	  that	  you	  do	  not	  need	  to	  modify	  hardware	  following	  programming	  
and	  re-­‐programming.	  	  
DSP	   has	   developed	   increasing	   importance	   in	   many	   key	   areas	   of	   technology	   including	  
telecommunication,	   media,	   financial	   markets	   and	   biomedicine.	   It	   is	   now	   at	   the	   core	   of	   many	  
emerging	  technologies	  that	  produce	  digital	  products	  that	  we	  use	   in	  everyday	  functions	  such	  as	  
digital	  phones,	  television	  media,	  cameras,	  and	  banking.	  	  
In	  medicine,	  perhaps	  greater	  advancement	  is	  expected	  as	  the	  medical	  community	  is	  persuaded	  
to	  collaborate	  with	  the	  engineering	  industry	  to	  continue	  to	  develop	  appropriate	  technology	  that	  
would	  enhance	  patient	  experience,	  improve	  quality	  of	  life,	  prevent	  development	  or	  worsening	  of	  
illness	   and	   as	   a	   harder	   end	   point,	   reduce	   mortality.	   This	   collaboration	   is	   the	   basis	   of	  
Bioengineering,	  which is	  the	  application	  of	  concepts	  and	  methods	  of	  biology	  to	  solve	  real-­‐world	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Biomedicine	   therefore	   represents	   an	   important	   and	   fertile	   area	   for	   both	   the	   application	   of	  
conventional	  DSP	  and	  more	  importantly	  for	  the	  development	  of	  new	  and	  robust	  DSP	  algorithms	  
that	  could	  improve	  patient	  care.	  	  
Biomedical	  scientists	  utilise	  DSP	  in	  developing	  algorithms	  for	  patient	  monitoring,	  scanners,	  EEG	  
brain	  mappers,	  ECG	  analysis,	  X-­‐rays	  amongst	  a	  few.	  Medicine	  poses	  a	  unique	  problem	  however	  
as	  its	  data	  is	  one	  of	  the	  most	  complex	  forms	  recorded.	  The	  reason	  being	  that	  they	  are	  generated	  
from	  patients	  who	  are	  inherently	  different	  in	  their	  physical	  and	  constitutional	  characteristics	  and	  
expectedly	   produce	   different	   outputs.	   The	   data	   produced	   from	   patients	   are	   also	   affected	   by	  
changes	   in	   individual	   physiology	   on	   a	   daily	   basis	   and	   particularly	   from	   healthy	   to	   non-­‐healthy	  
states	   as	   well	   as	   interactions	   with	   environmental	   factors.	   This	   represents	   a	   challenge	   to	   the	  
engineer	  who	  must	   come	  up	  with	  novel	  ways	  of	  manipulating	  and	   interpreting	   these	   complex	  
medical	  data.	  
1.19.1. Properties	  of	  a	  signal	  
Any	  physiological	  parameter	   can	  be	  described	  by	  a	   frequency	  which	   is	  measured	   in	  Hertz	   (Hz)	  
and	  this	  represents	  the	  number	  of	  times	  that	  parameter	  occurs	  in	  a	  second.	  	  An	  example	  is	  the	  
respiratory	  rate,	  which	  in	  a	  normal	  healthy	  adult	  occurs	  about	  12	  times	  a	  minute.	  A	  device	  that	  
measures	  it	  may	  therefore	  produce	  a	  signal	  that	  occurs	  at	  least	  0.2	  times	  per	  second=	  0.2Hz.	  It	  is	  
also	  described	  as	  an	  inverse	  of	  time:	  	  
T	  =	  1/f	  (where	  T	  =	  time	  in	  seconds	  and	  f	  =	  frequency)	  
In	  DSP	   the	   term	  sampling	   frequencies	  of	   signals	   is	  used	   representing	   the	  number	  of	   times	  per	  
second	   a	   signal	   is	   sampled	   during	   processing.	   It	   is	   important	   that	   the	   sample	   frequency	   (f)	   is	  
greater	  than	  twice	  the	  maximum	  frequency	  (fMax)	  of	  the	  signal	  otherwise	  it	  may	  be	  impossible	  
to	   record	   that	   signal	   especially	   if	   it	   is	   prone	   to	   variation.	   This	   is	   known	   as	   the	   Nyqist	   limit,	   a	  
concept	  that	  is	  similarly	  employed	  in	  transthoracic	  echocardiography	  for	  Doppler	  assessment	  of	  
valvular	  incompetence	  (f	  ≥	  2	  fMax).	  	  
The	  other	  properties	   that	   are	  of	   importance	   in	   signal	   analysis	   include	   the	  amplitude,	   the	   time	  
frequency	  behaviour,	  and	  regularity.	  This	  list	  is	  non-­‐exhaustive	  especially	  as	  signal	  processing	  is	  
usually	  specific	  to	  the	  functional	  parameter	  we	  want	  to	  measure.	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1.19.2. Key	  Digital	  Signal	  Processing	  (DSP)	  Operations	  
In	  this	  segment	  I	  will	  discuss	  a	  few	  key	  DSP	  operations	  (176),	  some	  of	  which	  I	  have	  used	  in	  some	  
detail	   in	  this	  thesis.	   I	  have	  focused	  on	  the	  main	  techniques	  that	   I	  have	  employed	  in	  generating	  
some	   of	   the	   algorithms	   for	   SleepMinderTM	   estimation	   of	   respiratory	   parameters	   used	   in	  
diagnosis	  and	  prediction	  of	  ADHF,	  which	  I	  will	  discuss	  in	  the	  next	  chapters.	  	  
I	   have	  also	  excluded	   the	   finer	  details	  of	   the	  mathematical	  permutations	   that	  are	  generated	   to	  
produce	  these	  algorithms	  as	  they	  are	  outside	  the	  focus	  and	  beyond	  the	  scope	  of	  my	  thesis.	  
	  
1.19.2.1. Digital	  filtering	  and	  Signal	  Enhancement	  
Both	  techniques	  essentially	  involve	  the	  removal	  of	  noise/artefact	  from	  the	  wanted	  signal.	  	  
Digital	  Filtering	  	  
Biomedical	   signals	   may	   sometimes	   contain	   high	   frequency	   distortion	   and	   digital	   filtering	  
preserves	   necessary	   components	   by	   using	   filters,	   which	   are	   devices	   or	   digital	   processes	   that	  
remove	  from	  a	  signal	  some	  unwanted	  component	  or	  feature.	  
In	  DSP,	  it	  is	  common	  to	  use	  a	  combination	  of	  various	  filters	  to	  achieve	  better	  results.	  These	  filters	  
act	   intelligently	   to	   remove	   some	   frequencies	   and	   not	   others	   in	   order	   to	   suppress	   interfering	  
signals	  and	  reduce	  background	  noise.	  
The	   main	   aim	   is	   to	   eliminate	   as	   much	   noise	   as	   possible	   so	   that	   the	   signal	   to	   noise	   ratio	   is	  
increased	  i.e.	   less	  noise	   is	  present.	  A	  high-­‐pass	  filter	   is	  one	  where	  signals	  of	  higher	  frequencies	  
are	  passed	   through,	  while	   low	   frequency	   signals	  are	  attenuated	  or	  eliminated	   (Figure	  12).	   The	  
converse	  is	  true	  for	  Low-­‐pass	  filters.	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Figure	  12:	  A	  high	  pass	  filter	  removing	  noise	  from	  the	  raw	  signal	  to	  produce	  a	  cleaner	  signal	  
Signal	  Enhancement	  
The	   need	   for	   signal	   enhancement	   arises	   from	   a	   similar	   problem	   of	   artefact	   or	   signal	  
contamination,	  which	  is	  pervasive	  in	  biomedicine.	  Artefacts	  can	  be	  generated	  by	  either	  external	  
(mains	  supply	  or	  conflicting	  medical	  equipment)	  or	  internal	  (body	  movements,	  cardiac	  activity	  or	  
illness)	   factors	   and	   these	   reduce	   the	   quality	   of	   the	   signals,	  which	   consequently	   affects	   clinical	  
usefulness.	  	  
Analysis	  of	  these	  signals	  whether	  done	  manually	  or	  automatically	  can	  thus	  become	  very	  difficult	  
to	  perform	  and	   sometimes	   impossible.	   Therefore	  a	   great	  deal	  of	   care	   is	   taken	   to	  enhance	   the	  
signals	  of	   interest	   to	   tackle	   the	  dual	  problem	  of	   low	  signal	   to	  noise	  ratio	  and	  overlap	  between	  
signal	  and	  noise	  spectra	  (Figure	  13).	  This	  is	  done	  in	  the	  hope	  that	  clinical	  information	  of	  interest	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Figure	  13:	  A.	  Greater	  overlap	  of	  noise	  and	  signal	  spectra	  and	  smaller	  signal	  to	  noise	  ratio	  before	  signal	  
enhancement.	  B.	  Lesser	  overlap	  of	  noise	  and	  signal	  spectra	  and	  higher	  signal	  to	  noise	  ratio.	  
Pattern	  recognition/Feature	  Extraction	  
The	   goal	   of	   pattern	   recognition	   is	   to	   classify	   objects	   of	   interest	   into	   one	   of	   a	   number	   of	  
categories	   or	   classes.	   These	   objects	   of	   interest	   are	   generically	   called	   patterns,	   which	   in	  
biomedicine	   may	   be	   from	   signals	   generated	   from	   a	   number	   of	   physiological	   parameters.	   An	  
algorithm	   is	   generated	  and	   implemented	  on	  a	   specific	   hardware	  which	  when	  applied	   to	   these	  
patterns	  would	  produce	  a	  result.	  
Supervised	  pattern	  recognition	  is	  a	  commonly	  utilized	  system	  in	  developing	  algorithms	  that	  are	  
effective	   in	   biomedicine	   and	   one	   that	   has	   been	   used	   in	   this	   project.	   A	   dataset	  may	   contain	   a	  
number	   of	   signals	   related	   to	   a	   physiological	   parameter,	   respiration	   for	   instance,	   that	   we	   are	  
interested	   in	   analysing.	   The	   important	   signals	  we	  are	   interested	   in	   are	   first	   removed	   from	   the	  
raw	  signals	  to	  create	  a	  set	  of	  labelled	  patterns	  and	  these	  comprise	  the	  ‘training	  set’.	  This	  process	  
is	   known	   as	   feature	   extraction.	   (See	   Glossary	   –	   Page	   96).	   A	   portion	   of	   these	   labelled	   signal	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patterns,	  collectively	  referred	  to	  as	  the	  ‘test	  set’	  are	  then	  used	  to	  test	  the	  derived	  classification	  
algorithm.	  Since	   the	  correct	  classes	  of	   the	   individual	   sampled	  patterns	  are	  already	  known,	   it	   is	  
easy	  to	  evaluate	  the	  performance	  of	  the	  algorithm	  (Figure	  14).	  
Depending	   on	   the	   results	   of	   the	   classification,	   the	   developer	   may	   make	   modifications	   to	   the	  
algorithm	   until	   a	   desired	   level	   of	   performance	   is	   achieved;	   which	   is	   measured	   in	   terms	   of	  
misclassification	   rates.	   Following	   on	   from	   this,	   the	   algorithm	   can	   now	   be	   used	   on	   unlabelled	  
data.	  Spot-­‐checking	  of	  results,	  as	  the	  feedback	  loop	  involving	  the	  developer	   is	  formally	  broken,	  
may	  be	  provided	  by	  an	  alternative	  classification	  algorithm	  or	   in	  some	  cases	  waiting	  a	   length	  of	  
time	  until	  the	  correct	  classification	  reveals	  itself.	  
	  
Figure	  14:	  Schematic	  showing	  the	  processes	  involved	  in	  Pattern	  recognition.	  
1.19.2.2. Discrete	  transformation	  
This	   is	   used	   in	   many	   DSP	   applications	   to	   allow	   for	   a	   more	   efficient	   implementation	   of	   DSP	  
algorithms.	  	  
In	   some	   situations,	   it	  may	   be	   necessary	   to	   transform	   the	   observed	   raw	   signal	   vector	   (x)	   to	   a	  
transformed	  features	  vector	  (y)	  for	  the	  classifier	  to	  produce	  a	  result	  (Figure	  15).	  	  
Transformation	  is	  necessary	  to	  reduce	  the	  number	  of	  features	  obtained	  from	  the	  original	  signal,	  
which	  are	  required	  to	  produce	  a	  result.	  It	  is	  important	  that	  while	  the	  features	  in	  the	  transformed	  
vector	  (y)	  are	  intended	  to	  be	  fewer	  than	  the	  observations,	  it	  should	  collectively	  contain	  most	  of	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Figure	  15:	  Schematic	  showing	  of	  transformation	  of	  vectors	  
The	   feature	   extraction	   procedures	   that	   are	   used	   now	   become	   very	   important	   here,	   so	   that	  
potentially	   important	   features	  are	  not	  discarded.	  This	  can	  be	  very	  difficult	   to	  achieve	  perfectly	  
especially	   if	   there	   are	   many	   variables	   and	   depending	   on	   the	   experience	   of	   the	  
developer/selector.	   In	   general	   features	   extraction	   procedures	   are	   either	   based	   on	   intuition,	  
physical	  consideration	  of	  the	  problem	  based	  on	  some	  prior	  knowledge	  or	  education	  about	  that	  
physiological	  parameter.	   It	   is	  also	  sometimes	  purely	  a	  mathematical	   technique	  that	  performs	  a	  
random	  selection.	  
Whatever	   mode	   is	   employed,	   the	   features	   vector	   (y)	   would	   be	   passed	   through	   the	   classifier,	  
which	  will	  make	  a	  decision	  about	   the	  pattern	  and	  as	  discussed	  earlier,	   the	  results	  can	  guide	   in	  
modifying	  either	  feature	  selection	  of	  classification	  algorithm	  especially	  if	  this	  was	  a	  development	  
phase	  of	  the	  program.	  
1.19.2.3. Correlation	  
Cross	   correlation	   is	   a	   measure	   of	   similarities	   or	   shared	   properties	   between	   two	   signals.	  
Applications	   include	   detection	   of	   signals	   buried	   in	   noise,	   pattern	   matching	   and	   delay	  
measurements.	  
When	  you	  want	  to	  compare	  two	  signals	  of	  varying	   frequencies	   for	   instance,	   this	  becomes	  very	  
important	   as	  we	   try	   to	   align	   or	  match	   their	   properties.	   For	   this	   process	   to	  work,	   a	   lot	   of	   the	  
previously	  discussed	  processes	  are	  employed	  initially	  to	  remove	  noise	  and	  to	  digitally	  transform	  
both	  signals	  onto	  similar	  vector	  planes	  from	  where	  they	  can	  be	  matched.	  Figure	  16	  below	  shows	  
how	  a	  32Hz	  respiratory	  signal	   is	  divided	   into	  segments	  from	  which	   integral	  absolute	  values	  are	  
obtained	  to	  form	  a	  new	  vector	  plane	  V1,	  V2,	  -­‐-­‐-­‐-­‐-­‐-­‐Vn.	  A	  similar	  process	  is	  performed	  on	  another	  
signal	  that	  may	  have	  similar	  properties	  but	  has	  been	  sampled	  at	  a	  different	  frequency	  to	  obtain	  a	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Figure	  16:	  32Hz	  Respiratory	  signals	  divided	  into	  1	  second	  blocks	  for	  new	  vector	  creation	  
Auto	  correlation	  in	  the	  other	  hand	  involves	  only	  one	  signal	  and	  provides	  information	  about	  the	  
structure	  of	  the	  signal	  or	  its	  behaviour	  in	  the	  time	  domain.	  
I	   have	   defined	   some	   other	   DSP	   operations,	   some	   of	   which	   I	   have	   used	   in	   small	   detail	   in	   this	  
project	  including:	  
1.19.2.4. Convolution	  
This	  is	  a	  frequently	  used	  operation	  in	  DSP	  particularly	  to	  filter	  signals	  by	  multiplication	  of	  signals	  
in	  the	  frequency	  and	  time	  domains.	  Essentially	  Convolution	  is	  a	  mathematical	  way	  of	  combining	  
two	   signals	   to	   form	   a	   third	   signal.	   More	   insight	   is	   gained	   and	   broader	   analysis	   can	   be	   made	  
because	  we	  can	  look	  more	  closely	  at	  the	  structure	  of	  the	  integrand	  signal.	  
1.19.2.5. Modulation	  
This	  process	  involves	  varying	  a	  property	  of	  a	  high	  frequency	  signal	  (the	  carrier)	  in	  sympathy	  with	  
the	  signal	  we	  wish	  to	  transmit	  known	  as	  the	  modulating	  signal.	  This	  is	  frequently	  employed	  in	  the	  
digital	   audio	   industry	   where	   signals	   are	   modulated	   to	   match	   the	   frequency	   characteristics	   of	  
those	   of	   the	   transmission	   and	   or	   storage	   media	   in	   order	   to	   minimize	   signal	   distortion,	   and	  
maximize	  available	  bandwidth.	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1.20. The	  SleepMinderTM	  Study	  
The	   SleepMinderTM	   study	   aims	   to	   validate	   the	   usefulness	   of	   a	   novel	   non-­‐contact	   device	  which	  
placed	  by	   a	   patient’s	   bedside	   is	   able	   to	   analyse	   respiratory	  patterns	  during	   sleep	   that	  may	  be	  
indicative	  of	  an	  upcoming	  decompensation	  episode	  in	  patients	  with	  chronic	  heart	  failure	  (CHF).	  
The	   SleepMinder™	   device	   (ResMed	   Ltd)	   utilises	   a	   biomotion	   sensor	   for	   contactless	   and	  
convenient	  measurement	  of	   sleep	  and	  breathing	   in	   the	  home.	   It	   contains	  a	  non-­‐contact	   radio-­‐
frequency	   sensor	   that	   continuously	   measures	   the	   biomotion	   due	   to	   breathing	   and	   body-­‐
movement	  of	  a	  subject	   in	  bed.	  The	  sensor	  operates	   in	  a	   license-­‐free	  band	  at	  5.8	  GHz,	  emits	  an	  
average	  power	  less	  than	  1	  mV	  and	  is	  capable	  of	  sensing	  movement	  and	  breathing	  over	  a	  distance	  
ranging	   from	   0.3	   to	   1.5	   meters;	   in	   the	   case	   of	   two	   people	   in	   the	   bed,	   a	   combination	   of	  
sophisticated	   sensor	   design	   and	   intelligent	   signal	   processing	   results	   in	   measuring	   only	   the	  
respiration	  of	  the	  person	  nearest	  to	  the	  sensor.	  
There	   is	   evidence	   from	   pilot	   analyses	   that	   show	   that	   the	   SM	   is	   able	   to	   estimate	   accurately	  
breathing	  rates	  and	  the	  AHI,	  which	  is	  the	  key	  parameter	  in	  making	  a	  diagnosis	  of	  SDB	  (177;178).	  
Certain	  nocturnal	   respiratory	  signals	  have	  also	  been	  suggested	  to	  be	  useful	   in	  predicting	  ADHF	  
from	  a	  small	  pilot	  study	  in	  Dublin.	  
I	   am	   carrying	   out	   SM	   analysis	   on	   a	   population	   of	   chronic	   heart	   failure	   patients	   from	   a	   west	  
London	  tertiary	  centre	  who	  are	  at	  moderate	  to	  severe	  risk	  of	  decompensation.	  The	  primary	  goal	  
of	  this	  study	  is	  to	  validate	  the	  diagnostic	  accuracy	  of	  the	  SM	  device	  in	  detecting	  ADHF	  events	  by	  
identifying	  sleep	  respiratory	  patterns	  that	  are	  peculiar	  to	  these	  episodes	  and	  correlating	  the	  SM	  
diagnosed	   events	   with	   clinical	   information.	   I	   will	   also	   examine	   how	   early	   these	   respiratory	  
patterns	  that	  are	  suggestive	  of	  ADHF	  appear	  in	  the	  build-­‐up	  to	  an	  overt	  deterioration.	  	  
To	   enable	  me	   achieve	   this,	   firstly	   I	   will	   validate	   the	   SM	   device	   against	   PSG	   in	   identifying	   and	  
classifying	   varying	   types	   of	   respiratory	   patterns	   associated	  with	   SDB.	   I	   will	   accomplish	   this	   by	  
developing	   event-­‐based	   algorithms,	   signal	   protocols	   and	   classifiers,	   which	   would	   detect	   SDB	  
events,	   by	   using,	   phase	   demodulation,	   amplitude,	   and	   correlation-­‐based	   signal	   processing	  
methods.	  Following	  the	  development	  of	  these	  algorithms	  identifying	  SDB,	  I	  would	  then	  use	  these	  
events	  occurring	  during	   sleep	  as	  ADHF	  episodes	  evolve	  and	   resolve	   to	  develop	  a	  SM	  predictor	  
algorithm	  for	  Acute	  Decompensation	  of	  Heart	  Failure	  (ADHF).	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SUMMARY	  OF	  THE	  LIST	  OF	  STUDIES	  
STUDY	  ONE	  –	  Chapter	  3	  
The	   validation	   of	   SleepMinderTM	   analysis	   of	   nocturnal	   respiratory	   patterns	   against	  
Polysomnography	   for	   diagnosing	   Sleep	   Disordered	   Breathing	   in	   patients	   with	   Chronic	   Heart	  
Failure	  
Main	  Hypothesis:	  	  
I	   hypothesised	   that	   there	   is	   a	   difference	   in	   the	  Apnoea	  Hypopnea	   Index	   (AHI)	   and	  quantity	   of	  
Cheyne-­‐Stokes	   Respiration	   (CSR)	   measured	   by	   the	   SleepMinderTM	   device	   compared	   to	   in	   –
hospital	  Polysomnography	  (PSG).	  
STUDY	  TWO	  –	  Chapter	  4	  
A	   Longitudinal	   Observation	   of	   Nocturnal	   Respiratory	   Patterns	   in	   patients	   with	   Chronic	   Heart	  
Failure	  using	  a	  Non-­‐Contact	  Breathing	  Monitor	  
Main	  Hypothesis:	  
I	  hypothesised	   that	  due	   to	  potential	  on-­‐going	  changes	   in	   the	  pathophysiology	  of	  CHF	  patients,	  
the	  AHI	  would	  have	  a	  high	  variability	  over	  a	   longer	  period	  of	  monitoring.	  My	   ‘Null’	  hypothesis	  
was	  therefore	  that	  there	  is	  a	  low	  variability	  in	  the	  Apnoea	  Hypopnea	  Index	  from	  night	  to	  night	  in	  
patients	  with	  Chronic	  Heart	  Failure	  over	  a	  long	  (12months)	  period	  of	  monitoring.	  	  
STUDY	  THREE	  –	  Chapter	  5	  
The	   Prediction	   of	   Acute	   Decompensation	   of	   Heart	   Failure	   Using	   a	   Non-­‐Contact	   Monitor	   of	  
Nocturnal	  Respiratory	  Patterns	  
Main	  Hypothesis:	  
I	  hypothesised	  that	  there	  is	  a	  measurable	  increase	  in	  the	  Apnoea	  Hypopnea	  Index	  (AHI)	  and	  the	  
%	   overnight	   Cheyne-­‐Stokes	   Respiration	   (CSR)	   by	   the	   SleepMinderTM	   device,	   within	   a	   7-­‐day	  
period,	  and	  which	  can	  be	  utilised	  as	  a	  predictor	  of	  acute	  decompensation	  of	  heart	  failure.	  
















































	   112	  
2.1. Ethical	  Considerations	  
This	  study	  received	  ethical	  approval	   from	  the	  National	  Research	  Ethics	  Service	  (NRES),	  London-­‐
Chelsea	   committee	   (REC	  Ref	   number	   08/H1307/41)	   as	  well	   as	   Site	   Specific	  Assessment	   by	   the	  
Research	  and	  Development	  department	  at	   the	  Royal	  Brompton	  and	  Harefield	  NHS	  Foundation	  
Trust	   prior	   commencing	   all	   aspect	   of	   this	   study	   (Ref	   number	   2008EP001B).	   An	   international	  
ethics	  approval	  for	  screening	  patients	  for	  sleep	  disordered	  breathing	  in	  heart	  failure	  patients	  was	  
also	   in	  place	  and	   this	   covered	  all	  patients	   recruited	   from	  the	  German	  centres,	   in	  Study	  2	   (Ref:	  
Freiburger	  IRB/IEC.	  FECCI	  Code	  010/1553).	  The	  group	  of	  patients	  recruited	  from	  Dublin,	   Ireland	  
were	  covered	  by	  local	  ethical	  approval	  from	  St.	  Vincent’s	  Hospital	  in	  Dublin.	  	  
The	   studies	   in	   this	   project	  have	  been	   conducted	   in	   accordance	  with	   the	   recommendations	   for	  
physicians	  involved	  in	  research	  on	  human	  subjects	  adopted	  by	  the	  18th	  World	  Medical	  Assembly,	  
Helsinki,	  1964,	  and	  later	  revisions,	  and	  are	  conducted	  in	  accordance	  with	  the	  principles	  of	  Good	  
Clinical	  Practice.	  	  
In	  addition,	  all	  patients	  in	  the	  study	  signed	  a	  written	  consent	  form	  before	  they	  were	  recruited	  to	  
take	  part	  and	  in	  line	  with	  strict	  data	  confidentiality,	  each	  participant	  was	  allocated	  an	  individual	  
study	  number	  for	  data	  collection	  and	  subsequent	  analysis.	  Further,	  all	  data	  relevant	  to	  the	  study,	  
was	  placed	  in	  a	  separate	  case	  record	  file	  for	  each	  participant	  and	  this	  was	  stored	  in	  our	  secure	  
research	   office	   unit	   based	   at	   the	   Royal	   Brompton	  Hospital	   London.	   Copies	   of	   ethical	   approval	  
letters,	  consent	  forms,	  patient	  information	  sheet	  and	  case	  record	  forms	  are	  included	  in	  Appendix	  
Section	  1-­‐4.	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2.2. Study	  Participants	  
2.2.1. Study	  One	  –	  The	  validation	  of	  SleepMinderTM	  analysis	  of	  nocturnal	  
respiratory	  patterns	  against	  Polysomnography	  for	  diagnosing	  Sleep	  
Disordered	  Breathing	  in	  patients	  with	  Chronic	  Heart	  Failure	  
	  
Patients	  in	  study	  one	  were	  consecutive	  adult	  patients	  from	  two	  tertiary	  heart	  failure	  units,	  one	  in	  
South-­‐West	   London,	   United	   Kingdom	   and	   the	   other	   in	   Essen,	   Germany.	   These	   patients	   had	  
presented	   for	   screening,	   to	   the	   heart	   failure	   clinic	  with	   recognized	   typical	   symptoms	   of	   Sleep	  
Disordered	  Breathing	  (SDB),	  including	  witnessed	  apnoeas	  and	  daytime	  somnolence.	  
They	   all	   had	   systolic	   heart	   failure	   defined	   by	   a	   recent	   transthoracic	   echocardiogram	   with	   an	  
ejection	   fraction	   (EF)	   of	   <45%.	  Patients	  with	   significant	  obstructive	   lung	  disease	  defined	  by	   an	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2.2.2. Study	  Two	  –	  A	  Longitudinal	  Observation	  of	  Nocturnal	  Respiratory	  Patterns	  
in	  patients	  with	  Chronic	  Heart	  Failure	  using	  a	  Non-­‐Contact	  Breathing	  
Monitor	  
Study	  Three	  –	  The	  Prediction	  of	  Acute	  Decompensation	  of	  Heart	  Failure	  
Using	  a	  Non-­‐Contact	  Monitor	  of	  Nocturnal	  Respiratory	  Patterns	  
	  
Patients	   in	   Study	   three	   comprised	  of	  a	  development	  group	  enrolled	   from	  chronic	  heart	   failure	  
patients	  attending	  St.	  Vincent’s	  Hospital	  in	  Dublin	  Ireland	  and	  a	  validation	  group	  of	  patients	  who	  
were	  enrolled	   from	  the	  heart	   failure	  disease-­‐monitoring	  programme	  at	   the	  Royal	  Brompton	   in	  
London,	   United	   Kingdom.	   They	   were	   all	   recruited	   based	   on	   identical	   inclusion	   and	   exclusion	  
criteria	  aimed	  to	  identify	  patients	  with	  a	  moderate	  to	  high	  risk	  of	  decompensation.	  	  Participants	  
were	   aged	   over	   18	   years	  with	   a	   diagnosis	   of	   CHF	   in	   accordance	  with	   the	   European	   Society	   of	  
Cardiology	  guidelines	  (4),	  with	  a	  BNP	  at	  recruitment	  of	  >58pmmol/L	  or	  a	  recent	  hospitalisation	  
for	  worsening	  heart	  failure	  in	  the	  last	  24	  months.	  	  Exclusion	  criteria	  were	  cognitive	  impairment,	  
unpredictable	   sleep	  patterns	   likely	   to	  affect	   the	  collection	  of	   sleep	  data	  and	  concurrent	  use	  of	  
continuous	  positive	  airway	  pressure	  (CPAP).	  Recruitment	  for	  the	  Dublin	  group	  of	  patients	  started	  
in	  October	  2010	  and	  finished	  in	  September	  2012,	  while	  the	  first	  and	  last	  London	  patients	  were	  
recruited	  in	  September	  2011	  and	  June	  2012	  respectively.	  	  
Patients	  in	  study	  two,	  which	  examined	  longitudinal	  variations	  in	  nocturnal	  respiratory	  patterns,	  
comprised	   of	   the	   entire	   validation	   group	   of	   patients	   enrolled	   into	   study	   three	   from	   the	   Royal	  
Brompton	  Hospital	  London.	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2.3. Investigations	  and	  Assessments	  
2.3.1. Polysomnography	  	  
Attended	   in-­‐hospital	   overnight	   PSG	   (Somnoscreen	   PSG	   Tele,	   Somnomedics	   GmbH)	   was	  
performed	  in	  our	  sleep	  laboratories	  using	  standard	  techniques	  and	  scoring	  criteria	  (148;179).	  
Thoracoabdominal	  motion	  was	  measured	  by	  respiratory	   inductance	  plethysmography	  (Mux	  RIP	  
Adaptors,	  Somnomedics	  GmBH	  with	  RIP	  belts,	  SLP	  Inc.,	  USA),	  and	  nasal	  airflow	  was	  monitored	  by	  
nasal	  pressure	   cannula	  and	  an	  oral	   flow	   thermistor.	  Arterial	  oxyhaemoglobin	   saturation	   (SaO2)	  
was	  monitored	  by	  pulse	  oximetry	  (Somnomedics	  Somnoscreen	  using	  Nonin	  PureLight	  Oximeter	  
technology).	  	  
Sleep	   was	   monitored	   using	   a	   standard	   neuro	   electrode	   placement	   system	   to	   include	   EEG	  
references	  (C4/A1),	  (C3/A2)	  and	  (O1/A2)	  (179).	  Submental	  and	  anterior	  tibialis	  Electromyogram	  
(EMG)	   were	   also	   recorded.	   Electrooculogram	   (EOG)	   electrodes	   placed	   on	   both	   lateral	   canthi	  
measured	  rapid	  eye	  movements	  (REM).	  Figure	  17	  shows	  a	  patient	  with	  a	  typical	  sleep	  laboratory	  
setup	  for	  an	  overnight	  PSG	  study.	  
The	   transducers	   and	   lead	   wires	   permitted	   normal	   positional	   changes	   during	   sleep	   as	   well	   as	  
movement	  out	  of	  bed.	  Bedtime	  and	  awakening	  time	  were	  at	  each	  subject's	  discretion;	  and	  the	  
Polysomnography	  was	  terminated	  after	  final	  wakening.	  This	  system	  was	  similar	  at	  both	  centres	  
where	  PSG	  was	  performed.	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Figure	  17:	  Example	  of	  Patient	  setup	  for	  overnight	  Polysomnography	  
	  
Polysomnography	  Scoring	  
Two	  expert	  respiratory	  physiologists	  scored	  the	  PSG	  data	  independently	  to	  determine	  PSGAHI	  and	  
PSGCSR	  and	  using	  standard	  scoring	  criteria	  (180).	  	  
An	  apnoea	  was	  defined	  as	  cessation	  of	  airflow	  or	  reduction	  >90%	  for	  ≥	  10	  s,	  and	  a	  hypopnea	  as	  a	  
reduction	  of	  ≥	  50%	  in	  flow	  amplitude	  lasting	  ≥	  10	  s	  or	  a	  30%	  reduction	  in	  flow	  amplitude	  with	  a	  
>3%	  desaturation	  measured	  on	  the	  pulse	  Oximeter	  channel.	  The	  respiratory	  event	  was	  scored	  as	  
obstructive	   apnoea,	   if	   it	  met	   apnoea	   criteria	   and	  was	   associated	  with	   continued	   or	   increased	  
respiratory	  effort	  throughout	  the	  entire	  period	  of	  absent	  airflow	  or	  central	  apnoea	  if	  respiratory	  
effort	  was	  absent	  throughout	  the	  entire	  period	  of	  absent	  airflow.	  	  
Cheyne	   –	   Stokes	   Respiration	   was	   scored	   as	   present	   when	   there	   were	   3	   consecutive	   central	  
apnoeas	  and	  hypopneas	   in	  a	  10-­‐minute	  epoch.	  The	  %	  overnight	  CSR	  was	  calculated	  by	  dividing	  
the	  number	  of	  epochs	  scored	  as	  CSR	  by	  the	  Total	  Sleep	  Time	  (TST).	  The	  apnoea-­‐hypopnea	  index	  
(AHI)	  was	  a	  fraction	  of	  the	  total	  number	  of	  apnoeas	  and	  hypopneas	  over	  the	  scored	  TST.	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2.3.2. SleepMinderTM	  Recordings	  and	  Data	  Transmission	  
The	  SleepMinderTM	  is	  a	  non-­‐contact	  bio-­‐motion	  recording	  system	  interpreting	  body	  movement	  
and	  breathing	  via	  two	  sinusoidal	  electromagnetic	  wave	  signals	  (factor	  10-­‐100	   less	  compared	  to	  
common	  household	  devices).	  The	  sensor	  operates	  in	  a	  license-­‐free	  band	  at	  5.8	  GHz	  and	  emits	  an	  
average	  power	  less	  than	  1	  mV.	  It	  sends	  and	  receives	  this	  reflected	  wave	  from	  the	  SM	  sensor	  to	  
the	  patient	  and	  back	  again	  to	  record	  the	  patient’s	  body	  movement	  and	  breathing	  associated	  with	  
sleep.	  
The	  SM	  emits	  two	  signals	  named	  I	  and	  Q,	  which	  are	  out	  of	  phase	  by	  90	  degrees	  with	  each	  other.	  
This	  maximizes	   its	   sensitivity	  within	   its	   cone	  of	   operation.	   This	  means	   that	   at	   any	   given	  point,	  
when	   the	   signals	  hit	   the	   subject,	  one	  component	  would	  be	   larger	   in	  amplitude	   than	   the	  other	  
enabling	  the	  sensor	  to	  capture	  all	  possible	  dynamics	  of	  patient's	  movement.	  (Figure	  18)	  
	  
Figure	  18:	  SleepMinderTM	  I	  and	  Q	  channels	  
The	  SM	  device	  sensor	  also	  has	  range	  gate,	  which	  is	  capable	  of	  sensing	  movement	  and	  breathing	  
over	  a	  distance	   ranging	   from	  0.3	   to	  1.5	  meters.	   Further,	  due	   to	   its	   intelligent	   sensor	  design,	   it	  
ensures	  that	   in	  the	  case	  of	  two	  people	  sleeping	   in	  the	  bed,	  only	  the	  person	  nearest	  the	  sensor	  
would	  have	  signals	  recorded.	  	  
The	  signals	  hit	  this	  first	  subject	  and	  are	  reflected	  immediately	  back	  to	  the	  SM	  sensor	  which	  now	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Figure	  19:	  Schematic	  showing	  Cone	  of	  Operation	  of	  SM	  Device	  
Study	  Environment	  
For	   the	  purposes	  of	   the	  validation	   in	   study	  1,	   simultaneous	  PSG	  and	  SM	  recordings	   took	  place	  
during	  an	  overnight	  hospital	  stay	  at	  the	  Royal	  Brompton	  Hospital	   in	  London	  and	  the	  University	  
Hospital	  Duisburg-­‐Essen	  Germany.	   The	  device	  was	  placed	   at	   a	   height	   of	   about	   10cm	   from	   the	  
patients’	  bed	  and	  100cm	  from	  the	  patients’	  chest.	  (See	  Figure	  20)	  
	  
	  Figure	  20:	  Schematic	  of	  SleepMinderTM	  placed	  by	  patients	  bedside	  
In	  the	  studies	  2	  and	  3,	  each	  patient	  was	  provided	  with	  a	  SM	  device,	  which	  they	  took	  home	  and	  
positioned	  at	  their	  bedside	  as	  aforementioned.	  They	  also	  received	  a	  set	  of	  scales	  to	  record	  their	  
daily	   weights	   with.	   They	   were	   instructed	   to	   weigh	   themselves	   at	   the	   same	   time	   every	   day,	  
preferably	  in	  the	  morning.	  The	  SM	  and	  scales	  transmitted	  this	  information	  collected	  via	  a	  study	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mobile	  phone	  using	  Bluetooth	  connectivity.	  This	  phone	  then	  automatically	  transferred	  this	  data	  
via	  a	  3G	  mobile	  network	  to	   the	  data	  collection	  centres	   in	  Dublin	  and	  Sydney	   for	   later	  analysis.	  
(See	  Figure	  21)	  
The	  data	  collection	  centre	  was	  a	  real	  time	  database	  and	  was	  quality	  controlled	  in	  Dublin.	  When	  
there	  were	  interruptions	  in	  recordings	  from	  either	  SM	  or	  scales,	  I	  was	  able	  to	  respond	  to	  this	  by	  
contacting	  the	  patient(s)	  involved	  and	  troubleshooting.	  
	  
Figure	  21:	  Schematic	  of	  SleepMinderTM	  showing	  data	  transmission	  
	  
2.3.3. Transthoracic	  Echocardiography	  
Transthoracic	  echocardiography	  was	  performed	  mainly	  to	  make	  an	  assessment	  of	  the	  patient’s	  
global	  left	  ventricular	  function	  systolic	  function	  by	  measuring	  the	  left	  ventricular	  ejection	  fraction	  
(LVEF).	   This	  was	  mainly	   for	   the	   purposes	   of	   classification	   of	   heart	   failure	   patients	   into	   low	   or	  
preserved	  EF	  categories	  but	  also	  a	  surrogate	  for	  severity	  of	  heart	  failure	  (181).	  CHF	  may	  be	  also	  
present	  in	  patients	  with	  a	  normal	  ejection	  fraction	  especially	  women	  and	  older	  patients	  (182).	  	  	  	  
The	   echocardiograms	   performed	   as	   part	   of	   this	   study	  were	   all	   part	   of	   routine	   clinical	   care.	   In	  
study	   one	   where	   I	   excluded	   patients	   with	   Heart	   failure	   with	   preserved	   or	   normal	   ejection	  
fraction	   (HFpEF,	  HFnEF),	  participants	  were	   required	   to	  have	   this	  assessment	  done	   if	   it	  had	  not	  
been	  performed.	  A	  Simpson’s	  biplane	  method	  was	  used	  to	  assess	  global	  left	  ventricular	  function	  
were	   possible	   otherwise	   a	   2D	   Teicholtz	  method	   was	   employed.	   However,	   the	   latter	  methods	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to	  convert	  a	  linear	  measurement	  to	  a	  3-­‐D	  volume.	  With	  reference	  to	  sex	  and	  body	  surface	  area,	  a	  
patient	  is	  considered	  to	  have	  a	  normal	  LVEF	  with	  a	  value	  above	  45%	  (183).	  
	  
2.3.4. B-­‐type	  Natriuretic	  Peptide	  (BNP)	  
BNP	  is	  released	  by	  the	  ventricular	  myocytes	  as	  a	  response	  to	  stretch	  due	  to	  volume	  overload.	  Its	  
actions	  include	  natriuresis	  and	  diuresis	  and	  antagonism	  of	  the	  renin	  angiotensin	  system	  leading	  
to	  a	  reduction	  in	  cardiac	  preload	  and	  afterload	  (43).	  BNP	  is	  used	  for	  diagnosis,	  risk	  stratification	  
and	  prognostication	  in	  heart	  failure	  (184).	  BNP	  was	  measured	  as	  part	  of	  inclusion	  criteria	  in	  study	  
three.	   Patients	   who	   had	   a	   BNP	   level	   of	   >200pg/ml	   (58pmol/L)	   were	   eligible	   for	   this	   study	  
provided	   there	   were	   no	   other	   exclusion	   criteria.	   This	   measurement	   was	   carried	   out	   at	   the	  
baseline	  visit,	   in	   the	  biochemistry	   laboratory	  at	   the	  Royal	  Brompton	  Hospital	   London,	  using	  an	  
AlereTM	  Triage	  immunoenzymatic	  assay.	  	  
	  
2.4. Statistical	  Analysis	  
All	   SleepMinderTM	   algorithm	   development,	   analysis	   and	   testing	   was	   performed	   using	  MATLAB	  
version	  15.	  All	  other	   statistical	   analyses	  were	  undertaken	  using	   IBM	  SPSS	  Statistics	   version	  21.	  
For	  studies	  1,	  2	  and	  3,	  I	  have	  described	  in	  detail,	  in	  the	  relevant	  chapters	  (3,	  4	  and	  5),	  the	  specific	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3.1. Introduction	  
Sleep	   Disordered	   Breathing	   (SDB)	   is	   prevalent	   in	   patients	   with	   chronic	   heart	   failure	   (CHF)	  
occurring	  in	  50-­‐80%	  of	  patients	  (6-­‐8;185).	  	  
The	   current	   gold	   standard	   for	   making	   a	   diagnosis	   of	   SDB	   is	   attended	   in-­‐hospital	  
polysomnography	  or	  polygraphy	  (PSG/PG).	  	  
The	   SleepMinderTM	   device	   is	   a	   novel	   non-­‐contact	   bedside	   monitor	   that	   contains	   a	   biomotion	  
sensor	  transceiver	  that	  utilises	  ultra-­‐low	  power	  radiofrequency	  signals	  to	  detect	  movement	  and	  
breathing	  of	  a	  patient	  sleeping	  next	  to	  it.	  	  
3.2. Hypothesis	  
The	  ‘Null’	  Hypothesis	  for	  this	  study	  is	  that	  there	  is	  no	  difference	  between	  the	  Apnoea	  Hypopnea	  
Index	   (AHI)	   and	   quantity	   of	   Cheyne-­‐Stokes	   Respiration	   (CSR)	  measured	   by	   the	   SleepMinderTM	  
device	  compared	  to	  in	  –hospital	  Polysomnography	  (PSG).	  
3.3. Aim	  
The	  main	  aim	  of	  this	  study	  was	  to	  evaluate	  the	  SM’s	  accuracy	  in	  identifying	  and	  quantifying	  SDB	  
in	  patients	  with	  CHF	  compared	  to	  full	  in	  hospital	  PSG,	  by	  developing	  specialised	  algorithms	  from	  
the	  reflected	  SM	  signals,	  which	  can	  calculate	  metrics	  of	  SDB.	  	  
This	   validation	   would	   be	   important	   as	   the	   algorithms	   generated	   and	  measurements	   obtained	  
from	  the	  SM,	  would	  be	  utilised	  in	  other	  areas	  of	  this	  thesis	  particularly	  in	  the	  chapter	  5	  looking	  at	  
predicting	  acute	  decompensation	  of	  chronic	  heart	  failure.	  
3.4. Study	  Population	  
The	  study	  population	  was	  made	  up	  of	  59	  consecutive	  adult	  patients	  with	  CHF	  enrolled	  from	  two	  
tertiary	  heart	  failure	  units,	  one	  in	  South-­‐West	  London,	  United	  Kingdom	  and	  the	  other	   in	  Essen,	  
Germany.	   	  They	  had	  presented	  to	  the	  heart	  failure	  clinic	  for	  screening	  for	  SDB	  with	  recognized	  
typical	  symptoms	  including	  witnessed	  apnoeas	  and	  daytime	  somnolence.	  	  
They	   all	   had	   systolic	   heart	   failure,	   with	   a	   recent	   transthoracic	   echocardiogram	  measured	   left	  
ventricular	   ejection	   fraction	   (EF)	   of	   <45%.	   Patients	   with	   significant	   obstructive	   lung	   disease	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defined	  by	  an	  FEV1	  of	  <50%	  or	  who	  were	  on	  treatment	  with	  any	  form	  of	  positive	  airway	  pressure	  
were	  excluded.	  	  
3.5. Methods	  
3.5.1. Overnight	  Polysomnography	  (PSG)	  
Each	   patient	   underwent	   simultaneous	   SleepMinderTM	   recordings	   and	   an	   overnight	   PSG	  
(Somnoscreen	   PSG	   Tele,	   Somnomedics	   GmbH)	   performed	   in	   our	   sleep	   laboratories	   using	  
standard	  techniques	  and	  scoring	  criteria	  (148).	  This	  has	  been	  described	  in	  detail	   in	  the	  Chapter	  
Two	  –	  General	  Methods.	  
To	  summarise,	  the	  PSG	  data	  acquired,	  included	  signals	  from	  respiratory	  effort	  bands	  at	  the	  chest	  
and	   abdominal	   level,	   airflow	   via	   nasal	   cannula,	   arterial	   oxygen	   saturation,	   electrocardiogram,	  
electroencephalogram	   (for	   staging	   of	   sleep),	   and	   electromyogram	   (for	   detecting	   arousals).	   In	  
addition	  a	  microphone	  was	  connected	  to	  detect	  snoring	  events.	  
A	  minimum	  of	  4	  hours	  was	  considered	  satisfactory	  for	  each	  study	  and	  this	  system	  was	  similar	  at	  
both	  centres.	  
3.5.2. PSG	  Scoring	  
Two	  independent	  experts	  who	  were	  blinded	  to	  each	  other,	  the	  patients’	  medical	  history	  or	  SM	  
recordings,	   performed	   the	   scoring	   of	   PSG	   signals.	   The	   specific	   criteria	   for	   scoring	   respiratory	  
events	  have	  been	  described	  in	  Chapter	  2	  –	  General	  Methods.	  	  
The	  main	  output	  from	  the	  scorers	  for	  the	  purpose	  of	  validation	  was	  the	  PSGAHI	  and	  PSGCSR.	  
3.5.3. SleepMinderTM	  Recording	  
The	  SleepMinderTM	  (SM)	  device	  is	  a	  non-­‐contact	  device	  that	  sits	  by	  the	  patient’s	  bedside.	  It	  emits	  
low	  frequency	  electromagnetic	  waves	  from	  an	   in-­‐built	  sensor	  to	  the	  patient,	  which	   is	   reflected	  
back	   to	   the	   SM	   sensor.	   Through	   this,	   it	   is	   able	   to	   record	   signals	   that	  pertain	   to	  breathing	   and	  
movement	  of	  the	  subject	  lying	  closest	  to	  it.	  Detailed	  description	  of	  this	  mechanism	  of	  operation	  
has	  been	  given	  in	  Chapter	  2	  –	  General	  Methods.	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On	  the	  night	  of	  the	  PSG	  study,	  the	  SleepMinderTM	  was	  positioned	  by	  the	  patients’	  bedside	  at	  a	  
height	  of	  10cm	  and	  3	  foot	  from	  their	  chest.	  It	  was	  turned	  on	  at	  the	  start	  of	  the	  PSG	  recording	  and	  
then	  turned	  off	  at	  final	  patient	  wakening.	  SM	  recordings	  were	  logged	  onto	  a	  Secure	  Digital	  card,	  
which	  was	  downloaded	  at	  the	  end	  of	  the	  study.	  	  
3.5.4. Sample	  Size	  
Based	   on	   previous	   validation	   studies	   of	   home	   screening	   devices	   for	   SDB	   (186;187),	   I	  
predetermined	  that	  a	  combined	  diagnostic	  accuracy	  of	  90%	  (sensitivity=specificity=0.90),	  would	  
be	  an	  acceptable	  measure	  of	  accuracy	  of	  the	  SleepMinderTM	  device.	  	  
Therefore	  using	  a	  prevalence	  rate	  of	  40%	  of	  CHF	  patients	  in	  the	  population	  who	  have	  SDB,	  and	  
for	   a	  maximum	  width	   of	   15%	   for	   a	   95%	   confidence	   interval,	   a	   sample	   size	   of	   40	   patients	  was	  
calculated	  as	  adequate	   for	   this	   study.	   I	   achieved	  higher	   than	   this	   target,	   recruiting	  66	  patients	  
into	  this	  study	  with	  7	  excluded	  due	  to	  incomplete	  or	  corrupted	  PSG	  (4)	  or	  SM	  (3)	  data.	  
3.5.5. Statistical	  Analyses	  
The	  combined	  data	  generated	  from	  the	  overnight	  studies	  at	  both	  centres	  were	  divided	  into	  two	  
datasets.	   A	   combination	   of	   the	   1st	   two	   thirds	   of	   each	   dataset	   from	   each	   centre	  made	   up	   the	  
‘Development’	  Set	  (London	  -­‐20,	  Essen-­‐	  20,	  n	  =	  40	  patients),	  for	  algorithm	  development.	  We	  then	  
validated	  our	  results	  on	  a	  combination	  of	  the	  final	  third	  of	  the	  remainder	  dataset	  in	  each	  centre,	  
which	  formed	  our	  ‘Validation’	  Set	  (London-­‐10,	  Essen-­‐	  9,	  n	  =	  19	  patients).	  	  
Normally	   distributed	   and	   continuous	   data	   are	   presented	   as	  means	   ±	   Standard	   Deviation	   (SD),	  
otherwise	   as	  Medians	   and	   Interquartile	   Ranges	   (IQR).	   Student’s	   t-­‐tests	  were	   used	   to	   compare	  
non-­‐paired	  continuous	  variables.	  For	  categorical	  variables,	   the	  χ2	  test	  with	  Yates’	  correction	  or	  
Fisher’s	  exact	  test,	  if	  necessary,	  was	  used.	  
Algorithm	   development	   and	   signal	   analyses	   were	   performed	   using	   Mat	   Lab	   version	   7.13.	   All	  
other	  statistical	  analyses	  were	  performed	  with	  IBM	  SPSS	  Statistics	  v.21	  software.	  All	  P	  values	  are	  
asymptotic	  two-­‐sided.	  Statistical	  significance	  was	  considered	  when	  P<	  0.05.	  	  
The	  correlation	  between	  the	  two	  diagnostic	  tools	  for	  the	  AHI	  was	  tested	  by	  Pearson’s	  correlation	  
co-­‐efficient	   and	   the	   degree	   of	   agreement	   was	   tested	   using	   a	   Bland	   and	   Altman	   analysis	  
examining	  for	  any	  systematic	  bias	  in	  scoring	  by	  either	  tool.	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Furthermore,	  I	  constructed	  Receiver	  Operator	  Characteristic	  (ROC)	  curves	  for	  various	  thresholds	  
of	  SleepMinderTM	  determined	  AHI	  (SMAHI),	  according	  to	  SDB	  severity,	  to	  obtain	  the	  best	  cut-­‐off	  
point	  compared	  to	  expert	  PSG	  scoring	  (PSGAHI	  and	  PSGCSR)	  in	  terms	  of	  sensitivity,	  specificity,	  and	  
positive	   and	   negative	   predictive	   values	   (188;189).	   I	   used	   a	   similar	  method	   for	   predetermined	  
thresholds	  of	  SleepMinderTM	  determined	  %	  overnight	  CSR	  (SMCSR).	  The	  accuracy	  of	  our	  algorithm	  
was	  the	  number	  of	  true	  positive	  and	  true	  negative	  cases	  divided	  by	  all	  cases	  and	  represented	  by	  
the	  area	  under	  the	  ROC	  curve.	  	  
Inter-­‐rater	   variability	   to	   assess	   agreement	  of	   sleep	   scoring	  between	   scorers	  of	   the	  PSG	   signals	  
was	  derived	  from	  Pearson’s	  correlation	  co-­‐efficient	  and	  Intra-­‐class	  correlation	  coefficients.	  
	  
3.6. Development	  of	  SleepMinderTM	  Algorithms	  
3.6.1. Alignment	  of	  PSG/SM	  Signals	  
The	   first	   step	   in	  developing	   the	  AHI	  and	  CSR	  Algorithms	  used	   in	   this	   study	  was	   to	  align	  signals	  
from	  both	  SM	  and	  PSG	  devices	  as	  accurately	  as	  possible	  and	  to	  a	  common	  timing	  stamp	  because	  
both	  signals	  were	  collected	  at	  different	  sampling	  frequencies	  –	  16GHz	  for	  the	  SM	  and	  20Hz/32Hz	  
for	  the	  PSG.	  
To	  achieve	   this,	  we	  have	  used	  a	   cross	   correlation	  and	   sliding	  window	  method	   to	   align	   feature	  
vector	   transformation	   of	   these	   signals.	   I	   have	   described	   these	   digital	   signal-­‐processing	  
techniques	  previously	  in	  section	  1.19.	  To	  summarise,	  the	  SM	  signals	  were	  initially	  combined	  into	  
one	  single	  channel	  to	  reduce	  computational	  costs	  i.e.	  the	  amount	  of	  time	  required	  to	  analyse	  the	  
SM	  signals	  in	  two	  separate	  channels	  as	  they	  are	  essentially	  identical	  signals	  but	  only	  collected	  at	  
different	  angles.	   The	  PSG	  signals	  were	  utilized	   in	   its	   single	   channel.	   The	  entire	   lengths	  of	  both	  
signals	   (SM	   and	   PSG)	   were	   then	   broken	   down	   into	   consecutive	   1-­‐second	   segments	   and	   an	  
Integral	  Absolute	  Value	  (IAV)	  for	  each	  segment	  was	  obtained	  based	  on	  the	  sampling	  frequency	  
and	  amplitude	  of	  each	  signal.	  Therefore	  each	  1-­‐second	  segment	  of	  PSG	  data	  for	  instance,	  would	  
contain	  20	  or	  32	  samples	  upon	  which	  the	  IAV	  was	  calculated	  and	  16	  samples	  for	  the	  SM.	  	  
The	   result	   of	   this	   process	  was	   the	   production	   of	   two	   vectors,	   one	   each	   for	   PSG	   flow	   and	   SM	  
signals.	  (Figure	  22)	  	  The	  IAV’s	  obtained	  for	  segments	  of	  both	  PSG	  and	  SM	  signals	  were	  then	  cross	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correlated	  to	  find	  the	  highest	  correlation	  value	  which	  corresponded	  to	  the	  best	  alignment	  points	  
of	  both	  signals.	  Once	  this	  vector	  alignment	  was	  achieved	  and	  because	  the	  timings	  had	  now	  been	  
unified,	   it	   was	   now	   possible	   to	   adjust	   the	   raw	   signals	   using	   our	   sliding	   window	   to	   achieve	   a	  
reasonable	   fit.	  This	  was	  achieved	  by	  essentially	   sliding	  one	  vector	  window	  V!	   for	  PSG	  over	   the	  
vector	  window	  V2	  for	  SM.	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  22:	  Integral	  Absolute	  Values	  created	  from	  1-­‐second	  samples	  of	  signals.	  (V1-­‐PSG	  Vector,	  V2-­‐
SleepMinder	  Vector)	  
	  
The	   alignment	   drift;	   which	   refers	   to	   how	   one	   vector	   is	   moved	   to	   align	   with	   the	   other;	   is	  
measured	  in	  seconds	  and	  this	  is	  what	  is	  subsequently	  applied	  to	  the	  RAW	  signals	  to	  obtain	  a	  final	  
result	   (Figure	   23).	   Even	  when	   there	  was	   an	   excess	   of	   signal	   (usually	  with	   the	   SM,	   as	   that	  was	  
turned	  on	   first	   before	   the	  PSG	   started),	   this	   could	  be	   trimmed	  at	   the	  end	  of	   alignment	  of	   the	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Figure	  23:	  Aligned	  RAW	  PSG	  and	  SM	  Signal	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  24:	  Summary	  of	  SM/PSG	  Alignment	  process	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3.6.2. AHI	  Algorithm	  Development	  
The	   first	   step	   in	   developing	   the	   AHI	   algorithm	   was	   to	   combine,	   both	   I	   and	   Q	   channels	   of	  
SleepMinderTM,	  into	  a	  single	  RAW	  channel	  (Z)	  as	  shown	  in	  Figure	  25.	  This	  was	  done	  to	  in	  order	  to	  
reduce	   computational	   time	  and	   resources.	   It	  was	  within	   this	   single	   channel	   that	  all	   operations	  
relating	  to	  algorithm	  development	  took	  place.	  
The	  combined	  channel	  was	  pre-­‐processed	  to	  filter	  noise	  and	  zero	  the	  baseline	  (also	  known	  as	  de-­‐
trending).	  Further,	  using	  pattern	  recognition	  and	  cycle	   interval	   techniques	  the	  pure	  respiratory	  
signals	  were	  then	  isolated.	  The	  SM’s	  proprietary	  Sleep/Wake	  analysis	  and	  integrated	  movement	  
detector	  algorithms	  were	  then	  applied	  to	  this	  signal	  to	  determine	  the	  SM	  calculated	  Total	  Sleep	  
Time	   (SMTST).	   This	   algorithm	   has	   been	   described	   in	   detail	   elsewhere	   (190).	   In	   summary,	   this	  
algorithm	   makes	   an	   estimate	   of	   the	   patients	   total	   sleep	   time,	   by	   measuring	   the	   patient’s	  
presence	  and	  movement	  away	  from	  the	  SleepMinderTM,	  through	  the	  night	  of	  recording.	  
	  
Figure	  25:	  AHI	  algorithm	  development	  process	  
The	  pure	  sleep	  respiratory	  signal	  was	  then	  divided	  into	  segments	  for	  AHI	  algorithm	  development	  
and	  analysis.	  These	  segments	  are	  also	  known	  as	  epochs,	  which	  are	  time-­‐defined	  segments	  upon	  
which	  gold	  standard	  PSG	  is	  routinely	  scored.	  Typically	  an	  epoch	  for	  scoring	  is	  usually	  30	  seconds	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We	   developed	   a	   new	   event	   based	   algorithm	   for	   the	   detection	   of	   SDB	   events;	   apnoeas	   or	  
hypopneas;	  with	  the	  fundamental	  criteria	  defining	  the	  detection	  of	  a	  disturbed	  breathing	  event	  
being	  a	  reduction	  in	  magnitude	  of	  50%	  or	  more	  in	  the	  amplitude	  of	  the	  non-­‐contact	  measure	  of	  
overall	  body	  breathing	  effort,	  lasting	  for	  10	  seconds.	  	  
To	   achieve	   this,	   we	   created	   a	   respiratory	   event	   detection	   envelope	   that	   mapped	   the	   entire	  
overnight	   SM	   respiratory	   signal	   channel	   (Figure	   26).	   This	   was	   then	   analysed	   using	  markers	   of	  
peaks	  and	  troughs	  to	  detect	  and	  label	  all	  potential	  events.	  	  
	  
Figure	  26:	  Signal	  Envelope	  Generation	  
Final	  confirmation	  of	  these	  events	  was	  based	  on	  the	  duration	  and	  amplitude	  of	  these	  SDB	  events	  
based	   on	   the	   pre-­‐defined	   criteria	   (Figure	   8).	   The	   SMAHI	   was	   then	   determined	   as	   a	   fraction	   of	  
SMTST	  as	  shown	  in	  figure	  27.	  Severity	  of	  SDB	  was	  defined	  as	  mild	  AHI	  >5,	  moderate	  AHI	  >15	  and	  
severe	  AHI	  >30.	  
	  
Figure	  27:	  Confirmation	  of	  SDB	  Event	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During	  development,	  the	  algorithm	  was	  trained	  to	   ignore	  non-­‐respiratory	  event	  signals	  such	  as	  
high	  amplitude,	  but	   low	   frequency	   signals	   that	  may	  arise	   from	  periodic	   leg	  movements	   (PLM),	  
which	  could	  potentially	  mimic	  a	  hyperpnoea.	  
3.6.3. CSR	  Algorithm	  Development	  
The	  SleepMinderTM-­‐based	  CSR	  algorithm	  used	  in	  this	  study	  was	  designed	  based	  on	  a	  framework	  
of	  pattern	  recognition	  [28],	  where	  sets	  of	  statistical	  descriptors,	  usually	  referred	  to	  as	  features,	  
were	  extracted	  from	  the	  raw	  SM	  signals,	  processed	  and	  then	  used	  to	  determine	  the	  probability	  
of	  CSR	  within	  a	  10	  minute	  epoch	  of	  SM	  signal.	  	  
The	   initial	   stages	   of	   this	   algorithm	   development	   are	   similar	   in	   process	   to	   those	   used	   in	  
developing	   the	   AHI	   metric	   in	   terms	   of	   combination	   of	   SM	   channels	   and	   identification	   of	  
respiratory	   events.	  We	   concentrated	   development	  mainly	   over	   these	   areas	  where	   there	  were	  
confirmed	  respiratory	  events,	  examining	  them	  for	  modulatory	  patterns	  of	  respiration	  which	  may	  
be	  representative	  of	  CSR.	  	  
The	  single	  combined	  SM	  channel	  was	  first	  pre-­‐processed	  to	  remove	  local	  trends	  that	  may	  cause	  
baseline	  wandering.	  The	  signals	  were	  then	  passed	  through	  a	   first	  order	  Band-­‐Pass	  Butterworth	  
filter	  with	  cut	  off	  frequencies	  [0.1Hz,	  0.7Hz],	  to	  remove	  any	  irrelevant	  effects	  of	  non-­‐respiratory	  
frequencies	  that	  may	  induce	  some	  CSR-­‐like	  modulated	  shapes	  in	  our	  SM	  signal.	  	  	  
Following	   this,	   all	   the	   apnoea/hypopnoea	   events	   were	   then	   detected	   using	   our	   previously	  
developed	  AHI	  algorithm.	  These	  events	  were	  subsequently	  labelled	  and	  then	  examined	  carefully	  
for	  any	  possible	  crescendo-­‐decrescendo	  modulations	  that	  qualify	  these	  sections	  of	  the	  signal	  to	  
be	  scored	  as	  CSR.	  	  
The	  main	  module	  of	  the	  CSR	  algorithm	  we	  have	  developed	  utilises	  a	  combination	  of	  the	  following	  
key	   statistical	   descriptors	   of	   the	   patterns	   of	   Apnoeas	   or	   hypopnoeas	   identified	   for	   possible	  
modulation.	  This	  is	  shown	  in	  Figure	  22.	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Statistical	  Descriptors	  	  
-­‐	  Number	  of	  zero	  crossings	  (ZC)	  –	  This	  is	  a	  measure	  of	  how	  many	  times	  the	  SM	  signal	  crosses	  the	  
x-­‐axis	  at	  zero	  point	  and	  an	  indicator	  of	  how	  fast	  the	  CSR	  signal	  oscillate	  within	  a	  specific	  cycle.	  
-­‐	  Energy	  of	  the	  CSR	  pattern	  (En)	  –	  the	  energy	  of	  the	  signal	  when	  divided	  into	  segments	  looking	  
for	   any	   possible	   crescendo-­‐decrescendo	   pattern	   (terminal	   regions	   exhibit	   lower	   energy	   than	  
middle	  regions).	  
-­‐	  Slope	  of	  the	  CSR	  Envelope	  (Slope)	  –	  This	  feature	  examines	  the	  upward	  and	  downward	  trends	  of	  
the	   potential	   CSR	   segment	   anticipating	   a	   positive	   slope	   for	   the	   first	   half	   of	   the	   cycle	   and	   a	  
negative	  slope	  for	  the	  latter	  half.	  The	  angle	  of	  each	  slope	  against	  the	  x-­‐axes	  is	  also	  examined.	  	  
-­‐	  Phase	  locking	  Value	  (PLV)	  –	  This	  feature	  describes	  the	  amplitude	  and	  phase	  of	  the	  CSR	  cycle.	  A	  
typical	  cycle	  would	  exhibit	  high	  phase	  similarity	  between	  two	  halves	  as	  opposed	  to	  one	  that	   is	  
corrupted,	  been	  dissimilar.	  	  
	  
Figure	  28:	  Statistical	  descriptors	  for	  CSR	  Algorithm	  development	  
!
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These	   above	   extracted	   features/statistical	   descriptors	   contribute	   a	   probability	   value	   or	   ‘vote’	  
that	  the	  segment	  should	  be	  scored	  as	  CSR.	  Each	  descriptor	  was	  of	  equivalent	  weight.	  The	  final	  
result	  was	   a	  probability	   score	  between	  0	   and	  1.	   The	   closer	   to	   1,	   the	   vote	  was,	   the	  higher	   the	  
probability	  that	  those	  segments	  should	  be	  scored	  as	  CSR.	  	  
During	   development	   of	   the	   algorithm	   the	   probability	   threshold	   was	   adjusted	   depending	   on	  
expert	   PSG	   scoring	   and	   to	   reduce	   the	   number	   of	   false	   positives.	   We	   selected	   a	   fairly	   high	  
probability	  value	  of	  >0.85	  as	  acceptable	  indication	  of	  CSR	  and	  this	  was	  used	  on	  the	  validation	  set	  
of	  patients.	  This	  threshold	  selection	  was	  based	  on	  strict	  scoring	  behaviour	  of	  the	  expert	  PSG	  on	  
valid	  CSR	  sections.	  	  
In	   the	   final	  module,	  we	   divided	   the	   entire	   overnight	   signal	   length	   into	   consecutive	   10-­‐minute	  
segments	   and	   employing	   universal	   scoring	   criteria	   (148),	   	   a	   section	  was	   scored	   as	   CSR	  where	  
there	   are	   at	   least	   3,	   or	  more,	   consecutive	   cycles	   of	   cyclical	   crescendo-­‐decrescendo	   change	   in	  
breathing	  amplitude.	  Figure	  29	  summarises	  this	  entire	  development	  process.	  
	  	  	  
Figure	  29:	  Schematic	  showing	  summary	  of	  entire	  CSR	  Algorithm	  development	  process	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3.7. Results	  
3.7.1. Demographics	  
66	  patients	  (London	  30)	  and	  (Essen	  36)	  had	  simultaneous	  PSG	  and	  SM	  data	  collected	  (Figure	  30).	  
7	  patients	  from	  the	  Essen	  dataset	  were	  excluded	  from	  analysis	  due	  to	  incomplete	  or	  corrupted	  
data	  (4	  PSG,	  3	  SM).	  In	  total	  59	  patients	  had	  adequate	  paired	  data	  (>4	  hours)	  suitable	  for	  analysis.	  
The	   median	   age	   (IQR)	   of	   all	   studied	   patients	   was	   71	   (60-­‐74)	   years.	   The	   mean	   (SD)	   ejection	  
fraction,	  NYHA	  class	  and	  Body	  Mass	  Index	  were	  31	  (9)	  %,	  2.5	  (0.5)	  and	  29	  (8)	  Kg/m2	  respectively.	  	  	  
There	  were	   no	   significant	   demographic	   or	   clinical	   differences	   between	   the	   London	   and	   Essen	  
population	  of	  patients	  (Table	  11).	  There	  was	  also	  no	  significant	  difference	  between	  Development	  
and	   Validation	   group	   of	   patients	  with	  more	   than	   half	   of	   patients	   in	   both	   groups	   treated	  with	  
Beta-­‐blockers,	  ACE-­‐inhibitors	  or	  Mineralocorticoid	  receptor	  antagonists	  (Table	  12).	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Table	  11:	  Demographic	  Chart	  –	  London	  versus	  Essen	  Group	  of	  Patients,	  (BMI	  –	  Body	  Mass	  Index,	  NYHA	  
–	  New	  York	  Heart	  Association	  Classification	  of	  Heart	  Failure,	  DM	  –	  Diabetes	  Mellitus,	  B-­‐Blocker	  –	  Beta	  
Blocker,	  ACEi	  –	  Angiotensin	  Converter	  Enzyme	  Inhibitor,	  AIIRB	  –	  Angiotensinogen	  II	  Receptor	  
Antagonist,	  MRA	  –	  Mineralocorticoid	  Receptor	  Antagonist,	  COPD	  –Chronic	  Obstructive	  Pulmonary	  
Disease	  and	  HTN	  –	  Hypertension)	  
Group& Total&(59)& London&(30)& Essen&(29)& p8value&
Age$(Years)$ 71$(60$/74)$ $71$(31/87)$ $72$(41/84)$ $0.43$
Male$Sex$n$(%)$ $51$(86)$ $28$(93)$ $23$(79)$ $0.16$
BMI$(Kg/m2)$ 29$±$8$ $29.4$±$5.1$ $29.3$±$4.3$ $0.91$
EjecFon$FracFon$
(%)$$
31$±$9$ $33.6$±$6$ $27.9$±$11.2$ $0.02$
NYHA$$ 2.5$±$0.5$ $2.3$±$0.4$ $2.8$±$0.5$ <0.001$
Ischaemic$$n$(%)$ 41$(70)$ $23$(77)$ $18$(62)$ $0.10$
HTN$n$(%)$ $35$(59)$ $15$(50)$ $19$(66)$ $0.02$
COPD$n$(%)$ 7$(12)$ $4$(13)$ $3$(10)$ $0.34$
DM$n$(%)$ 12$(20)$ 7$(23)$ 5$(17)$ 0.33$
BetaBlocker$n$(%)$ 41$(70)$ 22$(73)$ 19$(66)$ 0.27$
ACEi$or$AIIRB$n$(%)$ 47$(80)$ 26$(86)$ 21$(72)$ 0.05$
MRA$n$(%)$ 36$(61)$ 21$(70)$ 15$(52)$ 0.22$
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Table	  12:	  Demographic	  Chart	  –	  Development	  versus	  Validation	  Group	  of	  Patients,	  (BMI	  –	  Body	  Mass	  
Index,	  NYHA	  –	  New	  York	  Heart	  Association	  Classification	  of	  Heart	  Failure,	  DM	  –	  Diabetes	  Mellitus,	  B-­‐
Blocker	  –	  Beta	  Blocker,	  ACEi	  –	  Angiotensin	  Converter	  Enzyme	  Inhibitor,	  AIIRB	  –	  Angiotensinogen	  II	  
Receptor	  Antagonist,	  MRA	  –	  Mineralocorticoid	  Receptor	  Antagonist,	  COPD	  –Chronic	  Obstructive	  






Group& Total(59)& Development&(40)& Valida9on&(19)& P<value&
Age$(Years)$ 71$(60$/74)$ $72$(31/87)$ $72$(47/78)$ 0.43$
Male$Sex$n$(%)$ 51$(86)$ $34$(85)$ $16$(84)$ 0.63$
BMI$(Kg/m2)$ 29$±$8$ $29.7$±$5.4$ 28.6$±$2.9$ 0.42$
EjecFon$FracFon$(%)$$ 31$±$9$ $30.4$±$9.3$ 31.8$±$9.2$ 0.61$
NYHA$ 2.5$±$0.5$ $2.5$±$0.5$ 2.6$±$0.6$ 0.55$
Ischaemic$n$(%)$ 41$(70)$ $27$(68)$ 16$(84)$ 0.49$
HTN$n$(%)$ 35$(59)$ $20$(50)$ 14$(74)$ 0.08$
COPD$n$(%)$ 7$(12)$ $3$(0.1)$ 4$(0.2)$ 0.64$
DM$n$(%)$ 12$(20)$ $7$(0.2)$ 5$(0.3)$ 0.28$
B/Blocker$n$(%)$ 41$(70)$ $26$(65)$ $15$(79)$ 0.26$
ACEi/Aiirb$n$(%)$ 47$(80)$ $33$(83)$ $14$(74)$ 0.67$
MRA$n$(%)$ 36$(61)$ 21$(53)$ 15$(79)$ 0.05$
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3.7.2. Prevalence	  of	  SDB	  	  
The	  prevalence	  of	  clinically	  significant	  Sleep	  Disordered	  Breathing	  (SDB)	  (AHI>15),	  as	  determined	  
by	   expert	   PSG	   scoring	   in	   this	   cohort	   was	   47%.	   In	   this	   group	   of	   patients	   36%	   of	   them	   also	  
exhibited	  a	  Cheyne	  -­‐	  Stokes	  Respiration	  suggesting	  a	  central	  variety	  of	  SDB.	  (Table	  13)	  
	  
Table	  13:	  A	  2	  by	  2	  table	  showing	  prevalence	  of	  clinically	  significant	  SDB	  (AHI>15)	  and	  Cheyne	  –	  Stokes	  
Respiration	  based	  on	  expert	  PSG	  scoring.	  
3.7.3. AHI	  Algorithm	  Performance	  
There	  was	  good	  correlation	  between	  SleepMinderTM	  Algorithm	  scored	  AHI	  (SMAHI)	  and	  Expertly	  
scored	  AHI	  from	  Polysomnography	  (PSGAHI)	  with	  a	  correlation	  co-­‐efficient	  of	  0.91	  and	  0.80	  in	  the	  
development	  and	  validation	  set	  of	  patients	  respectively.	  (Figure	  31	  &	  32)	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Figure	  32:	  Pearson’s	  Correlation	  in	  Validation	  set	  of	  patients.	  r=0.80	  
	  
I	  have	  further	  constructed	  a	  Bland	  –	  Altman	  plot	  to	  examine	  the	  agreement	  and	  systematic	  bias	  
between	  the	  two	  AHI	  scoring	  techniques.	  This	  demonstrated	  that	  while	  there	  was	  a	  tendency	  for	  
a	   higher	   estimation	   of	   the	   AHI	   by	   SM,	   across	   the	   range	   of	   values	   overall	   agreement	   between	  
SMAHI	   and	   PSGAHI	   was	   good	   and	   consistent	   even	   as	   severity	   of	   SDB	   increased.	   The	   mean	   diff	  
between	  the	  two	  scores	  was	  5.6	  events	  per	  hour	  (95%	  Confidence	  Interval	  -­‐2.1	  -­‐13.4)	  and	  where	  
there	  was	  overestimation	  compared	  to	  gold	  standard	  PSG,	  this	  was	  not	  by	  more	  than	  10	  events	  
per	  hour	  in	  72%	  of	  patients,	  which	  is	  therefore	  unlikely	  to	  put	  the	  patient	  into	  a	  different	  severity	  
category	  of	  SDB.	  (Figure	  33)	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Figure	  33:	  Bland-­‐Altman	  Plot	  of	  agreement	  between	  SMAHI	  and	  PSGAHI.	  Shaded	  area	  is	  the	  agreement	  
band	  within	  10	  events	  per	  hour	  for	  both	  tests.	  
In	   terms	   of	   diagnostic	   accuracy,	   the	   SleepMinderTM	   was	   91%	   sensitive	   and	   50%	   specific	   for	  
identifying	  patients	  with	  SDB	  (AHI>15).	   It	  has	  a	  positive	  predictive	  value	  of	  71%	  and	  a	  negative	  
predictive	   value	   of	   80%.	   (Table	   12)	   The	   overall	   accuracy	   of	   the	   SM	  AHI	   algorithm	  was	   82%	   as	  
shown	   by	   the	   area	   under	   a	   Receiver	  Operator	   Characteristic	   (ROC)	   Curve	   constructed	   for	   this	  
diagnostic	   threshold.	   (Figure	   34)	   The	   performance	   of	   the	   algorithm	   was	   marginally	   improved	  
when	   the	   threshold	   for	   diagnosis	  was	   changed	   to	   an	   AHI	   of	   >30	   (i.e.	   Severe	   SDB	   –	   AUC	   0.88,	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Table	  14:	  A	  2	  by	  2	  Plot	  of	  diagnostic	  accuracy	  of	  SleepMinderTM	  for	  SDB	  (AHI>15)	  on	  Validation	  set	  of	  
patients	  (n=19)	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Figure	  35:	  ROC	  curve	  for	  diagnostic	  threshold	  of	  SDB	  of	  AHI>30	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3.7.4. CSR	  Algorithm	  Performance	  
The	   SleepMinderTM	   CSR	   algorithm	   was	   71%	   sensitive	   and	   75%	   specific	   for	   identifying	   the	  
presence	  of	  Cheyne-­‐Stokes	  Respiration	  (CSR	  >0%).	  The	  positive	  and	  negative	  predictive	  value	  of	  
this	   algorithm	   was	   63%	   and	   82%	   respectively.	   (Table	   15)	   Overall	   the	   accuracy	   of	   the	   CSR	  
algorithm	  was	  0.76	  as	  determined	  by	  the	  area	  under	  a	  ROC	  curve	  plotted	  at	  this	  threshold	  (See	  
Figure	  37).	   For	   a	  diagnostic	   threshold	  of	  CSR	  >5%,	   the	   accuracy	  was	  marginally	  worse	  with	   an	  
AUC	  of	  74%.	  (Figure	  38)	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Figure	  38:	  ROC	  curve	  for	  diagnostic	  threshold	  of	  overnight	  CSR	  >5%	  (P	  value	  and	  CI)	  
3.7.5. Total	  Sleep	  Time	  (TST)	  (Correlation	  between	  SM	  and	  PSG)	  
The	   SM	   estimated	   Total	   Sleep	   Time	   (TST)	   did	   not	   correlate	  well	   with	   that	   obtained	   from	   PSG	  
scored	  by	  experts	  (Intra-­‐class	  Correlation	  Co-­‐efficient	  0.22).	  To	  evaluate	  further,	  I	  constructed	  a	  
Bland-­‐Altman	   plot	   to	   evaluate	   agreement	   and	   for	   any	   systematic	   bias	   between	   this	   two	  
techniques	  (Figure	  39).	  Overall	  the	  SleepMinderTM	  tended	  to	  overestimate	  the	  TST	  compared	  to	  
the	   PSG	   but	   this	   trend	  was	   consistent	  with	   increasing	   TST	   suggesting	   no	   systematic	   bias.	   The	  
mean	   difference	   between	   the	   two	   scoring	   systems	   was	   87.35	   (minutes)	   but	   the	   limits	   of	  
agreement	   were	   quite	   wide	   suggesting	   that	   the	   two	   tests	   did	   not	   agree	   particularly	   well	   in	  
obtaining	  this	  parameter	  (95%	  Limits	  of	  Agreement	  39.8	  –	  134.8).	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Figure	  39:	  Bland	  Altman	  Plot	  of	  agreement	  between	  the	  SM	  calculated	  TST	  and	  expertly	  scored	  PSG	  
TST.	  (Red	  Line	  is	  mean	  difference	  between	  measurements	  of	  the	  	  2	  techniques,	  while	  black	  lines	  are	  
95%	  limits	  of	  agreement)	  
	  
3.7.6. Inter-­‐Rater	  Variability	  
To	   assess	   the	   reliability	   between	   the	   two	   independent	   scorers	   of	   the	   PSG	   signals,	   I	   calculated	  
correlation	  coefficients	  and	  intra-­‐class	  correlation	  coefficients	  for	  both	  scorers.	  
There	   was	   good	   agreement	   between	   the	   2	   scorers	   for	   the	   AHI	   as	   shown	   in	   figure	   40	   and	  
supported	  by	  the	  ICC.	  While	  the	  CSR	  correlation	  value	  seemed	  reasonable,	   it	  was	  evident	  from	  
the	   ICC	  of	  0.203,	   that	  agreement	  was	  poor	  between	  scorers,	  with	  one	  observer	  coding	  no	  CSR	  
while	  the	  other	  coded	  a	  variable	  degree	  of	  CSR	  in	  many	  of	  the	  same	  patients.	  (See	  Figure	  41)	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Figure	  40:	  Correlation	  between	  2	  PSG	  Scorers	  for	  AHI	  Correlation	  Coefficient	  r=0.907.	  Intra-­‐class	  
Correlation	  Coefficient	  =	  0.879	  (95%	  CI	  0.747,	  0.936)	  
	  
	  
Figure	  41:	  Correlation	  between	  2	  PSG	  Scorers	  for	  CSR.	  Correlation	  Coefficient	  r=0.625	  Intra-­‐class	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3.8. Discussion	  
In	   this	   study	   I	   have	   developed	   and	   validated	   two	   algorithms	   using	   signals	   obtained	   from	   the	  
SleepMinderTM	   (SM)	   device	   and	   shown	   that	   it	   is	   capable	   of	   identifying	   Sleep	   Disordered	  
Breathing	   (SDB)	   based	   on	   the	   Apnoea	   Hypopnea	   Index	   (AHI)	   with	   a	   reasonable	   diagnostic	  
accuracy	   (High	  Sensitivity-­‐91%,	  but	   very	  modest	   Specificity	   -­‐50%).	  To	  a	   lesser	  degree,	   it	   is	   also	  
able	  to	  identify	  Cheyne-­‐Stokes	  Respiration	  (CSR)	  (Sensitivity	  71%,	  Specificity	  75%).	  This	  has	  been	  
achieved	  using	  a	  mixed	  population	  of	  patients	  with	  Chronic	  Heart	  Failure	  (CHF)	  and	  compared	  to	  
the	  gold	  standard	  in-­‐hospital	  Polysomnography.	  	  
I	   successfully	   collected	   paired	   SM/PSG	   signals	   from	   59	   patients.	   In	   the	   7	   patients	   whom	   we	  
excluded,	  this	  was	  due	  to	  signal	  failure	  of	  the	  SM	  in	  3	  patients	  and	  loss	  of	  PSG	  signals	  in	  the	  other	  
4.	  The	  failure	  rate	  for	  SM	  was	  therefore	  4.5%,	  which	  is	  comparable	  to	  other	  contact	  devices	  used	  
either	  at	  home,	  or	  in-­‐hospital	  (See	  Table	  9,	  Chapter	  1)	  (146).	  	  
The	  clinical	  value	  of	  this	  method	  is	  the	  potential	  to	  simplify	  the	  sometimes-­‐laborious	  diagnostic	  
process	   for	  SDB	  as	  a	   result	  of	   the	  non-­‐contact	  and	  thus	  patient-­‐friendly	  design	  of	   the	  SM.	   It	   is	  
cheaper	   than	   PSG	   to	   perform	   and	   can	   be	   performed	   in	   the	   patients’	   home	   requiring	  minimal	  
engagement	  and	  competence	  from	  patients.	  
In	  addition,	  the	  performance	  of	  SM	  in	  detecting	  and	  diagnosing	  SDB	  in	  a	  heart	  failure	  cohort	   is	  
comparable	  to	  other	  forms	  of	  portable/home	  contact-­‐screening	  devices	  (132;144;191-­‐203).	  
In	   majority	   of	   these	   studies	   of	   portable	   home	   screening	   devices	   that	   are	   comparable	   to	  
SleepMinderTM	   –	   (i.e	   Type	   4	   portable	  monitors,	   See	   Table	   9	   and	   10,	   Chapter	   1),	   patients	  with	  
heart	   failure	  were	  not	   included.	  Most	  of	   these	  patients	  who	  were	   recruited	   into	   these	   studies	  
had	  suspected	  symptoms	  of	  Obstructive	  Sleep	  Apnoea	  (OSA)	  and	  had	  been	  referred	  to	  the	  sleep	  
clinics	   for	   further	   investigations.	   I	   will	   discuss	   two	   of	   these	   studies	   which	   have	   included	   a	  
predominantly	   heart	   failure	   population	   for	   their	   validation	   purposes	   (See	   Table	   16	  
below)(132;144;191).	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Table	  16:	  Studies	  of	  Portable	  Monitoring	  for	  the	  diagnosis	  of	  SDB	  in	  Heart	  Failure	  patients	  
(Abbreviations:	  HR	  –	  Heart	  Rate,	  AHI	  –	  Apnoea	  Hypopnea	  Index,	  ODI	  –	  Oxygen	  Desaturation	  Index,	  CSR	  
–	  Cheyne	  Stokes	  Respiration,	  VLFI	  –	  Very	  Low	  Frequency	  Increment,	  O2	  Sats	  –	  Oxygen	  Saturation,	  NA	  –	  
Not	  Available)	  
The	  ApneaLink	   (ResMed,	  Sydney,	  Australia)	   is	  a	   single-­‐signal	   screening	  device,	  which	  measures	  
flow	  via	  a	  nasal	  cannula	  connected	  to	  a	  pressure	  transducer.	  It	  has	  been	  validated	  for	  detecting	  
CSR	  compared	  against	  PSG	  in	  a	  population	  of	  heart	  failure	  patients	  (Sens-­‐87%,	  Spec	  94%)	  (191).	  
In	  this	  study	  70	  patients	  were	  recruited	  as	  part	  of	  screening	  for	  SDB	  and	  sleep	  studies	  took	  place	  
in	   a	   German	   sleep	   centre.	   58%	   of	   these	   patients	   had	   a	   diagnosis	   of	   CHF.	   It	   has	   also	   been	  
previously	  validated	  against	  PSG	  for	  calculating	  the	  AHI	  (Sens	  91%	  Spec	  95%),	  in	  a	  population	  of	  
59	  Type	  II	  diabetic	  patients,	  3%	  of	  whom	  had	  heart	  failure	  (144).	  
Ward	   and	   colleagues	   investigated	   the	   utility	   of	   overnight	   pulse	   oximetry	   and	   Heart	   Rate	  
Variabilty	  (HRV)	  for	  detecting	  SDB	  in	  a	  population	  of	  178	  stable	  CHF	  patients	  recruited	  from	  a	  UK	  
tertiary	   HF	   centre.	   The	   median	   left	   ventricular	   ejection	   fraction	   was	   40%	   and	   77%	   of	   these	  
patients	  had	  NYHA	  class	  I	  or	  II	  symptoms.	  They	  measured	  the	  percentage	  of	  Very	  Low	  Frequency	  
Increments	   (%VLFI)	   in	   heart	   rate	   from	  an	   ambulatory	   ECG	  worn	  by	   patients	   and	   a	   3%	  Oxygen	  
Desaturation	  Index	  (ODI)	  which	  was	  calculated	  as	  the	  mean	  number	  of	  ≥3%	  oxygen	  desaturations	  
per	   hour,	   using	   the	   ‘time	   in	   bed’	   as	   denominator.	   A	   pre-­‐specified	   3%	   ODI	   cutoff	   of	   >7.5	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In	  comparison	  to	  PSG	  and	  at	  a	  cutoff	  of	  ≥2.23%,	  the	  %VLFI	  had	  a	  sensitivity	  of	  58%	  and	  specificity	  
of	   48%,	   for	   diagnosis	   of	   SDB	   (AHI≥15).	   Overnight	   pulse	   oximetry	   performed	   better	   with	   a	  
sensitivity	  of	  97%	  and	  specificity	  of	  32%	  for	  diagnosis	  of	  clinically	  relevant	  SDB.	  
While	  the	  Apnoea	  Link	  and	  the	  use	  of	  a	  3%	  ODI	  as	  reported	  by	  Ward	  et	  al,	  have	  published	  better	  
results	  in	  comparison	  to	  the	  SleepMinderTM,	  a	  major	  advantage	  of	  the	  SM	  over	  these	  methods	  is	  
that	  it	  is	  unlikely	  to	  influence	  sleeping	  due	  to	  its	  non-­‐contact	  design,	  and	  therefore	  several	  nights	  
would	  be	   convenient	   to	  undertake	  and	   this	   could	  be	  used	   to	   identify	   clinically	   important	   SDB.	  
The	  ability	  of	  the	  SM	  to	  be	  used	  in	  the	  patient’s	  home	  as	  well	  also	  increases	  its	  acceptability	  as	  a	  
screening	  tool.	  
The	  SM	  is	  also	  validated	  for	  sleep/wake	  scoring	  against	  PSG	  (190)	  and	  therefore	  uses	  the	  Total	  
Sleep	  Time	  (TST)	  as	  the	  denominator	  for	  calculating	  the	  AHI,	  unlike	  other	  PM	  devices	  which	  use	  
the	  'Time	  In	  Bed'	  (TIB)	  or	  'Total	  Recording	  Time'	  (TRT),	  which	  could	  result	  in	  underestimation	  of	  
SDB.	  Therefore	  theoretically	  it	  should	  present	  a	  more	  accurate	  assessment	  of	  SDB.	  	  
I	  have	  however	  utilised	  the	  SM-­‐TST	  proprietary	  algorithm	  in	  the	  determining	  the	  SM	  calculated	  
AHI.	  This	  algorithm	  was	  developed	  and	  tested	  in	  14	  normal	  healthy	  volunteers	  (mean	  age	  27±5	  
years)	   and	   as	   yet	   is	   not	   validated	   in	   a	   heart	   failure	   population	   (190).	   The	   algorithm	  makes	   an	  
estimate	   of	   the	   total	   sleep	   time	   by	   detecting	   the	   patient’s	   presence	   in	   front	   of	   the	  
SleepMinderTM	  and	  the	  patient’s	  gross	  movement	  patterns	  through	  the	  night.	  This	  is	  in	  contrast	  
to	  PSG,	  where	  EEG	  recordings	  are	  used	  to	  determine	  the	  TST	  more	  accurately.	  	  
The	  SM	  has	  recently	  been	  validated	  against	  PSG	  for	  the	  diagnosis	  of	  OSA	  in	  a	  heart	  failure-­‐free	  
population	  of	  74	  patients	  who	  were	  referred	  for	  screening	   for	  SDB	  at	  a	  sleep	  centre	   in	  Dublin,	  
Ireland.	  Utilizing	   the	   current	   TST	  algorithm	  but	   a	  different	   version	  of	  AHI	   algorithm	  developed	  
and	   used	   in	   this	   thesis,	   the	   performance	   at	   detecting	   clinically	   important	   SDB	   (AHI>15)	   was	  
excellent	  (Sens	  0.90,	  Spec	  0.92,	  AUC	  0.97)	  (204).	  
From	  my	  results,	  I	  have	  demonstrated	  that	  the	  SM	  tended	  to	  overestimate	  the	  TST,	  compared	  to	  
expertly	   scored	  PSG,	   in	  more	   than	  half	  of	  our	  heart	   failure	  patients	   (see	  Figure	  39).	  While	   the	  
final	  result	  of	  the	  SM-­‐AHI	  does	  not	  seem	  to	  reflect	  this,	  it	  is	  possible	  that	  refining	  of	  the	  SM-­‐TST	  
to	  reflect	  the	  sleep	  patterns	  in	  a	  heart	  failure	  population	  may	  improve	  the	  diagnostic	  accuracy	  of	  
the	  SM	  in	  calculating	  the	  AHI.	  	  
	   148	  
The	  AHI	   algorithm	  has	   a	   PPV	   of	   71%	  meaning	   that	   7	   out	   of	   10	   patients	   diagnosed	   by	   the	   SM	  
would	  be	  confirmed	  on	  formal	  testing.	  Therefore	  clinicians	  can	  rely	  on	  the	  results	  of	  the	  SM	  and	  
appropriately	  prioritize	  patients	  with	  a	  high	  pre-­‐test	  probability	  of	  SDB	  for	  a	   formal	  PSG	  study.	  
But	  a	  NPV	  of	  82%	  means	  that	  2	  out	  of	  10	  patients	  who	  the	  SM	  indicates	  no	  SDB	  will	  have	  this	  on	  
formal	  PSG.	  
Portier	  and	  colleagues	  in	  a	  previous	  study	  observed	  individual	  differences	  between	  the	  portable	  
and	  the	   laboratory	  PSG	  AHI's	  values	  obtained	  from	  consecutive	  nights	  of	  studying,	  of	   less	  than	  
10events/hour	  in	  65%	  of	  the	  78	  subjects	  participating	  to	  the	  study	  (205).	  SM’s	  AHI	  estimate	  was	  
within	  10	  events	  per	  hour	  in	  72%	  of	  the	  cases.	  
The	  CSR	  algorithm	  was	  only	  71%	  sensitive	  at	  detecting	  Cheyne	  Stokes	  respiration	  and	  the	  false	  
positive	   rate	  was	   also	   high	   in	   the	   validation	   set	   of	   patients	   (37%).	  We	   found	   some	   situations	  
where	  our	  algorithm	  had	  scored	  CSR	  in	  some	  patients,	  who	  seemed	  to	  fulfil	  these	  criteria	  even	  
on	   PSG,	   but	  were	   not	   scored	   as	   so	   by	   the	   ‘expert’	   scorer.	   An	   example	   is	   shown	   in	   the	   figure	  
below.	  (Figure	  42)	  	  
	  
	  
Figure	  42:	  SM	  vs	  PSG	  –	  ‘Obvious’	  CSR	  pattern	  seen	  on	  both	  PSG	  and	  SM	  signals.	  Scored	  as	  present	  by	  
SM	  algorithm	  but	  scored	  as	  0	  by	  expert	  	  
The	  AASM	  provide	  guidelines	  for	  scoring	  CSR	  but	  this	  is	  fraught	  with	  varying	  interpretations	  due	  
to	   variations	   in	   scoring	   hypopnoeas	   (180).	   This	   may	   contribute	   to	   significant	   inter	   rater	  
variability.	  	  As	  a	  consequence,	  there	  are	  no	  firm	  rules	  in	  place	  for	  marking	  and	  quantifying	  CSR	  in	  
everyday	   clinical	   practice.	   It	   is	   therefore	   not	   surprising	   that	   our	   CSR	   algorithm	   which	   follows	  
strict	  rules	   in	  design	  and	  pattern	  recognition	  would	  overestimate	  the	  presence	  of	  CSR	  while	  an	  
expert	  may	  be	  more	  or	  less	  flexible	  in	  their	  definitions.	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This	   problem	   is	   less	   obvious	   with	   scoring	   of	   respiratory	   events	   (Apnoeas	   or	   Hypopneas)	   as	  
definitions	  in	  guidelines	  are	  clearer.	  This	  is	  confirmed	  by	  a	  much	  lower	  Inter	  observer	  variability	  
for	  AHI	  scoring	  compared	  to	  CSR.	  (AHI	  vs	  CSR	  Intra	  Class	  Correlation	  Coefficient	  –	  0.879	  vs	  0.203).	  
We	   also	   observed	  more	  noise	  within	   the	   Essen	  dataset	   compared	   to	   the	   London	  dataset.	   The	  
reasons	   were	   not	   clear,	   as	   techniques	   used	   for	   both	   sleep	   studies	   were	   similar.	   This	   may	  
however	  have	  reduced	  the	  performance	  of	  the	  CSR	  algorithm.	  We	  appeared	  to	  confirm	  this	  by	  
testing	  solely	  on	  the	  London	  validation	  population	  (n=10),	  who	  had	  cleaner	  signals.	  This	  resulted	  
in	  a	  drop	  in	  the	  False	  Positive	  Rate	  (FPR)	  from	  37%	  to	  11%.	  	  
The	  overall	  diagnostic	  accuracy	   for	   the	  CSR	  algorithm	  for	   the	  entire	  dataset	  was	  76%,	  which	   is	  
still	  comparable	  to	  other	  screening	  strategies	  (191).	  
The	  prevalence	  of	  SDB	  in	  our	  study	  population,	  using	  an	  AHI	  >15	  was	  47%,	  which	  is	  comparable	  
to	  published	  studies	  (7;137),	  but	  lower	  than	  some	  other	  studies	  that	  show	  a	  higher	  prevalence	  of	  
SDB	   in	   patients	   with	   CHF	   (127;136).	   This	   is	   however	   a	   relatively	   small	   cohort	   and	   good	  
contemporary	  drug	  and	  device	   therapy	   in	   these	  patients	  may	  have	  controlled	   the	  heart	   failure	  
syndrome	   better.	   Our	   sample	   size	   was	   however	   not	   powered	   to	   answer	   specific	   prevalence	  
questions.	  
The	   presence	   of	   Cheyne	   –	   Stokes	   Respiration	   is	   usually	   associated	  with	   Central	   Sleep	   Apnoea	  
(CSA)	  and	  sometimes	  used	  as	  a	  surrogate	  for	  classifying	  patients	  who	  have	  SDB,	  into	  this	  group,	  
particularly	  those	  with	  an	  AHI	  >15.	  36%	  of	  the	  patients	  in	  our	  cohort	  fitted	  this	  criterion,	  which	  is	  
lower	   than	   some	  documented	   literature	   that	   suggests	   CSA	   is	   the	  predominant	   form	  of	   SDB	   in	  
patients	  with	  CHF	  (7;9;206).	  However	  more	  recent	  data	  in	  contemporary	  cohorts	  of	  CHF	  patients	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3.9. Limitations	  
The	  main	   limitation	   from	  this	   study	  was	   that	  at	   this	   stage	  of	  development,	   the	  SleepMinderTM	  
device	  does	  not	  formally	  discriminate	  between	  obstructive	  and	  central	  events.	  The	  presence	  of	  
Cheyne-­‐Stokes	  Respiration	  (CSR)	  has	  been	  used	  a	  surrogate	  to	  categorise	  patients	  into	  a	  Central	  
Sleep	  Apnoea	  group.	  	  
Our	   results	  would	   have	   been	   strengthened	   by	   an	   algorithm	   that	   differentiates	   the	   two	  major	  
types	  of	  SDB,	  as	  there	  are	  implications	  for	  treatment.	  Accurate	  separation	  of	  respiratory	  events	  
into	  obstructive	  and	  central	  would	  however	  not	  matter	  a	  great	  deal,	   if	   there	  was	  a	  device	  that	  
could	  treat	  both	  types	  of	  SDB.	  
The	   patients	   recruited	   in	   this	   study	   did	   not	   also	   have	   any	   clinical	   risk	   assessments	   of	   SDB	  
performed,	   for	   instance	   using	   a	   physician	   administered	   Epworth	   Sleep	   Score	   (ESS).	   For	   this	  
reason,	   our	   study	   population	  may	   not	   represent	   a	   true	   at-­‐risk	   population	   for	   SDB	   and	   so	   the	  
number	  of	  patients	  with	  CSR	  may	  have	  been	  underestimated.	  The	  ESS	   is	  however	  notably	  very	  
subjective	  and	  not	  very	  sensitive	   (66%)	  or	   specific	   (32%)	   (207).	   In	  addition	  HF	  patients	  notably	  
have	  less	  subjective	  daytime	  sleepiness	  despite	  significantly	  reduced	  sleep	  time,	  whether	  or	  not	  
they	  have	  SDB	  (208).	  Perhaps	  screening	  our	  study	  population	  using	  a	  more	  objective	  clinical	  risk	  
assessment	  tool	   like	  the	  Oxford	  Sleep	  Resistance	  Test	  (OSLER)	  (Sensitivity	  85%;	  Specificity	  94%)	  
may	  have	  been	  useful	  to	  increase	  our	  pre-­‐test	  probability	  for	  identifying	  patients	  with	  SDB	  (209).	  	  
The	   TST	   in	   heart	   failure	   patients	   compared	   to	   a	   normal	   population	   is	   usually	   shortened	   by	  
haemodynamic	   and	   autonomic	   mechanisms	   that	   result	   in	   frequent	   arousals	   (ref	   –	   Bradley	  
Circulation).	  	  In	  this	  study,	  we	  have	  utilised	  the	  SM-­‐TST	  proprietary	  algorithm	  validated	  in	  a	  heart	  
failure-­‐free	   population,	   to	   estimate	   the	   SM-­‐AHI.	   Our	   results	   would	   perhaps	   have	   been	   more	  
accurate	  using	  a	  TST-­‐	  algorithm	  specifically	  developed	  using	  heart	  failure	  patients.	  	  
We	  have	  also	  only	  included	  patients	  with	  low	  left	  ventricular	  ejection	  fraction.	  It	  would	  therefore	  
be	  valuable	  to	  know	  if	  these	  algorithms	  are	  applicable	  to	  the	  group	  of	  heart	  failure	  patients	  with	  
normal	  or	  preserved	  ejection	  fraction	  (HFnEF,	  HFpEF)	  as	  this	  patient	  population	  are	  also	  known	  
to	  have	  SDB.	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Further	  research	   is	  needed	  to	  extend	  this	  work	  to	   involve	  a	   larger	  study	  cohort	   to	  confirm	  the	  
diagnostic	  value	  of	  this	  new	  tool,	  and	  improve	  the	  algorithm	  to	  enable	  grouping	  of	  SDB	  events	  by	  
type.	  	  
3.10. Conclusion	  
This	  validation	  study	  has	  confirmed	  the	  null	  hypothesis	  that	  there	  is	  no	  difference	  in	  the	  Apnoea	  
Hypopnea	   Index	   (AHI)	   and	   quantity	   of	   Cheyne-­‐Stokes	   Respiration	   (CSR)	   measured	   by	   the	  
SleepMinderTM	  device	  compared	  to	  in	  –hospital	  Polysomnography	  (PSG).	  
SDB	   is	   prevalent	   in	   an	   unselected	   population	   of	   patients	   with	   chronic	   heart	   failure	   and	   this	  
diagnosis	   can	   be	  made	  with	   a	   reasonable	   degree	   of	   accuracy	   using	   a	   non-­‐contact	  monitor	   of	  
nocturnal	  respiratory	  patterns	  –	  SleepMinderTM	  device,	  compared	  to	  full	  in-­‐hospital	  PSG.	  The	  AHI	  
algorithm	  seems	  robust	  and	  has	  been	  tested	  on	  a	  mixed	  population	  of	  patients	  with	  CHF.	  This	  
study	  should	  be	  extended	  to	  a	  larger	  and	  more	  varied	  cohort	  of	  patients	  including	  more	  women.	  
The	  quantification	  of	  CSR	  using	  this	  system	  needs	  further	  refinement	  to	  improve	  its	  accuracy.	  
Multi-­‐national	   randomised	   control	   trials	   (165;166)	   may	   demonstrate	   mortality	   benefit	   from	  
treating	  patients	  with	  CHF	  and	  SDB	  and	  this	  would	  increase	  the	  need	  for	  easier	  and	  convenient	  
diagnostic	  tools	  to	  aid	  this	  process.	  
The	  SM	  seems	  to	  be	  able	  to	  achieve	  this	  as	  a	  screening	  tool	  and	  the	  potential	  ability	  to	  observe	  
variations	  in	  SDB	  metrics	  such	  as	  AHI	  and	  CSR	  over	  long	  periods	  is	  also	  welcome	  to	  improve	  our	  
understanding	  of	  how	   these	  physiological	  parameters	   influence	   the	  course	  of	   the	  heart	   failure	  
syndrome	  over	  a	  long	  period	  of	  time.	  	  
In	  the	  next	  chapter,	  I	  will	  examine	  how	  nocturnal	  respiratory	  patterns	  including	  variations	  in	  SDB	  
metrics	   such	   as	   AHI	   and	   CSR	   vary	   over	   a	   longer	   period	   of	   monitoring.	   This	   may	   provide	  




























CHAPTER	  FOUR	  –	  Longitudinal	  Observation	  
of	  Nocturnal	  Respiratory	  Patterns	  in	  patients	  
with	  Chronic	  Heart	  Failure	  using	  a	  Non-­‐
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4.1. Introduction	  
The	  Apnoea	  Hypopnea	  Index	  (AHI)	  is	  the	  most	  commonly	  measured	  parameter	  for	  diagnosis	  and	  
classification	   of	   Sleep	   Disordered	   Breathing	   (SDB).	   However	   in	   small	   studies	   and	   over	   short	  
periods	  of	  monitoring,	  it	  is	  has	  been	  shown	  to	  be	  subject	  to	  variations	  in	  patients	  with	  or	  without	  
heart	  failure	  (147;154).	  
It	  however	  remains	  unknown	  what	  the	  true	  variation	  of	  the	  AHI	  is	  over	  a	  longer	  and	  consecutive	  
period	  of	  monitoring	  is,	  how	  often	  these	  variations	  take	  place	  and	  what	  the	  clinical	  significance	  
might	   be.	   This	   is	   because	   up	   till	   now,	   it	   has	   been	   difficult	   to	   accurately	   monitor	   patients’	  
respiratory	  patterns	  on	  a	  consecutive	  night-­‐to-­‐night	  basis	  and	  for	  a	  prolonged	  period	  due	  to	  the	  
impracticalities	   of	   consecutive	   nightly	   Polysomnography	   (PSG)	   studies.	   Specific	   respiratory	  
parameters	   including	   rates	   and	   duration	   of	   various	   components	   of	   SDB	   have	   also	   not	   been	  
described	  in	  literature	  on	  a	  longitudinal	  basis,	  due	  to	  this	  similar	  constraint.	  
The	   SleepMinderTM	   device	   is	   a	   non-­‐contact	   biomotion	   respiratory	   monitor	   that	   is	   capable	   of	  
recording	  signals	   related	  to	  breathing	  and	  movement	  when	  placed	  by	  the	  patient’s	  bedside.	   In	  
the	  previous	  chapter,	  I	  have	  validated	  its	  accuracy	  in	  measuring	  the	  Apnoea	  Hypopnea	  Index	  and	  
quantifying	  CSR	  in	  patients	  with	  CHF	  against	  ‘gold’	  standard	  Polysomnography.	  It	  can	  be	  used	  in	  
the	   patient’s	   home	   and	   can	   provide	   continuous	   measurements	   of	   nocturnal	   respiratory	  
parameters	  over	  several	  nights.	  
	  
4.2. Hypothesis	  	  
I	  hypothesised	   that	  due	   to	  potential	  on-­‐going	  changes	   in	   the	  pathophysiology	  of	  CHF	  patients,	  
the	  AHI	  would	  have	  a	  high	  variability	  over	  a	   longer	  period	  of	  monitoring.	  My	   ‘Null’	  hypothesis	  
was	  therefore	  that	  there	  is	  a	  low	  variability	  in	  the	  Apnoea	  Hypopnea	  Index	  from	  night	  to	  night	  in	  
patients	  with	  Chronic	  Heart	  Failure	  over	  a	  long	  (12months)	  period	  of	  monitoring.	  	  
	  
	   155	  
4.3. Aim	  
The	  main	  aim	  of	  this	  study	  was	  to	  determine	  the	  variability	  of	  the	  AHI	  over	  a	  prolonged	  period	  of	  
monitoring	   by	   employing	   the	   SleepMinderTM	   device	   (SM)	   to	   analyse	   nocturnal	   respiratory	  
patterns	  in	  CHF	  patients	  over	  a	  period	  of	  12-­‐month	  period.	  	  
The	  SM	  device	  is	  a	  non-­‐contact,	  biomotion	  sensor	  monitor	  that	  placed	  by	  the	  patient’s	  bedside,	  
is	  capable	  of	  recording	  signals	  that	  pertain	  to	  breathing	  and	  movement.	  In	  the	  previous	  chapter,	  I	  
have	   validated	   its	   diagnostic	   accuracy	   in	   measuring	   the	   Apnoea	   Hypopnea	   Index	   (AHI)	   and	  
quantifying	  CSR	  in	  patients	  with	  CHF	  against	  ‘gold’	  standard	  PSG.	  
	  
4.4. Methods	  	  
4.4.1. Participants	  
All	  patients	  who	  were	  recruited	  into	  the	  validation	  arm	  of	  the	  SleepMinderTM	  study	  were	  used	  in	  
this	  analysis.	  (See	  Figure	  43)	  I	  have	  described	  in	  detail	  the	  recruitment	  process	  for	  these	  patients	  
in	  Chapter	  2	  and	  Chapter	  4.	   These	  patients	  had	  consented	   to	   receive	  a	  SleepMinderTM	  device,	  
which	  they	  took	  home	  and	  placed	  by	  their	  bedside.	  They	  also	  received	  a	  set	  of	  weighing	  scales	  
which	   they	  measured	   their	   weights	   with	   daily.	   A	  mobile	   phone	  was	   provided	  which	   provided	  
wireless	   transmission	   of	   SM	   and	  weight	   data.	   All	   three	   devices	  were	   ‘paired’	   or	   connected	   to	  
each	  other	  via	  a	  Bluetooth	  wireless	  connection.	  (See	  Figure	  15	  –	  Chapter	  2)	  
The	  SM	  device	  recorded	  all	  activity	   related	  to	  breathing	  and	  movement	  during	  a	  window	  from	  
7pm	   in	   the	   evening	   till	   10am	   the	   following	   morning	   onto	   a	   removable	   Secure	   Digital	   (SD)	  
memory	   card.	   Periodic	   downloading	  of	   SM	  data	  occurred	  during	   a	   separate	   ‘Log	  Window’	   the	  
following	   day	   onto	   a	   live	   study	   database.	   Recording	   and	   transfer	   of	   data	   did	   not	   occur	  
simultaneously.	   Weight	   data	   were	   transferred	   immediately	   following	   measurement	   with	   the	  
scales.	  All	  data	  were	  transferred	  via	  a	  3G	  wireless	  mobile	  network.	  
	   156	  
Follow-­‐Up	  
The	  SM	  device	  was	  left	  switched	  on	  throughout	  the	  duration	  of	  the	  study.	  The	  mean	  follow	  up	  
period	  for	  all	  patients	  was	  11.2	  ±	  3.6	  months.	  	  Figure	  44	  shows	  a	  sample	  of	  the	  SleepMinderTM	  
recording	  in	  one	  patient	  over	  a	  12-­‐month	  period.	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Figure	  44:	  Sample	  SleepMinderTM	  recording	  over	  a	  12-­‐month	  period.	  Brown	  Lines	  represent	  periods	  of	  
decompensation	  of	  heart	  failure	  
	  
4.4.2. Trouble	  shoot	  and	  Loss	  of	  Data	  
Problematic	  acquisition	  or	  transfer	  of	  data	  occurred	  due	  to	  three	  main	  reasons.	  
• Loss	  of	  electrical	  power	  to	  SM,	  usually	  from	  being	  accidentally	  switched	  off	  
• Loss	  of	  battery	  power	  to	  scales	  
• Mobile	  Phone	  Signal	  Loss	  leading	  to	  un-­‐pairing	  with	  SM	  and	  scales	  resulting	  in	  inability	  to	  
transfer	  data	  
Our	  database	  was	  a	  live	  one,	  so	  we	  were	  informed	  early	  when	  data	  acquisition	  was	  inadequate.	  
The	  first	  two	  problems	  relating	  to	  power	  were	  easy	  to	  deal	  with,	  by	  replacing	  scale	  batteries	  and	  
reconnecting	  the	  SM	  to	  power.	  
The	  other	  problem	  relating	  to	  un-­‐pairing	  of	  equipment	  was	  resolved	  by	  placing	  a	  phone	  call	   to	  
the	  patient,	  to	  talk	  them	  through	  a	  phone/SM	  and	  scales	  reset,	  or	  a	  home	  visit	  that	  I	  performed.	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4.4.3. Nocturnal	  Respiratory	  Parameters	  Analysed	  	  
In	  this	  study	  the	  Apnoea	  Hypopnea	  Index	  (AHI)	  was	  the	  main	  measure	  I	  examined,	  for	  assessing	  
variability	  of	  sleep-­‐disordered	  breathing	  (SDB).	  I	  have,	  however,	  also	  examined	  the	  variability	  in	  
other	  nocturnal	  respiratory	  parameters	  including	  the	  Respiratory	  Rate	  (RR),	  quantity	  of	  Cheyne-­‐
Stokes	  Respiration	  (CSR),	  and	  Total	  Sleep	  Time	  (TST).	  
	  
4.4.4. Statistical	  Analyses	  
Baseline	   characteristics	   of	   patients	   were	   described	   by	   means	   and	   standard	   deviations	   for	  
continuous	  variables	  and	  as	  a	  number	  or	  percentages	  for	  categorical	  variables.	  	  
In	  order	  to	  assess	  variability	  of	  the	  AHI	  in	  this	  period,	  I	  have	  used	  a	  number	  of	  methods	  in	  order	  
to	  be	  comparable	  to	  reports	  in	  literature.	  	  
Intra-­‐patient	  variability	  was	  first	  determined	  by	  computing	  the	  distribution	  of	  the	  AHI	  using	  box-­‐
plot	  representation	  of	  interquartile	  ranges,	  and	  medians	  over	  the	  entire	  follow	  up	  (FU)	  period.	  	  
I	   then	   examined	   within-­‐subject	   means	   (MeanAHI)	   and	   standard	   deviations	   of	   the	   AHI,	   over	   3	  
groups	   of	   FU	   periods;	   2	   weeks,	   3	   months	   and	   12	   months;	   and	   compared	   these	   by	   using	   an	  
independent	  sample	  student	  t-­‐test	  with	  a	  significance	  level	  set	  at	  p<0.05.	  	  
I	  further	  assessed	  Inter-­‐patient	  variability,	  by	  calculating	  the	  co-­‐efficient	  of	  variation	  (CoV).	  (210)	  
The	   coefficient	   of	   variation	   is	   useful	   because	   the	   standard	   deviation	   of	   data	   must	   always	   be	  
understood	  in	  the	  context	  of	  the	  mean.	  In	  contrast,	  the	  actual	  value	  of	  the	  CoV	  is	  independent	  of	  
the	   unit	   in	   which	   the	   measurement	   has	   been	   taken,	   so	   it	   is	   a	   dimensionless	   number.	   It	   is	  
sometimes	  used	  as	  a	  percentage.	  Highly	   variable	  data	  has	  been	  described	  where	   the	  CoV	  was	  
>15%	  (211).	  	  
As	  an	  alternative	  to	  the	  Mean,	   I	  have	  further	  described	  as	  proportions	  of	  the	  overall	   follow	  up	  
period,	   periods	   when	   the	   AHI	   was	   above	   a	   commonly	   used	   treatment	   threshold	   of	   AHI>15	  
(FUAHI15).	  Correlation	  between	  the	  FUAHI15	  and	  MeanAHI	  was	  made	  by	  the	  Pearson’s	  correlation	  co-­‐
efficient.	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The	  Intra-­‐class	  correlation	  co-­‐efficient	  (ICC)	  together	  with	  the	  95%	  confidence	  interval	  was	  used	  
to	   determine	   inter-­‐patient	   AHI	   variability.	   I	   derived	   this	   by	   selecting	   consecutive	   nights	   of	  
simultaneous	  patients	  SM	  recordings	  and	  computing	  this	  value.	   (212;213)	  The	   ICC	   is	  defined	   in	  
this	  case	  as	  the	  ratio	  of	  between-­‐patient	  variances	  to	  the	  total	  variance,	  which	  is	  a	  combination	  
of	  the	  between-­‐	  and	  within-­‐	  patient	  variances	  and	  was	  used	  to	  measure	  consistency	  in	  the	  AHI	  
over	  the	  FU	  period.	  
I	  also	  assessed	  if	  the	  prevalence	  of	  clinically	  important	  (AHI>15)	  SDB	  in	  our	  cohort	  using	  a	  single	  
night	  AHI	  measurement	  was	  comparable	  to	  that	  from	  a	  longer	  period	  of	  monitoring.	  I	  achieved	  
this	   by	   comparing	   the	  MeanAHI,	   over	   the	   3	   FU	   periods	   used,	  with	   results	   from	   a	  Monte	   Carlo	  
simulation,	   which	   provided	   a	   probability	   estimate	   of	   the	   highest	   proportion	   of	   patients	   who	  
would	  have	  a	  clinically	  important	  AHI	  based	  on	  a	  single	  nights	  study.	  	  
To	  determine	  which	  patients	  had	  the	  most	  variable	  data	  for	  the	  AHI	  and	  because	  I	  elected	  not	  to	  
use	  an	  arbitrary	  determination	  of	  what	  may	  be	  considered	  highly	  variable	  based	  on	   the	  CoV,	   I	  
proposed	  that	  the	  more	  highly	  variable	  patients	  would	  be	  those	  whose	  mean	  AHI	  over	  the	  follow	  
up	  period	  was	  less	  than	  twice	  their	  standard	  deviation	  (MeanAHI<	  2xSD).	  95%	  of	  data	  points	  are	  
expected	  to	  lie	  within	  2SD	  of	  the	  mean	  and	  when	  the	  SD	  is	  greater	  than	  the	  mean,	  the	  dataset	  is	  
considered	  as	  skewed.	  Exploring	  my	  original	  dataset,	  I	  found	  that	  most	  patients	  had	  a	  meanAHI	  
that	  was	  greater	  than	  the	  SD	  suggesting	  minimal	  variability	  in	  each	  patient.	  However,	  to	  test	  the	  
strength	   of	   this	   assumption	   and	   to	   create	   the	   categories	   for	   analysis,	   I	   have	   increased	   this	  
threshold	  by	  doubling	  the	  SD.	  If	  the	  patients	  mean	  AHI	  was	  still	  >2SD	  then,	  I	  have	  accepted	  that	  
in	  this	  patient	  there	  was	  minimal	  variability	  for	  this	  parameter.	  
Using	  this	  criterion,	  I	  was	  able	  to	  divide	  the	  patients	  into	  two	  variability	  groups	  for	  the	  AHI	  (high	  
and	   low).	   I	   then	   assessed	   whether	   the	   severity	   of	   heart	   failure	   using	   surrogates	   such	   as	   the	  
ejection	  fraction	  and	  BNP	  levels	  had	  any	  influence	  on	  AHI	  variability.	  
Finally	  I	  have	  defined	  the	  severity	  of	  SDB	  by	  commonly	  used	  AHI	  cut-­‐offs,	  ≥5	  mild,	  ≥15	  moderate,	  
≥30	  severe,	  with	   the	  clinical	   treatment	  groups	  been	  the	   latter	   two.	  By	  doing	   this	   I	  was	  able	   to	  
calculate	  the	  percentage	  of	  patients	  who	  were	  misclassified	  into	  a	  different	  severity	  or	  treatment	  
category	  from	  night	  to	  night.	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4.5. Results	  
4.5.1. Demographics	  
In	  total,	  43	  adult	  patients	  with	  CHF	  were	  recruited	  into	  this	  study.	  They	  were	  mainly	  male	  (72%)	  
with	  a	  mean	  age	  of	  (76.7	  ±	  9	  years)	  and	  left	  ventricular	  ejection	  fraction	  of	  (38.3	  ±	  13.7	  %).	  Table	  
17	  summarises	  their	  other	  characteristics.	  	  
	  
Table	  17:	  Patient	  characteristics	  of	  all	  43	  patients	  recruited	  into	  the	  study	  (EF	  –	  Ejection	  Fraction,	  NYHA	  
–	  New	  York	  Heart	  Association	  Classification	  of	  Heart	  Failure,	  	  BNP	  –	  Brain	  Natriuretic	  Peptide,	  Anaemia	  
–	  HB	  <13g/dl	  women,	  <14	  g/dl	  men,	  DM	  –	  Diabetes	  Mellitus,	  HTN	  –	  Hypertension,	  AF	  –	  Atrial	  
Fibrillation,	  ACEi	  –	  Angiotensin	  Converting	  Enzyme	  Inhibitor,	  AIIRB	  –	  Angiotensin	  II	  Receptor	  Blocker,	  BB	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4	  patients	  were	  excluded	  from	  further	  analysis,	  from	  the	  original	  43,	  due	  to	  a	  combination	  of	  less	  
than	  3	  months’	  worth	  and	  corrupted	  data	  collected.	  Therefore	  for	  further	  statistical	  analysis	  used	  
in	   this	   chapter	   unless	   otherwise	   stated,	   this	   relates	   to	   the	   39	   patients	  who	  were	   eligible.	   The	  
mean	   (SD)	   follow	   up	   period	   for	   these	   patients	   was	   11.2	   ±	   (3.6)	   months.	   There	   were	   no	  
meaningful	  differences	  in	  terms	  of	  baseline	  characteristics	  between	  the	  4	  patients	  excluded	  and	  
the	  39	  analysed.	  
	  
4.5.2. Intra-­‐Patient	  Variability	  in	  AHI	  –	  Distribution	  and	  Prevalence	  
Figure	  45	  shows	  box-­‐plots	   in	  all	  39	  patients,	   showing	   the	   range	  of	  distribution	   in	  AHI	  over	   the	  
follow-­‐up	  period.	  The	  ‘whiskers’	  of	  the	  plot	  represent	  the	  range	  of	  values,	  that	  is,	  maximum	  and	  
minimum	  values	  of	  AHI.	  The	  boxes	  represent	  the	  values	  between	  the	  lower	  and	  upper	  quartiles	  
while	   the	   horizontal	   line	   in	   the	  middle	   of	   the	   box	   represents	   the	  median	   value.	   This	   analysis	  
demonstrates	  a	  wide	  variation	  in	  the	  value	  of	  the	  AHI	  with	  such	  ranges	  in	  some	  patients	  giving	  
the	  suggestion	  that	  a	  patient	  could	  record	  clinically	  important	  SDB	  (AHI≥15)	  on	  one	  night	  and	  in	  
some	  cases	  no	  SDB	  on	  another	  night.	  
	  
Figure	  45:	  Box-­‐Plots	  showing	  distribution	  of	  AHI	  over	  a	  12-­‐month	  follow-­‐up	  period.	  Mean	  Stdev	  
11.3events	  per	  hour	  (95%	  CI	  10.08-­‐12.95).	  Reference	  Line	  represents	  an	  AHI	  of	  15,	  which	  is	  clinically	  
significant	  SDB	  
AHI=15'
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Further	  I	  divided	  the	  follow-­‐up	  period	  into	  3	  groups	  as	  described	  earlier	  to	  assess	  if	  there	  was	  a	  
significant	   change	   in	   the	   percentage	   of	   patients	   whose	  Mean	   AHI	   was>	   15	   as	   the	   FU	   period	  
shortened.	   Figure	   46	   represents	   scatter	   plots	   that	   shows	   how	   the	   mean	   AHI	   of	   each	   patient	  
changes	  as	  the	  FU	  period	  is	  shortened.	  
	  
Figure	  46:	  Scatterplots	  showing	  proportion	  of	  patients	  with	  AHI≥	  15	  as	  FU	  period	  is	  increased.	  
Reference	  line	  represents	  mean	  AHI	  of	  15	  events/hour	  
	  
57%,	  60%	  and	  74%	  of	  all	  patients	  had	  a	  mean	  AHI≥	  15	  when	  monitored	  over	  a	  2-­‐week,	  3-­‐month	  
and	  12-­‐month	  FU	  period	  respectively.	  There	  was	  however	  was	  no	  significant	  statistical	  difference	  
in	  the	  actual	  mean	  value	  of	  the	  AHI	  in	  all	  39	  patients	  over	  the	  different	  FU	  periods.	  (2wk	  vs	  3mth;	  
20	  vs	  19	  p=0.84,	  2wk	  vs	  12mth;	  20	  vs	  24	  p=0.11,	  3	  mth	  vs	  12mth;	  19	  vs	  24	  p=0.06).	  Figure	  47	  is	  a	  
line	  plot	  that	  illustrates	  this	  similarity	  in	  the	  mean	  AHI	  over	  the	  3	  different	  FU	  periods	  examined.	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Figure	  47:	  Line	  Plots	  showing	  change	  in	  mean	  AHI	  over	  different	  FU	  periods	  
	  
4.5.2.1. Age	  and	  Sex	  Distribution	  
Male	  patients	  had	  a	  consistently	  higher	  mean	  AHI	  compared	  to	  the	  female	  patients	  regardless	  of	  
the	   duration	   of	   FU	   (Figure	   48).	  More	   patients	   however	   had	   a	   higher	   AHI	   in	   the	   12-­‐month	   FU	  
group.	  	  There	  was	  no	  specific	  distribution	  of	  the	  AHI	  according	  to	  patient’s	  age	  group	  (Figure	  49),	  
however	   similarly	  more	  patients	  who	  were	   followed	  up	   for	  12	  months	  had	  a	  higher	  mean	  AHI	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Figure	  48:	  Mean	  AHI	  according	  to	  Sex	  and	  period	  of	  follow-­‐up	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4.5.2.2. Prevalence	  of	  SDB	  (AHI>15)	  –	  Monte-­‐Carlo	  Simulation	  
We	  created	  a	   computational	  model	   that	  would	   select	   the	  best	  possible	  night	  with	   the	  highest	  
proportion	  of	  patients	  who	  have	  scored	  an	  AHI	  of	  15	  or	  more.	  	  
	  
Figure	  50:	  Monte-­‐Carlo	  simulation	  for	  the	  incidence	  of	  SDB	  (AHI>15)	  based	  on	  a	  single	  nights	  study	  
	  
Based	   on	   that	   best	   single	   night	   screening,	   the	   incidence	   of	   SDB	   in	   the	   cohort	   was	   62%.	   This	  
means	   that	   if	   all	   the	   patients	   in	   this	   study	   underwent	   Polysomnography/Polygraphy	   on	   that	  
night,	  62%	  of	  them	  would	  have	  clinically	  relevant	  SDB	  (Figure	  50).	  	  This	  is	  in	  comparison	  to	  74%,	  
60%	   and	   57%	   of	   patients	   who	   would	   have	   an	   AHI	   of	   15	   or	   more,	   using	   the	   mean	   AHI	   over	  
12months,	   3months,	   and	   2	   week	   follow	   up	   respectively.	   This	   model	   does	   not	   individualise	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4.5.3. Intra-­‐Patient	  Variability	  –	  Other	  Nocturnal	  Respiratory	  Parameters	  
The	   box	   plots	   below	   show	   the	   distribution	   of	   the	   Respiratory	   Rate	   (RR),	   quantity	   of	   Cheyne-­‐
Stokes	  Respiration	  (CSR)	  and	  Total	  Sleep	  Time	  (TST)	  over	  a	  12-­‐Month	  Follow-­‐up	  period.	  
4.5.3.1. Respiratory	  Rate	  
	  
Figure	  51:	  Box-­‐Plots	  showing	  distribution	  of	  Respiratory	  Rate	  (breaths	  per	  minute)	  over	  a	  12-­‐month	  
follow-­‐up	  period.	  Mean	  ±	  SD	  (18	  ±	  3)	  breaths	  per	  minute.	  95%	  CI	  (17-­‐19)	  
The	   mean	   nocturnal	   respiratory	   rate	   over	   the	   12-­‐month	   period	   (18	   ±	   3)	   breaths	   per	   minute	  
(Figure	   51)	   was	   above	   normal	   adult	   respiratory	   rates	   (10-­‐12	   breaths	   per	   minute).	   This	   may	  
represents	  hyperventilation	  associated	  with	  alveolar	  oedema	  as	  well	  as	  autonomic	  dysfunction	  
that	  are	  seen	  in	  heart	  failure	  patients	  and	  a	  proposed	  mechanism	  for	  the	  development	  of	  CSA.	  
This	   distribution	   does	   not	   take	   into	   account	   periods	   of	   decompensation	   where	   RR	   may	   be	  
expected	  to	  be	  higher.	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4.5.3.2. Total	  Sleep	  Time	  
	  
Figure	  52:	  Box-­‐Plots	  showing	  distribution	  of	  Mean	  estimated	  Total	  Sleep	  Time	  (hours)	  over	  a	  12-­‐month	  
follow-­‐up	  period.	  Mean	  ±	  SD	  (7.5	  ±	  1.5)	  hours.	  
The	  mean	  Total	  Sleep	  Time	  (TST)	   in	  the	  group	  as	  a	  whole	  was	  7.5	  hours.	   In	   individual	  patients,	  
there	  were	  wide	  variations	  over	  the	  12-­‐month	  period	  of	  follow	  up	  with	  a	  range	  of	  between	  4-­‐11	  
hours	  of	  TST	  (See	  figure	  52).	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Figure	  53:	  Box-­‐Plots	  showing	  distribution	  of	  %	  estimated	  overnight	  CSR	  using	  the	  Total	  Sleep	  Time	  (TST)	  
as	  denominator	  over	  a	  12-­‐month	  follow-­‐up	  period.	  Mean	  ±	  SD	  (4.4	  ±	  7)	  percentage	  TST.	  
Cheyne	   Stokes	   Respiration	   (CSR)	   occurred	   during	   a	   mean	   of	   4.4%	   of	   total	   sleep	   time	   in	   all	  
patients.	   Over	   the	   12-­‐month	   period	   there	  was	  wide	   variation	   in	   the	   amount	   of	   CSR	   that	   was	  
recorded.	  In	  some	  patients	  there	  were	  days	  when	  CSR	  was	  recorded	  for	  over	  40%	  of	  the	  TST	  and	  
days	  when	  CSR	  was	  not	  present.	  This	  distribution	  is	  demonstrated	  in	  the	  box	  plots	  in	  Figure	  53.	  
However	   this	   is	   not	   unexpected	   as	   previous	   data	   in	   chapter	   3	   showed	   that	   the	   SM	  diagnostic	  
accuracy	  for	  CSR	  is	  not	  well	  established.	  
	  
4.5.4. Intra-­‐patient	  Variability	  in	  AHI	  –	  Co-­‐Efficient	  of	  Variation	  	  
The	  coefficient	  of	  variation	  was	  determined	  as	  a	  ratio	  of	  the	  standard	  deviation	  to	  the	  mean	  AHI	  
and	  it	  is	  a	  useful	  way	  of	  assessing	  variability	  within	  a	  subject.	  Highly	  variably	  data	  are	  those	  with	  
a	  variation	  >15%	  (210).	  
The	  mean	  CoV	  in	  this	  group	  of	  patients	  was	  54%	  indicating	  a	  significant	  intra-­‐patient	  variability	  
for	   the	  AHI.	   Figure	  54	   shows	   the	  distribution	  of	  patients	  according	   to	   the	  CoV	   ranges	  and	   this	  
show	  that	  the	  majority	  of	  patients	  (59%)	  had	  a	  CoV	  above	  50%.	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Figure	  54:	  Distribution	  of	  patients	  according	  to	  CoV	  groups	  
	  
4.5.5. Proportion	  of	  Follow-­‐Up	  period	  with	  clinically	  significant	  SDB	  
I	  also	  determined	  what	  proportion	  of	  the	  follow-­‐up	  period	  that	  each	  patient	  had	  meaningful	  SDB	  
that	  may	  have	  warranted	  treatment.	  Figures	  55	  and	  56	  show	  this	  distribution.	  49%	  and	  41%	  of	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Figure	  55:	  Proportion	  of	  12-­‐month	  FU	  period	  when	  individual	  patients	  had	  an	  AHI>15	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Furthermore	  I	  proposed	  what	  proportion	  of	  the	  FU	  period,	  when	  a	  patient	  who	  had	  an	  AHI>15	  
may	  be	  considered	  clinically	  important	  or	  used	  as	  a	  diagnostic	  threshold.	  49%	  had	  an	  AHI>15	  for	  
>30%	   of	   Nights	   of	   a	   12	   month	   follow	   up	   period	   and	   59%	   of	   patients	   when	   this	   period	   is	  
shortened	   to	   2-­‐weeks.	   Figure	   57	   and	   58	   show	   the	   number	   of	   patients	  who	  would	   be	   in	   each	  
group	  respectively	  (<10%,	  10-­‐30%	  and	  >30%	  of	  the	  FU	  period).	  	  	  
	  
Figure	  57:	  Proportion	  of	  patients	  with	  and	  AHI>15	  according	  to	  proportion	  of	  Nights	  of	  FU	  –	  12	  Month	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4.5.5.1. Age	  and	  Sex	  Distribution	  
Figures	   59	   and	   60	   show	   that	   there	   was	   no	   sex	   or	   age-­‐specific	   distribution,	   in	   terms	   of	   the	  
proportion	  of	  FU	  period.	  However	   in	  the	  group	  with	  the	  proportion	  of	  the	  FU	  period	  when	  the	  
AHI>15	  was	  over	  30%,	  there	  were	  more	  men.	  
	  
Figure	  59:	  Sex	  distribution	  according	  to	  proportion	  of	  FU	  period	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4.5.6. Correlation	  between	  Mean	  AHI	  and	  Proportion	  of	  FU	  period	  
There	  was	   a	   good	   correlation	   (r=0.79)	  between	   the	  mean	  AHI	   (MeanAHI)	   and	  proportion	  of	   FU	  
(FUAHI15)	   period	  when	   patients	   had	   clinically	   significant	   SDB	   (AHI>15).	   This	   is	   demonstrated	   in	  
Figure	  61	  which	  showed	  that	  patients	  with	  a	  higher	  mean	  AHI	  also	  had	  a	  higher	  proportion	  of	  the	  
FU	   period	   where	   the	   AHI>15.	   This	   was	   as	   expected	   suggesting	   that	   both	   mean	   AHI	   and	  
proportion	  of	  FU	  period	  can	  be	  used	  interchangeably.	  
	  
Figure	  61:	  Correlation	  between	  MeanAHI	  and	  FUAHI15.	  Shaded	  area	  represents	  28%	  of	  patients	  who	  had	  
clinically	  important	  SDB	  for	  less	  than	  30%	  of	  follow	  up	  period	  and	  whose	  overall	  mean	  AHI	  for	  the	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4.5.7. Intra-­‐patient	  Variability	  in	  AHI	  –	  intra-­‐Class	  Correlation	  Co-­‐efficient	  (ICC)	  
The	   ICC	   is	  used	  to	  measure	  the	  consistency	   in	  Apnoea	  Hypopnoea	   Index	  (AHI)	   for	  each	  patient	  
throughout	  the	  follow-­‐up	  period.	  The	  ICC	  is	  defined	  as	  the	  ratio	  of	  between-­‐patient	  variances	  to	  
the	  total	  variance,	  which	  is	  a	  combination	  of	  the	  between-­‐	  and	  within-­‐	  cluster	  variances.	  	  
To	   preserve	   the	   independence	   and	   accuracy	   of	   this	   statistical	   tool	   I	   have	   selected	   only	  
consecutive	  nights	  where	  patients	  were	  simultaneously	  recorded	  by	  the	  SleepMinderTM	  device.	  




Figure	  62:	  Patient	  selection	  for	  Intra	  Class	  Correlation	  analysis	  
The	  AHI	  had	  an	  ICC	  value	  of	  0.33	  (95%	  CI	  0.23-­‐0.49)	  suggesting	  a	  high	  variability.	  Table	  18	  shows	  
the	   ICC	  values	   for	   the	  other	  nocturnal	  parameters	  analysed.	  The	  most	  variable	  parameter	  was	  
the	  Total	  Sleep	  Time	  (TST)	  with	  an	  ICC	  value	  of	  0.26	  (95%	  CI	  0.17-­‐0.40).	  As	  discussed	  in	  Chapter	  3	  
of	   this	   thesis,	   the	   SM-­‐TST	   algorithm	   used	   in	   calculating	   the	   Total	   Sleep	   Time	   is	   validated	   in	   a	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Table	  18:	  Intra-­‐class	  correlation	  co-­‐efficient	  for	  respiratory	  parameters.	  A	  value	  >	  0.75	  represents	  
excellent	  reproducibility.	  (AHI-­‐Apnoea	  Hypopnea	  Index,	  CSR-­‐	  Cheyne	  Stokes	  Respiration,	  TST-­‐	  Total	  
Sleep	  Time,	  RR	  –	  Respiratory	  Rate)	  
	  
4.5.8. Misclassification	  of	  Sleep	  Disordered	  Breathing	  
I	  proposed	  a	  misclassification	  rate	  according	   to	  severity	   (MRsev),	  as	   the	  number	  of	   times	  each	  
patient	   shifted	   from	   one	   severity	   category	   of	   SDB	   to	   the	   next,	   over	   the	   follow	   up	   period	   (2	  
weeks).	   The	  baseline	   severity	   category	   at	   the	   start	   of	   this	   period	  was	  used	  as	   the	   reference.	   I	  
have	   employed	   conventional	   cut-­‐offs	   for	   grading	   SDB	  with	  Mild	   ≥5	  Moderate	   ≥15	   and	   Severe	  
≥30.	  	  
In	  addition	  I	  have	  further	  determined	  the	  misclassification	  rate	  according	  to	  treatment	  grade	  of	  
SDB	  (MRrx).	  This	  was	  determined	  as	  the	  number	  of	  times	  a	  patient	  shifted	  from	  a	  non-­‐treatment	  
grade	  of	  SDB	  (i.e.	  AHI<15)	  to	  a	  treatment	  one	  (AHI>15)	  and	  vice-­‐versa.	  
The	  mean	  MRsev	  was	  35%	  ±	  24%.	  This	  means	  that	  on	  average,	  in	  the	  2-­‐week	  period	  of	  follow-­‐up,	  
a	  patient	  shifted	  from	  one	  severity	  category	  of	  SDB	  to	  the	  next,	  35%	  of	  the	  time.	  Only	  3	  of	  the	  39	  
patients	  (8%)	  did	  not	  have	  any	  shift	  in	  severity	  of	  SDB	  at	  all	  during	  this	  follow-­‐up	  period.	  Further,	  
using	  the	  baseline	  severity	  of	  SDB	  as	  diagnostic,	  there	  was	  no	  statistically	  significant	  differences	  
in	  the	  MRsev	  based	  on	  whether	  the	  patient	  was	  initially	  diagnosed	  as	  having	  No,	  Mild,	  Moderate	  
or	  Severe	  SDB.	  	  
The	  mean	  MRrx	  was	  21%	  ±	  19%.	  This	  means	  that	  on	  average,	  for	  21%	  of	  the	  2-­‐week	  follow-­‐up	  
period,	   a	  patient	   shifted	   from	  a	   treatment	   to	  non-­‐treatment	   category	  of	   SDB.	   6	  out	  of	   the	  39	  
PARAMETER' Intra'Class'Coeﬃcient' 95%'Conﬁdence'Interval' P;Value'
AHI$ 0.329$ 0.229$*$0.488$ 0.000$
CSR$ 0.398$ 0.286$–$0.562$ 0.000$
TST$ 0.256$ 0.172$–$0.402$ 0.000$
RR$ 0.361$ 0.254$–$0.523$$ 0.000$
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patients	   (15%)	   remained	   in	   the	   same	   treatment	   category	   for	   SDB	   throughout	   the	   follow	   up	  
period.	  
4.5.9. Severity	  of	  Heart	  Failure	  and	  Variability	  in	  AHI	  
We	   hypothesised	   that	   patients	   with	   a	   more	   severe	   form	   of	   heart	   failure	   may	   show	   more	  
variability	  in	  the	  AHI.	  To	  examine	  this,	  we	  divided	  the	  patients	  into	  two	  groups	  of	  High	  and	  Low	  
variability	   in	  AHI.	  To	  determine	  which	  patients	  had	  the	  most	  variability	   in	  the	  AHI	  and	  because	  
we	  elected	  not	  to	  use	  an	  arbitrary	  determination	  of	  what	  was	  considered	  ‘highly’	  variable	  using	  
the	  CoV,	  we	  proposed	  that	  the	  least	  variable	  patients	  would	  be	  those	  whose	  mean	  AHI	  over	  the	  
follow	  up	  period	  was	  >	  2	  times	  their	  standard	  deviation.	  15	  patients	  had	  highly	  variable	  AHI	  by	  
this	  criterion.	  
I	  have	  also	  used	  single	  baseline	  measures	  of	  B-­‐type	  Natriuretic	  Peptide	  (BNP),	  Ejection	  Fraction	  
(EF),	  and	  estimated	  Glomerular	  Filtration	  Rate	  (eGFR)	  as	  surrogates	  for	  severity	  of	  heart	  Failure	  
and	  analysed	  the	  means	  using	  independent	  sample	  Student’s	  t-­‐test.	  
	  
	  
Table	  19:	  Variability	  of	  AHI	  according	  to	  severity	  of	  heart	  failure.	  EF-­‐	  Ejection	  Fraction,	  BNP-­‐	  B-­‐type	  
Natriuretic	  Peptide,	  SGFR-­‐	  estimated	  Glomerular	  Filtration	  Rate.	  
From	   the	   results	   the	   variability	   of	   the	   AHI	   appears	   to	   be	   unaffected	   by	   the	   severity	   of	   heart	  




Number$ Mean$$ Std$Dev$ P$value$
BNP$ Low$ 24$ 129$ 80.2$ 0.54$
High$ 15$ 148$ 105.8$
EF$ Low$ 23$ 38$ 13.9$ 0.84$
High$ 15$ 37$ 14.7$
eGFR$ Low$ 24$ 47$ 25.1$ 0.88$
High$ 15$ 46$ 18.7$
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4.5.10. Longitudinal	  nocturnal	  respiratory	  parameters	  and	  survival	  
This	   study	  was	   not	   powered	   to	   assess	   survival	   however	  we	  made	   an	   observation	   of	   how	   the	  
respiratory	  parameters	  we	  collected	  related	  to	  survival.	  
	  
Table	  20:	  Relationship	  between	  survival	  and	  longitudinal	  respiratory	  patterns	  
There	  were	   8	   deaths	   in	   the	   12-­‐month	   follow	   up	   period	   and	   in	   these	   patients,	   the	  mean	   AHI,	  
maximum	  AHI,	  mean	  Respiratory	  rate	  and	  number	  of	  apnoeas	  (residual	  effort)	  were	  significantly	  
higher.	  Table	  20	  highlights	  this	  result.	  
	  
4.6. Discussion	  
The	  main	   result	   from	   this	   study	  was	   that	   the	  AHI,	  which	   is	   the	  most	   commonly	  used	   index	   to	  
measure	  SDB,	   is	  highly	   variable	   in	  patients	  with	  CHF	  observed	  over	  a	   long	  period	  of	   follow	  up	  
(Intra-­‐class	  Correlation	  Coefficient	  –	  0.329	  95%	  CI	  0.229	  –	  0.488).	  I	  also	  found	  that	  other	  indices	  
measured	   as	   part	   of	   nocturnal	   PG/PSG	  monitoring	   were	   also	   characterised	   by	   large	   night-­‐to-­‐
night	  variability.	  The	  ICC	  for	  TST,	  %CSR	  and	  RR	  were	  (0.256,	  0.398,	  0.361)	  See	  Table	  15.	  	  
The	  reason	  for	  this	  high	  variability	  is	  not	  clear.	  It	  is	  possible	  that	  changes	  in	  the	  pathophysiology	  
of	  the	  heart	  failure	  syndrome	  and	  how	  they	  affect	  the	  measures	  of	  SDB	  are	  more	  apparent	  over	  
a	   longer	   period	   of	  monitoring,	  which	   is	  why	   some	   studies	   over	   shorter	   periods	   of	  monitoring	  
have	  shown	  excellent	  consistency	  in	  these	  measures.	  	  
Parameter' Survivors'(31)' Non4Survivors'(8)' P4value'
Mean%AHI% 22% 33% 0.008'
Peak%AHI% 32% 42% 0.04'
Mean%CSR%>1%%(number)% 15% 7% 0.04'
Cycle%Length%CSR%(s)% 54% 59% 0.17%
TST%(hours)% 7.2% 8.3% 0.07%
Mean%Respiratory%Rate% 17% 20% 0.009'
Residual%Eﬀort%%(mv)% 21% 13% <0.001'
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Studies	  have	  shown	  that	  as	  heart	  failure	  worsens,	  particularly	  with	  fluid	  overload,	  the	  amount	  of	  
SDB	   increases	   (155).	  These	  patients	  may	  not	  necessarily	  have	  symptoms	  and	  clinical	   signs	  may	  
also	  not	  be	  overt.	  In	  this	  study,	  we	  have	  studied	  a	  sicker	  cohort	  of	  patients	  (mean	  EF	  38.3	  ±	  13.7	  
%;	  mean	  BNP	  134.6	   ±	   89.5)	  who	   are	  more	   likely	   to	   have	   frequent	   changes	   in	   their	   syndrome,	  
particularly	  fluid	  shifts.	  This	  in	  turn	  may	  influence	  the	  amount	  of	  SDB	  measured	  by	  the	  AHI,	  the	  
quantity	  of	  CSR	  and	  its	  variability.	  
Further	   I	   have	   employed	   the	   SleepMinderTM	   (SM)	   device	   to	   calculate	   the	   indices	   we	   have	  
analysed	   for	   variability	   assessment,	   including	   the	  AHI.	   This	   has	   been	   validated	   in	   the	   previous	  
chapter,	   with	   good	   diagnostic	   accuracy	   (Sens	   91%;	   Spec	   50%;	   AUC	   82%)	   against	   PG/PSG	   in	  
calculating	   the	   AHI.	   	   While	   it	   is	   unlikely	   that	   there	   would	   have	   been	   a	   significant	   error	  
contribution	  from	  using	  the	  SM	  as	  opposed	  to	  PSG/PG,	  which	  has	  been	  used	  in	  other	  studies	  to	  
assess	  variability,	  it	  is	  not	  implausible.	  	  
I	  also	  do	  not	  expect	  any	  significant	  contribution	  by	  ‘inter-­‐rater’	  variability,	  as	  each	  patient	  used	  
identical	   SM	   devices	   for	   the	   duration	   of	   the	   study.	   I	   cannot	   however	   totally	   exclude	   small	  
manufacturing	  differences	  in	  the	  SM	  devices.	  
The	  Total	  Sleep	  Time	  (TST)	  was	  the	  denominator	  used	  in	  making	  the	  SM-­‐estimates	  of	  the	  AHI.	  I	  
have	  shown	  in	  chapter	  3	  that	  the	  SM-­‐TST	  algorithm	  did	  not	  correlate	  well	  with	  expertly	  scored	  
PSG	  TST	   in	  our	  heart	  failure	  patients	  and	  this	  could	  have	  contributed	  to	  some	  of	  the	  variability	  
seen	  in	  some	  of	  the	  parameters	  investigated.	  
I	  have	  also	  shown	  that	  over	  different	  follow-­‐up	  periods,	  the	  mean	  AHI	  was	  consistently	  above	  the	  
generally	   accepted	   threshold	   for	   treatment	   (AHI>15)	   in	   a	  high	  proportion	  of	  patients,	   and	   this	  
was	   irrespective	  of	   the	   follow	  up	  period	   chosen.	  This	   raises	   the	   suggestion	   that	   the	  mean	  AHI	  
rather	  than	  a	  single	  night’s	  value	  may	  be	  more	  representative	  of	  a	  true	  diagnosis	  when	  screening	  
for	  SDB.	  
92%	  of	  all	  the	  patients	  studied	  shifted	  from	  one	  severity	  of	  SDB	  to	  the	  next;	  using	  conventional	  
cut-­‐offs	  for	  the	  AHI;	  at	  any	  time	  during	  a	  2-­‐week	  follow	  up	  period.	  This	  percentage	  is	  significantly	  
higher	  than	  the	  37%	  of	  patients	  who	  varied	  severity	  in	  the	  cohort	  studied	  by	  Vazir	  and	  colleagues	  
(147).	  Theirs	  was	  however	  a	   small	   group	  of	  patients	   (n=19)	  and	   sleep	   studies	  were	  performed	  
over	  4	  consecutive	  nights	  compared	  to	  the	  14	  nights	   I	  used	   in	  this	  analysis.	  Both	  cohorts	  were	  
however	  similar	  with	  predominantly	  less	  symptomatic	  heart	  failure	  (NYHA	  II	  –	  74%	  of	  patients	  in	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both	  studies).	  This	  suggests	  that	  the	  AHI	  is	  longitudinally	  a	  rather	  variable	  phenomenon	  in	  heart	  
failure	  patients	  and	  consistent	  with	  other	  literature	  (149;152;153).	  Comparing	  our	  findings	  with	  a	  
heart	  failure	  free	  population	  with	  the	  OSAHS,	  14%	  (Dean	  and	  Chaudhary	  1992),	  32%	  (Mendelson	  
1994)	  and	  54%	  (Lord	  et	  al	  1991)	  of	  these	  patients	  changed	  severity	  category	  of	  SDB,	  following	  a	  
second	  night	  of	  nocturnal	  cardiorespiratory	  monitoring	  (214-­‐216).	  	  
The	  average	  misclassification	  rate	  from	  one	  severity	  category	  to	  the	  other,	  for	  each	  patient	  was	  
35%	  of	  the	  follow-­‐up	  period.	  	  
In	  addition,	  84%	  of	  patients	  shifted	  from	  one	  treatment	  group	  of	  SDB	  (AHI>15)	  to	  the	  other	  with	  
an	   average	  misclassification	   rate	   of	   21%	   for	   each	   patient	   during	   this	   follow	   up	   period.	  When	  
compared	   to	   a	   similar	   population	   of	   patients	  with	  moderate	   to	   severe	   heart	   failure,	   but	  who	  
were	  studied	  on	  two	  consecutive	  nights,	  18%	  of	  patients	  were	  misclassified	  from	  one	  treatment	  
group	  to	  the	  next	  (152).	  	  
The	  presence	  of	  SDB	  in	  patients	  with	  CHF	  confers	  a	  worse	  prognosis.	  It	  is	  therefore	  it	  is	  important	  
that	  the	  severity	  of	  SDB	  is	  accurately	  diagnosed	  as	  this	  may	  have	  implications	  for	  treatment.	  This	  
study	   has	   demonstrated	   that	   patients	   may	   move,	   from	   a	   category	   of	   SDB	   that	   may	   warrant	  
treatment,	  to	  one,	  which	  may	  not.	  This	  seems	  to	  happen	  frequently	  and	  is	  identifiable	  even	  over	  
a	  short	  follow	  up	  period	  of	  14	  nights.	  	  
Based	  on	  these	  findings,	  it	  may	  seem	  a	  reasonable	  strategy	  for	  clinicians	  to	  be	  given	  the	  ability	  to	  
respond	   to	   changes	   in	   the	   amount	   of	   SDB	   by	   altering	   the	   management	   of	   these	   patients.	  
However	   it	   is	   impractical	   and	   cost-­‐ineffective	   to	   incorporate	   nightly	   PSG	   studies	   into	   any	  
treatment	   pathway.	   The	   SM	   device	   due	   to	   its	   novel	   design	  may	   proffer	   a	   realistic	   option	   for	  
monitoring	  SDB	  in	  this	  manner	  but	  its	  value	  may	  have	  to	  be	  tested	  on	  a	  larger	  and	  more	  varied	  
cohort	   of	   patients.	   This	   study	   has	   however	   highlighted	   the	   need	   to	   factor	   in	   the	   potential	   for	  
these	   changes	   into	  on-­‐going	   follow	  up	  and	  management	  plans	   for	   these	  patients.	  One	  current	  
real	  world	   solution	   is	   to	  perform	   interval	  PSG/PG	  studies	  either	   to	  confirm	  diagnosis	  or	   to	   see	  
how	  treatment	  is	  affecting	  the	  grade	  of	  SDB.	  
Treatment	  of	  SDB	  with	  newer	  devices	  such	  as	  Adaptive	  Servo	  Ventilation	  (ASV)	  has	  been	  shown	  
in	  small	  studies	  (217)	  and	  a	  meta-­‐analysis	  (218)	  to	  be	  beneficial	  to	  patients	  with	  CSA	  and	  HF.	  It	  is	  
currently	  been	   investigated	   in	   two	   large	  multicentre	  and	  multinational	   trials,	  one	   looking	  at	   its	  
effect	  on	  mortality	  in	  patients	  with	  CSA	  and	  HF	  (165)	  and	  the	  other	  looking	  at	  its	  effectiveness	  in	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patients	   with	   any	   form	   of	   SDB	   and	   HF	   (166).	   ASV	   has	   the	   potential	   to	   solve	   the	   problem	   of	  
frequent	  daily	  changes	  in	  severity	  of	  SDB	  in	  patients	  with	  heart	  failure.	  This	  is	  because	  this	  form	  
of	  positive	  airway	  pressure	  is	  designed	  to	  adapt	  therapy	  to	  patient’s	  minute	  ventilation	  delivering	  
more	  therapy	  when	  there	  are	  more	  episodes	  of	  apnoeas	  and	  hypopneas	  and	  reducing	  therapy	  
when	  these	  respiratory	  events	  are	  fewer.	  
I	  did	  not	  find	  any	  significant	  association	  between	  the	  severity	  of	  HF	  using	  surrogates	  such	  as	  BNP	  
levels,	   and	   Ejection	   Fraction	   and	   the	   variability	   of	   the	   AHI	   in	   this	   group	   of	   patients.	   These	  
surrogates	  used	  were	  however	  single	  point	  measures	  and	  while	  they	  have	  been	  shown	  in	  studies	  
to	  have	  prognostic	  importance,	  (181;184)	  it	  is	  pertinent	  to	  note	  that	  in	  this	  study,	  their	  changes	  
during	  the	  course	  of	  the	  follow	  up	  period	  was	  not	  assessed	  in	  relation	  to	  AHI	  variability.	  
Finally,	   in	   our	   small	   cohort	   and	   over	   the	   follow	   up	   period	   (mean	   11.2	   +/-­‐	   3.6	   months)	   non-­‐
survivors	   had	   a	   significantly	   higher	   mean	   AHI,	   Respiratory	   Rate,	   number	   of	   apnoeas	   and	  
percentage	   of	   Cheyne	   Stokes	   Respiration	   (CSR)	   overnight.	   	   Paradoxically	   these	   patients	   had	   a	  
tendency	  towards	  a	  higher	  Total	  Sleep	  Time	  (TST).	  This	   finding	   is	   in	  keeping	  with	  other	  studies	  
that	  assign	  prognostic	  importance	  to	  the	  presence	  of	  Cheyne	  Stokes	  Respiration	  and	  a	  high	  AHI	  
(9;127).	  
This	  observational	  study	  has	  shown	  that	  over	  a	  prolonged	  period	  of	  monitoring	  in	  patients	  with	  
heart	   failure,	   the	  AHI	   is	   highly	   variable.	  Based	  on	   these	   results,	   I	   am	   therefore	   recommending	  
that	  obtaining	  the	  mean	  AHI	  over	  a	  2-­‐week	  follow	  up	  period	  would	  be	  a	  practical,	   feasible	  and	  
more	   robust	   assessment	   of	   the	   severity	   of	   sleep	   disordered	   breathing	   in	   patients	   with	   heart	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4.7. Limitations	  
We	   have	   not	   separated	   these	   patients	   based	   on	   the	   predominance	   of	   Central	   or	   Obstructive	  
events	  but	  we	  have	  demonstrated	  that	  Cheyne	  Stokes	  Respiration	  (CSR)	  was	  present	  in	  up	  to	  a	  
third	  of	  our	  patients	  who	  had	  clinically	  important	  SDB	  (AHI>15).	  As	  CSR	  predominates	  in	  patients	  
with	  the	  central	  variety	  of	  sleep-­‐disordered	  breathing,	  we	  have	  used	  its	  presence	  as	  a	  surrogate	  
for	  classifying	  this	  group	  of	  patients	   into	  this	  category	  but	  have	  not	  assessed	  shifts	   in	  SDB	  type	  
based	  on	   this.	  Our	  study	  may	   therefore	  have	  been	  strengthened	   if	  we	  were	  also	  able	   to	  show	  
misclassification	  of	  SDB	  according	  to	  these	  broad	  types,	  as	  current	  treatments	  are	  different.	  
It	   is	   also	   important	   to	  note	   that	   the	  patients	  we	  have	  analysed	   in	   this	   study	  had	  moderate	   to	  
severe	  CHF	  and	  whether	  our	  findings	  are	  generalizable	  to	  patients	  with	  milder	  form	  of	  the	  heart	  
failure	  syndrome	  remains	  unknown.	  
	  
4.8. Conclusion	  
To	  our	   knowledge,	   this	   is	   the	   first	   time	   that	  a	  group	  of	  patients	  with	   chronic	  heart	   failure	  has	  
been	   studied	   longitudinally	   to	   assess	   the	   nocturnal	   variations	   in	   respiratory	   patterns	   and	   in	  
achieving	  this,	  we	  have	  raised	  important	  points	  that	  may	  influence	  how	  these	  patients	  should	  be	  
diagnosed	   and	  managed	   in	   the	   future.	   In	   particular	   we	   have	   shown	   that	   the	   AHI	   shows	   high	  
variability	  over	  a	  number	  of	  nights.	  We	  have	  also	  highlighted	  the	  frequent	  changes	  in	  the	  severity	  
of	  SDB	  that	  occur	  on	  a	  night-­‐to-­‐night	  basis	  as	  a	  result.	  
The	  next	  steps	  would	  be	  to	  study	  a	  larger	  and	  more	  varied	  cohort	  of	  CHF	  patients	  including	  those	  
with	  milder	  disease	  syndromes	  and	   to	   investigate	   the	  shifts	   in	  SDB	   from	  one	   type	   to	   the	  next,	  
observed	  over	  a	  longer	  period	  of	  monitoring.	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5.1. Introduction	  
Until	  recently	  it	  was	  not	  possible	  to	  monitor	  changes	  in	  sleep	  disordered	  breathing	  on	  a	  day	  to	  
day	  basis	   easily,	   as	   formal	   assessment	  of	   SDB	   required	   attachment	   to	  multiple	   electrodes	   and	  
usually	  an	  overnight	  stay	  in	  hospital,	  ultimately	  making	  it	  a	  cumbersome	  process.	  	  
The	  magnitude	  of	  change	  and	  durations	  of	  components	  of	  the	  ventilatory	  cycle	  might	  however	  
provide	  relevant	  information	  on	  the	  clinical	  impact	  of	  nocturnal	  breathing	  disorders;	  in	  particular	  
the	  likelihood	  of	  significant	  worsening	  of	  cardiovascular	  function;	  in	  patients	  with	  chronic	  heart	  
failure.	  
I	  have	  previously	  shown	  that	  the	  SleepMinderTM,	  through	  low	  frequency	  electromagnetic	  waves,	  
is	   able	   to	  measure	   the	   AHI	   and	   quantify	   the	   CSR	   based	   on	   a	   single	   night	   study	   and	   validated	  
against	   full	   in-­‐hospital	   PSG	   (219;220).	   Further,	   using	   an	   extended	   dataset	   in	   chapter	   3	   of	   this	  
thesis,	   the	   SM	   performed	   with	   a	   good	   combined	   diagnostic	   accuracy	   of	   82%	   and	   76%	  
respectively	  for	  these	  measures.	  	  
Due	   to	   its	  non-­‐contact	  nature,	   it	   appears	   to	  be	  a	  more	  convenient	  way	  of	  measuring	  SDB	  and	  
may	  be	  a	  useful	  means	  of	  detecting	  early	  deterioration	  of	  the	  heart	  failure	  syndrome,	  which	  can	  
be	  utilised	  in	  the	  patient’s	  home.	  	  	  
A	   preliminary	   analysis	   using	   this	   device	   in	   a	   heart	   failure	   unit	   in	   Dublin,	   and	   following	   up	   40	  
patients	   for	   six	   months,	   demonstrated	   that	   there	   might	   be	   some	   signals	   from	   changes	   in	  
respiratory	   patterns	   at	   night	   that	   may	   presage	   clinical	   deterioration	   (unpublished	   data	   K.	  
McDonald	  et	  al	  Dublin	  2011).	  	  
In	   this	   chapter,	   I	   will	   be	   describing	   the	   prediction	   of	   acute	   decompensation	   of	   chronic	   heart	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5.2. Hypothesis	  
My	  main	  hypotheses	   in	   this	   study	   is	   that	  as	  patients	  with	  chronic	  heart	   failure	  decompensate,	  
particularly	  in	  the	  weeks	  or	  days	  before	  they	  seek	  intervention,	  there	  may	  be	  a	  measurable	  rise	  
in	  the	  Apnoea	  Hypopnea	  Index	  (AHI)	  or	  the	  amount	  of	  Cheyne-­‐Stokes	  Respiration	  (CSR)	  present	  
and	  that	  this	  can	  act	  as	  a	  signal	  for	  predicting	  a	  potential	  acute	  decompensation.	  
The	  ‘Null’	  hypothesis	  therefore	  for	  this	  study	  is	  that	  there	  is	  a	  measurable	  increase	  in	  the	  AHI	  and	  
the	   %	   overnight	   CSR	   by	   the	   SleepMinderTM	   device,	   within	   a	   7-­‐day	   period,	   and	   which	   can	   be	  
utilised	  as	  a	  predictor	  of	  acute	  decompensation	  of	  heart	  failure.	  
	  
5.3. Aims	  
5.3.1. Primary	  Objective	  
The	   primary	   objective	   of	   this	   study	   is	   to	   validate	   whether	   a	   simple	   bedside	   device	  
(SleepMinderTM),	  that	  monitors	  the	  breathing	  patterns	  during	  sleep	  in	  the	  participant’s	  home	  can	  
be	  used	  to	   identify	  deterioration	  in	  heart	  failure	  reliably	  by	  confirming	  the	  diagnostic	  accuracy,	  
sensitivity	  and	  specificity	  of	  the	  device	  for	  this	  purpose.	  
With	   the	   SleepMinderTM	   device,	   I	   am	   afforded	   a	   unique	   opportunity	   to	   record	   nocturnal	  
respiratory	   patterns	   over	   consecutive	   nights,	   and	   this	   data	   can	   be	   analysed	   and	   utilised	   for	  
prediction.	  
I	  therefore	  plan	  to	  examine	  and	  use	  the	  serial	  changes	  in	  nocturnal	  respiratory	  metrics,	  including	  
the	  AHI,	  quantity	  of	  CSR,	  respiratory	  rates	  and	  total	  sleep	  time	  (TST),	  as	  ADHF	  episodes	  evolve	  
and	  resolve,	  to	  develop	  a	  SM	  ADHF	  predictor	  algorithm	  (SMApA).	  
Finally	   I	   will	   seek	   to	   show	  whether	   these	   SM	   signalled	   respiratory	   abnormalities	   incorporated	  
into	   the	  SMApA,	  predict	  ADHF	  by	  measuring	   its	  diagnostic	  accuracy	   in	   terms	  of	   sensitivity	  and	  
specificity	  against	  clinically	  detected	  ADHF	  episodes.	  This	  would	  validate	  the	  signals	  identified	  as	  
potentially	  valuable	  in	  the	  Dublin	  preliminary	  analysis	  in	  a	  different	  heart	  failure	  population	  and	  
over	  a	  longer	  period	  of	  time.	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5.3.2. Secondary	  Objective	  
To	  determine	  whether	   the	  bedside	   SleepMinderTM	  device	  monitoring	   is	   acceptable	   to	  patients	  
with	   chronic	   heart	   failure.	   I	   aim	   to	   measure	   this	   by	   calculating	   what	   proportion	   of	   patients	  
approached	   regarding	   the	   study	   agree	   to	   take	   part	   (‘recruitment	   proportion’),	   and	   the	  
proportion	  of	  patients	  who	   request	   that	   the	  SleepMinder™	  be	   removed	  before	   the	  end	  of	   the	  
study	  (‘withdrawal	  proportion’),	  as	  measures	  of	  patient	  acceptability	  of	  this	  form	  of	  monitoring.	  
	  
5.3.3. Study	  Design	  
This	  was	  a	  prospective	  observational	  study	  over	  an	  18-­‐month	  period	  seeking	  to	  validate	  in	  heart	  
failure	  patients	  at	  the	  Royal	  Brompton	  Hospital	   in	  London,	  potential	  signals	  predictive	  of	  Acute	  
Decompensation	  of	  Heart	   Failure,	   using	   the	   SleepMinderTM	  device,	   that	  were	  obtained	   from	  a	  
prior	   analysis	   of	   nocturnal	   respiratory	   signals	   in	   CHF	   patients	   from	   St.	   Vincent’s	   hospital	   in	  
Dublin,	  Ireland.	  
	  
5.3.4. Sample	  size	  and	  Statistics	  
I	  have	  calculated	  that	  for	  this	  pilot	  study,	  and	   in	  order	  to	  achieve	  a	  combined	  accuracy	  of	  85%	  
(sensitivity=specificity=0.85),	  which	  would	  be	  qualitatively	  rated	  ‘very	  good’	  to	  ‘excellent’,	  and	  to	  
achieve	  a	  15%	  width	  of	  a	  95%	  confidence	  interval,	  I	  would	  need	  to	  recruit	  40	  patients.	  I	  have	  also	  
made	  an	  ADHF	  event	   rate	  estimation	  of	  30%	  per	  year,	  based	  on	   the	  severity	  of	  disease	   in	   the	  
group	  that	  I	  am	  studying.	  I	  therefore	  expected	  that	  at	  least	  12	  out	  of	  40	  patients	  would	  have	  an	  
episode	  of	  decompensated	  heart	  failure	  in	  the	  follow	  up	  period,	  which	  would	  give	  a	  reasonable	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5.3.5. Study	  Population	  
The	  data	  used	   in	   this	   study	  was	   from	  a	   ‘development’	  dataset	  obtained	   from	  61	  chronic	  heart	  
failure	   patients	   attending	   St.	   Vincent’s	   Hospital	   in	   Dublin,	   Ireland,	   and	   a	   ‘validation;	   dataset	  
obtained	  from	  43	  chronic	  heart	  failure	  patients	  who	  were	  enrolled	   in	  the	  heart	  failure	  disease-­‐
monitoring	  programme	  at	  the	  Royal	  Brompton	  Hospital	  in	  London,	  United	  Kingdom.	  Recruitment	  
for	   the	  Dublin	  group	  of	  patients	   started	   in	  October	  2010	  and	   the	   last	  patient	  was	   recruited	   in	  
September	   2012.	   As	   above,	   preliminary	   observational	   findings	   from	   an	   initial	   sample	   of	   40	   of	  
these	   patients	   informed	   this	   formal	   validation	   study.	   Recruitment	   of	   patients	   into	   the	  
development	  dataset	  was	  overseen	  by	  a	  separate	  clinical	  research	  team	  based	  in	  Dublin,	  which	  
was	  not	  involved	  with	  enrolment	  or	  follow	  up	  of	  patients	  into	  the	  validation	  dataset.	  
I	   screened,	   recruited	   and	   collected	   follow-­‐up	   data	   for	   all	   the	   patients	   used	   in	   the	   validation	  
dataset.	  The	   first	  patient	  was	   recruited	   in	  September	  2011	  and	   last	  patient	   in	   June	  2012.	   (See	  
Figure	  63)	   In	  total	  827	  patients	  were	  screened	  from	  our	  heart	   failure	  programme	  database.	  75	  
patients	  were	  eligible	  who	  fulfilled	  the	  inclusion	  criteria	  and	  43	  patients	  consented	  to	  take	  part	  in	  
the	  study	  while	  the	  remainder	  32	  patients	  who	  were	  approached,	  declined.	  The	  primary	  reason	  
for	   failure	  of	  enrolment	  was	  patients	  who	  did	  not	  want	   to	   take	  part	   in	   research	  or	  who	  had	  a	  
perceived	  inconvenience	  at	  having	  medical	  equipment	  placed	  within	  their	  home	  environment.	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5.4. Inclusion	  and	  Exclusion	  Criteria	  
Both	  development	  and	  validation	  sets	  of	  patients	  were	  selected	  based	  on	  identical	  inclusion	  and	  
exclusion	  criteria	  listed	  below.	  These	  criteria	  aimed	  to	  identify	  patients	  with	  a	  moderate	  to	  high	  
risk	  of	  decompensation.	  (Table	  21)	  
INCLUSION EXCLUSION 
Plasma BNP>200pg/ml 
(58pmol/litre) when reviewed 
in heart failure clinic 
• Unpredictable sleep 
patterns based on 
work schedules e.g. 
night shifts 
• Age <18 years 
• Cognitive impairment 
sufficient to interfere 
with proper use of 
study equipment 
• Already on therapy 
for obstructive sleep 
apnoea i.e. CPAP 
OR 
History of any 
hospitalization due to heart 
failure within the preceding 
24 months 
 
Table	  21:	  SleepMinderTM	  ADHF	  Study	  Inclusion	  and	  Exclusion	  criteria	  
	  
5.5. Definition	  of	  Acute	  Decompensation	  of	  Heart	  Failure	  	  
The	  primary	  endpoint	  of	  this	  study	  was	  decompensation	  of	  chronic	  heart	  failure.	  The	  secondary	  
endpoints	   related	   to	   acceptability	   of	   SleepMinderTM	  monitoring	   to	   patients	   attending	   a	   heart	  
failure	  clinic.	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5.5.1. ADHF	  Criteria	  
The	  definitions	  used	  in	  this	  study	  were	  as	  follows:	  
I)	   DEFINITE:	  Non-­‐elective	  heart	  failure	  hospitalisation	  
This	  is	  the	  most	  definite	  evidence	  for	  decompensation	  of	  chronic	  heart	  failure,	  with	  admission	  to	  
hospital	  for	  management	  of	  deterioration	  in	  symptoms	  and	  signs	  of	  heart	  failure.	  To	  determine	  if	  
this	  was	  a	  definite	  heart	  failure	  decompensation,	  it	  was	  required	  that	  there	  was	  evidence	  of	  the	  
following:	  	  
-­‐	   Evidence	  for	  symptom	  deterioration,	  
	  And	  
-­‐	   Objective	   evidence	   of	   fluid	   overload:	   such	   as	   elevated	   jugular	   venous	   pressure	   and/or	  
lung	   crackles	   and/or	   dependent	   oedema	   and/or	   ascites;	   or	   chest	   radiograph	   evidence	   of	  
pulmonary	  oedema	  or	  at	  least	  50%	  increase	  in	  the	  plasma	  BNP	  value	  from	  euvolaemic	  level,	  	  
And	  
Requirement	  for	  at	  least	  one	  administration	  of	  intravenous	  diuretic	  
	  
ii)	   PROBABLE:	   Deterioration	   in	   the	   chronic	   heart	   failure	   syndrome	   was	   accepted	   if	   the	  
following	  criteria	  were	  met:	  
-­‐	   	  Symptom	   Deterioration	   (development	   of	   new	   symptom	   of	   dyspnoea	   or	   worsening	   of	  
established	  dyspnoea	  manifest	  as	  reduction	  in	  functional	  capacity	  and/or	  worsening	  orthopnoea	  
and/or	  increasing	  or	  new	  paroxysmal	  nocturnal	  dyspnoea),	  	  
OR	  
-­‐	   Evidence	  of	  weight	  gain	  of	  at	  least	  2Kg	  level	  within	  48	  hours,	  	  
And	  
-­‐	   Decision	  taken	  to	  increase	  diuretic	  therapy,	  	  
And	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-­‐	   Response	  of	  symptoms	  and/or	  weight	  within	  48	  hours	  to	  the	  increase	  in	  diuretic	  therapy	  
(if	  symptoms	  did	  not	  respond	  within	  this	  time	  course,	  the	  patient	  was	  routinely	  reviewed	  in	  the	  
heart	  failure	  clinic,	  where	  the	  decompensation	  could	  be	  confirmed	  and	  if	  appropriate	  the	  patient	  
was	  admitted	  to	  hospital	  to	  regain	  control	  of	  the	  syndrome).	  
	  
5.5.2. Adjudication	  of	  ADHF	  Events	  
A	  panel	  of	  two	  independent	  experts	  formed	  an	  adjudication	  committee.	  They	  were	  heart	  failure	  
consultants	   who	   were	   blinded	   to	   the	   outcomes	   of	   the	   study,	   and	   using	   the	   event	   criteria,	  
adjudicated	   every	   episode	   of	   suspected	   acute	   decompensation	   of	   heart	   failure.	   Where	   there	  
were	  individual	  disagreements,	  both	  adjudicators	  met	  to	  discuss	  this	  to	  reach	  a	  consensus,	  and	  
where	  this	  did	  not	  happen,	  a	  3rd	  independent	  adjudicator	  was	  entrusted	  with	  the	  final	  decision.	  
To	  aid	  the	  adjudication	  committee,	  each	  ADHF	  event	  was	  presented	  with	  anonymised	  supporting	  
documentation	  regarding	  that	  episode.	  These	  documents	  included	  discharge	  letters,	  GP	  contact	  
letters,	   investigations	   (Chest	   radiographs,	   Blood	   tests,	   and	   echocardiograms),	   drug	   charts,	   and	  
correspondence	  (telephone	  and	  text	  contacts)	  with	  the	  heart	  failure	  specialist	  nurses.	  
Similarly	   information	  for	  all	  Non-­‐heart	   failure	  admissions	  (non-­‐ADHF	  event)	  were	  collected	  and	  
passed	  on	   to	   the	  committee	   for	  adjudication	  and	   to	  ensure	   that	  events	  were	  not	  misclassified	  
into	  a	  non-­‐ADHF	  event	  group.	  
	  
5.6. Methods	  
All	   patients	   enrolled	   into	   both	   development	   and	   validation	   arm	   of	   this	   study	   continued	   their	  
usual	   heart	   failure	   care	   management	   according	   to	   the	   NICE	   and	   the	   European	   Society	   of	  
Cardiology	  heart	  failure	  guidelines	  (4;47)	  	  
Usual	  care	  within	  this	  service	  is	  that	  patients	  (and	  their	  partner	  or	  principal	  carer)	  are	  educated	  
to	  recognise	  symptoms	  and	  signs	  of	  emerging	  clinical	  deterioration,	  with	  specific	  attention	  given	  
to	   instructions	  on	  the	  meaning	  of	  weight	  change	  and	  how	  to	  react	  to	   increasing	  symptoms.	  All	  
patients	   were	   provided	  with	   the	   contact	   number	   for	   the	   heart	   failure	   service	   for	   easy	   access	  
during	  working	  hours	  Monday	  to	  Friday	  from	  8am	  to	  5pm.	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In	   addition	   to	   this	   usual	   care,	   all	   patients	   were	   provided	   with	   the	   SleepMinder™	   device,	   for	  
bedside	   monitoring	   of	   nocturnal	   breathing	   patterns	   during	   sleep	   in	   the	   patient’s	   home,	   a	  
weighing	  scale,	  and	  a	  study	  mobile	  phone	  that	  communicated	  by	  Bluetooth	  technology	  with	  the	  
SM	   device	   and	   scales.	   The	   data	   from	   these	   devices	   was	   transmitted	   first	   to	   the	   central	   data	  
collection	   centre	   in	   Dublin,	   Ireland	   for	   collation,	   and	   then	   into	   a	   secure	   database	   in	   Sydney	  
Australia	  for	  later	  analysis.	  This	  process	  of	  recording	  and	  data	  transmission	  has	  been	  described	  in	  
detail	  in	  Chapter	  2.	  
At	  commencement	  of	  the	  study	  all	  patients	  attended	  a	  recruitment	  visit	  in	  hospital	  and	  in	  some	  
cases,	   the	   study	   team	   comprising	   a	   research	   nurse	   and	   myself	   attended	   the	   patients	   home;	  
where	  they	  were	  instructed	  on	  how	  to	  use	  these	  devices.	  Baseline	  blood	  tests	  were	  performed	  at	  
that	  visit	  if	  in	  clinic	  or	  within	  a	  week	  of	  device	  collection	  if	  home	  recruitment.	  Patients	  were	  also	  
provided	  with	  contact	  details	  of	  the	  research	  office	  in	  case	  they	  needed	  to	  ask	  any	  questions	  or	  
for	  trouble	  shooting	  purposes.	  	  
5.6.1. Development	  Data	  Set	  and	  Follow-­‐up	  
61	  consecutive	  patients	  were	  enrolled	   from	   the	  heart	   failure	   clinics	  at	   St.	  Vincent’s	  hospital	   in	  
Dublin,	  into	  this	  arm	  of	  the	  study.	  
This	  purpose	  of	  this	  dataset	  was	  mainly	  for	  exploratory	  data	  analysis.	  We	  identified	  key	  features	  
and	  metrics	   from	  this	  dataset	  and	  developed	  methods	   for	   feature	  extraction,	   feature	  selection	  
and	  training	  and	  testing	  of	  the	  classifiers.	  Because	  this	  was	  a	  novel	  algorithm,	  it	  was	  not	  clear	  at	  
the	  start	  how	  much	  data	  would	  be	  needed	  to	  develop	  an	  algorithm	  development.	  Therefore	  the	  
follow	  up	  period	  was	  kept	  open	  initially,	  to	  allow	  time	  for	  events	  to	  accumulate.	  
We,	   however,	   placed	   an	   algorithm	   development	   embargo	   at	   12	  months	   into	   the	   start	   of	   the	  
validation	   study	   where	   no	   further	   input	   into	   development	   of	   the	   predictor	   algorithm	   was	  
permitted	  
Formal	  follow-­‐up	  of	  patients	  in	  the	  development	  dataset,	  took	  place	  at	  St.	  Vincent’s	  hospital	   in	  
Dublin;	   however	   I	   participated	   in	   clinical	   data	   collection	   and	   analysis	   regarding	   all	   acute	  
decompensation	  of	  heart	  failure	  episodes	  in	  these	  patients.	  This	  information	  was	  made	  available	  
concurrently	  during	  development	  of	  the	  SM	  ADHF	  predictor	  algorithm.	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5.6.2. Validation	  Data	  Set	  and	  Follow-­‐Up	  
43	   patients	   were	   enrolled	   into	   the	   validation	   arm	   of	   this	   study.	   (See	   Figure	   61)	   They	   were	  
followed	  up	  for	  a	  pre-­‐specified	  minimum	  period	  of	  12months	  and	  a	  maximum	  of	  18	  months	  and	  
took	  place	  in	  the	  heart	  failure	  clinics	  at	  the	  Royal	  Brompton	  Hospital	  London.	  During	  the	  follow	  
up	  period,	  I	  collected	  information	  relating	  to	  all	  decompensation	  episodes,	  from	  hospitalisation	  
records	  and	  contact	  with	  community	  heart	  failure	  nurses	  or	  the	  heart	  failure	  service	  at	  the	  Royal	  
Brompton	   Hospital.	   In	   addition,	   the	   patients	   also	   kept	   a	   diary	   of	   any	   change	   in	   their	   diuretic	  
dosages,	   weight	   gain	   or	   increased	   symptoms,	   which	   provided	   supplementary	   data	   on	  
decompensation.	  No	  part	  of	   these	  data	   in	   the	  validation	  arm	  were	  used	   in	  developing	   the	  SM	  
ADHF	   predictor	   algorithm,	   and	   as	   mentioned	   previously,	   was	   kept	   blind	   from	   algorithm	  
developers	  until	  the	  testing	  period	  of	  this	  study.	  
	  
5.7. Development	  of	  The	  SleepMinderTM	  ADHF	  Predictor	  Algorithm	  
(SMApA)	  
Development	   of	   SM	   ADHF	   predictor	   algorithm	   (SMApA)	   was	   achieved	   using	   clinical	   and	  
SleepMinderTM	  information	  from	  the	  Dublin	  development	  dataset	  only.	  
My	  main	   input	   into	   the	  SM	  ADHF	  predictor	   algorithm	  development	  was	  during	   signal	   features	  
selection	  and	  extraction,	  based	  on	  my	  clinical	  knowledge	  of	  the	  medical	  literature	  and	  the	  clinical	  
behaviour	  of	  chronic	  heart	  failure	  patients.	  My	  experience	  as	  a	  specialist	  registrar	  in	  cardiology,	  
who	  has	  been	   involved	   in	   the	  pharmacological	  and	  device	  management	  of	  patients	  with	  acute	  
decompensated	  heart	  failure	  was	  also	  utilised.	  	  
To	  this	  end,	  I	  provided	  clinical	  support	  to	  a	  small	  team	  of	  engineers	  at	  the	  applied	  research	  unit	  
of	  ResMed	  Ltd.	  (Sydney)	  and	  on	  two	  occasions	  travelled	  out	  to	  the	  research	  centre	  in	  Sydney	  for	  
algorithm	   development	   training	   and	   meetings.	   This	   was	   in	   addition	   to	   several	   telephone	  
conference	   meetings	   regarding	   the	   same.	   Some	   of	   these	   meetings	   involved	   the	   algorithm	  
development	  team	  and	  clinical	  team	  at	  St.	  Vincent’s	  hospital	  in	  Dublin,	  Ireland	  when	  we	  sought	  
to	  clarify	  data	  from	  the	  development	  arm	  of	  patients.	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Further,	   even	   though	   I	  was	  directly	   involved	   in	   the	   collection	  of	   suspected	   clinical	   episodes	  of	  
ADHF	   in	   the	   validation	   dataset,	   the	   final	   results	   of	   the	   adjudication	   committee	   on	   this	   events	  
were	  not	  available	  to	  me	  until	  one	  week	  before	  testing	  of	  the	  ADHF	  predictor	  by	  which	  time	  no	  
further	  changes	  were	  permitted	  to	  our	  developed	  algorithm.	  
	  
5.7.1. Features	  and	  Classifiers	  
The	  Sleep	  Minder	  collects	  and	  records	  data,	  which	  are	  represented	  as	  raw	  signals	  for	  every	  night	  
throughout	  the	  patients’	  participation	  in	  the	  study.	  This	  raw	  signal	  contains	  information	  including	  
those	  that	  are	  related	  to	  breathing,	  thoraco-­‐abdominal	  movement,	  leg	  movement,	  ocular	  activity	  
and	   patient	   presence	   or	   absence	   amongst	   others.	   Artefactual	   information	   is	   also	   invariably	  
collected.	  	  	  (Figure	  64)	  
	  
	  
Figure	  64:	  Data	  Transmission	  (‘A’-­‐‘Z’	  –	  are	  features	  extracted	  from	  RAW	  data:	  Breathing	  rates,	  cycle	  
length,	  sleep	  efficiency,	  HR,	  AHI,	  TST,	  CSR,	  Apnoea	  length,	  number	  of	  sleep	  sections	  etc.)	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Features	  
A	  feature	   is	  a	  characteristic	  of	  the	  raw	  signal	  that	  helps	  us	   identify	   its	  morphology	  and	  place	   it	  
into	  a	  physiological	  group,	  for	  instance,	  the	  heart	  rate	  or	  respiratory	  rate.	  A	  feature	  vector	  is	  then	  
produced	  which	  is	  a	  set	  of	  numbers	  that	  mathematically	  helps	  to	  classify	  these	  signals.	  	  
Generally	  the	  features	  quantify	  something	  about	  the	  morphology	  of	  the	  signal	  in	  either	  the	  time	  
or	   frequency	   domain	   and	   based	   on	   existing	   knowledge	   of	   frequencies	   of	   physiological	  
parameters,	  theoretically,	  this	  should	  easily	  be	  characterized.	  In	  practice	  however,	  due	  to	  noise	  
and	  other	  artefacts	  the	  signals	  can	  be	  complex	  and	  difficult	  to	  analyse.	  
Several	  features	  were	  collected	  on	  a	  nightly	  basis	  for	  each	  patient	  and	  a	  features	  database	  was	  
generated	  containing	  data	  for	  every	  night	  of	  the	  patient’s	  enrolment	  in	  the	  study.	  (Figure	  65)	  	  
	   	  





















1 $$2 $$$$$3 $$$$$$$$4…………........N$
(L2$FeaturesAnightly$–$Mean,$Max,$Min$RR:$Rate,$Range$Max$Min)$$
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Classifiers	  
A	  Classifier	  is	  essentially	  a	  mathematical	  function	  that	  can	  map	  those	  sets	  of	  features	  extracted	  
from	  the	   raw	  signals	   into	  a	  category.	   In	   the	  simplest	   sense,	  a	  classifier	  can	  be	  described	  by	   its	  
topology	  and	  a	  set	  of	  parameters,	  which	  are	  “learnt”	  during	  training.	  (Figure	  66)	  
	  
Figure	  66:	  Features	  Vector	  to	  Classification	  
There	   were	   2	   main	   classifier	   types,	   which	   we	   used	   in	   development;	   State	   Space	   Principle	  
Component	  Analysis	  (SSPCA)	  and	  Linear	  Discriminant	  Analysis	  (LDA)	  and	  we	  investigated	  around	  
131	  features.	  (Table	  22)	  
In	   terms	  of	  Feature	   selection,	  both	   intuitive	  and	   information	   theoretic	  methods	  were	  used	   for	  
feature	   selection	  and	  only	   the	  assumed	  best	   features	  were	   then	  passed	   through	   the	  classifier.	  
Pattern	   recognition	   as	   well	   as	   machine	   learning	   algorithms	   was	   used	   for	   training	   of	   the	  
classifiers.	  The	  unblinded	  clinical	  ADHF	  data	  from	  the	  development	  set	  was	  also	  utilised	  during	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No
.	  
Feature	  Names	   No.	   Feature	  Names	   No.	   Feature	  Names	  
1	   'Days'	   50	   'anfRate95th'	   99	   'cycleLengthPeriodNormStd'	  




























9	   'PercentMov'	   58	   'respRate75th'	   10
7	  
'cycleLengthPowerMean'	  
10	   'PercentNoMov'	   59	   'respRate95th'	   10
8	  
'cycleLengthPowerStd'	  




12	   'PercentCS'	   61	   'totSleepTime'	   11
0	  
'cycleLengthPowerKurtosis'	  
13	   'PercentHi'	   62	   'sleepEfficiency'	   11
1	  
'cycleLengthPower5th'	  
14	   'CSQuarters(1,:)'	   63	   'unscoredSections'	   11
2	  
'cycleLengthPower25th'	  
15	   'CSQuarters(2,:)'	   64	   'totPresenceTime'	   11
3	  
'cycleLengthPower50th'	  
16	   'CSQuarters(3,:)'	   65	   'activityTotHrs'	   11
4	  
'cycleLengthPower75th'	  




















70	   'activityKurtosis'	   11
9	  
'cycleLengthObwKurtosis'	  
22	   'BWCSQuarters(1,:)'	   71	   'activity5th'	   12
0	  
'cycleLengthObw5th'	  
23	   'BWCSQuarters(2,:)'	   72	   'activity25th'	   12
1	  
'cycleLengthObw25th'	  
24	   'BWCSQuarters(3,:)'	   73	   'activity50th'	   12
2	  
'cycleLengthObw50th'	  
25	   'BWCSQuarters(4,:)'	   74	   'activity75th'	   12
3	  
'cycleLengthObw75th'	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26	   'MDCSQuarters(1,:)'	   75	   'activity95th'	   12
4	  
'cycleLengthObw95th'	  
27	   'MDCSQuarters(2,:)'	   76	   'sdbIndex(AHI)'	   12
5	  
'sdbTimeHrs'	  
28	   'MDCSQuarters(3,:)'	   77	   'sdbAnalysisTime'	   12
6	  
'sdbTimeRatio'	  














32	   'HiQuarters(3,:)	   81	   'sdbEventLengthStd'	   13
0	  
'EventDay'	  





34	   'FreqHiQuarters(1,:)	   83	   'sdbEventLengthKurt
osis'	  
	   	  
35	   'FreqHiQuarters(2,:)	   84	   'sdbResidualAmplitud
eMean'	  
	   	  
36	   'FreqHiQuarters(3,:)	   85	   'sdbResidualAmplitud
eStd'	  
	   	  
37	   'FreqHiQuarters(4,:)	   86	   'sdbResidualAmplitud
eSkewness'	  
	   	  
38	   'BWHiQuarters(1,:)	   87	   'sdbResidualAmplitud
eKurtosis'	  
	   	  
39	   'BWHiQuarters(2,:)	   88	   'cycleLengthNumber'	   	   	  
40	   'BWHiQuarters(3,:)	   89	   'cycleLengthPeriodM
ean'	  
	   	  
41	   'BWHiQuarters(4,:)	   90	   'cycleLengthPeriodSt
d'	  
	   	  
42	   'MDHiQuarters(1,:)	   91	   'cycleLengthPeriodSk
ewness'	  
	   	  
43	   'MDHiQuarters(2,:)	   92	   'cycleLengthPeriodKu
rtosis'	  
	   	  
44	   'MDHiQuarters(3,:)	   93	   'cycleLengthPeriod5t
h'	  
	   	  
45	   'MDHiQuarters(4,:)	   94	   'cycleLengthPeriod25
th'	  
	   	  
46	   'anfRate5th'	   95	   'cycleLengthPeriod50
th'	  
	   	  
47	   'anfRate25th'	   96	   'cycleLengthPeriod75
th'	  
	   	  
48	   'anfRate50th'	   97	   'cycleLengthPeriod95
th'	  
	   	  
49	   'anfRate75th'	   98	   'cycleLengthPeriodNo
rmMean'	  
	   	  
Table	  22:	  List	  of	  Features	  extracted	  from	  SM	  signals	  used	  in	  ADHF	  predictor	  algorithm	  development	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5.7.2. Developing	  and	  Training	  the	  SM	  ADHF	  Predictor	  Algorithm	  (SMApA)	  
Developing	  the	  SMApA	  	  
The	  ADHF	  predictor	  algorithm	  was	  developed	  from	  21,659	  nights	  of	  data	  from	  51	  patients	  in	  the	  
Dublin	  development	  dataset,	  using	  some	  of	  the	  features	  identified	  in	  Table	  18.	  (See	  Figure	  67)	  
During	   development	   a	   ‘Leave	  One	  Out	   Cross	   Validation’	   (LOOCV)	   system	  was	   used	   to	  make	   a	  
more	   robust	   assessment	   of	   the	   features	   selected	   (221).	   It	   is	   a	   tedious	   but	   robust	   system	   that	  
involves	  systematically	  removing	  a	  single	  feature	  from	  the	  original	  dataset,	  which	  is	  then	  used	  as	  
a	  validation	  on	  the	  remainder	  feature	  set	  to	  see	  if	  there	  were	  significant	  changes	  to	  the	  SMApA.	  
This	   is	   repeated	  such	   that	  each	   feature	   in	   the	  sample	   is	  used	  once	  as	   the	  validation	  data.	  This	  
way	  the	  best	  features	  are	  selected	  and	  inputted	  into	  the	  final	  algorithm.	  	  	  
At	   the	   end	   of	   development,	   3	   SMApA	   Classifiers,	   which	   contain	   a	   feature	   set	   and	   a	   trained	  
classifier,	  were	  selected	  based	  on	  their	   sensitivity,	   specificity	  &	  ROC	  as	  potential	  predictors	   for	  
validating	  the	  London	  group	  of	  patients	  (Tables	  23,	  24	  &	  25).	  The	  target	  was	  to	  correctly	  identify	  
an	  ADHF	  episode	  within	  the	  7-­‐day	  window	  before	  it	  was	  clinically	  detected.	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SM	  ADHF	  Predictor	  Algorithm	  1	  –	  CLASSIFIER	  1	  
Type	  of	  Classifier	  –	  SPCCA	  
Features	  
	  
Table	  23:	  Features	  used	  for	  SM	  ADHF	  Predictor	  Algorithm	  1	  
	  
	  
SM	  ADHF	  Predictor	  Algorithm	  2	  –	  CLASSIFIER	  2	  
Classifier	  –	  LDA	  
Features	  
	  




Feature Index Feature Name Brief Description 
1 MovCUM Total Movement duration during the Session. 
2 HiCUM Total Regular Breathing duration during the Session. 
3 FreqCSQ4 Breathing Frequency duration during the 4th Quarter of the night. 
4 BWCSQ4 CS Breathing Bandwidth duration during the 4th Quarter of the night. 
Feature Index Feature Name Brief Description
1 totSleepTime Total estimated Sleep Time during the night.
2 activity75th 75th centile of all detected activity.
3 cycleLengthPeriodNorm50th' median of the duration of all periodic breathing.
4 ‘RE 2nd - 1st' Difference between the mean Residual Effort (of detected periodic breathing) between the second part 
and the first part of the night.
5 AL mean/std A measure of the variability of apnea length.
6 CycleLength Range Cycle length range.
7 activity5th 5th percentile of all detected activity.
8 sdbEventNumber' Number of detected SDB events.
9 Resp 95th - 50th' Difference between the 95th and the 50th percentile of all the respiration rates estimated during the 
night.
10 Residual effort range Residual effort range.
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SM	  ADHF	  Predictor	  Algorithm	  3	  –	  CLASSIFIER	  3	  
Classifier	  –	  LDA	  
Features	  
	  






Feature Index Feature Name Brief Description
1 PercentCS' Percent CS during the night.
2 CSQuarters(2,:)' CS in 2nd quarter of the night.
3 BWCSQuarters(1,:)' Bandwidth of the CS in the first quarter of the night.
4 MDCSQuarters(3,:)' Modulation depth of the CS in the 3rd quarter of the night.
5 HiQuarters(3,:)' Entropy in the 3rd quarter of the night.
6 ‘respRate25th' 25th percentile of all respiration rates during the night.
7 sdbEventNumber' Number of detected SDB events.
8 sdbEventLengthMean' Mean length of all detected SDB events during a night.
9 sdbEventLengthStd' STD of the duration, of all detected SDB events during a night.
10 sdbResidualAmplitudeStd'     STD of the residual effort of all detected SDB events during a night.
11 sdbResidualAmplitudeStd2nd' STD of the residual effort of all detected SDB events during the second part of the night.
12 sdbEventLengthMean1st' Mean duration of all detected SDB events during the first part of the night.
13 cycleLengthPeriodNorm25th' 25th percentile of the duration of all cycles of modulated breathing detected during the night.
14 cycleLengthPeriodNorm50th' 50th percentile of the duration of all cycles of modulated breathing detected during the night.
15 cycleLengthPeriodNorm75th' 75th percentile of the duration of all cycles of modulated breathing detected during the night.
16 cycleLengthPeriodNorm2ndHalfMean' Mean duration of all cycles of modulated breathing detected during the second part of the night.
17 cycleLengthPeriodNorm2ndHalfStd' STD of the duration of all cycles of modulated breathing detected during the second part of the 
night.
18 sdbTimeMinsPerHour' AHI x mean Cycle Length.
19 Resp 95th - 50th' Difference between the 95th and the 50th percentile of all the respiration rates estimated during the 
night.
20 CL 95th - 75th' Difference between the 95th and the 75th percentile of the duration of all the cycles of modulated 
breathing detected during the night.
21 ‘RE 2nd - 1st' Difference between the mean residual effort of detected SDB events between the second part of 
the night and the first part of the night.
22 AL 2nd - 1st' Difference between the mean duration of detected SDB events between the second part of the night 
and the first part of the night.
23 CL 2nd - 1st' Difference between the mean duration of the residual effort between of detected SDB events 
between the second part of the night and the first part of the night.
24 RespRate50thVsBaseline' Difference between the 50th percentile of all estimated respiration rate during a night versus 
baseline from previous days.
25 RespRate75thVsBaseline' Difference between the 75th percentile of all estimated respiration rate during a night versus 
baseline from previous days.
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5.7.2.1. Testing	  the	  SMApA	  	  
Once	   the	   SM	   ADHF	   predictor	   algorithm	   (SMApA)	   development	   was	   completed,	   testing	  
commenced	  on	  the	  London	  database.	  Only	  ADHF	  events	  that	  had	  been	  recorded,	  completed	  and	  
adjudicated	  upon	  at	  commencement	  of	  testing	  (20/01/2013)	  were	  included.	  There	  were	  20	  such	  
adjudicated	   ADHF	   events	   and	   13	   were	   usable,	   which	   translated	   to	   10,730	   nights	   that	   were	  
available	   for	   testing	   the	   SMApA.	   The	  mean	   (SD)	   FU	   at	   this	   stage	  was	   10.2	   ±	   4.6	  months.	   In	   a	  
similar	  fashion	  only	  the	  best	  features,	  which	  had	  been	  selected	  a	  prior	  during	  development,	  were	  
extracted	   from	  this	  validation	  set	  and	  put	   through	  the	  classifier	  algorithm	  to	  give	  a	  prediction.	  
Figure	  68	   is	   the	  consort	   chart	   for	  ADHF	  event	   selection	  while	  Figure	  69	   summarises	   the	  entire	  
development	  and	  testing	  process	  of	  the	  SMApA.	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Figure	  69:	  Schematic	  showing	  summary	  of	  entire	  development	  and	  validating	  of	  the	  SleepMinderTM	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5.8. Results	  
5.8.1. Patient	  Characteristics	  
There	  were	  61	  patients	  in	  the	  development	  and	  43	  patients	  in	  the	  validation	  arms	  of	  this	  study.	  
The	  characteristics	  of	  these	  patients	  are	  shown	  in	  Table	  26.	  All	  patients	  had	  chronic	  heart	  failure	  
secondary	   to	   left	   ventricular	   systolic	   dysfunction	   and	   majority	   were	   on	   contemporary	   heart	  
failure	  therapy	  with	  a	  beta-­‐blocker,	  ACE	  inhibitor	  or	  Angiotensin	  II	  Receptor	  Blocker.	  
There	   were	   significantly	   more	   patients	   in	   the	   validation	   set	   who	   were	   treated	   with	   cardiac	  
resynchronisation	  therapy	  (CRT)	  (40%	  versus	  5%.	  p<0.001).	  Furthermore,	  the	  baseline	  BNP	  was	  
significantly	  higher	  in	  the	  development	  arm	  (mean±SD-­‐170±179)	  compared	  to	  the	  validation	  set	  
of	  patients	  (mean±SD-­‐134±89).	   In	  addition,	  significantly	  more	  patients	   in	  the	  development	  arm	  
of	  the	  study	  had	  atrial	  fibrillation	  and	  hypertension	  however	  more	  patients	  in	  the	  validation	  set	  
had	  documented	  renal	  impairment	  or	  anaemia.	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Table	  26:	  Showing	  baseline	  characteristics	  of	  Development	  and	  Validation	  set	  of	  patients.	  Values	  are	  
expressed	  as	  mean	  ±	  SD	  or	  percentages.	  
There	  were	  no	  significant	  differences	  in	  the	  key	  respiratory	  parameters	  used	  in	  the	  development	  
of	  the	  SMApA,	  compared	  to	  the	  number	  of	  events	  in	  the	  validation	  set	  of	  patients	  as	  shown	  in	  
Table	  27.	  
	  
Table	  27:	  	  Showing	  comparisons	  between	  Development	  and	  Validation	  set	  of	  patients	  of	  key	  respiratory	  
parameters	  used	  in	  SM	  ADHF	  predictor	  algorithm.	  Values	  are	  expressed	  as	  mean	  ±	  SD	  
Group& Development(DUB)(61)& Valida8on&(LON)(43)& P?value&
Age$(Years)$ 74.8$±$9$ 76.7$±$8.97$ 0.28$
Male$Sex$n$(%)$ 42$(69)$ 31$(72)$ 0.72$
EF$(%)$ 36.6$±$13$ 38.3$±$13$ 0.53$
Ischaemic$n$(%)$ 30$(49)$ 20$(47)$ 0.82$
BNP$(pmol/L)$ 170$±$179$ 134.6$±$89$ 0.008$
Weight$(Kg)$ 76.5$±$16$ 78.5$±$18$ 0.563$
Anaemia$n$(%)$ 11$(18)$ 19$(44)$ 0.004$
Renal$Impairment$n$(%)$ 27$(44)$ 29$(67)$ 0.002$
DM$n$(%)$ 13$(21)$ 6$(14)$ 0.34$
HTN$n$(%)$ 35$(57)$ 14(32)$ 0.01$
CRTSPacing$n$(%)$ 3$(5)$ 17$(40)$ <0.001$
AF$n$(%)$ 35$(57)$ 12$(28)$ 0.001$
ACEi$or$AIIRB$n$(%)$ 52$(85)$ 34$(79)$ 0.069$
Beta$Blocker$n$(%)$ 51$(84)$ 34$(79)$ 0.098$
MRA$n$(%)$ 24$(39)$ 14$(33$)$ 0.102$
Parameter' Development'(51)' Valida5on'(39)' P8value'
AHI$(events$per$hour)$ 26.4$±$10$ 24$±$11$ 0.34$
Cycle$Length$CSR$(ms)$ 56$±$10$ 55$±$10$ 0.51$
Number$of$Apnoeas$ 17$±$2$ 18$±$3$ 0.81$
Respiratory$Rate$ 19.7$±$4.9$ 19.9$±$5.3$ 0.54$
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5.8.2. Acute	  Decompensation	  of	  Heart	  Failure	  	  
In	  the	  validation	  set	  of	  patients,	  there	  were	  29	  documented	  ADHF	  episodes,	  which	  occurred	  in	  15	  
of	  the	  43	  patients	  recruited,	  over	  the	  entire	  follow	  up	  period	  [mean(SD)	  11.2	  ±	  3.6	  months].	  The	  
adjudication	  committee	  deemed	  one	  event,	  as	  not	  being	  a	  true	  ADHF	  episode	  as	  it	  did	  not	  fulfil	  
all	  of	  the	  pre-­‐specified	  event	  criteria.	  There	  were	  therefore	  28	  true	  ADHF	  episodes	  in	  15	  patients.	  
This	  gave	  an	  ADHF	  event	  rate	  for	  this	  group	  of	  patients	  in	  this	  period	  of	  35%,	  which	  was	  higher	  
than	  our	  projected	  rate	  (30%)	  in	  our	  sample	  calculation.	  	  
Multiple	  ADHF	  episodes	  occurred	  in	  8	  of	  these	  patients	  up	  to	  a	  maximum	  of	  3	  episodes	  as	  shown	  
in	  Figure	  70.	  
	  
Figure	  70:	  Number	  of	  ADHF	  Episodes	  per	  patient	  
Compared	  to	  those	  patients	  who	  did	  not	  decompensate,	  ADHF	  patients	  were	  more	  symptomatic	  
at	  baseline	  in	  terms	  of	  NYHA	  grading	  and	  more	  (67%)	  had	  an	  ischaemic	  substrate	  as	  the	  aetiology	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Table	  28:	  Comparison	  of	  patients	  who	  did	  or	  did	  not	  have	  an	  ADHF	  episode	  	  
5.8.2.1. Hospital	  Managed	  ADHF	  
An	  ADHF	  episode	  resulted	  in	  a	  hospital	  admission	  in	  19	  of	  the	  28	  ADHF	  episodes.	  The	  mean	  time	  
to	  intervention,	  which	  is	  from	  documented	  symptom	  onset	  as	  recorded	  by	  the	  patients	  in	  their	  
diary	  or	  reported	  to	  the	  admitting	  medical	  team,	  to	  hospital	  admission,	  was	  6.3	  ±	  4.2	  days	  (Mean	  
±	  SD).	  Following	  hospital	  admission	   the	  average	   length	  of	   stay	   (LOS)	   for	  each	  episode	  of	  ADHF	  
was	  18	  ±	  15	  days	  (Mean	  ±	  SD).	  83%	  of	  these	  patients	  managed	  in-­‐hospital	  received	  intravenous	  
loop	   diuretic	   Furosemide	   and	   47%	   of	   these	   patients	   received	   this	   in	   combination	   with	   ‘renal	  
dose’	  dopamine.	  Ultrafiltration	  was	  used	  as	  adjunctive	   therapy	   to	  manage	  2	  patients	  who	  had	  
failed	   to	   respond	   to	   the	   initial	   combination	   treatment	  with	   IV	   diuretics	   and	  Dopamine	   and	   to	  
help	  preserve	  renal	  function	  as	  shown	  in	  Table	  29.	  Arrhythmia	  and	  sepsis	  were	  causative	  of	  the	  
ADHF	   episodes	   in	   22%	   and	   11%	   of	   these	   events,	   respectively,	   and	   in	   one	   patient	   an	   acute	  
coronary	   event	   was	   deemed	   important.	   The	   exact	   trigger	   for	   a	   decompensation	   episode	   was	  
unidentified	  (‘other’)	   in	  52%	  of	  patients.	  Examination	  of	  records	  by	  the	  adjudication	  committee	  
however	   suggested	   that	   non-­‐adherence	   to	   fluid	   balance	  management	   and/or	   non-­‐compliance	  
with	  medication	  may	  have	  been	  causative	  in	  these	  patients.	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Table	  29:	  Showing	  characteristics	  of	  ADHF	  events	  managed	  in	  hospital.	  ‘Other’	  –	  Non-­‐compliance	  with	  
fluid	  balance	  or	  medication	  management	  (IV	  =	  Intravenous,	  LOS	  –	  Length	  of	  Hospital	  Stay,	  Pre-­‐Adm-­‐LOS	  
–	  Time	  to	  hospital	  admission/intervention,	  UF	  –	  Ultrafiltration,	  Loop-­‐	  Loop	  Diuretic,	  Furosemide)	  
5.8.2.2. Home	  Managed	  ADHF	  
Home	  management	   of	   ADHF	   occurred	   in	   9	   of	   the	   28	  ADHF	   episodes	   and	  was	   initiated	   by	   the	  
patient	  based	  on	  expert	  knowledge	  of	  their	  condition	  or	  following	  a	  call	  to	  the	  heart	  failure	  nurse	  
(community/hospital)	   or	   GP.	   They	   had	   complained	   of	   weight	   gain	   or	   increased	   symptoms	  
(dyspnoea	   or	   orthopnoea),	   which	   led	   to	   an	   intervention.	   It	   was	   difficult	   to	   obtain	   a	   definite	  
trigger	   for	   decompensation	   in	   these	   patients	   but	   from	   interviewing	   patients	   and	  obtaining	  GP	  
notes	   I	  established	  that	  most	  of	  these	  episodes	  were	  triggered	  by	  a	   loss	  of	  control	  of	  a	  usually	  
strict	  fluid	  balance	  by	  these	  patients.	  On	  average,	  these	  patients	  delayed	  intervention	  by	  up	  to	  6	  




1" LON"002" 7" 15" Other" IV"Loop"+Dopamine"
2" LON"012" 16" 27" Arrhythmia" IV"Loop"+"Dopamine"
3" LON"015" 7" 17" Other" IV"Loop"+"Dopamine"
4" LON"005" 7" 6" Sepsis" IV"Loop"+"Dopamine"
7" LON"016" 7" 15" Valvular" Increase"Oral"Loop"
9" LON"035" 14" 70" Other" IV"Loop"+"Dopamine"
10" LON"024" 2" 10" Arrhythmia" Increase"Oral"Loop"
13" LON"024" 7" 25" Arrhythmia" IV"Loop"+"Dopamine"
14" LON"016" 7" 34" Valvular" IV"Loop"
15" LON"024" 4" 28" Arrhythmia" IV"Loop"
18" LON"015" 5" 16" Other" IV"Loop"+"UF"
20" LON"035" 0" 21" Other" IV"Loop"+"Dopamine"
21" LON"036" 9" 19" Other" Increase"Oral"Loop"
22" LON"036" 0" 3" Other" Increase"Oral"Loop"
23" LON"039" 0" 10" Ischaemia" IV"Loop"
24" LON"015" 21" 12" Other" IV"Loop"+"UF"
25" LON"036" 15" 1" Other" IV"Loop"
27" LON"017" 7" 13" Sepsis" IV"Loop"
29" LON"021" 7" 6" Other" IV"Loop"
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Table	  30:	  Showing	  characteristics	  of	  ADHF	  events	  managed	  at	  home.	  ‘Other’	  –	  Non-­‐compliance	  with	  
fluid	  balance	  or	  medication	  management	  (Loop	  –	  Loop	  Diuretic,	  Furosemide,	  Pre-­‐I-­‐Adm	  –	  Time	  at	  home	  
from	  symptom	  onset	  to	  intervention)	  
5.8.3. Non	  Heart	  Failure	  Related	  Admissions	  
Table	   31	   below	   shows	   the	   reasons	   for	   admissions	   to	   hospital	   that	   were	   not	   related	   to	   heart	  
failure	  decompensation	  (non-­‐ADHF	  admissions).	  19	  such	  events	  occurred	  in	  11	  patients.	  5	  (26%)	  
events	  were	  elective	  and	  14	  (74%)	  were	  emergency	  admissions.	  The	  average	  LOS	  was	  5.3	  ±	  4.2	  




6" LON"014" 6" Other" Increase"Oral"Loop"
8" LON"014" 7" Sepsis" Increase"Oral"Loop"
11" LON"034" 3" Other" Increase"Oral"Loop"
12" LON"029" 7" Other" Increase"Oral"Loop"
16" LON"029" 3" Other" Increase"Oral"Loop"
17" LON"007" 3" Other" Added"Thiazide"
19" LON"034" 8" Other" Increase"Oral"Loop"
26" LON"014" 5" Sepsis" Increase"Oral"Loop"
28" LON"029" 14" Other" Increase"Oral"Loop"
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Table	  31:	  Aetiology	  of	  Non-­‐	  Heart	  Failure	  Admissions	  (UTI	  =	  Urinary	  Tract	  Infection,	  LOS	  –	  Length	  of	  
Hospital	  Stay,	  PPM	  –	  Permanent	  Pacemaker,	  PCI	  –	  Percutaneous	  Coronary	  Intervention,	  LRTI	  –	  Lower	  
Respiratory	  Tract	  Infection)	  	  
5.8.4. Mortality	  	  
During	   the	   entire	   follow	   up	   period	   9	   (21%)	   patients	   died.	   The	   cause	   of	   death	  was	   end-­‐	   stage	  
Heart	   Failure	   in	   8	   (89%)	   of	   these	   patients.	   One	   death	   was	   following	   complications	   from	   a	  
pulmonary	  embolus	  following	  a	  hip	  operation.	  
	  
	  




1$ 3$ Anaemia$ Elec1ve$
2$ 4$ Anaemia$ Elec1ve$
3$ 6$ Angiogram$ Elec1ve$
4$ 3$ Anaemia$ Emergency$
19$ 1$ Anaemia$ Elec1ve$
LON$003$ 5$ 1$ Anaemia$ Elec1ve$
LON$007$ 6$ 14$ UTI$ Emergency$
LON$010$ 7$ 7$ Hip$Opera1on$ Emergency$
LON$014$ 8$ 4$ Pneumonia$ Emergency$
LON$017$ 9$ 11$ PPM$Implant$ Emergency$
LON$020$
$
10$ 0$ Mechanical$Fall$ Emergency$
11$ 10$ Fall/LRTI$ Emergency$
LON$027$ 12$ 4$ Acute$Pancrea11s$ Emergency$





14$ 1$ PPM$Implant$ Emergency$
15$ 1$ UTI$ Emergency$
16$ 1$ Groin$Pain$ Emergency$
17$ 9$ PCI$ Emergency$
LON$017$ 18$ 11$ PPM$Implant$ Emergency$
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5.8.4.1. Overall	  Mortality	  versus	  ADHF	  episodes	  
5	  of	   the	  patients	  who	  died	   suffered	  at	   least	  one	  ADHF	  episode	  prior	   to	   their	  demise	  and	  3	  of	  
these	  patients	  had	  2	  or	  more	  ADHF	  episodes	  as	  shown	  in	  Figure	  71.	  
	  
Figure	  71:	  Patients	  who	  died	  in	  relation	  to	  the	  number	  of	  ADHF	  episodes	  (Mean	  FU	  Period	  11.2	  ±	  3.6	  
months)	  LON	  010	  was	  patient	  who	  died	  following	  emergency	  Hip	  Operation.	  
5.8.5. Compliance	  with	  Diary	  Documentation	  
We	  had	  instructed	  patients	  at	  the	  start	  of	  the	  study	  to	  document	  changes	  in	  diuretic	  therapy	  and	  
symptoms	   into	   provided	   diaries.	   Compliance	   with	   diary	   documentation	   was	   assessed	   by	  
comparing	  patient	   entries	   into	   the	  diaries	   regarding	   change	   in	  diuretic	   therapy	   and	   symptoms	  
with	   information	   regarding	   actual	   clinical	   events,	   obtained	   from	   outpatient	   letters	   or	   hospital	  
notes,	  and	  contact	  with	  HF	  nurses	  and	  GPs.	  Overall	  compliance	  was	  very	  poor	  with	  only	  10	  (23%)	  
of	   eligible	   recruited	   patients	   making	   an	   entry	   at	   all.	   Of	   these	   only	   6	   patients	   appropriately	  
correlated	   their	   entries	  with	   clinical	   information,	  which	  we	  had,	   access	   to.	   The	   remaining	   four	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5.8.6. Sleep	  Minder	  Acceptability	  	  
5.8.6.1. Recruitment	  Proportion	  
There	  were	  43	  patients	  who	  consented	  to	  take	  part	  in	  this	  study	  and	  the	  pre-­‐specified	  follow	  up	  
period	   was	   for	   a	  minimum	   of	   12	  months.	   Comparatively,	   our	   recruitment	   proportion	   for	   this	  
study	  was	  high	  (222)	  at	  57%	  with	  43	  of	  the	  75	  eligible	  patients	  approached,	  who	  agreed	  to	  take	  
part	   in	   the	   study.	   The	   primary	   reason	   for	   failure	   of	   enrolment	   was	   patient’s	   perceived	  
inconvenience	  at	  having	  medical	  equipment	  placed	  within	  their	  home	  environment.	  (See	  Figure	  
63)	  
5.8.6.2. Withdrawal	  Proportion	  
3	  patients,	  who	  had	   initially	  consented	  to	  take	  part	   in	  the	  study,	  returned	  their	  devices	  after	  1	  
day	  due	  to	  unexpected	  family	  reasons	  (2)	  or	  unexpected	  travel	  abroad	  (1).	  	  
Of	  the	  40	  remaining	  patients,	  only	  2	  patients	  pulled	  out	  voluntarily	  before	  the	  end	  of	  the	  follow	  
up	   period.	  One	   patient	   found	   the	   SleepMinderTM	   device	   a	   constant	   reminder	   of	   their	  medical	  
problems	  and	  dropped	  out	  of	   the	   study	   after	   122	  days.	   The	  other	  patient	   entered	  a	  palliative	  
phase	  of	  their	  management	  and	  dropped	  out	  after	  118	  days	  of	  the	  study,	  as	  they	  could	  no	  longer	  
actively	  participate.	  	  
Therefore,	   apart	   from	   patients	  who	   died	   or	  who	  were	   excluded	   as	   a	   result	   of	   early	   return	   of	  
study	  equipment,	   acceptability	  of	   the	   SM	  device	  was	  excellent	  with	  95%	  of	  patients	  using	   the	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5.8.7. SM	  ADHF	  Algorithm	  Prediction	  
We	   developed	   3	   SleepMinderTM	   ADHF	   predictor	   Algorithms	   (SMApA)	   using	   the	   techniques	  
described	  earlier	   in	   Section	  5.7.	   Table	  32	   shows	   the	   results	  of	   all	   three	  algorithms	   in	   terms	  of	  
sensitivity,	   specificity	   and	   diagnostic	   accuracy	   by	   means	   of	   the	   area	   under	   receiver	   operator	  
characteristic	  curve	  (AUC).	  Due	  to	  the	  design	  of	  SMApA	  1,	  we	  were	  only	  able	  to	  produce	  binary	  
predictions.	  With	  SMApA	  2	  and	  3	  however,	  we	  were	  able	   to	  generate	  prediction	  probabilities,	  
which	  enabled	  us	  to	  plot	  ROC	  curves.	  
Of	   the	   3	   algorithms,	   the	   SM	   ADHF	   predictor	   algorithm	   2	   was	   deemed	   to	   have	   the	   best	  
combination	   in	   terms	   of	   accuracy	   parameters	   and	   was	   selected	   as	   the	   final	   algorithm	   or	  
prediction.	  The	  sensitivity	  and	  specificity	  of	  this	  algorithm	  was	  38%	  and	  71%,	  respectively,	  in	  the	  
validation	  group	  of	  patients.	  Positive	  predictive	  value	  (PPV)	  and	  Negative	  Predictive	  Value	  (NPV)	  
was	  1%	  and	  99%	  respectively.	  The	  False	  Positive	  Rate	  (FPR)	  was	  71%.	  
The	  AUC	  for	  this	  classifier	  was	  53%.	  See	  Figure	  72.	  
	  

















Measure Development (Dublin) Validation (London) 
Sensitivity 0.696  [0.567 .. 0.801] 0.538  [0.291 .. 0.768] 
Specificity 0.568  [0.550 .. 0.585] 0.574  [0.550 .. 0.598] 
AUC n/a n/a 
Weeks 3376 1812 
Events 56 13 
TP 39 7 
FN 17 6 
TN 1756 912 
FP 1336 676 
Measure Development (Dublin) Validation (London) 
Sensitivity 0.821  [0.702 .. 0.900] 0.385  [0.177 .. 0.645] 
Specificity 0.801  [0.786 .. 0.815] 0.713  [0.690 .. 0.735] 
AUC 0.8078 0.5304 
Weeks 3376 1812 
Events 56 13 
TP 46 5 
FN 10 8 
TN 2447 1107 
FP 608 446 
Measure Development (Dublin) Validation (London) 
Sensitivity 0.821  [0.702 .. 0.900] 0.385  [0.177 .. 0.645] 
Specificity 0.725  [0.708 .. 0.741] 0.711  [0.688 .. 0.734] 
AUC 0.7627 0.5192 
Weeks 3376 1812 
Events 56 13 
TP 46 5 
FN 10 8 
TN 2095 1047 
FP 796 425 
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Figure	  72:	  Receiver	  Operator	  Characteristic	  (ROC)	  curve	  for	  SMApA	  2,	  (Blue	  line	  –	  ROC	  curve	  for	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5.8.8. Weight	  Analysis	  
I	  also	  compared	  the	  changes	  in	  weight	  seen	  before	  an	  ADHF	  episode	  compared	  to	  Non	  –	  ADHF	  
episodes.	  There	  was	  no	  statistically	  significant	  difference	  between	  the	  two	  events	  with	  a	  mean	  
difference	  of	  1kg	  weight	  change	  between	  the	  two	  event	  types	  but	  this	  is	  underpowered	  as	  there	  
were	  fewer	  non-­‐ADHF	  events.	  This	  is	  shown	  in	  table	  33.	  
	  
Table	  33:	  Weight	  change	  between	  ADHF	  event	  and	  Non-­‐ADHF	  event	  days.	  
5.9. Discussion	  
An	  effective	  tool	  for	  predicting	  acute	  decompensation	  of	  chronic	  heart	  failure	  (ADHF)	  should	  be	  
one	   using	   a	   parameter	   or	   a	   combination	   of	   parameters,	   which	   has	   a	   high	   positive	   predictive	  
value	   for	   ADHF.	   It	   should	   also	   be	   detectable	   early	   enough	   to	   allow	   for	   intervention	   by	   the	  
physician	  in	  order	  to	  institute	  management	  changes	  that	  could	  prevent	  further	  deterioration	  of	  
heart	  failure.	  	  
In	  this	  study	  we	  have	  shown	  that	  our	  SM	  ADHF	  predictor	  algorithm	  (SMApA),	  which	  incorporates	  
components	   of	   nocturnal	   respiration	   obtained	   from	   a	   non-­‐contact	   bedside	   monitor	   –	   the	  
SleepMinderTM	  device,	  is	  not	  clinically	  useful	  for	  predicting	  decompensation	  of	  heart	  failure.	  	  Our	  
best	  SMApA	  had	  a	  sensitivity	  of	  38%	  and	  specificity	  of	  71%	  with	  a	  PPV	  of	  1%	  and	  NPV	  of	  99%,	  for	  
predicting	  ADHF	  in	  the	  week	  before	  a	  clinical	  event,	  in	  the	  validation	  group	  of	  patients.	  The	  AUC	  
was	  53%	  which	  suggests	  its	  predictive	  value	  is	  only	  a	  little	  better	  than	  chance.	  Overall	  and	  on	  its	  
own,	  its	  clinical	  use	  is	  therefore	  of	  little	  clinical	  value.	  
The	  results	  of	  the	  SMApA	  in	  the	  development	  set	  of	  patients	  alone	  were	  better	  than	  published	  
weight–based	  algorithms	  for	  predicting	  ADHF	  with	  a	  sensitivity	  and	  specificity	  of	  82%	  and	  80%	  
respectively.	   These	   weight-­‐based	   algorithms	   shown	   in	   Table	   34	   (101)	   were	   developed	   and	  
validated	  on	  the	  same	  group	  of	  patients	  and	  as	  a	  result,	  may	  have	  been	  artefactually	  optimistic	  
in	  their	  results.	  It	  is	  therefore	  more	  robust	  to	  develop	  and	  test	  on	  different	  sets	  of	  patients.	  
Event& Mean& Std.Dev& MeanDiﬀ& 95%&CI& P5value&
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Table	  34:	  Comparison	  of	  SM	  ADHF	  predictor	  algorithm	  with	  Weight	  based	  algorithms	  –	  developed	  and	  
validated	  in	  same	  group	  of	  patients	  
When	  our	  results	  are	  compared	  with	  other	  studies	  on	  ADHF	  prediction,	   (Table	  35)	  which	  were	  
developed	  and	  validated	  on	  different	  groups	  of	  patients,	  the	  SM	  ADHF	  predictor	  algorithm	  was	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Table	  35:	  Comparison	  of	  SM	  ADHF	  algorithm	  with	  ADHF	  algorithms	  –	  developed	  and	  validated	  in	  
different	  group	  of	  patients.	  
Cowie	  and	  colleagues	  developed	  a	  dynamic	  HF	  risk	  score	  (low	  ≤5%,	  Medium	  5-­‐20%,	  High>20%),	  
derived	  from	  combining	  diagnostic	  parameters	  monitored	   in	   implantable	  devices	  for	  predicting	  
HF	  hospitalisations	  in	  the	  next	  30	  days.	  The	  parameters	  used	  in	  this	  study	  included	  intra-­‐thoracic	  
impedance	  (IMP),	  atrial	   fibrillation	  (AF)	  burden,	  ventricular	  rate	  during	  atrial	   fibrillation	  (VRAF),	  
ventricular	  tachycardia	  (VT)	  episodes,	  patient	  activity	  (ACT),	  day	  and	  night	  heart	  rate	  (NHR),	  and	  
heart	  rate	  variability	  (HRV)	  (223).	   
They	  developed	  this	  score	  using	  data	  from	  a	  development	  set	  of	  921	  HF	  patients	  with	  an	  average	  
follow-­‐up	  duration	  of	  10.6±5.8	  month and	  validated	  their	  findings	  on	  1310	  HF	  patients	  who	  were	  
followed	  up	  for	  an	  average	  of	  8.1±5.0	  months.	  All	  patients	  had	  an	   implanted	  CRT-­‐D	  or	   ICD	  and	  
were	  derived	  from	  Europe,	  Hong	  Kong	  and	  the	  USA. 
In	  patients	  with	  a	  low	  to	  medium	  HF	  risk	  score	  (5%),	  the	  sensitivity	  and	  specificity	  of	  the	  score	  for	  
predicting	  a	  future	  HF	  hospitalisation	  in	  the	  next	  30	  days	  was	  83%	  and	  46%	  respectively. 
The	  COMPASS-­‐HF	  (Chronicle	  Offers	  Management	  to	  Patients	  with	  Advanced	  Signs	  and	  Symptoms	  
of	   Heart	   Failure)	   study	   was	   a	   prospective,	   multicenter,	   randomized,	   single	   blind,	   parallel-­‐
controlled	   trial	   of	   274	   New	   York	   Heart	   Association	   functional	   class	   III	   or	   IV	   HF	   patients	   who	  
received	  an	  implantable	  continuous	  hemodynamic	  monitor	  (ICHM).	  Patients	  were	  randomized	  to	  
a	  Chronicle	  (Medtronic	  Inc.,	  Minneapolis,	  Minnesota)	  (n	  =	  134)	  or	  control	  (n	  =	  140)	  group	  (111).	  
All	   patients	   received	   optimal	   medical	   therapy,	   but	   the	   hemodynamic	   information	   from	   the	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monitor	   was	   used	   to	   guide	   patient	   management	   only	   in	   the	   Chronicle	   group.	   The	   ICHM	  
continuously	  monitored	  and	  stored	  information	  including	  heart	  rate,	  body	  temperature,	  patient	  
activity	   and	   changes	   in	   right	   ventricular	   systolic	   and	   diastolic	   pressure.	   There	   was	   a	   21%	  
reduction	   in	   HF	   related	   events	   in	   the	   Chronicle	   group	   but	   this	   did	   not	   reach	   statistical	  
significance,	  (See	  Table	  32).	  
SENSE-­‐HF	  was	  a	  large	  prospective,	  multicentre,	  double	  blind	  study	  that	  evaluated	  an	  impedance-­‐
based	  algorithm,	  OptiVol	  (Medtronic,	  Inc.,	  Minneapolis,	  MN,	  USA),	  in	  501	  NYHA	  class	  II	  and	  class	  
III	  HF	  patients	  implanted	  with	  CRT-­‐D	  devices.	  Using	  OptiVol,	  the	  trial	  results	  demonstrated	  a	  low	  
sensitivity	  of	  42%	  and	  low	  positive	  predictive	  value	  of	  only	  38%	  for	  future	  HF	  events	  that	  is	  from	  
6	  months	  to	  24	  months	  post	  implantation	  (121).	  
We	   have	   developed	   the	   SM	   ADHF	   predictor	   algorithm	   by	   using	   various	   components	   of	  
respiration	  derived	  from	  nocturnal	  monitoring	  with	  the	  SM	  device	  and	  then	  incorporated	  them	  
into	   a	   ‘yes’	   or	   ‘no’	   predictor.	   These	   respiratory	   parameters	   are	   essentially	   a	   reflection	   of	  
pulmonary	  congestion	  and	  in	  theory	  should	  give	  a	  good	  indication	  of	  a	  patient’s	  fluid	  status.	  We	  
however	  know	  that	  in	  the	  days	  or	  weeks	  preceding	  an	  ADHF	  episode,	  there	  may	  be	  a	  significant	  
increase	   in	   extracellular	   fluid	   volume,	   without	   evidence	   of	   peripheral	   oedema	   or	   pulmonary	  
congestion	  (104).	  We	  have	  not	  incorporated	  other	  physiological	  parameters	  into	  our	  algorithm,	  
which	  have	  been	  shown	  to	  have	  some	  added	  advantage	   in	  ADHF	  prediction	  such	  as	  heart	   rate	  
monitoring	   or	   oxygen	   saturation	   (121;132).	   Other	   studies	   that	   have	   combined	   multiple	  
parameters	  that	  assess	  not	  only	  fluid	  status,	  have	  produced	  arguably	  better	  results	  (223)	  and	  it	  is	  
possible	   that	   by	   adding	  more	   diagnostic	   variables,	   the	   performance	   of	   the	   algorithm	  may	   be	  
improved.	  
There	  was	   a	   44%	   drop	   in	   sensitivity	   of	   the	   algorithm	  when	   tested	   on	   the	   validation	   group	   of	  
patients.	  The	  reason	  for	   this	   is	  not	  clear.	   In	   terms	  of	  baseline	  characteristics,	   there	  were	  some	  
differences	  between	  the	  two	  groups	  of	  patients	  (development	  and	  Validation)	  that	  could	  account	  
for	   this.	   In	   particular,	   the	   BNP,	   which	   is	   a	   reliable	   marker	   of	   severity	   of	   heart	   failure,	   was	  
significantly	  higher	  in	  the	  development	  group	  of	  patients	  (Validation	  vs	  Development;	  135	  ±	  89;	  
170	  ±	  179).	  Conversely	  a	  significant	  number	  of	  patients	  in	  the	  validation	  arm	  were	  treated	  with	  
cardiac	   resynchronisation	   therapy	   (CRT),	  which	  may	  also	   suggest	   the	  presence	  of	   severe	  heart	  
failure	  despite	  optimal	  medical	   therapy	   (Validation	  vs	  Development;	  40%	  vs	  5%	  p<0.00).	  There	  
are	  some	  small	  studies	  that	  show	  that	  CRT	  reduces	  the	  amount	  of	  SDB	  in	  heart	  failure	  (224)	  and	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perhaps	  this	  may	  have	  had	  some	  undetected	  effect	  on	  the	  number	  of	  respiratory	  events	  in	  the	  
validation	   group	   of	   patients,	   which	   may	   have	   influenced	   the	   manner	   in	   which	   the	   SMApA	  
performed.	  Despite	  the	  higher	  use	  of	  CRT	  in	  the	  validation	  arm,	  the	  event	  rate	  of	  35%	  was	  still	  
high,	  so	  they	  were	  still	  notably	  a	  ‘sick’	  group	  of	  patients.	  The	  mean	  AHI	  was	  marginally	  higher	  at	  
26.4	  events	  per	  hour	   in	  the	  development	  set	  of	  patients	  compared	  to	  the	  validation	  group	  (24	  
events	   per	   hour).	   This	   difference	   is	   probably	   not	   enough	   to	   cause	   such	   a	   sharp	   drop	   in	  
performance	  but	  it	  is	  worth	  noting	  this.	  	  
Overall	  however,	  there	  was	  no	  clear	  difference	  in	  clinical	  or	  demographic	  characteristics,	  which	  
contrasted	  either	  development	  or	  validation	  group	  of	  patients.	  Neither	  was	  there	  any	  statistically	  
significant	  difference	  in	  terms	  of	  other	  nocturnal	  respiratory	  patterns	  utilised	  for	  the	  purpose	  of	  
developing	  the	  predictor	  that	  demarcated	  either	  group	  of	  patients.	  (Table	  24)	  
I	   have	   shown	   in	   the	  previous	   chapter	   that	   amongst	   other	   respiratory	  parameters,	   the	  Apnoea	  
Hypopnea	  Index	  (AHI)	  was	  highly	  variable	  over	  a	  prolonged	  period	  of	  monitoring.	  As	  the	  SMApA	  
was	  derived	  from	  components	  of	  this,	  it	  is	  possible	  that	  this	  large	  variability	  may	  have	  influenced	  
the	  performance	  of	  the	  algorithm	  in	  the	  validation	  group.	  	  
Another	  possible	  explanation	  for	  the	  drop	  in	  performance	  of	  the	  SMApA	  in	  the	  validation	  group,	  
may	  be	  from	  ‘over	  fitting’	  of	  the	  algorithm	  during	  development	  such	  that	  it	  becomes	  too	  trained	  
or	  moulded	  on	  one	  particular	  group	  of	  patients.	   In	  statistics	  and	  machine	   learning,	  over	   fitting	  
occurs	   when	   a	   statistical	   model	   describes	   random	   error	   or	   noise	   instead	   of	   the	   underlying	  
relationship.	  Over	   fitting	  generally	  occurs	  when	  a	  model	   is	  excessively	  complex,	  such	  as	  having	  
too	  many	   parameters	   relative	   to	   the	   number	   of	   observations.	   A	   model	   which	   has	   been	   over	  
fitted	  will	  generally	  have	  poor	  predictive	  performance,	  as	  it	  can	  exaggerate	  minor	  fluctuations	  in	  
the	  data	  (225).	  	  
This,	  in	  theory,	  should	  however	  not	  affect	  the	  performance	  of	  the	  algorithm	  particularly	  if	  there	  
was	   no	   major	   clinical	   difference	   between	   the	   two	   groups.	   It	   is	   however	   the	   most	   likely	  
explanation	   because	   not	   all	   factors	   that	   could	   have	   influenced	   the	   final	   development	   of	   the	  
SMApA	   can	   be	   accounted	   for,	   even	   if	   the	   design	   of	   the	   study	   involved	   matching	   clinical	  
characteristics	  of	  the	  validation	  group	  to	  the	  development	  group.	  
There	  were	  fewer	  usable	  events	   in	  the	  validation	  group	  of	  patients	  with	  13	  adjudicated	  events	  
that	  the	  SM	  ADHF	  predictor	  Algorithm	  (SMApA)	  was	  tested	  on	  compared	  to	  the	  56	  events	  from	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which	  it	  was	  developed.	  We	  speculate	  that	  by	  testing	  the	  SMApA	  on	  a	  larger	  dataset	  with	  more	  
ADHF	  events,	  it	  is	  possible	  that	  the	  results	  may	  have	  been	  slightly	  better.	  Perhaps	  this	  is	  an	  area	  
where	  further	  work	  needs	  to	  be	  carried	  out.	  
67%	  of	   the	  validated	  ADHF	  episodes	  resulted	   in	  a	  hospital	  admission	  while	   the	  remainder	  23%	  
were	   successfully	  managed	   at	   home	  without	   the	   need	   for	   a	   hospital	   admission.	   This	   supports	  
guidelines	  that	  encourage	  patient	  education	  empowering	  them	  to	  manage	  their	  heart	  failure	  at	  
home	   (3).	   These	   patients	  who	  were	  managed	   at	   home	   adjusted	   their	   diuretics	   in	   response	   to	  
their	   symptoms	  or	   signs	  on	   their	   own,	   or	   did	   so	   following	   advice	   from	   the	  heart	   failure	  nurse	  
specialists	  or	  general	  practitioners.	  	  
The	  mean	  length	  of	  stay	  for	  a	  hospital	  admission	  for	  heart	  failure	  decompensation	  was	  longer	  at	  
18	  days	   compared	   to	  13	  days	  nationally	   (63).	  But	   this	   is	   comparing	  our	  group	  of	  patients	  who	  
potentially	  had	  a	  more	  severe	  heart	  failure	  syndrome,	  with	  a	  general	  heart	  failure	  population.	  	  
We	  have	  also	  shown	  that	  the	  SM	  device	  as	  a	  novel	  non-­‐contact	  monitor	  was	  convenient	  to	  use	  
and	  acceptable	  by	  heart	  failure	  patients	  with	  only	  a	  5%	  withdrawal	  during	  the	  follow	  up	  period	  
(mean	  11.2	  ±	  3.6	  months).	  This	   is	  encouraging	  and	  suggests	   that	  patients	  are	  agreeable	   to	   the	  
use	  of	  technology	  in	  the	  management	  of	  their	  chronic	  conditions.	  Majority	  of	  our	  patients	  were	  
elderly	   (mean	   age	   76.7	   ±	   8.9	   years)	   and	  were	   still	   able	   to	   use	   the	   various	   components	   of	   the	  
equipment	  provided	  including	  the	  SM	  device	  itself,	  a	  mobile	  phone	  and	  a	  set	  of	  scales,	  without	  
much	   difficulty.	   This	   is	   in	   line	   with	   reviews	   of	   studies	   that	   have	   shown	   success	   and	   good	  
compliance	  when	  technology	  was	  utilised	  as	  a	  tool	  for	  improving	  management	  of	  chronic	  disease	  
regardless	  of	  the	  age	  of	  the	  patient	  (226).	  	  
There	  was	  no	  clear	  differentiation	  in	  weight	  gain	  compared	  to	  non-­‐	  ADHF	  events.	  Again	  this	  is	  in	  
agreement	  with	  majority	  of	   studies	   that	  weight	   is	  not	  a	  sensitive	  predictor	  of	  decompensation	  
(103).	  	  
This	   study	   has	   added	   to	   the	   body	   of	   evidence,	   which	   suggests	   that	   the	   prediction	   of	   Acute	  
Decompensation	   of	   Heart	   Failure	   (ADHF)	   remains	   a	   challenge.	   More	   research	   is	   needed	   to	  
determine	   what	   optimal	   diagnostic	   parameters	   would	   reliably	   identify	   decompensation	   and	  
which	   may	   be	   robust	   enough	   to	   be	   clinically	   useful	   in	   practice	   by	   physicians.	   This	   may	   help	  
reduce	  the	  incidence	  of	  ADHF	  and	  potentially	  overall	  mortality	  in	  chronic	  heart	  failure	  patients.	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The	  development	  of	  multimodality	  monitoring	  of	  heart	  failure	  patients	  in	  on-­‐going	  studies	  such	  
as	  the	  MULTISENSE	  trial	  (Boston	  Scientific)	  may	  be	  a	  useful	  way	  of	  collecting	  more	  information	  
that	  may	  be	  useful	   for	  predicting	  decompensation	  of	  heart	   failure	  (227).	  This	  trial	   is	  evaluating	  
the	   predictive	   power	   of	   multiple	   physiological	   parameters	   obtained	   from	   implanted	   CRT-­‐D	  
devices	   that	   have	   a	   multi-­‐sensor	   design.	   This	   would	   be	   used	   in	   combination	   with	   its	   remote	  
monitoring	  system	  (Latitude)	  where	  this	  clinical	  information	  from	  the	  implanted	  devices	  may	  be	  
available	  to	  physicians	  to	  enable	  them	  take	  clinical	  action	  sooner	  to	  avoid	  hospitalization	  due	  to	  
heart	  failure.	  	  
REM-­‐HF	   (Remote	  Monitoring	   in	   Heart	   Failure)	   is	   another	   on-­‐going	  UK	  multi-­‐centre	   trial	  which	  
aims	   to	   evaluate	   the	   effectiveness	   of	   automatic	   remote	   monitoring	   using	   implanted	   device	  
technology	   (Medtronic,	   St.Judes)	   for	   the	   management	   of	   chronic	   heart	   failure	   in	   the	   home,	  
compared	  to	  usual	  care	   involving	  face-­‐to-­‐face	  hospital	  visits.	  Patients	  with	  stable	  CHF	  and	  who	  
have	  had	  an	   implantable	  device	   (CRT-­‐D	  or	   ICD),	   for	  at	   least	  6	  months	  are	  being	  randomized	  to	  
receive	   device-­‐based	   care,	   where	   Information	   from	   periodic	   downloads	   from	   these	   devices	  
would	   be	   made	   available	   to	   clinicians	   to	   aid	   management	   of	   these	   patients	   or	   usual	   care	  
according	  to	  ESC	  guidelines.	  They	  will	  be	   followed	  up	  for	  a	  minimum	  of	  2	  years.	   In	  addition	  all	  
patients	  will	  be	  asked	  to	  complete	  quality	  of	  life	  questionnaires	  at	  regular	  intervals.	  This	  study	  is	  
due	  to	  complete	  its	  findings	  in	  2015	  and	  it	  is	  hoped	  that	  the	  results	  from	  this	  study	  will	  help	  to	  
provide	  robust	  evidence	  of	  the	  clinical	  and	  cost-­‐effectiveness	  of	  remote	  monitoring	  of	  patients	  
with	  such	  devices	  (228).	  
The	  signs	  and	  symptoms	  that	  constellate	  to	  the	  development	  of	  ADHF	  results	  from	  disturbances	  
in	   multiple	   intersecting	   processes	   including	   neurohormonal	   circuits,	   inflammatory	   mediators,	  
cardiorenal	   interactions,	   and	   myocardial	   performance	   (229).	   In	   theory	   therefore,	   there	   are 
multiple	  opportunities	   for	  detecting	  early	   changes	   in	   the	  processes	   that	   lead	   to	  ADHF.	  Further	  
research	   is	   therefore	   required	   to	   develop	   ideal	   predictive	   tools	   incorporated	   with	   remote	  
monitoring	   programmes	   that	   monitors	   and	   detects	   early	   and	   subtle	   changes	   in	   these	  
physiological	  parameters,	  which	  may	  lead	  to	  earlier	  intervention	  to	  abort	  the	  ADHF	  cascade.	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5.10. Conclusions	  
I	   have	   shown	   that	   the	   non-­‐contact	   monitoring	   of	   Sleep	   Disordered	   Breathing	   is	   unreliable	   in	  
detecting	   Acute	   Decompensation	   of	   Heart	   Failure	   (ADHF).	   Although	   an	   algorithm	   could	   be	  
developed	   in	  one	  cohort	  of	  HF	  patients,	   its	  value	  was	  no	  better	   than	  chance	  when	   tested	   in	  a	  
second	  cohort	  of	  similar	  patients.	  
There	   are	   no	   simple	   SM	   parameters	   that	   provide	   a	   clear	   differentiation	   between	   stable	   and	  
acutely	   decompensated	   heart	   failure.	   Limited	   but	   non-­‐statistically	   significant	   trends	   in	   some	  
respiratory	   parameters	   such	   as	   the	   mean	   nightly	   respiratory	   rate,	   duration	   of	   SDB	   and	   cycle	  
length	  of	  CSR,	  have	  been	  noted	  but	  these	  are	  not	  consistent	  for	  all	  patients	  or	  all	  events.	  	  
Further	  work	  with	  the	  addition	  of	  other	  physiological	  parameters	  and	  possibly	  implanted	  device	  















































	   224	  
6.1. Summary	  of	  Main	  Aims	  
Sleep	   Disordered	   Breathing	   (SDB)	   is	   an	   important	   but	   under-­‐diagnosed	   co-­‐morbidity	   that	   is	  
prevalent	  in	  patients	  with	  chronic	  heart	  failure	  (CHF).	  The	  need	  for	  simple	  and	  reliable	  tools	  for	  
screening	  and	  diagnosis	  is	  therefore	  desirable.	  	  
To	  this	  end,	  the	  first	  aim	  of	  this	  thesis	  was	  to	  validate	  the	  SM	  device	  as	  a	  diagnostic	  tool	  for	  SDB	  
in	   these	  patients	  compared	   to	   in-­‐hospital	  Polysomnography	   (PSG).	  This	  may	  provide	  a	   suitable	  
alternative	  for	  clinicians	  towards	  improving	  identification	  of	  this	  important	  condition.	  	  
The	   second	   aim	   was	   to	   describe	   the	   variability	   of	   nocturnal	   respiratory	   parameters	   in	   CHF	  
patients	   (in	   particular	   the	   Apnoea	   Hypopnoea	   Index	   (AHI))	   over	   a	   prolonged	   period	   of	  
monitoring.	  The	  value	  of	   this	  analysis	  was	   to	   improve	  our	  experience	  of	  how	  changes	   in	   these	  
parameters	  may	  influence	  the	  diagnosis	  and	  management	  of	  SDB.	  
In	  addition,	  Acute	  decompensation	  of	  Chronic	  Heart	  Failure	  (ADHF)	  leads	  to	  increased	  morbidity	  
and	   mortality	   and	   early	   diagnosis	   has	   the	   potential	   to	   improve	   survival	   outcomes	   in	   these	  
patients.	   The	   Third	   aim	  of	   this	   thesis	  was	   to	   investigate	   the	   predictive	   value	   of	   a	   non-­‐contact	  
respiratory	  monitor	   –	   the	   SleepMinderTM	   device	   (SM)	   for	   early	   identification	   of	   ADHF,	   using	   a	  
prediction	  algorithm	  derived	  from	  SM	  signals.	  
6.2. Summary	  of	  Main	  Results	  
I	  studied	  59	  patients	  with	  chronic	  stable	  systolic	  heart	  failure	  to	  investigate	  the	  accuracy	  of	  the	  
SleepMinderTM	   device	   for	   the	   diagnosis	   of	   Sleep	   Disordered	   Breathing	   (SDB).	   To	   achieve	   this,	  
these	  patients	  underwent	  simultaneous	  overnight	  Polysomnography	  (PSG)	  and	  SM	  recordings	  in	  
our	  sleep	  laboratories.	  I	  then	  developed	  algorithms	  from	  the	  SM	  signals	  for	  the	  calculation	  of	  the	  
Apnoea	   Hypopnoea	   Index	   (AHI)	   and	   %	   overnight	   Cheyne-­‐Stokes	   Respiration	   (CSR).	   The	  
algorithms	  generated	  as	  a	  result	  of	  this	  study	  formed	  the	  baseline	  metrics	  for	  developing	  the	  SM	  
ADHF	  predictor	  algorithm	  evaluated	  in	  chapter	  five.	  	  
The	   results	   from	   this	   study	   showed	   that	   the	   SM	   was	   accurate	   for	   the	   diagnosis	   of	   clinically	  
relevant	  SDB	  (AHI>15)	  with	  a	  sensitivity	  of	  0.91	  and	  less	  moderately	  a	  specificity	  of	  0.50.	  The	  area	  
under	  the	  receiver	  operator	  characteristic	  curve	  (AUC)	  at	  this	  threshold	  was	  0.82	  (95%	  CI	  0.63-­‐
1.0).	  The	  SM	  was	  less	  accurate	  for	  identifying	  CSR	  in	  this	  population	  of	  patients	  with	  a	  sensitivity	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of	  0.71	  and	  specificity	  of.	  0.75	  The	  AUC	  using	  a	  threshold	  of	  %	  overnight	  CSR	  of	  0	  was	  0.76	  (95%	  
CI	  0.56-­‐1.0).	  	  
In	  comparison	  to	  PSG,	  even	  where	  there	  was	  a	  disagreement	  in	  the	  AHI	  score	  between	  the	  two	  
techniques,	  this	  was	  not	  more	  than	  10	  events	  per	  hour	  in	  over	  70%	  of	  these	  patients.	  This	  means	  
that	   even	  with	   this	   difference,	   these	   patients	  were	   unlikely	   to	   be	   categorised	   into	   a	   different	  
severity	  group	  of	  SDB.	  The	  mean	  difference	  between	  the	  two	  techniques	  was	  5.6	  events	  per	  hour	  
(95%	  CI	  -­‐2.1	  -­‐13.4)	  
Based	  on	  the	  high	  sensitivity	  (0.91)	  but	  at	  the	  expense	  of	  a	  negative	  predictive	  value	  (0.80)	  of	  the	  
SM	  AHI	  algorithm,	   I	  have	  argued	  that	   it	  would	  be	  a	  reliable	   indicator	  when	  the	  test	   result	  was	  
negative,	   and	   can	   therefore	  be	  used	  as	   a	   screening	   tool	   to	   rule	  out	   SDB	  or	   select	  patients	   for	  
further	   confirmatory	   tests	   such	   as	   PSG.	   This	  would	   reduce	   the	   burden	  on	   overstretched	   sleep	  
laboratories	   for	   formal	   sleep	   studies	   by	   excluding	   patients	   who	   may	   not	   require	   further	  
investigations.	  
To	  determine	  the	  variability	  of	  the	  AHI	  over	  a	  prolonged	  period	  of	  monitoring,	   I	  have	  analysed	  
13,104	   consecutive	  patient	  nights	  of	   nocturnal	   respiratory	  data	   in	   a	   group	  of	   39	  patients	  with	  
moderate	  to	  severe	  CHF.	  The	  mean	  (SD)	   follow	  up	  period	  was	  336	  ±	   (108)	  days	  and	  this	   is	   the	  
first	  study	  in	  the	  published	  literature	  that	  has	  been	  able	  to	  make	  an	  observation	  of	  this	  nature,	  
based	  on	  more	  than	  four	  nights’	  recording.	  
I	   have	   demonstrated	   that	   there	   was	   a	   substantial	   night-­‐to-­‐night	   intra-­‐	   and	   inter-­‐	   patient	  
variability	   in	   the	   AHI.	   [Mean	   Stdev	   11.3	   events	   per	   hour	   (95%	   CI	   10.08-­‐12.95)]	   [Intra	   Class	  
Correlation	  Co-­‐efficient	  0.329	  (95%	  CI	  0.229-­‐0.488)].	  	  
Based	   on	   these	   results,	   I	   have	   argued	   that	   a	   single	   night’s	   assessment	  may	   be	   insufficient	   to	  
make	   a	   definitive	   diagnosis	   of	   SDB.	   I	   have	   therefore	   investigated	   alternative	   diagnostic	  
thresholds	   using	   the	   mean	   AHI	   or	   the	   proportion	   of	   the	   follow	   up	   period	   where	   there	   was	  
clinically	  relevant	  SDB	  (AHI>15).	  I	  observed	  that	  there	  were	  a	  high	  percentage	  of	  patients	  whose	  
mean	  AHI	  was	  above	  treatment	  thresholds	  for	  SDB	  (AHI>15)	  and	  this	  percentage	  was	  consistent	  
over	   varying	   follow-­‐up	  periods.	   For	   this	   reason,	   I	   have	   recommended	   the	  mean	  AHI	   over	   a	   2-­‐
week	  period	  as	  an	  alternative	  diagnostic	  criterion.	  
My	  argument	   is	   strengthened	  by	   the	  high	   individual	  patient	  misclassification	   rate	   for	   SDB	   that	  
was	  observed.	  I	  found	  that	  on	  average	  a	  patient	  was	  misclassified	  into	  a	  different	  severity	  group	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for	   35%	   of	   a	   2-­‐week	   follow-­‐up	   period	   and	   into	   a	   different	   treatment	   group	   for	   21%	   of	   the	  
analysed	   FU	   period.	   These	   results	   may	   have	   significant	   implications	   for	   the	   diagnosis	   and	  
management	  of	  SDB	  in	  heart	  failure	  patients.	  
Finally,	   I	   have	   demonstrated	   that	   the	   SleepMinderTM	   ADHF	   predictor	   algorithm,	   which	   uses	   a	  
combination	   of	   nocturnal	   respiratory	   parameters,	   has	   no	   value	   in	   predicting	   acute	  
decompensation	  of	  chronic	  heart	  failure.	  This	  algorithm	  had	  a	  sensitivity	  and	  specificity	  of	  38%	  
and	   71%	   respectively.	   The	   false	   positive	   rate	   was	   observed	   to	   be	   significantly	   high	   (71%)	  
rendering	  the	  algorithm	  of	  no	  utility	  in	  identifying	  a	  higher	  risk	  of	  ADHF.	  	  
	  
6.3. Clinical	  Relevance	  and	  Future	  Directions	  
This	  thesis	  has	  evaluated	  the	  usefulness	  of	  a	  novel	  non-­‐contact	  monitor	  of	  nocturnal	  respiration	  
in	  heart	   failure	  patients,	   for	  diagnosing	  Sleep	  Disordered	  Breathing	   (SDB)	  and	  predicting	  acute	  
decompensation	   of	   chronic	   heart	   failure	   (ADHF).	   It	   has	   also	   described,	   for	   the	   first	   time,	   the	  
variability	  of	  nocturnal	  respiratory	  and	  sleep	  parameters	  over	  a	  prolonged	  period	  of	  monitoring.	  
The	  results	  of	  my	  studies	  may	  have	  some	  important	  clinical	  implications	  for	  how	  heart	  failure	  is	  
managed	  in	  the	  near	  future.	  
6.3.1. Diagnosis	  of	  SDB	  using	  the	  SleepMinder	  device	  	  
Increased	   survival	   from	   acute	   coronary	   syndromes	   and	   sudden	   cardiac	   death,	   has	   led	   to	   an	  
increased	  prevalence	  of	  heart	  failure	  (230).	  Advancement	   in	  contemporary	  drug	  and	  implanted	  
device	   therapy	   has	   been	   associated	   with	   improved	   outcomes	   in	   patients	   with	   left	   ventricular	  
systolic	   dysfunction	   in	  particular,	   but	   attendant	  morbidity	  or	  mortality	   remains	  high	   (63).	  As	   a	  
consequence,	  newer	  therapeutic	  targets	  for	  managing	  this	  condition	  are	  been	  investigated.	  Due	  
to	  its	  high	  prevalence	  (40-­‐50%)	  and	  negative	  prognostic	  association	  in	  patients	  with	  CHF	  (6)	  (9),	  
the	   treatment	   of	   SDB	   is	   one	   such	   area	   that	   is	   continuing	   to	   attract	   a	   lot	   of	   interest.	   Further,	  
studies	   (165;166)	   investigating	   newer	   treatment	   options	   for	   SDB	   may	   provide	   morbidity	   and	  
mortality	  data	   that	  would	  persuade	  the	   introduction	  of	  clear	   treatment	  strategies	   for	  SDB	   into	  
current	  heart	  failure	  management	  guidelines	  	  
In	   clinical	   practice	   however,	   there	   remains	   a	   large	   percentage	   of	   patients	   who	   remain	   under	  
diagnosed	   due	   to	   lack	   of	   investigation	   by	   the	   clinician	   (231).	   Attended	   in-­‐hospital	   overnight	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Polysomnography	   (PSG)	   remains	   the	  gold	   standard	   for	  diagnosing	  SDB,	  which	   is	  expensive	  and	  
not	  always	  readily	  available.	  It	  is	  arguable	  that	  amongst	  clinicians,	  the	  low	  awareness	  and	  drive	  
to	  diagnose	  this	  co-­‐morbidity	  may	  be	  in	  part	  due	  to	  the	  lack	  of	  clear	  guidelines,	  available	  sleep	  
services	   or	   the	   cumbersomeness	   of	   referring	   frail	   heart	   failure	   patients	   for	   the	   intrusive	  
investigation	  of	  in-­‐hospital	  polysomnography	  which	  they	  do	  not	  consider	  valuable.	  
I	  have	  found	  that	  the	  SM	  has	  a	  high	  diagnostic	  value	  for	  clinically	  relevant	  SDB	  (AHI>15)	  in	  heart	  
failure	  patients	  and	  a	  negative	   result	  may	  be	  used	   to	   rule	  out	   the	  presence	  of	  SDB.	  This	   study	  
potentially	  provides	  a	  novel	  exclusion	  tool	  that	  is	  convenient	  and	  easy	  to	  use	  by	  patients	  and	  can	  
be	  interpreted	  by	  clinicians.	  One	  of	  the	  major	  advantages	  of	  this	  method	  is	  its	  novel	  non-­‐contact	  
feature,	  which	  means	  it	  can	  also	  be	  used	  in	  the	  home	  environment.	  As	  this	  validation	  study	  was	  
undertaken	   in	   the	   hospital	   setting,	   it	  may	   be	   useful	   to	   further	   compare	   the	   SM	  with	   existing	  
home	   portable	   monitors.	   The	   addition	   of	   a	   qualitative	   assessment	   evaluating	   patients’	  
preference	  of	  either	  device,	  as	  one	  of	  the	  outcomes	  of	  this	  proposed	  study,	  would	  be	  useful.	  
The	  SM	  device	  is	  able	  to	  diagnose	  SDB	  based	  on	  the	  AHI	  calculated	  from	  its	  algorithms.	  It	  does	  
not	   separate	   respiratory	   events	   of	   apnoeas	   or	   hypopnoeas	   into	   central	   or	   obstructive	  
components.	   Further	  work	   to	   improve	   the	   algorithm	   for	   this	   discrimination	   is	  warranted.	   This	  
would	   be	   an	   important	   addition	   to	   the	   algorithm,	   as	   appropriate	   categorisation	   of	   SDB	   has	  
important	  treatment	  implications.	  	  
Due	  to	  a	  lack	  of	  firm	  guidelines	  in	  place,	  there	  are	  limited	  clinical	  management	  pathways	  for	  SDB	  
in	  heart	  failure.	  The	  SM	  device	  is	  a	  convenient	  tool	  that	  has	  the	  potential	  to	  be	  introduced	  in	  to	  
diagnosis	   and	   clinical	  management	   pathway	   of	   SDB	   in	   CHF	   patients.	   It	   would	   also	   be	   easy	   to	  
perform	   a	   clinical	   trial	   to	   evaluate	   the	   performance	   of	   a	   diagnostic	   pathway	   including	  
SleepMinderTM	   against	   that	   of	   conventional	   PSG.	   A	   proposed	   diagnostic	   pathway	   is	   shown	   in	  
Figure	   73	   below.	   In	   this	   model,	   I	   have	  made	   allowance	   for	   false	   negative	   patients	   by	   adding	  
symptoms	  into	  the	  screening	  pathway.	  While	  not	  very	  sensitive	  or	  specific,	  some	  symptoms	  such	  
as	  witnessed	  apnoeas	  have	  been	  shown	  to	  increase	  the	  odds	  ratio	  of	  making	  a	  diagnosis	  of	  SDB	  
(132).	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Figure	  73:	  Proposed	  Screening	  Pathway	  For	  SDB	  using	  the	  SleepMinderTM	  device.	  (AHI	  –	  Apnoea	  
Hypopnea	  Index,	  PSG	  –	  Polysomnography,	  SDB	  –	  Sleep	  Disordered	  Breathing,	  GP	  –	  General	  Practitioner)	  
	  
6.3.2. Diagnosis	  of	  SDB	  using	  the	  Mean	  AHI	  
In	  Study	  two,	  using	  the	  SleepMinderTM	  device,	  I	  have	  shown	  that	  the	  AHI	  was	  highly	  variably	  over	  
prolonged	  periods	  of	  monitoring	  in	  heart	  failure	  patients.	  In	  addition,	  I	  demonstrated	  that	  a	  high	  
percentage	   of	   patients	  were	   reclassified	   into	   a	   different	   severity	   and	   treatment	   group	   of	   SDB	  
over	   several	   nights.	   The	   clinical	   implications	   are	   that	   a	   single	   night	   PSG	   study	   may	   not	   be	   a	  
sufficient	  risk	  assessment	  for	  this	  group	  of	  patients.	  	  
The	  mean	  AHI	  over	  a	  2-­‐week	  follow	  up	  period	  is	  proposed	  as	  an	  alternative	  and	  potentially	  more	  
robust	  measure	  of	  the	  presence	  of	  SDB.	  To	  evaluate	  the	  diagnostic	  value	  of	  this	  measure	  it	  may	  
be	  necessary	  to	  perform	  a	  randomised	  controlled	  trial	   that	  evaluates	  the	  outcomes	  of	  patients	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In	  theory	  this	  should	  be	  a	  straightforward	  study	  to	  perform,	  however	  the	  follow	  up	  period	  would	  
be	   expected	   to	   be	   long,	   as	   the	   outcomes	   would	   invariably	   include	  mortality.	   In	   addition,	   the	  
sample	  size	  for	  a	  trial	  like	  this	  would	  be	  expected	  to	  be	  large	  for	  it	  to	  sufficiently	  collect	  data	  on	  
these	  endpoints	  to	  detect	  a	  significant	  difference	  in	  the	  two	  pathways.	  
The	  potential	  utility	  of	  this	  diagnostic	  criterion	  using	  the	  mean	  AHI	  would	  need	  to	  be	  evaluated	  
further.	  
6.3.3. Predicting	  decompensation	  of	  ADHF	  using	  the	  SleepMinderTM	  device	  
In	  Study	  three,	  I	  have	  utilised	  a	  combination	  of	  nocturnal	  respiratory	  parameters	  to	  develop	  the	  
SleepMinderTM	   ADHF	   predictor	   algorithm	   (SMApA)	   and	   found	   that	   its	   predictive	   value	   was	   of	  
little	  value.	  The	  algorithm	  performed	  with	  a	  sensitivity	  of	  0.38	  and	  specificity	  of	  0.71.	  	  
We	  have	  only	  utilised	  respiratory	  parameters	  in	  developing	  this	  algorithm	  but	  we	  observed	  some	  
limited	   but	   non-­‐statistically	   significant	   trends	   in	   some	   of	   the	   respiratory	   features	   when	  
comparing	  ADHF	  event	  days	  to	  Non-­‐Event	  Days.	   	   I	  found	  In	  particular	  that	  the	  duration	  of	  SDB,	  
number	  of	  apnoeas,	  and	  Cycle	   length	  of	  CSR,	  tended	  to	  be	  higher	   in	  the	  week	  before	  an	  ADHF	  
episode	  but	   this	  was	  not	   consistent	   for	  all	   event	  days	  and	  not	   in	  all	  patients.	  This	  may	   in	  part	  
explain	  why	  the	  prediction	  algorithm	  was	  not	  successful.	  	  
Perhaps	  the	  addition	  of	  other	  easily	  measurable	  physiologic	  parameters	  such	  as	  heart	  rate	  and	  
blood	  pressure,	  could	  improve	  the	  predictive	  value	  of	  the	  SM.	  Further	  research	  is	  required.	  
	  
6.4. Conclusions	  
The	  prediction	  of	  Acute	  Decompensation	  of	  heart	   failure	   is	   challenging	  and	   further	   research	   is	  
required	  to	  identify	  clinically	  relevant	  parameters	  that	  may	  aid	  early	  identification.	  The	  use	  of	  the	  
SleepMinderTM	  device,	  which	  is	  a	  non-­‐contact	  bedside	  monitor	  of	  nocturnal	  respiration,	  for	  this	  
purpose,	  is	  limited.	  	  
This	   device	   is	   however	   acceptably	   accurate	   at	   detecting	   SDB	   in	   patients	  with	   heart	   failure.	   Its	  
value	   as	   part	   of	   a	   clinical	   diagnostic	   and	  management	   pathway	   however,	   needs	   to	   be	   further	  
evaluated.	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